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3. Abbreviations 
5-FU 5-Fluoruracil 
A-MuLV Abelson murine leukemia virus 
ABC ATP-binding cassette 
Abl Abelson murine leukemia viral oncogene 
AdMIDAS Adjacent to MIDAS 
ADP Adenosine diphosphate 
AGM Aorta-gonad-mesonephros 
ALL Acute lymphoblastic leukemia 
AML Acute myeloid leukemia 
Ang-1 Angiopoietin-1 
AP Accelerated phase 
ATP Adenosine triphosphate 
Bcr Breakpoint cluster region 
BM Bone marrow 
BMP Bone morphogenetic protein 
BMT BM transplantation 
BP Blast phase 
BrdU 5-bromo-2'-deoxyuridine 
Ca2+ Calcium ions 
CAFC Cobblestone area forming cell 
Cal-DAG-GEF Ca
2+ and diacylglycerol-regulated guanine nucleotide exchange 
factor 
CAM Cell adhesion molecule 
CaR Calcium receptor 
CAR cells CXCL12-abundant reticular cells 
CBF-1 C-promoter-binding-factor-1 
Cbl Casitas B-lineage lymphoma pro-oncogene protein 
CCyR Cumulative complete cytogenetic response 
CFC Colony forming cell 
CFU-S Spleen colony forming unit 
CLL Chronic lymphocytic leukemia 
CLP Common lymphoid progenitor 
CML Chronic myelogenous (or myeloid) leukemia 
CMP Common myeloid progenitor 
c-Myc MYC v-myc avian myelocytomatosis viral oncogene homolog 
CNS Central nervous system 
CP Chronic phase 
Crkl CRK-like protein 
CSC Cancer stem cell 
CXCL12 CXC-motiv-chemokine 12 
CXCR4 CXC-motiv-chemokine receptor type 4 
DAG Diacylglycerol 
DCs Dendritic cells  
Dkk1 Dickkopf-1 
DNA Deoxyribonucleic acid 
E7.5 Embryonic day (E) 7.5 
ECM Extracellular matrix 
EGF Epidermal growth factor 
ERK Extracellular signal-regulated kinase 
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ESCs Embryonic stem cells 
FACS Fluorescence activated cell sorting 
FAK Focal adhesion kinase 
FERM domain 4.1 protein, ezrin, radixin, moesin domain 
FGF-1 Fibroblast growth factor-1 
FGFR 1-4 Fibroblast growth factor receptor 1-4 
FN Fibronectin 
Frz Frizzled 
G-CSF Granulocyte colony-stimulating factor 
GEF Guanine nucleotide exchange factor 
Gli-1 Glioblastoma-1 
GMP Granulocyte-macrophage progenitor 
GPCRs G protein-coupled receptors 
GPVI Glycoprotein VI 
Grb2 Growth factor receptor-bound protein 2 
HLA-matched Human leukocyte antigens-matched 
Ho Hoechst 33342 
HSC Hematopoietic stem cell 
HSPC Hematopoietic stem and precursor cell 
ICAM-1 Intercellular adhesion molecule-1 
ICM Inner cell mass 
IFN-α Interferon-α 
IP3 Inositol trisphosphate 
iPSCs Induced pluripotent stem cells 
IRS1 Insulin receptor substrate 1 
JaK Janus kinase 
Lef Lymphoid enhancer-binding factor 
LPS Lipopolysaccharide 
LRP5/6 low-density lipoprotein-receptor-related protein 5/6 
LSC Leukemic stem cell 
LT-HSC Long-term HSC 
LTC-IC Long-term culture-initiating cell 
M-Bcr Major breakpoint cluster region 
m-Bcr Minor breakpoint cluster region 
MAdCAM-1 Mucosal addressin cell adhesion molecule-1 
MAML-1 Mastermind-like-1 
MAPK Mitogen-activated protein kinase 
MDR1 Multidrug resistance-1 
MDS Myelodysplastic syndromes 
MEP Megakaryocyte erythroid progenitor 
Mg2+ Magnesium ions 
MIDAS Metal ion-dependent adhesion site 
mKL Membrane-bound kit ligand 
MM Multiple myeloma 
MMP Matrix metalloproteinase 
MPL Myeloproliferative leukemia virus oncogene 
MPP Multipotent progenitor 
MSC Mesenchymal stem cell 
MUC-1 Mucin-1 
Mx1-Cre myxovirus (influenza virus) resistance 1 
NK Natural killer cell 
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OBs Osteoblasts 
OCLs Osteoclasts 
OPN Osteopontin 
PB Peripheral blood 
PECAM-1 Platelet endothelial cell adhesion molecule-1 
PCK-ζ Protein kinase C-zeta 
PDGF Platelet-derived growth factor 
Ph chromosome Philadelphia chromosome 
PH-domain Pleckstrin homology-domain 
PI-PLC Phosphatidylinositol-specific phospholipase C 
PI3K Phosphoinositide-3-kinase 
PIP2 Phosphatidylinositol 4,5-bisphosphate or PtdIns(4,5)P2 
PIP3 phosphatidylinositol 3,4,5-trisphosphate or PtdIns(3,4,5)P3 
PIPKI phosphatidylinositol-4-phosphate 5-kinase 
PLC Phospholipase C 
PPR PTH/PTH-related peptide (PTHrP) receptor 
PSGL-1 P-selectin glycoprotein ligand-1 
PSI domain Plexin, Semaphorin and Integrin domain 
pSP Para-aortic splanchnopleurae 
PTB domain Phosphotyrosine-binding domain 
Ptch1 Patched 
PtdIns Phosphatidylinositol 
PtdIns(3,4,5)P3 PIP3 
PtdIns(4,5)P2 PIP2 
PTEN Phosphatase and tensin homolog 
PTH Parathyroid hormone 
PYK-2 Protein tyrosine kinase-2 
RACK-1 Receptor for activated C kinase 1 
RANKL Receptor activator of nuclear factor kappa B ligand 
RGDS Arg-Gly-Asp-Ser motif 
RIAM Rap1 interacting adaptor molecule 
S1P Sphingosine-1-phosphate 
SCF Stem cell factor (also known as kit-ligand, KL, or steel factor) 
SCID Severe combined immunodeficiency 
SDF-1 Stromal-derived factor-1 
SH Src-homology domain 
Shc SRC homology containing protein 
Shh Sonic hedgehog 
SLAM Signaling lymphocytic activation molecule 
Smad Small mothers against decapentaplegic 
Smo Smoothened 
SNO Spindle-shaped N-cadherin+ osteoblastic 
SNS Sympathic nervous system 
Spl Spleen 
SP Side population 
ST-HSC Sort-term HSC 
STAP Stimulus-triggered acquisition of pluripotency 
STAT Signal transducer and activator of transcription 
SyMBS Synergistic metal ion binding site 
Tcf Transcription factor 
TGF-β Transforming growth factor-β 
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Tie2 Tyrosine kinase with immunoglobulin-like and EGF-like domains 2 
TLR Toll-like receptor 
tm-SCF Transmembrane-stem cell factor 
TPO Thrombopoietin 
trOPN Thrombin-cleaved osteopontin 
TYK 2 Tyrosine kinase 2 
UGR urogenital ridges 
UNC-112 Uncoordinated protein 112 
VCAM-1 Vascular cell adhesion molecule-1 (CD106) 
VLA-4 Very late antigen-4 
Wnt Wingless-type 
wt wild-type 
µ-Bcr Micro breakpoint cluster region 
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5. Summary 
Integrins are a superfamily of cell adhesion molecules that link the extracellular matrix 
(ECM) to the cytoskeleton. They mediate the attachment between cells and their environment 
and transduce signals from the outside into the cell. Integrins require a pre-activation step 
prior to high affinity ligand binding, which is characterized by a conformational change of the 
integrin ectodomain and the separataion of the transmembrane and cytoplasmic domains 
leading to the modulating numerous intracellular signaling pathways such as proliferation, 
migration or survival. Integrin activation is induced by the binding of two cytoplasmic 
proteins, talin and kindlin, to the cytoplasmic tail of β subunits. The kindlin protein family 
studied in this thesis consists of three evolutionarily conserved members, kindlin-1, -2 and -3. 
Kindlin-1 is expressed in epithelial cells, kindlin-2 widely and kindlin-3 in the hematopoietic 
system. 
Loss of kindlin-3 in mice leads to a lethal phenotype within one week after birth. The mice 
suffer from severe hemorrhage due to an integrin activation defect on platelets, neutrophelia 
due to a leukocyte integrin activation defect, severe osteopetrosis due to dysfunctional 
integrins and an erythrocyte defect caused by an unknown mechanism. Kindlin-3 deficient 
hematopoietic chimeras (K3-/- chimeras) generated with kindlin-3 null fetal liver cells are 
unable to generate T cells and show an increased lethality compared to wild-type (wt) control 
chimeras. 
In my thesis work I first investigated the role of kindlin-3 in the regulation and maintenance 
of hematopoietic stem and precursor cells (HSPCs) (paper 1). Adhesion molecules maintain 
interactions between hematopoietic stem cells (HSCs) and their microenvironment, called 
niche, in the bone marrow (BM). The increased lethality of the K3-/- chimeras and their severe 
pancytopenia point to HSC defects. Indeed, I could show that K3-/- HSPCs have a reduced 
BM homing potential due to an extravasation defect. The K3-/- HSCs found in the BM of 
recipient mice are unable to enter quiescence and instead are in an active, proliferating state. 
Furthermore, K3-/- HSPCs have a severe BM retention defect resulting in increased levels of 
HSPCs in the peripheral blood (PB). These defects exhaust HSCs in old K3-/- chimeras and 
under situations of hematopoietic stress such as 5-FU treatment or serial transplantations. 
Finaly, I was able to show that HSPCs have different requierements for kindlin-3. The 
maintenance of active HSCs and HPCs is dependent on kindlin-3, while quiescent HSCs do 
not require kindlin-3 but are imidetly lost after activation in the absence of kindlin-3. These 
results show that kindlin-3 is an essential regulator for HSPCs homeostasis. 
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In the second study we investigated why K3-/- chimeras exhibit neutrophila (paper 2). We 
found that kindlin-3 is required to activate β2 integrins on leukocytes. Furthermore, we found 
that the phenotype of the kindlin-3 deficient mice resembles human patients suffering from 
the autosomal recessive leukocyte adhesion deficiency syndrome type III (LAD-III), which is 
characterized by severe hemorrhages and a leukocyte extravasation defect. Indeed, LAD-III 
patients were shown to have null mutations in their KINDLIN-3 gene. 
In paper 3 I helped analyzing the pronounced osteopetrosis in kindlin-3 deficient mice. We 
found that kindlin-3 deficient osteoclasts (OCLs) have an adhesion and spreading defect due 
to defects in the activation of β1, β2, and β3 integrins. By comparing the properties of K3-/- 
OCLs with OCLs deficient in one, two or all three integrin classes, respectively, we observed 
that loss of a single intergin class already affects the functions of OCLs, while the loss of all 
integrin classes resembles the defects of kindlin-3 deficient osteoblasts indicating that 
kindlin-3 affects the activation of β1, β2 and β3 integrins. 
In paper 4 I participated in the analysis of T cell development in kindlin-3-deficient mice. We 
observed that they develop progressive thymus atrophy. In transplantation experiments of 
fetal liver cells into irradiated or RAG-2-null mice we observed that T cell progenitor homing 
to the adult thymus is kindlin-3 dependent, while homing of kindlin-3 deficient T cell 
progenitors during early development, i.e. before thymus vascularization has taken place is 
unaffected and that they can leave the vascular system, migrate towards and enter the thymus 
primordium, indicating that the initial population of the thymus anlage by T cell progenitors 
apparently occurs in a kindlin-3 and integrin-independent manner. We also showed that the 
T cell progenitors, which entered the thymus, show a reduced proliferation due to a weakened 
crosstalk with the thymus microenvironment but can mature into single CD4+ and CD8+ 
T cells. 
In paper 5 we tested whether kindlin-3 supports the essential function of β1 integrins in the 
development of autoimmune diseases such as multiple sclerosis (MS) in humans and 
experimental autoimmune encephalitis (EAE) in mice. We showed that K3-/- T effector cells 
were able to extravasate through inflamed endothelial cells with high integrin ligands on their 
surface into central nervous system (CNS) and induce EAE. T cell extravasation did not occur 
under naïve conditions where ligand expression was low. This finding was confirmed with in 
vitro assays showing that kindlin-3 in T effector cells is required to induce α4β1 and αLβ2 
integrin mediated ligand binding if ligand levels are low, but is less important if ligand levels 
are high indicating that loss of kindlin-3 is, at least in part, compensated by integrin ligand 
avidity. 
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In paper 6 I helped addressing how much kindlin-3 is needed by hematopoietic cells to fulfill 
their biological tasks. We observed that mice expressing only 5% and 10% of normal 
kindlin-3 levels were viable, but were only able to activate a limited number of integrins with 
the consequence that they had a severe bleeding tendency and a leukocyte adhesion defect. 
Furthermore, we found that platelets and neutrophils have a similar number of kindlin-3 and 
talin proteins while the integrin levels differed. Leukocytes have twofold more integrins 
compared to talin and kindlin-3, while platelets have twofold more kindlin-3 and talin 
compared to integrins, These findings suggest that platelets need high kindlin-3 levels, while 
leukocytes require lower level for integrin activation. 
In paper 7 I contributed to an analysis in which we studied the role of β1 integrins and its 
interaction with kindlin-3 for platelet functions such as granule secretion. While the 
platelet-specific αIIbβ3 integrin is fundamental for platelet-mediated hemostasis, the 
relevance of β1 integrins on platelets is controversial. We found that mice lacking β1 integrin 
or expressing an activation-deficient β1 integrin have prolonged bleeding times due to 
insufficient activation of Rac-1, actin dynamics, granule secretion, and platelet aggregation. 
Furthermore, we also observed that hypomorphic mice expressing only 3% of β1 integrins on 
platelets have normal bleeding times but reduced platelet adhesion. Interestingly, the studies 
also revealed that integrin outside-in signaling leading to platelet spreading FAK 
phosphorylation, and platelet aggregation does not require a direct interaction of kindlin-3 
with the β1 integrin tail. 
Finally, in paper 8 I was involved in the analysis of mice lacking kindlin-1 in cutaneous 
epithelial cells. These mice recapitulate Kindler syndrome in human patients and have a 
hyperactive stem cell compartment leading to hyperthickened epidermis, development of 
ectopic hair follicle and increased skin tumor susceptibility. Mechanistically, we found that 
kindlin-1 regulates keratinocyte adhesion through β1 integrins and stem cell homeostasis by 
balancing on the one hand wingless-type (Wnt)/β-catenin mediated growth-promoting signals 
through an integrin-independent regulation of Wnt ligand expression and on the other hand 
growth inhibitory signals through αvβ6 integrin-mediated activation of transforming growth 
factor-β (TGF-β). 
Altogether these findings revealed that kindlins are essential regulators of integrin activation 
on different cell types, for integrin outside-in signaling and for integrin-independent signaling 
tasks. The functions of kindlin-3 seem to depend on the type of integrin, type of 
hematopoietic cell and physiological status of the cell. Many questions are still open; for 
example, it is unclear how integrin-independent functions are executed at the molecular level 
Summary 
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and how outside-in signaling of integrins is achieved. It is also unclear how the crosstalk 
between kinlins and talin at the cytoplasmic tails of integrins is mediated. 
During the time of my Phd thesis I also collaborated with international groups that did not 
directly relate to my thesis work. In one study I collaborated with Mark Ginsberg (at UCSD) 
to investigate the role of the CD98 heavy chain (hc) on B cells (paper 9). We were able to 
show that CD98hc facilitates humoral immunity by supporting B cells proliferation, in an 
integrin-dependent manner. In another study I helped him to study the activation of αIIbβ3 by 
talin and kindlin-3 (paper 10). We observed that kindlin-3 does neither enhance the activation 
of αIIbβ3 mediated by the talin head domain nor the affinity of purified αIIbβ3. Apparently, 
kindlins promote αIIbβ3 binding to multivalent but not monovalent ligands and increase the 
clustering of ligand-occupied αIIbβ3. I also helped Sabine Werner (at ETH Zürich) to 
examine the role of β1 integins on hepatocytes during liver regeneration (paper 11). We 
found that loss of ß1 integrins on hepatocytes results in a severe liver necrosis and reduced 
hepatocyte proliferation	   after partial hepatectomy due to impaired ligand-induced 
phosphorylation of epidermal growth factor (EGF) and hepatocyte growth factor (HGF) 
receptors indicating a strong cooperation between β1 integrin signaling and the two growth 
factor receptor signaling pathways. 
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6. Introduction 
6.1. Stem Cells: The Origin of Life 
A single stem cell, the fertilized egg (zygote), gives rise to all cells in a mammalian 
multicellular organism that consists of more than 240 different cell types. The principle of 
stem cells was already formulated 1858 by Rudolf Virchow who postulated that all cells in an 
organism are derived from preexisting cells. He coined the famous sentence “omnis cellula e 
cellula” (all cells come from cells) [1]. Stem cells are undifferentiated cells that have the 
abilities for unlimited or prolonged self-renewal by generating identical copies of themselves 
and to give rise to differentiated cell types. Development, tissue repair and cancer, resulting 
from uncontrolled cell division and additional imbalance of cell differentiation or cell death, 
are the three major processes in which stem cells play a central role. Stem cells can be 
classified into four categories with different stem cell potency: the embryonic stem cells 
(ESCs), the adult or somatic stem cells, induced pluripotent stem cells (iPSCs) and 
stimulus-triggered acquisition of pluripotency cells (STAP cells) [2-5]. 
The zygote is a totipotent stem cell that develops into all cell types including the embryonic 
membranes (amnion, chorion, allantois, and yolk sac). After fertilization, mammalian 
development starts with several cell divisions until cells are arranged in a solid ball, the 
morula, which occurs at the 32- to 64-cell stage. These cells called blastomeres at this stage 
still remain totipotent. In the next stage a hollow ball of cells, termed blastocyst, is formed. 
Beyond the blastocyst stage, development proceeds with a combination of cell division and 
cell movements. Cells of the blastocyst’s outer layer, the trophoblasts, will form the 
embryonic membranes and the placenta, while the inner cell mass (ICM) develops into the 
fetus. The ICM is pluripotent and differentiates into cell types of the three germ layers known 
as the ectoderm, mesoderm, and endoderm. These three germ layers develop during a process 
called gastrulation in which the single-layered blastula is reorganized into the trilaminar 
structure giving rise to the gastrula. The ectoderm emerges first from the outer layer of the 
blastula, termed epiblast, and is the most exterior layer. It gives rise to the epidermis (skin and 
associated organs) and the future nervous system. The mesoderm is the middle layer and 
differentiates to the connective tissue, muscles, bones and blood. The endoderm is the 
innermost layer and develops into the gastrointestinal tract, the lungs and associated 
structures. Interestingly, germinal cells from the gonadal or genital ridge, which are the 
precursor of the gonads, are not derived from any of these three germ layers but rather 
develop outside the embryo (figure 1). 
Introduction 
 15 
 
 
© 2001 Terese Winslow, C aitlin Duckwall 
Figure 1: Differentiation from zygote into the specialized tissues during mammalian early development 
(picture: © 2001 Terese Winslow, Caitlin Duckwall) 
 
During stem cell fate determination, cells encounter progressive restrictions of their 
developmental potential for gaining higher specialization. For example, during differentiation 
of the small intestine epithelium (see figure 2) the initial totipotent zygote undergoes several 
determination steps to finally become fully specialzed. Some of the ESCs differentiate into 
multipotent endodermal germ layer stem cell, which have potential to give rise to several 
different tissues such as gut, pancreatic, thyroid, and lung tissue. The next determination step 
includes oligopotent lineage stem cells occurring e.g. in yolk sack and gut endoderm. 
Tissue-determined stem cells such as the quadripotent intestinal progenitor cells can give rise 
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to mucous, absorptive, neuroendocrine, or paneth cells, which in turn further terminally 
differentiate in nullipotent mature cells [6]. 
 
Figure 2: Differentiation potential of stem and progenitor cells in the developing small intestine 
During the process of determination the stem cells lose their stem cell potential and gain specialized functions. 
The differentiation potential ranges from totipotent for the fertilized egg to nullipotent for a terminal 
differentiated cell (e.g. paneth cell) (adapted from Stem Cells Handbook by Stewart Stell 2004). 
 
During self-renewal (or self-regeneration) and differentiation stem cells use two different 
mechanisms of cell divisions, a symmetric or asymmetric division (Figure 3). 
 
Figure 3 : Symmetric and asymmetric stem cell division 
Stem cells can divide symmetrically thereby generating either two stem cells (expansion), or two differentiated 
cells (depletion). During an asymmetric division a stem cell generates one new stem cell (self-renewal) and one 
differentiated cell (differentiation) (adapted from Lee et al., 2008) [7]. 
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During self-renewal stem cells divide symmetrically leading to an increased number of 
daughter stem cells with the same stem cell properties as the origin cells. This type of cell 
division is not only predominantly observed during very early embryonic developmental 
stages, but also during wound healing and regeneration. During asymmetric cell division the 
stem cell divides into one daughter cell with stem-cell fate (self-renewal) while the other 
daughter cell differentiates. This type of cell division also leads to self-renewal as the 
symmetric division, but not to an expansion of stem cells [7]. Asymmetric divisions are 
particularly important later in development when it comes to tissue specification, but also in 
adult stem cells, e.g. in HSCs. In asymmetric cell divisions the correct orientation of the 
mitotic spindle can be regulated by either cell intrinsic mechanism such as an asymmetric 
localization of cell polarity factors and/or the polarized localization of cell fate determinants 
or by asymmetric exposure of extrinsic cues, represented by the microenvironment, to initially 
identical daughter cells, resulting in the acquisition of different cell fates [8] see figure 4. 
 
Figure 4: Three different modes of asymmetric division of stem cells 
A) Intrinsic asymmetric division mediated by the asymmetric localization of cell polarity factors (red). B) 
Intrinsic asymmetric division mediated by cell fate determinants (red), which can be associated with the 
centrosome or the membrane being differentially distributed to the daughter cells or, as shown here, segregated 
to the cytoplasm of one daughter cell. C) Extrinsic asymmetric division; here, the to daughter cells have the same 
developmental potential but due to exposure to different stem-cell microenvironments (stem cell niche in red) 
only one daughter cell becomes essential, extrinsic cues from the environment retaining the stem cell fate, while 
the other cell is exposed to differentiation factors. Orange: stem cells. Green: differentiated cells (adapted from 
Morrison et al., 2006). 
 
Stem cells are not only important during development. The somatic stem cells can be found in 
several types of differentiated tissues and organs such as BM, blood, skin, skeletal muscle, 
CNS, small intestine, teeth, heart, liver or gut epithelial. Their main functions are the 
replacement of dying or injured cells and thereby maintenance of the tissue. For somatic stem 
cells also the potential of transdetermination was described, which defines the differentiation 
of a stem cell from one adult tissue to another tissue [9] (figure 5). This has to be 
distinguished from an other type of cell plasticity termed transdifferentiation which occurs 
when a differentiated cell directly transforms into another differentiated lineage without 
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dedifferentiation into a stem or precursor cell [10]. Many of the experiments proving the 
plasticity of somatic stem cells were done with HSCs originated from the mesodermally 
derived BM showing that they were able to differentiate into other mesodermally derived 
tissues such as liver [11-13], cardiac muscle [14,15] and skeletal muscle [16,17], or even into 
tissues from an other germ layer, e.g. into neural tissue, which is derived from the ectoderm 
[18,19]. The novel possibilities to use the plasticity of somatic stem cells for therapeutic tissue 
regenerations are controversially discussed, as the yield of plastic differentiation, e.g. with 
HSCs, is extremely low and, therefore, of questionable therapeutic relevance [20]. 
 
Figure 5: Adult stem cell plasticity 
The term plasticity, describes the ability of a stem cell from one adult tissue to generate differentiated cell types 
of another tissue either, from the same or from a different embryonic germ layer. For example HSCs (derived 
from mesoderm), have the potential to transdeterminate into skeletal muscle (also derived from mesoderm) or 
neurons (derived from ectoderm) (adapted from Kumar et al., 2010) [21]. 
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6.2. Hematopoietic Stem Cells 
The blood forming system, known as the hematopoietic system, contains more than 
10 distinct mature cell types including erythrocytes (red blood cells), platelets, myeloid cells 
such as granulocytes (neutrophils, basophils and eosinophils), monocytes, dendritic cells 
(DCs), mast cells and macrophages and lymphocytes such as B and T cells. Many blood cells 
and certain kinds of epithelial cells have a very short lifetime and hence, have to be 
continuously replenished. For example human erythrocytes have a lifetime of approximately 
120 days. To maintain the homeostasis of blood cells and to ensure survival, an adult human 
needs to produce approximately one trillion new hematopoietic cells every day [22]. This 
continuous production of mature blood cells mainly takes place in the BM where a small pool 
of HSCs resides, which are the ultimate, and only, source of blood cells (figure 6). HSCs are 
defined primarily by their ability to self-renew and to give rise to all kinds of blood cells. 
These properties of HSCs makes it possible for a single cell to regenerate the entire 
hematopoietic system of an organism as shown in transplantation experiments in mice [23]. 
HSCs are very rare, e.g. in mice only around 1 in 10,000 to 15,000 BM cells are HSCs [24]. 
In general, two types of HSCs are distinguishable: the long-term HSCs (LT-HSCs), which 
have the ability to proliferate and self-renew during the entire lifetime of the organism, and 
sort-term HSCs (ST-HSCs), which show higher proliferation rates but only for a limited time, 
possibly a few months. In order to maintain the life long survival of LT-HSCs, they are most 
of the time quiescent [25]. Only around 8-10% of LT-HSCs enter the cell cycle each day 
[26,27]. 
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Figure 6: Overview of hematopoietic cell differentiation in the BM 
HSC predominantly located close to the dense bone in a specific microenvironment containing stroma cells. All 
hematopoietic cells can be derived from a single HSC through cell division and differentiation into several 
intermediate precursor cell stages to the finally terminal differentiated effector cells. A related differentiation and 
maturation is also observed for stroma cells (picture: © 2001 Terese Winslow, Lydia Kibiuk). 
 
First evidence for the existence of HSCs came from observations of people, which were 
exposed to high doses of radiation after the Hiroshima and Nagasaki bombings in 1945. 
Survivors of the atomic bombs had an immune-compromised hematopoietic system and died 
of normally nonpathogenic infections or an insufficient production of platelets resulting in 
hemorrhages. In 1949 Jacobsen et al. showed that mice that received a minimal lethal dose of 
whole body irradiation developed the same radiation syndromes and died from hematopoietic 
failures approximately two weeks after irradiation. Furthermore, they were able to 
demonstrate that shielding organs such as single bones or the spleen (Spl), in which 
hematopoiesis occurs, can prevent the irradiation syndrome [28]. Thereafter, in 1951 
transplantation experiments with cells isolated from BM or Spl showed that these cells were 
able to rescue lethally irradiated animals [29,30]. In the early 1960s, when it was clear that 
cellular rather than humoral factors are essential for the rescue of lethally irradiated organism, 
Till and McCulloch further analyzed the cellular composition of the BM to determine the cell 
type(s) responsible for the reconstitution of the hematopoietic system. They observed the 
formation of colonies within the spleen composed of myeloid and erythroid cells 8 to 10 or 12 
days after transplantation of BM cells into lethally irradiated recipients [31]. Furthermore, 
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they proved the clonal nature of the Spl colonies by showing that the different cells within one 
colony were all derived from a single HSPC [32]. Spleen colony forming cells (CFC) were 
also further transplantable and had the potential to reconstitute the hematopoietic system of 
lethally irradiated secondary recipients [33]. Although the development of more precise 
markers for the characterization of HSCs revealed that the Spl colonies are formed by more 
differentiated myeloid progenitor cells, rather than by HSCs, [34] the discovery of spleen 
colony forming units (CFU-S) were a milestone in hematopoietic research and immensely 
contributed to the identification of HSCs. 
6.3. Hematopoietic Stem Cell Hierarchy 
Although the current understanding of the hematopoietic development is not complete, the 
hematopoietic system is one of the best-described systems of stem cell development. For the 
different cell types of the hematopoietic system a hierarchical model has been proposed by 
arranging stem and progenitor cells according to their lineage differentiation potential 
(figure 7). At the top of the hierarchy is a small pool of LT-HSCs with an indefinite 
self-renewal potential. These cells are most of the time quiescent and can give rise to all 
different hematopoietic cell types on a single cell level throughout the entire lifetime of an 
organism. Once HSCs commit to differentiation, they cannot revert to a self-renewing state 
indicating that specific signals, provided by specific factors, seem to be needed to maintain 
HSCs. 
ST-HSCs are derived from LT-HSCs. They are still multipotent but have a restricted 
self-renewal potential and their reconstitution potential, in a murine system, is restricted to a 
few months [35]. ST-HSCs give rise to multipotent progenitors (MPPs). These briefly 
self-renewing cells are pluripotent but have no long-term reconstitution capability [36,37]. 
The MPPs further differentiate into oligolineage-restricted progenitors that are committed to 
the lymphoid or myeloid lineages through irreversible maturation steps. The differentiation 
into common lymphoid progenitors (CLPs) and common myeloid progenitors (CMPs) is the 
first major branching point of the hematopoietic tree. The CLPs are restricted to give rise to 
innate lymphoid cells, such as B, T and natural killer (NK) cells, while CMPs first 
differentiate into granulocyte-macrophage progenitors (GMPs), which in turn give rise to 
monocytes, macrophages and granulocytes or into megakaryocyte-erythroid progenitors 
(MEPs), which in turn produce megakaryocytes, platelets and erythrocytes. Once the 
precursors have become lineage restricted they stop to proliferate and mature, through several 
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maturation steps, into the different lineage-committed effector cells of the hematopoietic 
system. 
This differentiation pathway is not rigid. Under certain conditions developmental steps can be 
bypassed as cells of the heterogeneous MPP population can directly give rise to MEPs 
without passing through CMPs [37]. Furthermore, the fact that both CMPs and CLPs can give 
rise to DCs [38,39] or that MEPs maintain the potential to differentiate at an extreme low 
frequency into B cells [40] further suggests the existence of alternative commitment 
pathways. 
The molecular mechanisms regulating lineage commitment within the hematopoietic system 
is a complex stepwise process combining the alternate expression of specific transcriptional 
regulators, growth factors, and growth factor receptors, whose combination determines 
lineage commitment and maturation [41,42]. 
All of these different stem and progenitor populations, shown in figure 7, can be separated as 
pure populations by using cell surface markers as described in the next section. 
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Figure 7: Model of the hematopoietic hierarchy 
On top of the hierarchy are highly self-renewing LT-HSCs, which are most of the time quiescent and give rise to 
all hematopoietic cell types (multipotency). While LT-HSCs have the ability to reconstitute the whole blood 
system of an organism with a single cell, ST-HSCs have gained a higher proliferative potential and have a 
limited reconstitution potential, athough they are still multipotent. The ST-HSCs differentiate into multipotent 
progenitors (MPPs), which are not self-renewing and have no long-term reconstitution capability but are highly 
proliferating. The MPPs give rise to oligopotent precursors that are committed to the myeloid or lymphoid 
lineages, the common myeloid progenitor (CMP) or common lymphoid progenitor (CLP). The CLPs can further 
differentiate into lineage restricted precursors which finally give rise to dendritic, T, NK, or B cells while CMP 
further differentiate into committed megakaryocyte-erythroid progenitors (MEPs) giving rise to erythrocytes and 
platelets or granulocyte-macrophage progenitors (GMPs) giving rise to granulocytes and macrophages. Lineage 
restricted precursors are maturing into the mature effector cells and are not proliferative active (modified from 
Passegué et al., 2003) [43]. 
 
6.4. Hematopoietic Stem Cell Characterization 
A major challenge in the hematopoietic research since the 1960s has been the identification, 
characterization and isolation of HSCs. The identification of HSCs is strenuous for several 
reasons. First, the number of HSCs in a large mix of several other BM resident populations is 
very small. Second, HSCs appear and behave similar to other white blood cells in culture, 
which makes it impossible to identify them only by morphological characteristics, e.g. size 
and shape. Third, phenotypical and functional characteristics of HSCs are not uniquely 
consistent, meaning that a HSC population characterized by its specific, homogeneous 
phenotypic marker expression could contain cells that are heterogenic in other properties such 
as their longevity, self-renewal or multipotency. 
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However, the advance in transplantation assays, genetic engineered mouse models, antibody 
and cell culture technologies in the last 20 years improved the understanding of processes 
involved in the differentiation of HSCs into progenitor cells and finally mature blood cells 
and led to further development and improvement of various methods for the characterization 
of stem and progenitor cell populations that are now available for use in HSC research. 
For the immunophenotypical analysis of HSPCs the development of fluorescence activated 
cell sorting (FACS) has been crucial. The FACS-based methods enable the recognition, 
quantification and purification of small numbers of HSCs in large mixed populations. The 
purity of FACS isolated HSC populations has increased in recent years, so that around 
50%-96% of the isolated cells in a certain population, depending on the combination of 
antibodies against specific surface marker that had been used, can give rise to long-term 
reconstitution after transplantation [44,45]. For mouse HSCs these markers include panels of 
8 to 14 different antibodies recognizing cell surface proteins present on differentiated lineages 
(e.g. macrophages, B and T cells etc.) therefore collectively referred to as “Lin”, as well as 
the proteins c-kit, Sca-1, CD34, CD150, CD48, CD41, CD135, CD49b, CD127, and 
CD16/32. The combination of surface markers used for the recognition of human HSPCs 
differs from this and have been defined by using Lin, CD34, CD38, CD45RA, CD90, CD49f, 
CD135, CD10, and CD7. While none of these markers alone recognize functional stem cell 
activity, several cell surface marker combinations of at least 3 different markers, see figure 8, 
are used to purify near-homogenous populations of HSCs [46,47]. 
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Figure 8: Models of adult mouse and human hematopoietic hierarchies 
The major classes of stem and progenitor cell populations defined by cell surface phenotypes in adult mouse 
(top) and human (bottom). Antibody panels are listed next to each population and in the gray bars below each 
schematic (adapted from Doulatov et al., 2012) [46]. 
 
In addition to antibodies, fluorescent dyes such as rhodamine123, which stains mitochondria, 
or the DNA-binding dye Hoechst33342 (Ho) have been used to explore the high drug efflux 
properties of HSCs [48-52]. Both of these dyes are fast released from HSCs due to a high 
efflux mediated by membrane pumps of the adenosine triphosphate (ATP)-binding cassette 
(ABC) transporter superfamily, highly expressed in HSCs and can so be distinguished from 
mature cells, which retain the dyes at a higher intensity [48,51]. With the advancement of this 
method, the Ho side population (SP) [48] is more commonly used today. Hereby, cells stained 
with Ho are simultaneously visualized at two wavelengths. The SP cells, a population 
containing HSPCs, appear in a distinct “tail” profile [48]. 
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However, all of the mentioned phenotypically defined populations are not 100% 
homogeneous. In theory, the best strategy to dissect this heterogeneity is the analysis of single 
cells, which is not realistic due to the lack of differentiation criteria. Furthermore, none of the 
currently used HSC markers are directly linked to an essential HSC function and there are 
variations of these markers depending on genetic alleles [53], mouse strains [54], 
developmental stages [55] or activation stages [56,57] as well as differences of markers 
between species such as humans and mice. Thus, the functional potential of HSCs and 
progenitors cannot be measured solely based on surface expression markers, which makes 
additional functional assays absolutely necessary for the identification of HSCs. 
For the functional characterization of hematopoietic stem and progenitor cells several in vitro 
and in vivo assays with certain advantages but also critical limitations, have been developed 
and are currently commonly used (figure 9). 
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Figure 9: Overview of assays used to detect hematopoietic stem and progenitor cells 
The right side shows two in vivo assays. In both assays test cells are transplanted into irradiated recipient mice. 
The spleen colony forming (CFU-S) assay measures the presence of predominantly HPCs in the test cell 
population by their ability to form colonies in the Spl of the recipient after a certain period of time. Each colony 
derives from one HPC. The long-term reconstitution assay addresses the ability of HSCs within a test population 
to mediate long-term engraftment and to produce multilineage effector cells. The left side shows two in vitro 
assays. In vitro assays do not have the resolution for identifying HSCs as in vivo transplantation assays but are 
often the only possibility, e.g. to investigate human cell samples. The Cobble-stone Area Forming Cell (CAFC) 
assay measures the ability of HSCs to grow for up to seven weeks in specific types of colonies under stroma 
cells, which are easy to identify. In the Long-Term Culture-Initializing Cell (LTC-IC) assay, test cells are plated 
on a feeder layer for at least 5 weeks. After that time, only HSCs maintain the ability to give rise to progenitor 
cells with clonogenic potential (adapted from the homepage of National Institutes of Health “Regenerative 
Medicine 2006“). 
 
In vitro, tissue culture based assays are especially important for the investigation of human 
hematopoietic cells because of the limitation of in vivo transplantation assays for human cells. 
The CFC assay quantifies progenitor cells, but does not quantify HSCs, in a given population. 
In the process, the test cells are plated in a semisolid agar or methylcellulose culture media 
supplemented with specific growth factors [58]. The majority of colonies in this assay are 
derived from oligolineage-restricted progenitors. The colony formation is normally measured 
2 weeks after plating. In vitro assays for measuring HSCs content in a test population include 
the long-term culture-initiating cell (LTC-IC) and the cobblestone area forming cell (CAFC) 
assays [59]. Both assays are co-culture systems that are used to measure HSC frequencies. 
The LTC-IC assay is based on the ability of HSCs to maintain their clonogenic potential over 
more than 4 weeks in co-culture compared to progenitor cells. The CAFC assay measures the 
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ability of HSCs to grow in specific colonies under the stromal feeder layer (so called 
cobblestone areas) for 5 to 7 weeks after initial plating. Progenitor cells are not able to grow 
for such a long time period under this culture conditions. 
The classical CFU-S assay described by Till and McCulloch’s [31] is an in vivo assay that 
measures the ability of progenitor cells, rather than HSCs, to build large colonies in the Spl of 
recipients, see figure 9, after transplantation into lethally irradiated mice. However, the best 
assays for analyzing HSC content are in vivo reconstitution assays [60,61]. During this 
process the specific test populations, single pre-purified HSCs or mixed populations in the 
case of competitive assays, are transplanted into lethally irradiated recipient mice and the 
overall survival of the recipients or the repopulation potential of the entire hematopoietic 
system from the test cells is measured. For this kind of assays, especially in competitive 
transplantation assays, the differentiation between host and donor-derived cells is essential. 
For this differentiation several types of marker systems are used. For example, the injection of 
male cells into a female host allows detection of donor cells by the male-cell-specific 
Y-chromosome. However, the expression of different variations of cell-surface proteins that 
are recognized by specific monoclonal antibodies such as CD45 is most commonly used (see 
figure 9). To measure the long-term reconstitution potential of HSCs in mouse models, the 
recipients have to be monitored at least up to 4 to 6 months after transplantation [62]. 
In serial transplantations the BM from a previous reconstituted recipient is used as donor cells 
for the reconstitution of the second generation of lethally irradiated recipients and so on and 
so forth. This assay should address the lifespan and expansion limits of HSCs but one has to 
take into account that not only the lifespan but also the transplantability, which can alter under 
different conditions, influences these result. 
Small numbers or frequencies of stem cells in a given hematopoietic population can be 
addressed in competitive reconstitution assays, in which different amounts of test cells are 
mixed with a defined population of (mostly total BM) host type cells. The host cells should 
mediate radioprotection and thereby ensure the survival while the reconstitution potential of 
the test cell or cells can be determined by the percentage of donor derived effector cells. An 
example of a competitive reconstitution assays for the quantification of the HSC frequency in 
a test cell population is shown in figure 10. 
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Figure 10: Limiting dilution assay for the quantification of HSCs in vivo 
Different numbers of test cells are always mixed with the same amount of host type rescue cells and transplanted 
into lethally irradiated mice. After 3 to 4 months the contribution of donor-derived multilineage cells in the PB is 
measured. Positive recipients are defined as showing at least 1% donor-derived cells (dotted mice). Because of 
the linear relationship between the number of injected cells and the proportion of negative recipients, Poisson’s 
statistics can be used to calculate the frequency of HSCs (adapted from Coulombel et al., 2004) [63]. 
 
For the investigation of human HSCs in mice several experimental models with 
immunologically incompetent mice are available including severe combined 
immunodeficiency (SCID) [64-66], NOD-SCID [67] and Rag-2-/-Cγ-/- [68] mice. These 
mutant mice cannot mount an immune response against foreign cells and can therefore be 
used as recipients for human cells. However, the limitation of this system is that it is not 
mimicking the natural human environment and that only a fraction of the total lifespan of a 
human HSC can be measured in mice. Hence, only clinical HSC transplantations can address 
long-term functions of human HSCs. 
There are several factors that have to be considered in all in vivo transplantation experiments 
especially if transgenic mice are investigated; they include the homing properties to the BM, a 
potentially impaired differentiation of HSCs into hematopoietic lineages, an altered 
proliferative kinetics of progenitors or defects of HSCs in the interaction with the BM 
microenvironment [47]. 
In summary, the ability to obtain highly purified HSCs population combined with functional 
in vitro and in vivo assays has greatly facilitated the functional and biochemical 
characterization of HSCs. However, no definite HSC marker, gene or other criterion has been 
found so far. Probably the progress in genomic sequencing, genome wide analysis of RNA 
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expression and protein levels and their comparisons among various types of stem cells may 
help to identify sets of genes allowing to clearly define “stemness” for HSCs. 
6.5. Origin of Hematopoietic Stem Cells: From Hemangioblast to Adult HSCs  
HSCs development during embryogenesis is a complex process involving multiple stages that 
are temporally and anatomically distinct, involving several anatomical sites such as the yolk 
sac, the aorta-gonad-mesonephros (AGM) region (figure 11), the placenta, the fetal liver and 
finally the BM (see also figure 12 and 14), thereby requiring unique cellular and molecular 
regulators. Defining the developmental origins of hematopoiesis is further complicated 
compared with stationary tissues by the fact that cells of the hematopoietic system circulate, 
thereby changing their site of “potential” origin. 
The conceptus consists of an intra-embryonic compartment that will become part of the fetus 
and supportive extra-embryonic tissues such as the allantois and the yolk sac. During 
development multiple waves of hematopoiesis take place at different times and locations 
involving both compartments. In zebrafish there are at least three distinct phases, while in 
mammals at least two phases of haematopoietic development exist. The initial wave, referred 
to as “primitive” phase, takes place in specific areas of the yolk sac called blood islands at 
embryonic day 7.5 (E7.5) in mice. The primitive hematopoietic system is only transient and is 
rapidly replaced by the adult-type, also termed ‘‘definitive’’ hematopoiesis. The main site of 
definitive hematopoiesis is the AGM region [69-72]. The AGM consists of the dorsal aorta 
surrounded by mesenchyme and the urogenital ridges (UGR) [73] (Figure 11). 
 
Figure 11: Ventral and sagittal images of the AGM region and the flanking urogenital ridges 
(A) Ventral view of the dissected UGR and AGM of an E11 mouse embryo. Germ cells are visualized. 
(B) Sagittal section of the UGR/AGM region from an E11.0 embryo. The UGR is ventral to the dorsal aorta, 
which is ventral to the neural tube. (C) Higher magnification of B. Ao = dorsal aorta, NT = neural tube (adapted 
from Pietila et al., 2005). 
 
AGM STEM CELLS
Fig. 1. Ventral and sagittal illustrations of the aorta-
gonad-mesonephros (AGM) region in close proxim-
ity to the urogenital ridge (UGR). A. Ventral view of
the dissected UGR of an E11.0 mouse embryo with
the AGM. The germ cells are visualized with the
EMA-1 antibody. The haematopoietic stem cells are
thought to be located on both sides of the dorsal
aorta. The aorta is in the middle of the UGRs. B.
Sagittal view of the UGR/AGM from an E11.0 em-
bryo. The cells stained blue represent migrating neu-
ral crest cells that express the LacZ gene. The UGR
is ventral to the dorsal aorta, which is also located
ventral to the neural tube. C. A higher magnification
of the sagittal view of the UGR/AGM region. The
UGR, cut away from the coelomic epithelium, the
Wolffian duct and the mesonephros are seen lateral
to the dorsal aorta (Ao) and dorsal to the gut epithel-
ium. NT, neural tube. Figs. B & C courtesy of P. Ita¨r-
anta.
number of circulating definitive HSCs increases
between days 11–13 of gestation, suggesting that
the AGM HSCs become motile and may be
routed to the fetal liver via the blood stream
(23). Future studies should be directed towards
characterizing the routes of migration and
spread of the AGM stem cells. Current mouse
embryological methods allow researchers to cul-
ture the whole embryo ex utero for 24–48 h, and
this technology may provide new possibilities
for studying the differentiation of the HSCs in
the AGM region (17).
GENERATION OF MESENCHYMAL
STEM CELLS IN THE AGM REGION
Mesenchymal stem cells (MSCs) are thought to
be important for the synthesis of the haemato-
poietic microenvironment, which contributes to
807
the maintenance and differentiation of the
HSCs (22). In the adult, MSCs and their pro-
geny are to be found predominantly in the bone
marrow. MSCs have the capacity to differentiate
into cells of connective tissue lineages, including
bone, cartilage and adipose tissue cells (24).
MSCs were first identified by Friedenstein,
who reported that they were an undifferentiated
cell population within the adult bone marrow
(25). In addition to generating cells of several
connective tissue lineages, MSCs have the ca-
pacity to differentiate into the stroma that sup-
ports haematopoiesis (26, 27), as is typical of
adult bone marrow.
MSCs are also found within the AGM region,
as shown by an analysis with markers expressed
after cell culture under specific conditions. Al-
kaline phosphatase activity and osteopontin
and osteocalcin expression serve as markers of
osteogenic differentiation, and up-regulated ex-
pression of the peroxisome proliferation-acti-
vated receptor g can be used as a marker for
adipocytes in these studies (22). As is the case
with other cells of the AGM, the MSCs are
likely to originate from the mesodermal tissue
of the embryo, and these cells are thought to be
related to the HSCs through the mesangioblasts
mentioned above (28).
The ability of MSCs to regulate haema-
topoiesis both in culture and in vivo is thought
to be mediated by cell-to-cell contact and the
production of growth factors involved in the
homing, proliferation and differentiation of
haematopoietic cells (29, 30). Recent reports
show that osteoblastic cells provide a critical
microenvironment in the bone marrow to sup-
port the development of HSCs (31, 32).
Despite our increased understanding of the
mesenchymal lineages involved in supporting
the growth of HSCs in adult bone marrow, we
still know very little about the mesenchymal
cells supporting HSCs in the embryo. The pro-
gressive increase in the numbers of HSCs during
development indicates that the haematopoietic
sites, the AGM, fetal liver and neonatal and
adult bone marrow, all provide a microenviron-
ment that supports the generation, maintenance
and proliferation of HSCs (22).
Recent evidence favours the idea that the
AGM may indeed possess the various progeni-
tors that support the generation of HSCs. Cul-
tures from both the embryonic dorsal aorta
Introduction 
 31 
This region develops from the lateral plate mesoderm and is first called para-aortic 
splanchnopleurae (pSP) before it becomes the AGM. Already at E8.5, before the circulation is 
established, the pSP contains progenitor cells with myeloid potential [69]. Before the 
development of HSCs with adult repopulating potential in the AGM at E10.5 [71,72,74,75], 
not only in the pSP but also in other sites of the mouse conceptus such as the yolk sac, 
allantois or placenta, cells with hematopoietic potential were found at specific times. 
Therefore, at least 4 further classes of hematopoietic cells can be defined, before the 
appearance of adult-definitive HSCs, see figure 12 and 14 [76]. 
 
Figure 12: Generation of hematopoietic cells during development of the mouse conceptus 
Shown are four different embryonic days from left to right: E7.5, E8.25, E9 and E10.5. The five different classes 
of hematopoietic cells, defined by their function, are generated at specific time points indicated by arrows. The 
hematopoietic potential of the different classes of definitive HSCs is indicated by the cell type they can give rise 
to (below the line). The pro-, meso-, meta- and adult-definitive classes are derived from hematogenic 
endothelium, while the primitive class is derived from hemangioblasts. At E7.5 and E8.25 the placenta will form 
by the fusion of the outgrowing allantois and the chorion. At E9 the embryo is enveloped in the yolk sac and the 
colonization of the fetal liver by hematopoietic progenitors commences. At E10.5 hematopoietic clusters and the 
first HSCs are found in the dorsal aorta in the AGM region, the vitelline (V) and umbilical (U) arteries (adapted 
from Dzierzak et al., 2008). 
 
While primitive hematopoietic cells are derived from a hemangioblast, the definitive 
hematopoietic cells are generated from a hemogenic endothelium. Already long time ago, the 
hemangioblast was hypothesized as a common origin for primitive hematopoietic and 
vascular cells because of the close physical association of primitive erythrocytes and 
endothelial cells in the developing yolk sac [77]. The hemangioblast is a mesodermal 
precursor whose activity has been detected earliest in the posterior region of the primitive 
streak [78] from where the cells migrate to the yolk sac (see figure 13). Thus, fate decisions to 
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become endothelial or hematopoietic cells are already been made before the blood island 
formation. 
 
Figure 13: Migration of mesodermal cells during early-streak and mid- to late-steak stage in the mouse 
Mesoderm emerging from the primitive streak forms first the extra-embryonic yolk sac and later the allantois in 
the early-steak stage. Red arrows indicate the emigration of mesoderm cells from the primitive streak. Red dots 
indicate blood islands derived from mesodermal hemangioblasts (adapted from Dzierzak et al., 2008). 
 
The process from which the definitive classes of hematopoietic progenitors arise, the 
haemogenic endothelium hypothesis, seems to be related but still distinct to the 
haemangioblast hypothesis. Discrete subsets of vascular endothelial cells seem to show 
hemogenic potential during development [79], indicating an endothelial origin for definitive 
hematopoietic cells. This was further supported by the fact that developing, definitive HSCs 
have specific properties in common with endothelial cells, such as surface marker expression 
or the ability to incorporate acetylated low-density lipoprotein [80]. Furthermore, it was 
possible to visualize in several species cluster of hematopoietic cells budding from the ventral 
wall into the lumen of the dorsal aorta as well as the vitelline and umbilical arteries [81]. 
Other studies have suggested that definitive HSCs originate from the mesoderm/mesenchyme 
adjacent to endothelial cells in the ventral aspect of the dorsal aorta [82] or that mesenchymal 
cell populations in discrete patches ventral-lateral to the dorsal aorta (subaortic patches) poke 
through the aorta and bud off HSCs [83]. Individual cells in the subaortic patches, expressing 
surface marker characteristic for HSCs and displaying reconstitution potential, further 
confirmed this. While the localization of hematopoietic clusters in the chick aorta is strictly 
localized to the ventral wall, it was shown that in mice hematopoietic cluster can be found on 
both the ventral and dorsal endothelium of the dorsal aorta and that both contain 
hematopoietic progenitors, while fully potent HSCs are restricted to the ventral aspect [75]. 
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Figure 14: Timeline of hematopoietic development in mice 
The arrows above the timeline indicate the onset of hematopoietic cell generation and/or appearance in the 
specific parts of the mouse conceptus. Organs that are subsequently seeded by HSCs from the locations above at 
specific time points are shown below the timeline. The circulation is established at 8.25-8.5. Arrows denote the 
earliest time points of hematopoiesis in the associated tissue or organ; bars represent the duration of 
hematopoiesis in that tissue or organ (adapted from Dzierzak et al., 2008). 
 
Following the definitive hematopoietic activity in the AGM starting at E10.5, additional 
activity was detected subsequently in the umbilical artery connecting dorsal aorta to the 
placenta, the yolk sac and the placenta proper [84-86]. HSCs detected in the yolk sac and the 
placenta could arise by de novo generation or expansion of pre-existing HSC populations 
coming from the AGM through the circulation, which is established at E8.25-8.5 (figure 14) 
[87], or both. However, quantitative spatial and temporal analyses of HSCs suggest that both 
yolk sac and placenta contribute to the pool of HSC in the fetal liver [85,86,88], because the 
number of HSCs is to high to be derived only by cells coming from the AGM alone. Most 
likely an additive production of HSCs by AGM, yolk sac and placenta, plus the expansion of 
HSCs in the fetal liver itself, is responsible for the large number of fetal liver HSCs [85,89]. 
While the colonization of the fetal liver starts at E9 with myeloerythroid progenitors that 
generate definitive erythroid cells, the first definitive HSCs appear at E11.5 (see figure 14). 
After E12.5 the fetal liver is the main hematopoietic organ where massive HSC expansion 
takes place. By E15.5-16.5 a plateau with the maximum number of around 1000 HSCs is 
reached and thereafter the HSC number starts to decline [55,85,90]. 
The definitive hematopoiesis is followed by the colonization of the thymus at E11, the Spl at 
E12.5 and finally the BM starting at E15 (see figure 14) [76,91,92]. In none of this 
hematopoietic organs de novo HSC generation takes place [93,94]. It is rather believed that a 
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massive expansion and subsequently differentiation of HSCs occurs, which initially seeds 
these organs. These processes are specifically supported and controlled by the 
microenvironment surrounding the HSCs within the different organs. 
Interestingly, the population of the thymus might originate from the circulation as well as 
from direct migration of HSCs through tissues, as it was suggested by experiments in birds 
showing the migration of progenitors to the thymus along the thoracic duct [95]. 
Before the colonization of the BM a specific, supportive microenvironment for the HSCs has 
to be created. The skeletal development commences at E12.5 with mesenchymal cells first 
giving rise to chondrocytes that create a cartilaginous mold of the skeleton during 
mesenchymal condensation [96]. Calcified bone is subsequently generated, through 
endochondral ossification by osteoblasts (OBs) replacing chondrocytes. Invasion of a vascular 
system into the developing bones facilitates the seeding of hematopoietic cells through the 
circulation. 
6.6. Trafficking of HSCs in the adult organism 
As described in the section above, HSC trafficking is absolutely essential during embryonic 
development for the sequential colonization of different hematopoietic organs to finally build 
a functional life-long hematopoietic system. However, the trafficking of HSCs is not only 
restricted to embryogenesis. Migration and circulation of HSCs is also essential in the adult 
organism during hematopoietic homeostasis [97]. It contributes to innate immune responses, 
reproduction of mature effector cells after hematopoietic injury [98] and is also crucial for 
clinical applications such as BM or stem cell transplantations [99]. In adult mice and humans 
the majority of HSCs reside in the BM. The engraftment of HSCs in the BM during 
organogenesis, after BM transplantation (BMT) and after treatment with chemotoxic drug or 
irradiation refers to a complex multistep process, in which transiently circulating cells become 
resident tissue cells. Furthermore, they refill the entire hematopoietic system by their ability 
to proliferate, self-renew, differentiate and thereby give rise to multilineage progenitors. 
The first step of this process, the specific recruitment of circulating HSCs to the BM, is 
known as “homing” (see figure 15) and refers to the initial interaction of HSCs with the 
microvasculature and their consecutive transendothelial migration, called diapedesis. The next 
step is the interstitial migration of HSCs through the ECM within the marrow, which is an 
active amoeboid movement that can occur independently of blood flow. For this mode of 
trafficking the HSCs need to recognize and respond to extravascular guidance cues. Finally, 
the HSCs lodge in suitable, specific anatomical sites, also termed “niche”, where they 
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establish complex regulatory interaction with their environment that controls their survival, 
proliferation and differentiation. This step is widely termed “lodgement”. 
Homing of HSPCs into the BM is a fast and efficient process, occurring within minutes or 
few hours rather than days [100], and involves a multiple adhesion cascade with similarities 
to the homing process described for mature blood leukocytes into peripheral tissues [101-105] 
controlled by the actions of cytokines, chemotactic factors and cell adhesion molecules 
(CAMs). For the homing of HSPCs into the BM, the cells not only have to recognize BM 
specific endothelial cells in the sinusoids but also have to firmly adhere to them in order to 
resist the constant hydrodynamic shear resulting from the blood flow. In the initial step of at 
least three intravascular adhesion steps [101,106], the fast flowing cells tether and then slowly 
roll along the vascular surface. This slowing down of HSPCs is mediated mainly by the 
endothelial selectins, P- and E-selectin, as well as vascular cell adhesion molecule-1 
(VCAM-1, or CD106), which are expressed on BM microvessels and interact with their 
counter-receptors P-selectin glycoprotein ligand (PSGL)-1 and low affinity α4β1 (very late 
antigen-4, VLA-4) expressed on HSPCs [107]. As the specific expression of these three 
adhesion molecules in a unique side-by-side combination is restricted to the BM [108] and 
only rarely expressed on endothelial cells outside the BM in the absence of inflammatory 
stimulation, it seems that they also function as the specific recognition signal for the BM 
extravasation. Important for this initial binding is a fast binding kinetics, however, their bond 
lifetime is rather short so that in the next step of the cascade a firm adhesion has to be 
established. To adhere firmly, the rolling cells must receive an activation signal that leads to 
conformational changes of integrins, mainly α4β1 but also αLβ2 (lymphocyte 
function-associated antigen 1, LFA-1), which interact with VCAM-1 and intercellular 
adhesion molecule-1 (ICAM-1), respectively [109,110]. The most important chemokine, 
triggering this integrin activation, is the soluble or surface-bound CXCL12 
(CXC-motiv-chemokine 12, also known as stromal-derived factor-1; SDF-1), which is 
sampled by the rolling cells and activates the HSPCs through the Gαi protein-coupled 
receptor CXCR4 (CXC-motiv-chemokine receptor type 4) [111]. In addition, also signals 
mediated by Gαs protein-coupled receptor have been shown to be involved in BM homing 
and engraftment [112]. While the importance of α4β1 during homing is widely accepted, the 
role of α4β7 is not entirely clear. There are reports implicating α4β7 in HSPC rolling [113] 
and the expression of its specific ligand mucosal addressin cell adhesion molecule-1 
(MAdCAM-1) on BM endothelium [114], while others have not found a role of this pathway 
during HSPC homing into the BM [109]. Another adhesion molecule contributing to BM 
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homing of HSPCs is CD44 [115]. It has been shown that CD44 can also bind to E-selectin 
[115] but the major ligand of CD44 is hyaluronic acid, an anionic ECM glycosaminoglycan 
expressed on BM endothelial cells and in the interstitium [116,117]. 
The above-mentioned interaction of CXCL12 with CXCR4 is not only important in homing 
but also plays a critical role for the retention of HSCs in the BM niche, mobilization (see 
below) and as guiding cue during interstitial migration towards the stem cell niche. CXCR4 
mediated downstream signaling involves the activation of phosphatidylinositol-specific 
phospholipase C (PI-PLC) and phosphoinositide-3-kinase (PI3K) that activate protein kinase 
C-zeta (PKC-ζ), which then induces protein tyrosine kinase-2 (Pyk-2) and extracellular 
signal-regulated kinase (ERK) thereby influencing adhesion and chemotaxis of HSPCs 
[104,118]. Following firm adhesion, CXCL12 is also responsible for the integrin-dependent 
diapedesis of HSPCs, although it is believed that also other adhesion molecules such as CD31 
(platelet endothelial cell adhesion molecule-1; PECAM-1) or CD99 may be involved 
[119,120]. 
As described above, the process of HSPC homing shares several similarities with the 
multistep process described for leukocytes but there are also notable differences. For example, 
while E-selectin interacts with α4 integrins during HSC homing, E-selectin closely cooperates 
with P-selectin in neutrophil recruitment to inflamed sites [121]. 
Another interesting point is that the BM homing efficiency of transplanted HSCs can also 
vary according to the cell cycle status of the cell. Several studies showed that the ability of 
phenotypically identical HSCs to engraft irradiated recipients becomes dramatically decreased 
if the cells were activated [122,123]. How and at which point the cell cycle status can 
influence the engraftment process is not yet clear. 
A detailed understanding of the process of BM homing is also essential to improve BMT 
strategies, which is often the only way to treat patients with blood cancers. A successful BMT 
is in first line dependent on the ability of intravenously injected HSPCs to rapidly traffic to 
BM niches. Most HSPCs used for transplantations are obtained from cord blood, having the 
advantage to overcome problems in finding fully human leukocyte antigens (HLA)-matched 
donors in allogeneic BMT [124-126]. However, a potential disadvantage of cord 
blood-derived HSPCs is that their homing potential is less effective than that of HSPCs 
derived from adult BM, increasing the risk of early post-transplant complications. One 
explanation for this problem is the reduced expression of molecules important for homing on 
the surface of cord blood HSPCs [127]. To overcome these problems, transplantation of 
higher numbers of HSPCs is necessary, which is difficult to obtain due to the rare sources of 
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these cells. Other approaches to overcome these problems include improving the homing 
potential, as it was shown that a fast migration of HSPCs into the BM is directly correlated 
with a faster hematopoietic recovery [128]. Therefore, various protocols are used to incubate 
cord blood HSPCs with different cytokine cocktails to enhance the expression of adhesion 
molecules before transplantation [127,129]. 
After HSCs have migrated through the BM intersitium and lodged into their suitable niches 
they may undergo several symmetrical cell divisions to expand their cell numbers before they 
turn from the active cycling stage into quiescence, while still retaining a tightly regulated 
balance between self-renewal and lineage differentiation to maintain the entire hematopoietic 
system [130]. 
 
Figure 15: Migration of adult hematopoietic stem and progenitor cells 
The top of the figure shows the multistep adhesion cascade of HSPCs homing from the blood into the BM. The 
middle part illustrates the trafficking of migratory HSPCs under physiological conditions. Some HSPCs are 
continuously entering the blood circulation from the BM. They then either return to the BM or enter peripheral 
organs which they exit via lymphatic vessels and return into the blood. HSPCs remain in the circulation only for 
a few seconds, while in peripheral tissues they can spend more than 36 h before they enter the draining 
lymphatics in a S1P-dependent manner (shown at the bottom). HSPCs in peripheral tissues can spontaneously or 
under stress conditions (such as infection or tissue necrosis) via Toll-like receptors (TLRs) differentiate into 
immune cells (adapted from Laird et al., 2008). 
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Despite the continuous BM retention signals that HSCs receive from direct and/or indirect 
interactions with different components of their specific niches (in detail discussed below in 
section 6.7), there is always a small but significant fraction of HSPCs found in the blood 
circulation and peripheral tissues (see figure 15) [98,131] indicating that the lodgment into the 
niche is by no means the final stop in the journey of HSPCs. A previous study using a 
parabiosis mouse model, in which two mice are surgically joined so that they share a common 
blood circulation, showed that around 400 HSPCs are constantly circulating in the blood at 
any given time and have the ability to re-engraft the BM and that other or even the same HSC 
are newly released into the circulation. This re-engraftment of HSPCs was observed under 
normal, non-inflammatory, physiological conditions and in the absence of myelosuppressive 
treatment indicating that a HSPC recirculation is important for the maintenance of the 
hematopoietic homeostasis [131]. 
The BM to blood migration, also termed “mobilization” starts with a de-adhesion step of the 
HSPCs from the BM microenvironment. The process is tightly controlled by specialized 
signals modulating chemo-attractant cytokines, growth factors and hormones, which are 
controlling the release from the BM [132,133]. Stromal elements upregulate proteolytic 
enzymes such as matrix metalloproteinase (MMP)-9 and cysteine protease cathepsin K 
leading to the proteolytic cleavage of CXCL12, KitL and VCAM-1 [134-137]. In addition, the 
activation of surface-expressed proteases produced by HSPCs such as the dipeptidase CD26 
leads to the increased cleavage of CXCL12 [138], resulting in the loss of adhesive contacts 
between stromal cells and HSPCs. It has been shown that also certain niche cell types such as 
OCLs are involved in the release of HSPCs after direct cytokine stimulation [136]. 
Interestingly, also the sympathic nervous system (SNS) that innervates bone and BM stromal 
cells has a regulatory influence on the hematopoietic system [139-141]. Previous studies 
showed that the HSPCs released into the circulation follow a circadian pattern in mice with a 
peak of blood HSPCs 5 h after onset of light and a nadir 5 h after darkness. This circadian 
oscillation is regulated by adrenergic signals transduced by the β3 adrenoreceptor, which 
plays a major role in controlling CXCL12 expression, as it results in down regulation of 
CXCL12 and thus promotes the HSPC release [142]. 
Mobilization can also be induced by certain drugs including a variety of cytokines such as 
granulocyte colony-stimulating factor (G-CSF), chemokines such as IL-3, IL-6, IL-8, Mip-1α 
or Groβ and small molecules such as the CXCR4 antagonist AMD3100 [137,143,144]. Most 
commonly used is the mobilization with G-CSF. The G-CSF influences HSPCs trafficking in 
several ways and may involve several cellular targets. For example, G-CSF induces the 
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activation of several proteases such as neutrophil elastase and cathepsin G or the release of 
membrane bound stem cell factor (SCF) through MMP-9 activity [134,135]. It was further 
shown that signals from the SNS also contribute to G-CSF-induced HSPC mobilization via 
β-adrenergic stimuli [141] and that G-CSF mobilization can be enhanced when used in 
combination with AMD3100 [144]. Also antibody-based inhibition of integrins such as α4β1 
or β2 have been shown to induce HSPCs mobilization [145,146]. 
Induced HSC mobilization has an important clinical relevance. For example, HSCs mobilized 
in the PB greatly facilitates their collection for allogeneic stem cell transplantations, 
compared to conventional isolation of HSC directly from the BM. Furthermore, mobilizing 
argents are administered to patients after chemotherapy or BM transplantations to reduce the 
time required of normalizing the numbers of circulating blood cells [147]. 
A few years ago, new, additional migration routes of HSPCs have been discovered by 
showing that BM-derived HSPCs not only travel from the BM into the blood and vice versa 
but also from the blood into multiple peripheral tissues such as liver, kidneys, and lung, 
thereafter into the lymph and from the lymph via the thoracic duct, which is the main draining 
lymph vessel, back into the blood. From the blood they might return into the BM or directly 
repeat the peripheral migration cycle (see figure 15) [98]. It is still not clear if the HSPCs, 
which enter this migration cycle are somehow a specialized subpopulation or if all circulating 
HSPCs have the potential to patrol through peripheral tissues. Furthermore, little is known 
about the regulatory signals controlling adhesive cascades involved in the homing of HSPCs 
from the blood into other tissues than the BM. However, the egress of HSPCs from the 
peripheral tissues seems to depend on sphingosine-1-phosphate (S1P) and S1P receptors, 
which are also involved in the egress of lymphocyte from secondary lymphoid organs into the 
lymph [148-150]. However, there are also distinct difference in entering the lymphatic system 
between HSPCs and mature lymphocytes. While HSPCs enter the system mostly in 
non-lymphoid tissues via the lymphatic vasculature, mature lymphocytes get access to the 
lymphatic vasculature by homing to lymphoid organs. 
A gradient of S1P exists between the peripheral organs and the lymphatic vessels, with 
highest concentration in the lymph and lowest in the tissues of peripheral organs [151,152]. 
This S1P gradient is formed and maintained by the S1P lyase, degrading S1P in the tissues 
[153]. HSPCs follow this gradient to leave the peripheral organs (see figure 15). 
Although the biological reason for this migration of HSPCs through peripheral tissues is not 
entirely clear, there is evidence that these cells might provide a rapidly recruitable source for 
local production of immune and inflammatory effector cells. Stress signals mimicking an 
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inflammation, induced by Toll-like receptor 4 (TLR4) agonists, led to diminished S1P 
receptor expression on HSPCs resulting in their prolonged retention in peripheral organs 
providing the necessary time for HSPCs to differentiate into immune cells. Mouse HSPCs 
express TLRs (e.g. TLR2 and TLR4) [132,154], which can recognize foreign molecules such 
as the bacterial outer membrane component, lipopolysaccharide (LPS) [155]. Binding of LPS 
to TLRs on HSPCs leads to their activation shifting them from quiescence into the cell cycle 
and finally differentiation into myeloid cells including several subsets of monocytes, 
macrophages, and DCs [156]. In this way the locally generated HSPC-derived leukocytes not 
only participate in classical innate immune responses but also contribute to the suppression of 
local infection and elimination of dead cells. 
6.7. Hematopoietic stem cell niche 
HSCs are the best characterized somatic adult stem cells today and are often used as a 
paradigm for other types of stem cell. However, despite this knowledge their exact 
localization within the BM is not fully resolved, which is mainly due to the complex structure 
of the BM compared to other tissues such as the skin, intestine, muscle or brain, where the 
localization of stem cells is well identified and described. 
The stem cell “niche” is defined as specialized cellular and molecular microenvironment 
surrounding a stem cell that is together with stem cell autonomous mechanisms involved in 
the regulation of their functions including a tightly regulated balance between self-renewal, 
proliferation, differentiation and quiescence as well as the activation of specific cellular 
programs in response of hematopoietic stress (e.g. bleedings). The concept of the HSC niche 
was first proposed by Schofield in 1978 [157] and has remained largely undisputed until 
today, although it markedly evolved. The concept of the niche includes specific anatomically 
and functionally defined locations with several cell types, soluble molecules, gradients and 
signaling pathways, as well as physical components, such as shear stress, temperature and 
oxygen levels, see figure 16 [158-163]. 
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Figure 16: Model showing two localizations for HSCs in the mouse BM interstitium 
The left side depicts the endosteal niche harboring quiescent LT-HSCs. The right side shows the 
perivascular/vascular niche thought to be in more distance to the endosteum and next to sinusoids promoting the 
self-renewal of active HSCs. For details see the main text (adapted from Ehninger et al., 2011) [164]. 
 
Two different areas within the BM are discussed as HSCs niches: the endosteal and vascular 
niche. The endosteal niche is located near the endosteum in the trabecular or cortical bone. 
The endosteum is the inner surface of the bone and in immediate proximity to the BM. A cell 
layer containing mature cells but also precursors, heterogeneous in their degree of 
differentiation, of bone forming OBs and bone-resorbing OCLs, covers the endosteal surface. 
In contrast, the vascular niche is located around sinusoids, which are reticular fenestrated 
venules that predominantly compose the vascular bed of the BM. Although the exact location 
of HSCs is still controversial [165] (discussed below) there is evidence that single quiescent 
HSCs are predominantly located in the endosteal niche, while activated HSCs are in closer 
contact to sinusoids [166]. 
OBs were one of the first cell types identified as niche components involved in HSC 
regulation in vivo by two independent studies showing that the number of HSCs is increased 
by the expansion of OBs, thereby enlarging the HSC niche, through the activation of 
parathyroid hormone/parathyroid-hormone-related peptide (PTH/PTHrP) receptors (PPRs) 
[167], or through the conditional deletion of the bone morphogenetic protein 1a (BMP1a) 
receptor [168] in the BM. This indicates that PTH and BMP signaling influence the number of 
HSCs by regulating the niche size. In addition, the deletion of osteoblastic cells in a 
transgenic mouse model results in a 3- to 10-fold decrease in primitive hematopoietic cells 
[169]. 
Introduction 
 42 
Contrary to these studies, other data revealed that OBs are not essential for the function of 
stem cells. One report showed that biglycan-deficient mice have reduced OBs but no 
alteration in the numbers of HSCs [170] and the increase of OBs by strontium chloride 
exposure did not lead to an increase in HSC numbers in mice [171]. A possible explanation 
for the discrepancy between these studies could be the use of different mouse models or the 
heterogeneity of OB differentiation stages. It is possible that only a small subpopulation of 
OBs with a certain degree of differentiation is influencing hematopoiesis and the different OB 
subtypes have a differential sensitivity to biglycan or strontium. 
However, there are several reports indicating that molecules expressed on or secreted from 
OBs are involved in HSC regulation. Most controversially discussed is the function of 
N-cadherin in the regulation of HSCs [170,172]. On the one hand, use of 
5-bromo-2'-deoxyuridine (BrdU) label-retaining assays indicated that label-retaining, 
slow-cycling HSCs localized near a specialized subpopulation of OBs expressing N-cadherin, 
spindle-shaped N-cadherin+ osteoblastic (SNO) cells. HSCs also express N-cadherin on their 
surface, where it interacts and forms a homophilic adhesion complex with β-catenin 
[171,166][168,173]. Furthermore, transient knock-down of N-cadherin increased cell division 
of HSPCs in in vitro experiments and inhibited long-term engraftment of HSPCs after 
transplantation [174]. Contrary to these findings, it was not possible to detect N-cadherin by 
using two commercially available antibodies or by using a N-cadherinlacZ/+ gene trap mouse 
[170]. The same group further showed that the conditional deletion of N-cadherin in 
hematopoietic cells using the Mx1-Cre+N-cadherinfl/+ mouse model did not lead to reduced 
HSC frequencies. They also observed no defects in the engraftment of HSCs isolated from 
Mx1-Cre+N-cadherinfl/+ mice after N-cadherin deletion [175]. According to these conflicting 
findings, it is still not clear if N-cadherin plays a critical role in HSC regulation. 
Further, it was shown by transplantation experiments with HSCs into tm-SCF deficient mice 
that the interaction of transmembrane-stem cell factor (tm-SCF), also termed 
membrane-bound kit ligand (mKL) and its specific receptor c-kit on HSCs are essential for 
HSCs localization into the endosteal niche [176]. 
OBs also secrete several factors that are important for the regulation of HSCs in the endosteal 
niche. The interaction between angiopoietin-1 (Ang-1) expressed on OBs can induce HSC 
quiescence through the interaction with its specific receptor Tie2 (tyrosine kinase with 
immunoglobulin-like and EGF-like domains 2) on HSCs and enhance the long-term 
repopulation capacity of HSCs in vivo [177]. The cytokine thrombopoietin (TPO), which is 
also released from OBs, binds to the myeloproliferative leukemia virus oncogene (MPL) 
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receptor on HSCs and thereby positively regulates HSC quiescence and survival. HSCs 
lacking MPL exhaust with time due to overproliferation and loss of quiescence. In addition, 
blocking of TPO signaling in OBs leads to a reduction of quiescent HSCs, while exogenous 
TPO inhibits HSC proliferation [178]. 
The interaction between CXCR4 on HSCs and CXCL12, which is manly secreted from 
stroma cells in the vascular niche, but also at lower amounts by OBs, is essential for the 
localization, retention and quiescence of HSCs in the niche [164]. Furthermore, the fibroblast 
growth factor-1 (FGF-1) secreted by niche cells is involved in the regulation of HSCs by 
promoting stem cell self-renewal and expansion [179] through FGFR1-4 mediated activation 
of several signaling pathways such as the mitogen-activated protein kinase (MAPK) pathway, 
STATs (signal transducer and activator of transcription) and PI3K [180]. 
Additionally, the ECM molecule osteopontin (OPN) is also produced by OBs. HSCs can 
interact with OPN through CD44 and β1 integrins and thereby are retained in the endosteal 
niche. This interaction is suggested to further enhance HSC quiescence as it negatively 
regulates proliferation and differentiation of HSCs, which was shown by markedly enhanced 
cycling of HSCs in Opn-/- mice [181]. Another important regulatory factor for HSC in the 
endosteal niche are extracellular calcium ions (Ca2+), which can be sensed by HSCs through 
the calcium receptor (CaR). The expression of the CaR on HSCs is important for their 
localization in the endosteum, probably by regulating the interaction of HSCs with collagen I, 
as CaR null mice show a defective homing of HSCs to the endosteal niche and reduced in 
vivo long-term engraftment capacity [182]. The MUC-1 mucin can initiate calcium signaling 
through binding to ICAM-1 [183] and could therefore also play a role in the interaction 
between HSCs and their niche. 
Various cell types other than OBs located in the endosteal niche have also been shown to play 
a role in HSCs regulation. For example, stimulation of OCLs with receptor activator of 
nuclear factor kappa B ligand (RANKL) mobilizes HSCs into the PB [136]. However, more 
recent data indicate that the influence of OCLs on HSCs must be rather indirect, by 
influencing other niche components such as OBs, as RANKL-deficient mice showed no 
increased mobilization of HSCs [184]. Furthermore, a specialized group of F4/80+ 
macrophages, termed osteomacs, are located in the endosteal region. Deletion of osteomacs 
reduced the number of OBs and induced mobilization of HSCs into the PB [185]. 
Megakaryocytes might also have an indirect influence on HSCs by regulating the 
development of OBs within the endosteal niche [186]. Adipocytes, located in the endosteal 
niche, seem to have a negative influence on the HSC function and maintenance [187]. Finally, 
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input from the SNS influences OBs and seems to be required for HSC attraction to the 
endosteal niche [141]. 
The identification of the “SLAM code” (signaling lymphocytic activation molecule) [45,188], 
which combines the use of antibodies against CD150 (SLAMF1) and CD48 together with 
commonly used antibodies for the identification of HSCs (described in section 6.4), as novel 
HSC marker revealed that around 70% of CD150+CD48- HSCs are located to or within 5 cell 
diameters from endothelial or perivascular cells [188]. This was the first proof for the 
existence of the vascular niche as supportive microenvironment next to the previously 
described endosteal niche. Several cell types including perivascular mesenchymal stem cells 
(MSCs), especially nestin+ MSCs, CXCL12-abundant reticular cells (CAR cells) and neuronal 
cells are essential for the regulation of HSCs in the perivascular space [189-192]. MSCs are 
thought to give rise to different niche cell types such as OBs, chondrocytes, adipocytes, 
fibroblasts, and endothelial cells, but are also directly involved in HSC regulation [168,193]. 
Nestin+ MSCs are strictly perivascular but are also found in the endosteum, albeit at lower 
frequencies and therefore, could also influence the regulation of HSCs in the endosteal niche. 
Nestin+ MSCs express HSC maintenance factors such as CXCL12, SCF, Ang-1, IL-7, 
VCAM-1 or OPN. Depletion of Nestin+ MSCs in mice resulted in a reduced number of HSCs 
in the BM and also in a diminished homing efficiency of wt HSCs into the BM [189]. CAR 
cells are found close to sinusoids in the BM and express CD44, VCAM-1, platelet-derived 
growth factor receptor (PDGFR)-α and PDGFR-β, and secrete SCF and CXCL12. 
Furthermore, CAR cells can also differentiate into OBs and adipocytes [191]. It is 
hypothesized that CAR cells regulate the proliferation of HSCs rather than their quiescence as 
deletion of CAR cells in a mouse model led to a decreased total number of HSCs by reducing 
the number of cycling HSCs as well as cycling lymphoid and erythroid progenitors [191,192]. 
It has been shown that not only the stroma cells surrounding the vasculature, but also the BM 
sinusoidal endothelial cells themselves influence HSCs [194]. Therefore, some reports 
distinguish a perivascular niche from a pure vascular niche. Recently, it has been shown that 
the nonmyelinating Schwann glial cells located in the vascular niche are important for HSC 
quiescence by regulating the activation of latent TGF-β that is critical for the TGF-β/Smad 
signaling in HSC maintenance [190]. Not only the direct influence from niche components on 
HSCs is essential for their regulation, but also the crosstalk between different niche cells is 
important for the regulatory properties of the entire niche: it was shown that CD169+ 
macrophages regulate CXCL12 levels and cross talk with nestin+ niche cells promoting the 
retention of HSCs in the niche [195]. 
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The contradictions within the literature regarding differential functions of the vascular and 
endosteal niche indicate that the models based on anatomically separated niches are not able 
to fully explain the complex regulatory influences of the environment on HSCs. Rather, the 
available data today indicate that a single HSC receives input from multiple, distinct niche 
cell types at different location at different stages of development and that HSCs may even be 
able to move quite readily between these locations. Recent real-time 3-dimensional (3D) 
imaging studies indicated that HSCs reside in a complex meshwork with both vascular and 
mesenchymal components of the BM indicating that the vascular and endosteal niche 
components are intimately entwined within trabecular bone, being in a close relationship 
rather than mutually exclusive [196,197]. However, it seems that the interplay between the 
vascular and endosteal niche will remain a point of intensive discussion, at least for the near 
future [165]. 
Furthermore, it is well accepted that in addition to cell-cell contacts also the interaction with 
ECM components associated with either niche type regulates HSC functions. ECM proteins 
secreted from stroma cells build up a 3D network, which includes the above-mentioned OPN 
and in addition fibronectins, laminins, collagen types I, III, and IV, vitronectin, 
thrompospondin, hemonectin, hyaluronic acid, and various proteoglycans. Several of these 
proteins are located in distinct areas of the BM intersitium [198], which is an indication that 
they might have different regulatory effects for HSCs during homing and lodgment. However, 
most of the data showing a role of ECM proteins in HSC regulation are based on in vitro 
co-culture experiments with HSC and stroma cells after elution of the BM, which have the 
disadvantage that they only weakly reflect the complex structure of the BM intersitium. One 
study showed that the adhesion of HSPCs to fibronectin varied with the cell lineage and the 
maturation stage of the cells [199]. Further it was shown that the disruption of the interaction 
between α5β1 and fibronectin results in a decreased engraftment into the BM [200]. 
Transplantation experiments with HSCs, which were prior treated with hyaluronidase to 
remove the hyaluronic acid, resulted in alteration in HSC lodgment at the endosteum arguing 
for a regulatory function of hyaluronic acid, which was further confirmed in in vitro 
experiments [201]. As it is not possible for most ECM components to remove them from the 
BM in vivo, little is known about the function of different ECM proteins on the regulation of 
HSC quiescence or long-term maintenance. 
The niche also protects HSCs from damage by reactive oxygen species, which is important 
for their long-term survival and repopulation potential [202,203]. It is suggested that the BM 
intersitium is hypoxic (low oxygen levels) due to low blood perfusion [204]. According to 
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this theory, the localization of LT-HSCs in hypoxic regions was investigated by their 
distribution between areas with lower or higher blood perfusion measured with the fluorescent 
dye Ho after injection into mice. After a certain period of time, cells next to the vasculature 
with a high blood perfusion, were more stained with Ho than cells in regions with poor blood 
perfusion. Transplantation experiments into lethally irradiated mice were performed to 
investigate the properties of HSCs with low or high Ho signal. The results indicated that cells 
with lowest Ho uptake inferred to be hypoxic had the highest long-term repopulation potential 
[205]. These and other reports argue that quiescent HSCs are predominantly located in areas 
containing hypoxic sinusoids within the endosteum [206,207]. 
The BM niche also expresses several developmental factors, which are important for the 
regulation of HSC self-renewal, such as components of the Smad, Wnt, sonic hedgehog 
(Shh), and Notch pathways [208]. The Smad signaling pathway transduces signals from 
receptor complexes activated by ligands of the TGF-β superfamily, including TGF-β itself, 
activins, nodal and BMPs. Both, HSCs and niche cells secrete TGF-β. In vitro experiments 
showed that TGF-β is a potent inhibitor of HSPCs proliferation [209]. However, whether 
TGF-β is a regulator of HSC quiescence under physiological in vivo conditions is unclear, as 
there is an apparent discrepancy between in vitro and in vivo data. Studies inducing a 
conditional deletion of TGF-β type I or II receptors using a Mx1-Cre driver line showed no 
effect on HSPC numbers, their cell-cycle distribution or self-renewal properties [210-212], 
indicating that TGF-β signaling is not important for the maintenance of HSC quiescence in 
vivo. Furthermore, BMP-4 had no effect on the proliferation of purified murine HSCs [213]. 
On the other hand, in vivo experiments with a conditional deletion of the intracellular 
mediator Smad 4 impaired the self-renewal properties of HSPCs [214], which was not 
observed in TGF-β type I or II receptor knock-out mice. This argues for the existence of other 
ligands and receptors important for the HSC regulation that induce the Smad pathway. 
In vitro treatment of HSPCs with Wnt ligands led to their expansion and maintained their 
immature phenotype [215] indicating that the Wnt/β-catenin pathway is important for HSC 
maintenance and self-renewal. Wnt signaling can be mediated via a β-catenin-dependent 
(canonical) pathway or β-catenin-independent (non-canonical) pathway. In HSCs the 
canonical Wnt pathway mediates the majority of Wnt signaling. Wnt ligands are secreted 
from niche cells and interact with a receptor complex on HSCs, wich consists of Frizzled 
(Frz) and two co-receptors, low-density lipoprotein-receptor-related protein 5/6 (Lrp5/6), 
leading to the stabilization and nuclear transolcation of β-catenin, where it binds the 
transcription factor (Tcf) and Lymphoid enhancer-binding factor (Lef) to induce the 
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transcription of target genes such as cyclinD1 and c-Myc. Data from in vivo experiments are 
less clear regarding the role of Wnt signaling for HSC regulation. Constitutive active nuclear 
β-catenin signaling activated HSCs, increased their proliferation and blocked their 
differentiation leading to HSC exhaustion [216,217]. More recently it was shown that 
non-canonical Wnt signaling through the interaction between Flamingo and Frz 8 on HSCs 
occuring in close proximity to N-cadherin+ OBs is important for the maintenance of HSC 
quiescence [218]. Furthermore, the overexpression of the Wnt-inhibitor Dickkopf-1 (Dkk1) in 
OBs results in a increased proliferation and reduced in vivo repopulating ability of HSCs 
[219] indicating that Wnt signaling in the niche is crucial to maintain HSC quiescence. These 
reports argue that the fine-tuning of Wnt/β-catenin activity can have different (positive as well 
as negative) effects on the maintenance of HSC long-term quiescence [220]. In contrast, there 
are reports showing in in vivo experiments that Wnt signaling is dispensable for adult HSC 
homeostasis, as conditional deletion of β-catenin or both β-catenin and its homolog γ-catenin 
in hematopoietic cells failed to affect HSC numbers, their self-renewal or engraftment 
potential [221,222]. These discrepancies make it difficult to value the importance of the Wnt 
signaling pathway for the in vivo regulation of HSCs. 
The importance of the Notch signaling pathway for HSC maintenance is also controversial. 
First indications that the Notch pathway has a regulatory influence in the development of the 
hematopoietic system came from mice in which Notch-1, the ligand Jagged-1 or the 
coactivator protein C-promoter-Binding-Factor-1 (CBF-1) were deleted. The mutant mice had 
defects in embryonic HSC development [223-225]. It has also been shown that Notch 
signaling is involved in the regulation of the adult hematopoiesis. In several different in vitro 
experimental settings it was shown that induction of the Notch signaling pathway leads to an 
expansion of HSPCs [226-228]. The importance of Notch for the maintenance of 
undifferentiated HSPCs was further supported by in vivo data showing that activation of the 
Notch pathway increases HSC activity and is required for the increased self-renewal upon 
Wnt activation [229]. Furthermore, expression of activated Notch in HSPCs resulted in 
enhanced HSC self-renewal and decreased differentiation in recipient mice [230]. In contrast, 
another report showed that conditional deletion of Jagged-1 alone or together with Notch-1 in 
hematopoietic cells and/or BM stromal cells had no effect on HSC regulation in mice [231]. 
Also experiments with mice expressing dominant-negative forms of Notch signaling 
inhibiting Mastermind-like1 (MAML-1) and CBF-1in hematopoietic cells had no influence on 
HSC frequency, total numbers or function [232]. Altogether these results postulate a 
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debatable role of the Notch signaling pathway in the maintenance of adult HSCs by limiting 
their proliferation and differentiation. 
Also the data about Shh signaling for HSCs is controversial. While HSCs cultured in vitro 
with Shh promotes their proliferation [233], in vivo data are contradictory. Deletion of the 
receptor Smoothened (Smo), which is a key signal transducer in the hedgehog signaling 
pathway, had no defects on the lineage differentiation of HSCs but reduced their 
reconstitution potential in serial transplantations [234,235]. Deletion of the transcription 
factors Glioblastoma-1 (Gli-1) increased the HSC pool [236] and decreased expression of the 
hedgehog receptor Patched (Ptch1) in mice also results in increased numbers of HSPCs due to 
elevated proliferation and led to a higher short-term but lower long-term reconstitution 
potential of lin- cells [237]. These results argue for a function of Shh signaling in maintaining 
HSC self-renewal but rate under conditions of hematopoietic stress such as serial 
transplantation than under homeostatic condition. Contrary to this finding, there are reports 
showing that Shh is not essential for the regulation of HSC maintenance as adult mice with a 
conditional deletion of Smo in hematopoietic cells had no defects in the HSC compartment 
during steady-state hematopoiesis, after transplantation, or after induction of hematopoietic 
stress with a 5-FU treatment [238,239]. 
The extrinsic cues essential for the regulation of the HSC homeostasis are highly complex and 
require a bidirectional communication between the HSCs and niche components. The junction 
between a HSC and its niche cells can also be compared to the complex and tightly regulated 
processes taking place at a neuronal or immunological synapse. Therefore, in some reports 
this adhesion and signaling unit is also termed stem-cell–niche synapse [240]. Figure 17 
summarizes the most important ligand-receptor interactions between HSCs and niche cells. 
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Figure 17: Model of the interaction processes between a HSC and a niche OB 
Shown are the most important ligand–receptor interactions, adhesion molecules, soluble cytokines and growth 
factors as well as signaling pathways, which have been postulated to play a role in the regulation of HSC 
maintenance by a delicate balance between HSC self-renewal and differentiation. The complexity of the 
interaction between the HSC and niche cells underlines how important a precise localization with a certain 
distance to the niche components is for correctly responding to the signals from the niche. It is important to note 
that the interactions are bidirectional indicating that HSCs can also modulate their microenvironment. For details 
see the main text (adapted from Wilson et al., 2006). 
 
Regarding this complexity within the stem cell niche it is easily conceivable that the precise 
positioning of the HSC within the niche is absolutely critical for correct interactions with 
membrane bound ligands as well as exposure to certain thresholds and gradients of soluble 
regulatory factors released from niche cells. HSCs express a wide variety of adhesion 
molecules mediating not only the homing and lodgment of HSCs after transplantation but also 
by indirectly mediating HSC homeostasis via positioning HSCs in the niche and by directly 
mediating regulatory signaling pathways. The most important adhesion molecules on HSCs 
are therefore discussed in the next section. 
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6.8. Adhesion Molecules on HSCs 
To secure an orderly progression of hematopoiesis a tightly coordinated interaction between 
HSPC and their surrounding microenvironment is absolutely essential. Therefore, HSPCs 
express a wide variety of adhesion molecules, which mediate cell-cell and cell-ECM 
interactions required for their homing into the BM interstitium and residence in the BM niche. 
They further play an important role for HSC survival, death, specific gene expression, 
proliferation, differentiation and quiescence. Signaling pathways that are regulating HSPC 
behavior could be either activated directly by the adhesive interactions themselves or by 
modulating responses to cytokine- or growth factor-dependent signals [241-243]. Vice versa, 
cytokines and growth factors can modulate the adhesive interactions between HSPCs and 
their environment, thereby providing a further possibility to influence the hematopoietic 
system [244]. First evidence for a contact dependent inhibition of the HSPC proliferation 
came from in vitro experiments where CD34+ HSCs were co-cultured with stroma cells. The 
proliferation of HSCs was inhibited when they were in direct contact with the stroma cells, 
whereas an increased proliferation occurred when the direct contact was prevented [241,245]. 
More than 20 different CAMs have been discovered on HSCPs [246] making it difficult to 
reveal the specific contribution of each single molecule on the regulation of HSPCs as an 
extensive crosstalk is known to occur between them. CAMs on HSPCs and their 
microenvironmental cells include members of the integrin family, CD44, selectins, cadherins, 
sialomucins and the immunoglobulingene superfamily, see figure 18. 
 
Figure 18: Cell adhesion molecules (CAMs) and ligands expressed on HSCs and stromal cells 
α4β1 (VLA-4, CD49d/CD29), α5β1 (VLA-5, CD49e/CD29), α6β1 (CD49f/CD29), αLβ2 (LFA-1, CD11a/CD18), 
Sialophorin (CD43), P-selectin glycoprotein ligand-1 (PSGL-1, CD162), Sialomucin core protein 24 (CD164), 
Thy-1 (CD90), c-kit (CD117) (modified from Lam et al., 2010) [247]. 
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The classical cadherins namely E-, P-, VE- and N-cadherin are single-pass transmembrane 
glycoproteins and the major CAMs, mediating Ca2+-dependent cell-cell adhesions in a 
homophilic manner. The expression pattern of the different cadherins is temporally and 
spatially restricted during development and in adult tissues. E- and P-cadherin are often 
co-expressed but they do not co-express with N-cadherin [173]. While the expression of 
N-cadherin on stromal cells e.g. OBs has been shown [168,218] the expression on adult HSCs 
as well as the contribution of N-cadherin for the development and maintenance of HSPCs is 
controversially discussed (see section 6.7) [170,172,173,175]. 
CD44 binds to hyaluronate and is expressed on almost all hematopoietic cells [248]. The 
receptor further cooperates with β1-integrins to promote adhesion of HPCs to fibronectin 
[249]. 
The family of selectins contains three proteins, E- (endothelial, CD62E), L- (leukocyte, 
CD62L) and P- (platelet, CD62P) selectins [250]. Selectins predominantly play an essential 
role in leukocyte trafficking, but there is also evidence that they are important for the homing 
of HSPCs into the BM. HSPCs express L-selectin [251] but L-selectin-/- mice have no obvious 
HSC defect [252]. Furthermore, E-selectin-/- and P-selectin-/- mice or different combination of 
double as well as the triple knock-out mice have no severe HSC phenotype [253,254]. 
In addition, ten different sialomucins have been found on HSPCs including the stem cell 
antigen CD34 [251], PSGL-1 [255], CD43 [256], CD164 [257] and CD45RA [258]. The 
sialomucins are involved in HSPC adhesion to the BM microenvironment thereby negatively 
regulating their proliferation and/or differentiation. CD34 was the first sialomucin described 
on HSPCs [259] and might play a role in HSPC adhesion [260]. CD34 deficient mice have a 
decreased number of HSPCs in the yolk sack and in fetal livers probably due to a premature 
differentiation [261]. PSGL-1 is the receptor for P-selectin on HSPCs and is involved in the 
adhesion of HSPCs to endothelial cells during processes such as homing into the BM [262]. 
In addition, CD164 might have a function during HSPC adhesion and homing, as this receptor 
is not only expressed on CD34+ and BM stroma cells but also on the endothelium [263]. 
Engagement of CD164 on CD34+ cells prevents the activation of quiescent HSCs after 
cytokine stimulation, an indication of a regulatory function for HSPC proliferation [264]. 
How sialomucin transmit their regulatory signals on HSPCs is not yet clear but additional 
signaling and/or adaptor proteins must be required as the cytoplasmic tails of sialomucins lack 
enzymatic activity [265]. 
HSPCs also express a wide variety of integrins including αvβ3, α4β1, α2β1, α5β1, α6β1, αLβ2, and 
α9β1 [266]. An essential role in HSPCs homing to and migration through the BM interstitium 
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as well as HSPC retention in the BM niche, has been reported for β1 integrins, particularly 
α4β1 and α5β1, by several groups [111,200,267-270]. The importance of β1 integrins for the 
development of a normal hematopoietic system has been shown in β1 integrin deficient mice. 
By injection of β1-deficient ES cells into wt blastocysts it was possible to generate 
β1-deficient chimeric mice, in which β1-deficient hematopoietic progenitor cells were not 
able to colonize the fetal liver or to be retained in the fetal liver microenvironment [268]. 
Furthermore, it was shown that β1-deficient HSPCs were not able to engraft adult mice after 
irradiation, confirming the importance of β1 integrins for HSPC trafficking [269]. However, if 
β1 integrins are deleted in HSPCs after the engraftment was completed, no obvious defects in 
the hematopoietic system were observed under steady state conditions [271], which might be 
explained by the fact that under normal homeostasis other adhesion molecules, most likely 
further integrins, are sufficient to maintain normal hematopoiesis. The α4β1 integrin on HSPCs 
mediates both cell-cell and cell-ECM interactions by binding to VCAM-1 on other cells or by 
binding to at least three distinct sites on FN [272,273], while α5β1 only binds to the 
Arg-Gly-Asp-Ser (RGDS) binding domain of FN [274]. Disruption of the α5β1 leads to 
reduced BM engraftment of HSCs [200]. Homing and engraftment defects were also 
demonstrated for α4 deficient HSPCs [110,267,275-277], but with reduced severity compared 
to β1-deficient cells. Furthermore, it was shown that α4-deficient HSPCs were differently 
located in the BM interstitium after homing compared to wt HSPCs [278], underlining the 
importance of integrins for a precise HSCs localization in the BM niche. Additionally, it has 
been shown in several reports that the interaction between β1 integrins and its ligands is 
important for the regulation of HSPCs mobilization into the PB [275,279-281]. 
High affinity states of integrins cannot only be transiently induced by direct ligand binding, a 
process called outside-in signaling (described in section 6.9.2) or by cross talk with activated 
receptors for cytokines and/or chemokines, a process called inside-out signaling (described in 
section 6.9.1). It has been shown that TPO, CXCL12, IL-3 and SCF all can activate α4β1, 
leading to an increased adhesion of HSPCs to BM stroma cells [282]. 
The integrin-mediated interactions of HSCs with their environment are not only important for 
HSC localization but also for HSC proliferation, as β1 integrin mediated adhesion to stroma 
cells inhibits HSPCs proliferation [242,283]. This was also shown by several in vivo studies 
investigating signaling pathways important for maintaining HSC quiescence. For example, 
quiescence mediating signaling pathways such as Tie2/Ang-1 or MPL/TPO induce 
upregulation of β1 integrins on LT-HSCs, thereby leading to an increased adhesion of HSC 
on niche components [177,178]. Furthermore, c-Myc, which is important for controlling the 
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balance between HSC quiescence and proliferation, regulates the expression of integrins. 
Forced c-Myc expression in HSCs reduces the expression of integrins. Quiescent HSCs, 
therefore, express low levels of c-Myc and are retained in the niche by upregulation of 
integrins. Activated HSCs downregulate their integrin expression, due to increased c-Myc 
levels, resulting in the departure from the niche [284]. Also the interaction of α4β1 and α9β1 
integrins on HSCs with thrombin-cleaved OPN (trOPN) within the endosteal region functions 
as a chemoattractant for HSCs and is important for the suppression of the HSC proliferation 
by regulating their lodgment into the BM niche after transplantation [181,285]. This was 
further confirmed by OPN-deficient mice, in which the lack of OPN results in an impaired 
retention of HSCs in the endosteal BM niche [266]. These findings indicate that regulation of 
hematopoiesis may be maintained by the combined effects of cytokines and chemokines 
together with contact mediated interactions. 
There are also reports postulating that β2 and β3 integrins are expressed on HSCs. The 
interaction of β2 integrins with their specific ligand ICAM-1 might also be involved in 
mediating adhesion of HSC within the BM niche [286] and during HSPCs mobilization into 
the blood circulation [287,288]. The β3 integrin was discussed as a potential HSPC marker, as 
HSPCs with a SP phenotype (explained in section 6.4) also express higher amounts of β3 
integrin. However, its function on HSPCs is not clear [289]. 
Like most adhesion receptors, integrins do not have an intrinsic catalytic activity; therefore 
recruitment of non-receptor kinases is necessary for the activation of signaling pathways 
[290]. For signal transduction integrins activate focal adhesion kinase (FAK) or the related 
PYK-2 [291], which activate adaptor proteins containing a Src-homology domain (SH)-2 and 
SH-3, thereby activating the PI3K pathway and/or the Ras/MAPK pathway [292]. Both 
signaling pathways regulate cell growth, proliferation, differentiation and survival. How 
sialomucins, CD44 and selectins mediate signaling is not that well understood. 
6.9. Integrin Structure and Function 
Integrins are receptors with dual function mediating both adhesion (cell-cell or cell-matrix 
adhesion) and signaling, thus enabling the cell to bind and respond to the environment. They 
are heterodimeric type I transmembrane glycoproteins consisting of non-covalently associated 
α and β subunits [293]. The integrin protein family is evolutionary highly conserved from 
sponges to mammals [294]. In mammals there are 18 different α and 8 β subunits, which form 
at least 24 functional αβ heterodimers [293], see figure 19. Integrins can be grouped in four 
major classes by their ligand binding properties although there is a significant overlap in 
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binding e.g. the same ligand can be recognized by several different integrin heterodimers and 
one integrin heterodimer can bind several different ligands (figure 19) [295]. An additional 
level of complexity arises from different splice isoformes and distinct developmental and 
tissue expression profiles [295,296]. For example, the β1D isoform is expressed in muscle 
and heart, while β1A isoform is expressed in remaining tissues. Therefore, deletion of β1A in 
mice cannot be compensated by expression of β1D isoform [297]. 
The name integrins refers to their imminent role in maintaining the cytoskeletal-ECM 
integrity [298,299]. All integrins link ECM to the actin cytoskeleton with exception of α6β4, 
which connects ECM to intermediate filaments. Integrins provide a bidirectional connection 
across the cell membrane thereby linking the cell interior with the extracellular environment. 
Upon ligand binding integrins can transduce a variety of signaling events to regulate 
numerous cellular processes such as adhesion, proliferation, survival, apoptosis, cell shape, 
polarity, motility, gene expression, and differentiation, most of which depends on the ability 
of integrins to modulate the cytoskeleton [300]. 
 
Figure 19: The integrin family 
Indicated are 18 α and 8 β subunits that are able to form 24 different integrin heterodimers known to be 
expressed in mammals. Highlighted are ligands specific for certain integrin subgroups (adapted from Hynes, 
2002). 
 
The function of integrins is tightly related to their structure. Each subunit is a type I 
transmembrane protein with an extracellular domain, consisting of 700 to 900 amino acids, a 
single transmembrane helix and a cytoplasmic domain, containing 10 to 70 amino acids. The 
exception is β4 integrin with a 1074 amino acids long cytoplasmic tail [301]. In an inactive 
heterodimer the α-β subunits are connected via hydrophobic and electrostatic interactions 
formed between the KπGFFKR sequence (π standing for a conserved apolar amino acid) in 
the α and the HDR(R/K)E motif in the β subunit [302,303]. It has been postulated that the 
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arginine residue in the α subunits and the aspartate residue in the β subunits form a salt 
bridge, at least in some heterodimers [304,305]. 
The cytoplasmic domain of integrins lacks enzymatic activity as well as actin binding motifs 
and therefore, depends on the binding of other molecules to mediate processes such as signal 
transduction and/or coupling to the cytoskeleton. The cytoplasimc tail of the β subunit 
contains two NPxY motifs, which are part of a canonical recognition sequence for 
phosphotyrosine-binding (PTB) domains, present in a large number of proteins [306]. 
Most of our structural knowledge about the transmembrane domains of integrins comes from 
studies of αIIbβ3 integrin [307]. The β3 transmembrane domain forms a 30 amino acid long α 
helix, which is longer than the average thickness of membrane lipid bilayer suggesting that 
this structure is tilted within the membrane. The αIIb transmembrane domain forms a 24 
amino acids long α helix followed by a backbone reversal and therefore, does not display the 
tilt within the membrane [308]. 
The extracellular domains of α and β subunits in a heterodimer adopt a head on a stalk 
conformation (figure 20). The αvβ3 and αIIbβ3 crystal structures have been analyzed and 
serve as a model for other integrin heterodimers [307], however it is not clear if this structure 
indeed applies to other integrin heterodimers. The extracellular domain of the β subunit is 
composed of a βA (also named βI) domain inserted into an immunoglobulin (Ig)-like “hybrid” 
domain, a N-terminal PSI (plexin, semaphorins and integrin) domain, four tandem 
cysteine-rich EGF-like repeats and a β tail domain (β-TD) with a disulfide bond connecting 
the PSI and distal EGF domain (figure 20) [293,301]. The extracellular domain of α subunit 
contains an N-terminal seven bladed propeller domain followed by an Ig-like (thigh) domain, 
a genu domain, which is a short disulfide-bonded loop with a Ca2+-binding site at which the 
head-piece folds over its leg when the integrin turns in its bent, inactive conformation 
(mechanism described below) and two β sandwich domains (calf 1 and calf 2) (figure 20). 
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Figure 20: Model of an integrin heterodimer with the different sub-domains 
Integrin heterodimer in its activated, extended conformation. The α subunit is shown in green and the β subunit 
in violet. A detailed description of the different sub-domains is in the main text (modified from Moser et al., 
2009). 
 
The head domain represents the ligand binding part of the heterodimer with the extracellular 
domain of the α subunit determining the ligand specificity of the integrin. The ligand-binding 
pocket lies at the interface between the β propeller and the βA domain. The interaction of 
integrins with their ligands also depends on the binding of divalent cations. The head of the α 
chain contains a Ca2+-binding β-propeller domain. Several heads of α subunits have an 
inserted domain (I-domain) [309], which has a metal ion-dependent adhesion site (MIDAS) 
coordinating the binding of magnesium ions (Mg2+) and thereby controlling the ligand 
binding [310]. The binding of ligands in the head of the β chains is mediated by three binding 
sites in the βA domain, containing a central Mg2+ binding MIDAS flanked by two Ca2+ sites 
termed synergistic metal ion binding site (SyMBS) and adjacent to MIDAS (AdMIDAS), 
respectively [311]. 
Unlike most other transmembrane molecules integrins have the ability to transduce signals 
bidirectionaly across the plasma membrane, meaning from the extracellular environment into 
the cell (called outside-in signaling) and vice versa, from the intracellular compartment to the 
cell surface (called inside-out signaling). Both processes are described in the following 
sections. 
6.9.1. Inside-out signaling 
Integrins exist in different conformations. Depending on their activation, integrins can assume 
the low (bent conformation of the extracellular domains), intermediate and high affinity state 
(extended conformation), for ligand binding, see figure 21. 
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Figure 21: Model of conformational changes during integrin activation 
A) The bent conformation of the inactive integrin, in which the α and β extracellular, the transmembrane and 
cytoplasmic domains are tightly associated. B) The “primed” conformation in which the relaxation in the legs 
leads to an exposure of epitopes for stimulatory antibodies (yellow stars). The head-piece is still closed but a 
small outward movement of the hybrid domains might bring the ligand-binding pocket in a conformation 
necessary to achieve the high-affinity conformation in the next step. C) High affinity, ligand bound conformation 
with an opened head-piece and separated legs. Green triangle represents the ligand (modified from Askari et al., 
2009) [312]. 
 
The process of integrin activation occurs through inside-out signaling. It requires the binding 
of intracellular proteins to the integrin tail, thereby transducing signals to the cell surface 
through conformational changes within the integrins. 
The enormous relevance for a precise regulation of the integrin activation becomes clear if 
one focuses on integrins expressed on hematopoietic cells. For example leukocytes have to 
extravasate the blood circulation to migrate towards the inflammatory side in the case of an 
inflammation. For this process the precise and tight regulation of integrin activation is 
essential, as defects can lead to severe diseases such as leukocyte adhesion deficiency (LAD). 
Also HSCs critically depend on integrin activation for the extravasation from blood vessels, 
homing and BM retention. Alteration in the integrin activation on HSCs can result in 
hematopoietic defects leading to pancytopenia. Most extensively studied is integrin activation 
on platelets, which express αIIbβ3 integrin that mediate their aggregation to seal injured blood 
vessels. Activation defects can prevent platelet aggregation leading to extensive bleedings, 
while hyper-activation results in pathological platelet aggregation, which can lead to arterial 
thrombosis and finally cause heart attacks or stroke [313]. 
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Activation of platelets upon vascular injury is driven by signaling events that are triggered by 
insoluble proteins such as collagen and von Willdebrand factor and soluble factors such as 
adenosine diphosphate (ADP), thrombin and thromboxane A2 [314]. These factors activate 
G-protein coupled receptors (GPCRs) or the collagen receptor glycoprotein VI (GPVI), a 
non-GPCRs, leading to the activation of PLC, which hydrolyzes phosphatidylinositol 
resulting in the production of the secondary messengers inositoltrisphosphate (IP3) and 
diacylglycerol (DAG). Consequently, IP3 causes increase of cytoplasmic Ca2+, and DAG 
activates the protein kinase-C (PKC) and the Rap guanine nucleotide exchange factor 
(Rap-GEF), a Ca2+ and DAG-dependent GEF (Cal-DAG-GEF) for Ras-like small GTPases 
such as Rap1 [314]. Activated Rap 1, in turn binds to its effector Rap1-interacting adapter 
molecule (RIAM) allowing its interaction with talin, thereby unmasking talin’s integrin 
binding site and allowing integrin activation, see figure 22 [315]. In addition to talin it has 
also been shown that kindlin-3 binds β1, β2 and β3 integrin tails and is critically involved in 
integrin activation, further discussed below [316,317]. It is unclear, however, how kindlin-3 is 
activated. 
 
Figure 22: Connection between agonist stimulation (e.g. thrombin binding) and αIIbβ3 activation 
Thrombin binding to its receptor leads to phospholipid hydrolysis resulting in the generation of IP3 and DAG. 
IP3 causes an increased level of Ca2+ in the cytosol, which together with activated protein kinase C (PKC) 
isoforms activates Rap1 guanine a Ca2+ and DAG-dependent GEF (Cal-DAG-GEF). The Cal-DAG-GEF 
complex converts the GDP-bound form of Rap1 into the active GTP-bound form. Active Rap1 recruits RIAM 
and talin to the plasma membrane. Unmasking the integrin binding site in the F3 domain of talin enables talin to 
bind to the β3 integrin tail, leading to integrin activation (adapted from Shattil et al., 2010) [318]. 
 
In other cell types such as lymphocytes, chemokines can trigger additional signaling pathways 
that involve activation of PI3K and small GTPases, RhoA and most likely Rac1, which in turn 
trigger downstream PtdIns(4,5)P2 and activate kinases such as 
phosphatidylinositol-4-phosphate 5-kinase (PIPKI). This in turn leads to local increase of 
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PtdIns(4,5)P2 and activation of talin [319]. A schematic drawing of activation and binding of 
talin to the β integrin tail is shown in figure 23. 
 
Figure 23: Talin-mediated activation of integrins 
A) In an unstimulated cell (e.g. platelets), talin is predominantly localized to the cytoplasm [320] in an 
autoinhibitory conformation, in which the integrin-binding domain within the head is blocked by its own 
C-terminal rod [321,322]. B) Signaling via PtdIns(4,5)P2 abrogates the autoinhibition, recruiting talin to the 
plasma membrane where it binds with its F3 subdomain to the NPxY motive in the β integrin tail. C) Thereafter 
a talin-specific loop in the F3 subdomain binds a membrane proximal (MP) α helix in the β integrin tail, leading 
to the separation of the α and β integrin cytoplasmic tails and finally resulting in the active integrin conformation 
(adapted from Moser et al., 2009). 
 
Next to kindlins, talin is considered a major activator of integrins [323]. It is a 
cytoskeleton-associated protein present in two isoforms, talin-1 and talin-2 in humans and 
mice [324]. Functional talin is structured as an antiparallel homodimer of two 270 kDa 
proteins. Each protein consists of a N-terminal, globular FERM (4.1, ezrin, radixin, moesin) 
domain and a C-terminal rod with several helical bundles, containing multiple vinculin 
binding sites, a second integrin-binding site and an F-actin binding site [324]. The FERM 
domain consists of three subdomains, known as F1, F2 and F3. The F3 subdomain harbors a 
Introduction 
 60 
PTB motif essential for binding to the cytoplasmic tail of the β integrin subunits, see figure 
24. 
 
Figure 24: Structural model of talin 
The head contains a FERM (4.1, ezrin, radixin, moesin) domain with three subdomains (F1, F2, and F3) and a 
F0 subdomain (adapted from Moser et al., 2009). 
 
Talin binds the integrin β tail at the membrane-proximal NPxY motif, see figure 25, which 
allows electrostatic interaction between the positively charged F3 subunit and the polar head 
groups of lipids in the plasma membrane. 
 
Figure 25: The cytoplasmic tails of α and β integrin subunits 
The transmembrane and membrane proximal cytoplasmic domains of the α and β subunits. Indicated are the 
membrane distal (MD) NxxY and proximal (MP) NPxY binding motifs (modified from Moser et al., 2009). 
 
Binding of talin to both, the membrane proximal and membrane distal NPxY motifs is 
necessary for integrin tail separation [304,305]. In addition to actin and vinculin binding sites, 
the talin rod domain contains another integrin binding motif possibly involved in integrin 
clustering [325] as it has been shown that full length talin is required for the connection of 
integrins to the cytoskeleton and integrin clustering [326]. 
However, talin is not the only integrin activator. It was shown that also the kindlin family of 
proteins is also necessary for this process [316]. A series of in vivo and in vitro experiments 
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showed that the conformational shift from the low- to the high-affinity state was only possible 
in the presence of kindlins [316,327-329]. In contrast to talin, kindlins bind to the distal NxxY 
motif of β1, β2 and β3 integrin tails (figure 25). In addition, kindlins bind serine/threonine 
motif, located between two NxxY patches. The integrin interaction site within the kindlin 
sequence has been mapped in the F3 subdomain of the FERM domain, as the substitution of 
particular glutamate and tryptophan residues with alanine prevents integrin binding and 
activation [316,330]. A scheme illustrating the recruitment of kindlin to the β integrin tail is 
shown in figure 26. For a precise description of the kindlin structure, see section 6.10.1. 
 
Figure 26: Recruitment of kindlin to the β integrin tails 
Kindlins binding to plasma membrane phosphoinositides via their PH domain and/or further phosphorylation 
might activate kindlins, leading to their interaction with the membrane distal (MD) NxxY motif of the β integrin 
cytoplasmic tail (adapted from Moser et al., 2009). 
 
Kindlins alone are not sufficient to shift integrins to a high-affinity state but they cooperate 
with talin, as it was shown that co-expression of kindlin-1 or -2 with the talin-head domain 
synergistically increase αIIbβ3 activation [331]. Furthermore, overexpression of the talin-head 
domain failed to increase αIIbβ3 activation in kindlin knock-down CHO cells [332]. These 
results argue that talin alone is not sufficient to increase the integrin activation and that it 
requires kindlins. Controversially, recent reports postulate that talin alone is both necessary 
and sufficient for integrin activation, as it was possible to activate integrins and even a kindlin 
binding-defective integrin mutant by the talin head domain alone in an in vitro experimental 
setting, using recombinant proteins and membrane lipid nanodiscs [333]. A follow-up study, 
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investigated the influence of kindlins on the talin recruitment to β integrin tails and vice versa 
and postulated that kindlins do not promote talin recruitment to the plasma membrane or to 
αIIbβ3 integrin and that talin does not promote a interaction between kindlins and αIIbβ3 
integrin [334]. Furthermore, in neutrophils talin alone is able to induce a conformational shift 
of the αLβ2 integrin from its inactive to the intermediate conformation but kindlin-3 is 
essential to acquire the high-affinity conformation [335], arguing for distinct functions of talin 
and kindlin during integrin activation, which can even differ between different integrin 
heterodimers. 
However, a cooperation of talin and kindlin through their distinct binding sites in the integrin 
β tail is necessary for full integrin activation in vivo and neither of these proteins is sufficient 
alone [328,336]. Further studies are necessary to elucidate details of their interactions with 
integrin tails, as it is still unclear whether kindlin and talin bind integrin β tails simultaneously 
or in a sequential manner. It is possible that both activators bind sequentially, e.g. kindlin first 
and then facilitates the talin binding. Alternatively, they may bind simultaneously to the β 
integrin tail, which has recently been show to be possible [337] and together activate 
integrins, maybe by recruiting further known or unknown proteins. A further possibility is, 
that one of the two proteins is the primary activator and the other an “enabler” mediating 
supportive functions such as signaling events leading to the binding of the activator to the β 
integrin tail or displacing inhibitors from the integrin tails, which prevent the binding of the 
activator. This interaction between both proteins can occur on the same integrin heterodimer, 
or involving several integrins so that kindlins and talins are bound to different integrin tails 
and trans-communicate [318,338], which was recently shown by our group to be rather 
unlikely [339]. However, it is clear that talin and kindlin binding induces a conformational 
change of integrin tails. This conformational change is further propagated through the 
transmembrane domains to the extracellular domains of the integrins. 
The exact mechanism of the integrin conformational changes is not fully understood, 
however, two major models have been proposed. The “switchblade” model states that the 
conformational changes leading to the extracellular extension starts with the dissociation of 
the cytoplasmic and the transmembrane domains of the inactive bent integrin. According to 
this model a salt bridge between the cytoplasmic domains of the integrin heterodimers 
becomes disrupted. The separation of integrin tails occurs upon binding of kindlin and/or 
talin. Furthermore, this model states that ligand binding only occurs in the extended, 
high-affinity state [301,338]. In contrast, the “debolt” model states that integrins do not 
depend on full extension of their extracellular domain for ligand binding, but rather the 
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extension occurs only after ligand binding and actomyosin pulling. According to this model 
the change in the tilt of the transmembrane domain leads to the change in the conformation of 
the head domain and the exposure of ligand binding sites [301,311,312,340]. 
6.9.2. Outside-in signaling 
Outside-in signaling of integrins is initiated by ligand binding and results in recruitment of 
further proteins to the integrin cytoplasmic tail [341]. Since integrins do not possess 
enzymatic activity, they depend on the interaction with a variety of auxiliary proteins to 
transduce signals. Recent findings demonstrate the presence of more than 245 proteins 
associated directly or indirectly with the cytoplasmic domains of integrins [342,343] [344]. 
These proteins can either have a mechanical role linking integrins to the cytoskeleton, mainly 
F-actin, or a signaling role in diverse signaling pathways controlling processes such as cell 
spreading, migration, proliferation and apoptosis [323,345,346]. 
One can distinguish between three temporal stages in integrin downstream signaling, shown 
in figure 27 [326]. Up-regulation of lipid kinase activity, leading to an increase in the local 
concentrations of phosphoinositide second messengers such as phosphatidylinositol 
4,5-bisphosphate (PtdIns(4,5)P2) and phosphatidylinositol 3,4,5-trisphosphate 
(PtdIns(3,4,5)P3) as well as rapid phosphorylation of specific proteins, is one of the 
immediate events downstream of integrin activation. Subsequently, these changes lead to 
activation of various signaling pathways, within several minutes. The cell adhesion-dependent 
phosphorylation of FAK and Src kinases is considered a central event in the integrin-mediated 
signaling. Particularly important is the phosphorylation of FAK at the tyrosine-397, which 
enables its interaction with Src family kinases, as it creates the docking site for the SH2 
domain of Src. Interaction of FAK and Src leads to activation of Src. The resulting activated 
FAK/Src complex subsequently phosphorylates other focal adhesion proteins such as FAK, 
paxillin, and p130Cas, leading to the recruitment of intermediate signaling molecules such as 
the adaptor protein growth factor receptor-bound protein 2 (Grb2). In this way, it leads to the 
activation of downstream signaling pathways such as the Ras/MAPK pathway. Another 
important event in downstream integrin signaling is activation of Rho family GTPases and 
other actin regulatory proteins, which leads to the reorganization of the actin cytoskeleton, 
changes in cell shape, and initiation of cell migration. Finally, integrin outside-in signaling, 
on the long-term scale, leads to activation of proliferation pathways as well as the initiation of 
genetic programs controlling cell morphology [326]. This is mainly achieved by cross talking 
with GFRs such as EGFR, IGFR, PDGFR, and TGFR. These extensive cross-talks are 
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regulated on multiple levels and are essential for physiological and pathological conditions 
[347-350]. 
 
Figure 27: Effects of integrin outside-in signaling 
Signaling processes downstream of the activated integrins can be divided into three temporal stages. First, the 
immediate effects combine the rapid phosphorylation of specific proteins as well as increased lipid kinase 
activity leading to higher concentrations of PtdIns(4,5)P2 and PtdIns(3,4,5)P3. Second, the short-term effects 
occur within several minutes and are reflected in activation of signaling pathways as well as of Rho family 
GTPases and other actin regulatory proteins leading to the reorganization of the actin cytoskeleton. Third, the 
long-term effects include activation of signaling pathways regulating proliferation and survival as well as 
induction of genetic programs controlling cell fate (adapted from Legate, Wickström et al., 2009). 
 
6.10. The Kindlin Protein Family 
The kindlin protein family consists of three members (kindlin-1, kindlin-2 and kindlin-3) in 
mice and humans, while C. elegans expresses one kindlin ortholog, named uncoordinated 
protein 112 (Unc-112) and Drosophila two, named fermitin-1 and -2. The kindlin family of 
proteins bears its name after a human autosomal recessive genodermatosis called Kindler 
syndrome [351]. 
The kindlin genes are evolutionary conserved with 15 exons in both the human and the 
murine gene. All three kindlin genes contain the ATG start codon within the second exon. 
The three kindlin proteins show a high sequence similarity to each other, with 74% similarity 
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and even 60% identity between Kindlin-1 and -2. Kindlin-3 shows 69% similarity and 53% 
identity to Kindlin-1 and 67% similarity and 49% identity to Kindlin-2 [352]. 
 
6.10.1. Structure of the Kindlin Proteins 
All kindlin proteins share the same domain structure with a C-terminal FERM domain and a 
short N-terminal F0 domain [353]. The FERM domain consists of three subdomains: F1, F2, 
and F3 (figure 28). The F1 subdomain has an ubiquitin like structure, the F2 subdomain has 
an α-helix bundle structure harboring a pleckstrin homology (PH) domain, while the F3 
subdomain contains a PTB domain, belonging to the PH superfold family [354-356]. 
 
Figure 28: Structural model of kindlin 
All kindlins contain a C-terminal FERM domain with the three subdomains F1, F2, F3. The FERM domain is 
separated into two halves by a pleckstrin homology (PH) domain, which is inserted within the F2 subdomain 
(adapted from Moser et al., 2009). 
 
The FERM domain is found in a variety of cytosceletal-associated proteins (e.g. talin) and 
was shown to be involved in the interaction between the membrane and the cytoskeleton. For 
example, FERM containing proteins are involved in the connection of actin to transmembrane 
proteins such as integrins, CD43, CD44, ICAM-2 and ICAM-3 [357]. PH/PTB-domains have 
a common folding structure, with two perpendicular anti-parallel β-sheets followed by a 
C-terminal α-helix [356,358,359]. Initially this domain was described in the SRC homology 
2-containing protein (Shc), a Src homology 2-domain adaptor protein, to serve as interaction 
site for activated receptor tyrosine kinases. To date, there have been approximately 50 
proteins discovered containing PTB domains, one of which is talin. Besides binding 
phosphorylated NPxpY motif, these proteins can also bind non-phosphorylated NPxY with 
the same or higher affinity [360,361]. 
Approximately 250 pleckstrin homology-domain (PH-domain) containing proteins, including 
protein kinases, guanine nucleotide exchange factors (GEFs), phospholipases and cytoskeletal 
proteins have been discovered [358,362]. The main function is the binding to 
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phosphatidylinositol (PtdIns) lipids within cell membranes and therefore recruiting the 
proteins to cellular membrane structures [362-364]. PtdIns differ in their phosphorylation of 
the inositol moiety and exhibit a specific spatial and temporal distribution within various 
cellular membranes, e.g. PtdIns(4,5)P2 is predominantly found in the plasma membrane and 
steady state Golgi apparatus, while PtdIns(3,4)P2 and PtdIns(3,4,5)P3 are found transiently in 
the plasma membrane upon receptor stimulation. As various PH domains differ in their ability 
to bind to distinct PtdIns, they in turn can recruit the PH containing proteins to different 
sub-cellular compartments. In addition, the phosphorylation and dephosphorylation of PtdIns, 
executed by kinases (e.g. PI3K) and lipid phosphatases (e.g. phosphatase and tensin homolog 
(PTEN)) [359], create additional level of distribution regulation for PH containing proteins. 
6.10.1.1. Kindlin-1 
Kindlin-1 is expressed mainly in epithelial cells. The highest levels of kindlin-1 mRNA are 
detected in bladder and colon, and lower levels in kidney, stomach, small intestine and skin. 
Epidermal expression levels are generally much higher than the levels in dermis. 
In humans, loss of function mutations in kindlin-1 occur throughout the entire gene and lead 
to various truncated forms of the protein. The mutations result in skin disease called Kindler 
syndrome [365]. Patients with Kindler syndrome are suffering from numerous skin 
pathologies with various severities [366]. Main characteristics of this condition include skin 
atrophy and trauma induced skin blistering appearing in very young patients and becoming 
less severe with age. However, Kindler patients also develop increased poikiloderma and 
photosensitivity with age and have greater predisposition for squamous cell carcinoma [367]. 
Additionally, cases of ulcerative colitis have been described [365]. The full mechanism of this 
disease remains unclear, as the defective anchorage of actin cytoskeleton to cellular matrix 
adhesion sites cannot explain the poikiloderma, photosensitivity and cancer predisposition 
[368,369]. Similar to humans, kindlin-1 deletion in mice leads to early post-natal lethality due 
to skin atrophy and ulcerative colitis [329]. Epidermal basal keratinocytes show polarized 
distribution of kindlin-1 at the dermal-epidermal junction zone between hemidesmosomes. 
Deletion of kindlin-1 in these cells leads to loss of polarity, reduced proliferation, and 
increased cell death [329]. Kindlin-1 deficient keratinocytes also demonstrate reduced and 
undirected migration due to defects in adhesions, actin organizations and loss of polarity 
[329,353]. Kindlin-1 interacts with β1, β3 and β6 integrin subunits [329] and localizes to 
integrin mediated adhesion sites in cultured cells. 
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6.10.1.2. Kindlin-2 
Kindlin-2 is almost ubiquitously expressed with the exception of hematopoietic cells. The 
highest levels are present in striated muscles [328]. In contrast to kindlin-1, kindlin-2 shows 
higher expression in dermis and low levels in epidermis [352], which could together with the 
different subcellular localization explain the inability of kindlin-2 to rescue kindlin-1 loss and 
the symptoms of Kindler patients. 
Like kindlin-1, kindlin-2 binds β1 and β3 integrin subunits and localizes to adhesion sites in 
cultured keratinocytes. In addition, kindlin-2 shows a specific co-localization with E-cadherin 
and localizes to cell-cell contacts in differentiated keratinocytes [328,332,352]. In 
cardiomyocytes, kindlin-2 also localizes to actin stress fibers [352] and to α-actinin in Z discs. 
Interestingly, kindlin-2 contains a nuclear localization sequence in its N-terminus, which 
would suggest some unknown, nuclear functions. Kindlin-2 nuclear localization was observed 
in leiomyosarcomas and leiomyomas [370]. 
Kindlin-2 deletion in mice leads to peri-implantation lethality due to a severe endoderm and 
epiblast detachment from the basement membrane [328]. Loss of kindlin-2, similar to loss of 
kindlin-1, leads to defective cell spreading and impaired adhesions [371]. 
6.10.1.3. Kindlin-3 
Kindlin-3 expression is restricted to the hematopoietic system [352], where it can be detected 
in various hematopoietic cells such as macrophages, monocytes, DCs, neutrophils, 
erythrocytes, B cells, T cells, platelets, OCLs, megakaryocytes, and HSPCs [352]. Kindlin-3, 
similar to kindlin-1 and -2, localizes to integrin adhesion structures, where it interacts with the 
β1, β2 and β3 integrin tail [316,352]. However, unlike keratinocytes and fibroblasts, 
hematopoietic cells do not adhere to ECM via focal adhesion, but instead form specific 
structures called podosomes, which contain a central actin core surrounded by a ring of 
plaque proteins such as talin, vinculin, and paxillin [372,373]. In podosoms kindlin-3 
colocalizes with vinculin [352]. 
Kindlin-3 deficiency in mice leads to an early post natal lethality due to numerous defects 
including, anemia, severe hemorrhage in the gastrointestinal tract, skin, brain, and bladder 
[316], see figure 29. The hemorrhages can be detected already during E13 to E17 days of 
embryonic development, and are similar to the phenotype observed in Glanzmann´s 
trombasthenia, which occurs due to defective αIIb or β3 integrins. 
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Figure 29: Kindlin-3 deficient mice suffer from severe hemorrhages 
A) E15.5 embryos having bleedings at several locations. B) Newborn mice (P2) with severe bleedings in the 
abdomen. C) The bleedings occur especially in the bladder and intestinal tract (arrows) (modified from Moser et 
al., 2008). 
 
The hemorrhages in kindlin-3 deficient mice can be explained by impaired platelet function 
[316]. In vitro and in vivo assays performed with kindlin-3 deficient platelets revealed a 
defect in aggregation, adhesion, and spreading, while the platelet maturation and production is 
unaffected as shown by experiments with fetal liver cell chimeras [316]. The bleeding 
phenotype of kindlin-3 deficient mice led to the discovery of mutations in the human 
KINDLIN-3 gene causing leukocyte adhesion deficiency syndrome type III (LAD-III, also 
known as LAD-I variant), a rare autosomal recessive immunodeficiency syndrome [374]. In 
humans two further types of LAD exists, named according to their chronological discovery 
LAD-I and LAD-II, which have independent defects from kindlin-3 but share several 
common phenotypic characteristics such as recurrent bacterial infections and leukocytosis 
[374]. LAD-I is caused by null mutations in the β2 integrin gene results in an extravasation 
defect of leukocytes due to impaired firm adhesion [375]. LAD-II is due to impaired 
posttranslational fucosylation of selectin ligands causing a dramatically reduced leukocyte 
rolling [376]. 
Patients suffering of LAD-III show mild immunodeficiency with recurrent fungal and 
bacterial infections, leukocytosis, and severe hemorrhages similar to Glanzmann’s 
trombasthenia. A list of known mutations in kindlin-3 gene carried by members of 21 families 
with LAD-III patients has recently been published [377], showing that most of the mutations 
are nonsense mutations leading to truncated forms of the kindlin-3 protein devoid of the 
C-terminal integrin binding region. However, kindlin-3 can indirectly interact with integrins 
via the scaffold protein receptor for activated C kinase-1 (RACK-1) [378], thereby enabling 
integrin-mediated signaling. This fact could explain the differences in severity of phenotype 
between LAD-III patients. In addition, some patients show increased bone density [379], 
similar to the osteopetrosis that has been observed in kindlin-3 deficient mice [380], which 
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can be explained by the absence of the kindlin-3 protein in the bone resorbing OCLs. These 
cells adhere less to the bone structure, due to defects in the podosome formation [380]. 
6.11. Hematopoietic malignancies 
Malignant transformation involves the acquisition of one or a series of genetic mutations in 
HSCs or more mature progenitor cells, disrupting the normal hematopoietic balance between 
maturation and replenishment. This could lead to increased proliferation rates, decreased 
apoptosis, enhanced self-renewal, maturational arrest and defective telomere maintenance. 
For the complete understanding of these processes one needs to resolve both the molecular 
events underlying the malignant growth as well as the cellular context in which the oncogenic 
mutations occurs. Hematological malignancies are malignant neoplasms comprising 
leukemias, lymphomas, myelodysplastic syndromes (MDS), multiple myeloma (MM) and 
myeloproliferative disorders. 
Lymphomas are clonal malignant disorders derived from lymphocytes, either precursors or 
mature T cells or B cells originating from the lymphoid organs or extranodal tissues. In 
general, they can be divided into low-grade and high-grade lymphomas. Low-grade 
lymphomas show a lower cellular proliferation rate and also progress more slowly than 
high-grade lymphomas, which will, if untreated, cause death relative quickly. Therefore, it is 
beneficial that high-grade lymphomas are easier to treat than low-grade lymphomas. 
Additionally, they are divided into two broad categories, the Hodgkin and non-Hodgkin 
lymphomas. Hodgkin lymphomas are diagnosed histologically by the presence of 
characteristic mutated B-lineage cells called Reed-Sernberg cells within the appropriate 
cellular background and are relatively restricted in their pathology compared to non-Hodgkin 
lymphomas, which are very diverse in nature. Lymphomas were initially thought to be ‘solid’ 
compared with leukemia being ‘liquid’, where malignant cells are spilling into the PB. 
However, this differentiation is sometimes blurred as lymphomas often enter a leukemic 
phase, where malignant lymphoid cells, which were restricted to a particular lymphoid organ, 
overspill into the blood and BM. Therefore, nowadays the classification, based on the cell of 
origin and define biological entities e.g. follicular center cells giving rise to follicular 
lymphoma, is rather used. 
Leukemias are first classified according to the cell lineage, which is affected into myeloid or 
lymphoid leukemias. They are further divided into acute and chronic types. In acute leukemia, 
the clinical course is rapidly progressive and the leukemic cells are immature blasts, leading 
to death relatively rapidly if untreated. In contrast, a chronic leukemia has a slow and indolent 
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clinical course and the tumor cells are mature-looking in lymphoid leukemia and intermediate 
forms (promyelocytes, myelocytes, and metamyelocytes) in myeloid leukemia. Chronic 
leukemias are less aggressive and have blasts below 20%. Maturational arrest does not occur 
in chronic leukemias, although the cells often fail to undergo apoptosis, allowing the 
malignant cells to accumulate. In lymphomas one does not separate between acute or chronic 
types, but its clinical course is essentially determined by the maturity of the tumor cells. By 
combining the four differentiation criteria one can separate four major classes of leukemias. 
The acute forms include Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid 
Leukemia (AML) and the chronic forms include Chronic Lymphocytic Leukemia (CLL) and 
the Chronic Myelogenous Leukemia (CML). 
The MDS, also termed ‘pre-leukemia’, describes a range of heterogeneous diseases restricted 
to the myeloid lineage. MDS are all disorders of HSCs leading to an increased number of 
precursors in the BM but accompanied with cytopenia in the PB due to the premature death of 
the immature cells in the BM. The MM is a malignancy of the lymphoid compartment and 
associated with the proliferation of malignant plasma cells, which accumulate in the BM 
leading to myelosuppression and the activation of OCLs. The OCL activity causes breakdown 
of bone, leading to pathological fractures. In addition, an increased production of monoclonal 
antibodies occurs, which can damage the kidney if present in the plasma at excessive 
concentrations. Myeloproliferative disorders is a collective term describing disorders affecting 
the myeloid lineage leading to an increased proliferation including: the polycythaemia, a 
increased proliferation of red cell precursors leading to an accumulation of mature red cells in 
the PB; the myelofibrosis, leading to a increased proliferation of fibroblasts in the BM and 
thereby modulating the BM microenvironment as well as HSPCs and the essential 
thrombocythaemia, which is a inappropriate proliferation of megakaryocytes leading to an 
increased number of platelets [381]. 
6.11.1. Chronic Myeloid Leukemia (CML) 
CML is a clonal multi-lineage myeloproliferative disorder of stem cell origin characterized by 
the Philadelphia (Ph) chromosome so called after the city in which it was discovered [382]. 
The course of disease is triphasic, starting with an early chronic phase (CP) in which most of 
the patient are diagnosed lasting 3 to 6 years without treatment, followed by an accelerated 
phase (AP) and finally leading to a terminal blast phase (BP) of short duration characterized 
by a block of cell differentiation leading to an accumulation (more than 30%) of myeloid or 
lymphoid blast cells in the PB or BM [383]. CML makes around 15 % of all types of 
leukemia in adults and has an incidence of 1 case per 100000 people per year [384]. The 
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median age of patients diagnosed with CML is from 45 to 55 years, while 1/3 of the patients 
are over 60 years old. The high age of the patients is a critical factor for therapeutic strategies 
such as stem cell transplantation or INF-α treatment, which work well in younger patients, but 
can have severe side effects in older people. The high age together with limited donor 
availability, therefore exclude approximately 75% of patients for these treatment strategies 
[385]. 
CML was the first human neoplasm explained by a chromosomal abnormality, in which a 
reciprocal translocation between the long arms of chromosomes 9 and 22, t(9,22)(q34,q11), 
leads to the shortened Ph chromosome containing the BCR-ABL fusion gene [386], see figure 
30. 
The human ABL gene encodes a ubiquitously expressed 145 kD nonreceptor tyrosine kinase 
[387] and is the homologue of the v-abl oncogene carried by the abelson murine leukemia 
virus (A-MuLV) [388]. The normal ABL protein is involved in the regulation of the cell cycle 
and apoptosis [389], in the cellular response to genotoxic stress [390] and in integrin signaling 
[391]. The 160 kD BCR protein is a ubiquitously expressed serine threonine kinase [387]. 
Several in vitro experiments argue for a role of BCR in signal transduction [392,393] but the 
biological relevance is still not clear as the bcr knock-out mice are viable and have no severe 
defects that would confirm a critical role of BCR for the signal transduction [394]. 
 
Figure 30: The translocation of t(9,22)(q34;q11) and the fusion mRNA molecules in CML 
The shortened chromosome 22 (known as Ph chromosome) is generated by the translocation of the 3’ segments 
of the ABL gene on chromosome 9 to the 5’ parts of the BCR gene on chromosome 22. Different breads at 
several BCRs on chromosome 22 results in different sizes of the BCR gene that is fused to the 3’ segments of the 
ABL gene leading to four different mRNAs of various length (e1a2, b2a2, b3a2, e19a2) encoding for three 
different BCR-ABL fusion proteins with different molecular weights and probably functions (p190, p210, p230) 
(adapted from Faderl et al., 1998). 
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The breakpoints within the ABL gene at 9q34 can occur at different positions over a more than 
300 kb area at the 5’ end either upstream of the first alternative exon Ib, downstream of the 
second alternative exon Ia or more frequently between the two [395]. However, splicing of 
the primary hybrid transcript leads to an mRNA in which the different BCR sequences are 
always fused to the ABL exon a2. The breakpoints within the BCR gene localize to 1 of 3 
breakpoint cluster regions (bcr). In most CML and AML as well as in 1/3 of Ph-positive ALL 
patients the break occurs in the major breakpoint cluster region (M-bcr) spanning exons 
b1-b5. Alternative splicing leads to fusion transcripts with either b2a2 or b3a2 junctions. 
From these mRNAs is the 210 kD chimeric protein (P210BCR-ABL) derived. In other patients 
with ALL, AML and rarely with CML, the breakpoints are further upstream in the minor 
breakpoint cluster region (m-bcr) between the alternative exons e1 and e2. The spliced e1a2 
mRNA is translated into the 190 kD protein (P190BCR-ABL). In patients with neutrophilic CML 
[396] as well as in some rare cases of CML [397], breakpoints downstream of exon 19 within 
the micro breakpoint cluster region (µ-bcr) give rise to the fusion transcript e19a2, which is 
translated into a 230 kD protein (P230BCR-ABL), see figure 30. 
During the reciprocal translocation not only the BCR-ABL fusion gene is formed but also a 
second fusion gene, the ABL-BCR gene, on the 9q+ chromosome. It is only expressed in 2/3 
of all the CML patients [398] and the contribution to the pathogenesis of CML is still unclear. 
While under non-transforming condition the ABL proto-oncoprotein is restricted to the 
nucleus where it is bound to chromatin or in the cytoplasm colocalized to F-actin [387], the 
chimeric oncoprotein BCR-ABL is exclusively located to the cytoplasm. The abnormal 
cytoplasmic localization and the constitutively activated tyrosine kinase activity, which is 
5-10 fold increased compared to ABL, are crucial to the transforming activity of BCR-ABL 
by recruiting and activating several pathways such as the Ras, PI3K, and Jak/STAT pathways 
transducing intracellular signals, which ultimately lead to abnormal cellular adhesion, survival 
and differentiation as well as enhanced proliferation and inhibition of apoptosis [398], see 
figure 31. 
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Figure 31: Signaling pathways influenced by BCR-ABL in CML 
Together with several mediators BCR-ABL leads to the activation of Ras, which together with Raf activates 
MEK1/2 resulting in the activation of the MAPK pathway, thereby increasing growth factor independent 
proliferation. BCR-ABL also increases cell survival by suppressing apoptosis through activation of the PI3K 
pathway. The interfering of BCR-ABL with components of the focal adhesion complex, such as FAK, actin or 
paxillin leads to the activation of the CRKL/FAK/PYK2 complex resulting in reduced cell adhesion. BCR-ABL 
also associates with the JAK/STAT pathway further influencing cell growth, differentiation and death. 
BCR-ABL further influences survival proteins from the Bcl-2 family of anti- and proapoptotic regulators. 
Finally, BCR-ABL also interferes with pathways mediating responses to chemotactic factors, thereby increasing 
cell migration (adapted from Weisberg et al., 2007) [399]. 
 
P210BCR-ABL has several domains that are able to bind adapter proteins such as Grb2, Shc, 
CRK-like protein (Crkl) and casitas B-lineage lymphoma pro-oncogene protein (Cbl), leading 
to the activation of the Ras signaling pathway [400-402], which plays a key role in the 
pathogenesis of CML [403]. Downstream signaling from Ras is mediated by the MAPK such 
as the Jun kinase pathway [404]. P210BCR-ABL also constitutively activates the PI3K pathway 
by binding to insulin receptor substrate 1 (IRS1) [405] and Crkl or Cbl [406,407] leading to 
the suppression of the programmed cell death and increasing cell survival. 
STAT1 and STAT5 of the JAK/STAT5 pathway are constitutively phosphorylated directly by 
P210BCR-ABL and independent of the RAS signaling pathway [408], which leads to the 
up-regulation of the anti-apoptotic protein BCL-XL [409]. Raf, Akt, c-Myc and Bad have also 
been identified to be involved in the BCR-ABL signaling pathways as they can be activated 
by P210BCR-ABL [410-413]. 
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BCR-ABL is also associated with proteins of the focal adhesion complex like actin, paxillin, 
vinculin, talin and FAK, as it constitutively phosphorylates tyrosine residues of Crkl. The fact 
that Crkl was still phosphorylated in cell lines with a mutant form of BCR-ABL unable to 
bind Crkl and still associated with P210BCR-ABL argues not only for a direct but also indirect 
influence of BCR-ABL on Crkl [414]. This activation of CRKL/FAK/PYK2 leads to a 
decrease in cell adhesion. However, the reduced adhesion of BCR-ABL transformed cell lines 
is controversial as there are also several reports postulating an increased integrin mediated 
adhesion potential of P210BCR-ABL expressing cells [415]. Although all the different signaling 
pathways affected by the BCR-ABL have been extensively investigated, none of them alone 
can explain all the phenotypic features described in CML, arguing for a complex interplay 
between the signaling pathways being necessary for the transforming effect of BCR-ABL. 
6.11.1.1. CML Treatment Strategies 
The most curative treatment strategy for CML is the allogeneic BM transplantation. But as 
mentioned before, this treatment is not possible for most of the CML patients because critical 
risk factors such as high age and the phase of the disease in which the patients are, stem cell 
transplantation are usually only performed by CP patients, make a transplantation feasible, 
because of the high risk of mortality during the treatment. Another limitation is the 
availability of BM donors. 
Alternatives for the patients who are not eligible for a transplant are cytoreductive 
chemotherapies with agents like hydroxyurea and busulfan to control the leukocyte counts 
and reduce the tumor weight. In the 1980s a new therapy with the antiproliferative agent 
interferon-α (IFN-α) became the treatment of choice for CP CML patients, as it was superior 
to preceding regimes leading to complete cytogenetic remissions in up to 30% of CML 
patients [416]. However, duration of remission was unpredictable and many patients only 
poorly tolerated the IFN-α therapy, therefore limiting the drug dosage due to the severe side 
effects or breaking up the treatment. From 2001 on, imatinib mesylate (STI571, Gleevec, 
Glivec, Novartis, Basel, Switzerland) came on the marked for the treatment of CML. The 
remarkable therapeutic efficacy of imatinib displaced the IFN-α and all the other previous 
therapies and became the gold standard for CML treatment. Imatinib is a small molecule 
inhibitor of the tyrosine kinase activity of BCR-ABL, c-ABL, PDGF and c-kit [417-419], 
which acts by blocking the tyrosine kinase ATP-binding site. The effect on other tyrosine 
kinases than BCR-ABL is the reason for several off-target effects of imatinib, such as changes 
of serum phosphate levels [420], a reversible and dose-dependent hypogammaglobulinemia 
and lymphocytopenia [421], apoptosis induction of cardiomyocytes [422], 
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immunosuppression [423] and impaired function of several hematopoietic cell types such as 
monocytes [424], DCs [425] and T cell [426]. Nevertheless, imatinib treatment leads to a 
significantly greater percentage of cytogenetic remissions with less treatment-related 
morbidity [427]. The remarkable success of the imatinib treatment was given by a 85% 
estimated overall survival rate, a 81% event-free survival rate and a 83% cumulative complete 
cytogenetic response (CCyR) rate for first-line imatinib-treated patients after 8 years of 
follow-up [428]. But the remaining heterogeneity in the response to imatinib treatment shows 
that this therapy is not a pharmacological cure and further development of new drugs such as 
second-generation small molecule inhibitors (i.e. Dasatinib, Ponatinib or Deciphera [429]), as 
well as new therapies targeting other biological targets in the CML cells in conjunction with 
imatinib are necessary to help patients which e.g. developed a resistance to imatinib due to 
mutations in the BCR-ABL kinase domain [430]. A further problem with imatinib is that in 
the majority of patients, expected to achieve CCgR, a minimal residual disease persists. Even 
patients where BCR-ABL transcripts are not detectable anymore, harbor around 107 leukemic 
cells in their bodies [431]. For these patients, there is a high likelihood for relapse of CML if 
the administration of imatinib is stopped [432]. Furthermore, it was shown that the remaining 
Ph chromosome positive BM cells had HSC character [433] and that these CML leukemic 
stem cells (LSC) are highly resistant to the imatinib treatment compared to the bigger mass of 
differentiated CML cells. The LSCs retain the ability to reproduce multilineage hematopoietic 
cells [434], leading to a fast and vast expansion of malignant myeloid cells displacing normal 
hematopoiesis and finally leading to CML relapse upon discontinuation of treatment. 
Currently, for most patients an indefinite medication is the only possibility to prevent disease 
relapse [435], which is associated with a risk of incompatibility or even toxicity and, not to 
underrate, considerable expense [436]. 
6.12. The leukemia (Cancer) Stem Cell Hypothesis 
More than 50 years ago it was first shown that leukemias and other types of cancer are 
heterogeneous in their growth potential, as only a small fraction of leukemic cells isolated 
from patients were able to grow or form colonies in vitro, or were able to build Spl colonies in 
in vivo mouse transplantation experiments [437,438]. This observation could be explained by 
two possibilities. First, it could be that all the leukemic cells have the same low growth 
potential. Second, the clonogenic and leukemogenic activity could be restricted to a small, 
more primitive fraction of the whole leukemic cell pool. Bonnet and Dick as well as Lapidot 
and colleagues demonstrated in the 1990s that in human AML only leukemic blasts, purified 
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as Thy1-, CD34+, CD38- cells, were able to induce AML after transplantation into SCID mice 
[439,440]. This was in contrast to more committed progenitors, which are CD34+, CD38+ 
positive and lacked such a potential. Thereafter, it became clear that only a small, defined 
subset of cells was consistently clonogenic. These results argue for the LSC hypothesis, 
which postulates that leukemias and many other cancer types arise from rather small 
populations of stem cell like cancer cells that have the ability for indefinite self-renewal 
[438]. The concept of LSC is nowadays well established and similar tumorigenic cells could 
have been identified in other solid tumors such as e.g. pancreatic, colorectal and breast 
cancers [441-443]. 
In most leukemia as well as cancers the origin of LSCs or cancer stem cells (CSCs), 
respectively, has not been identified with certainty. In general, there are two possibilities how 
LSCs or CSCs can develop. Since LSCs and CSCs have several properties with HSCs in 
common such as the ability to self-renew or certain developmental pathways, it is most likely 
that LSCs or CSCs are derived from neoplastic transformed normal HSCs. HSCs also have a 
greater opportunity to accumulate mutations as they are retained throughout the entire lifespan 
of an organism compared to more mature cells, which persist only for a short period. But also 
more committed progenitors or differentiated mature cells that have reacquired self-renewal 
properties by mutations, could be the origin for LSCs or CSCs, see figure 32. 
 
Figure 32: Two different origins of LSCs 
As LSCs share several properties with normal HSCs, it is possible that mutations in these stem cells lead already 
very early during cell development to neoplastic transformations (right). But also more restricted progenitors can 
become LSCs when they reacquire stem cell properties such as self-renewal through mutations (left). In both 
cases the LSCs will produce leukemic cells leading to comparable end-stage leukemias (adapted from Passegue 
et al., 2003) [43]. 
 
In subtypes of human AML and CML there is increasing evidence that leukemias arise from 
mutations that accumulate in HSCs. For example, in the case of CML the Ph chromosome can 
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be detected in several different hematopoietic lineages like nearly all myeloid, erythroid and 
some B and T cells [444], indicating that the original translocation takes place in a HSC with 
multilineage differentiation capacity. BCR-ABL positive cells, isolated from CML BM, are 
CD34+ CD38- CD90+, a cell population with a high HSC activity in normal BM [445,446]. 
In CML and AML a small pool of the LSCs are in a quiescent, G0 phase of the cell cycle 
[447-449], which might be one explanation why these cells are relatively resistant to 
chemotherapy. The regulation of LSC self-renewal and quiescence is, as for normal HSCs, 
dependent on the BM microenvironment [450]. It is postulated, that the machinery for 
migration, homing and lodgment in BM niches usually used by HSCs is “hijacked” by LSCs 
and that LSCs occupy and even displace HSCs from their niches [451]. The important 
regulatory signals from the environment to the LSCs are postulated to be critical for the 
resistance of LCSs to conventional therapies. Therefore, a new strategy could be to alter the 
microenvironment or to interfere with the supportive bidirectional interactions between the 
LSCs and their niches to overcome the primary disease resistance. This could be e.g. the 
inhibition or alteration of homing mechanisms, cell adhesion molecules, cytokine signaling or 
self-renewal pathways (e.g. Notch or Wnt). 
The integrins α4β1, important for homing to and interaction with the BM niche (described 
above) is also expressed on AML blasts and it was shown that patients with reduced levels of 
α4β1 had a better response to chemotherapy [452] probably due to the altered interaction of 
the leukemic cells with their environment. Furthermore in vitro experiments showed that 
AML blasts bound to fibronectin via α4β1 trigger PI3K-Akt signaling, which protects these 
blasts from chemotherapy. In contrast, neutralizing α4β1 antibody in combination with the 
chemotherapeutic agent cytarabine can eradicate residual AML in a SCID xenograft 
transplantation model [452]. In addition, antibodies against the adhesion molecule CD44, 
expressed on normal HSC but also LSCs, had an eliminating effect on AML stem cells in 
patients, which might be explained by the disruption of the LSC from its microenvironment 
[453]. These results argue for the use of antibodies, targeting adhesion molecules, as an 
alternative treatment strategy to eliminate LSCs. 
An example for therapies targeting cytokine signaling networks are chemical compounds such 
as the CXCR4 antagonists AMD3465 or AMD3100 effecting the interaction between 
CXCL12 and its specific receptor CXCR4 on leukemic cells, leading to the disruption of the 
chemoprotective effects of stromal cell-leukemia cell interactions or the mobilization of 
leukemic cells increases chemosensitivity [454,455]. Signaling pathways involved in 
stem-cell self-renewal such as the Wnt and Notch pathways are partly regulated by 
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components of the niche [167,219]. Data that support a regulatory role of the Notch pathway 
in AML LSCs or Wnt signaling in CML BC [446,456] argue for the use of inhibitors of these 
pathways as a further promising approach to eliminate LSCs protected by the niche. 
Primarily quiescent LSCs are also discussed as a reason for CML relapse in patients, who had 
sustained, complete cytogenetic remission in response to continuous imatinib treatment after 
the stop of therapy [457,458]. These observations and findings from transplantation 
experiments with BCR-ABL positive BM cells of imatinib pretreated mice that were still able 
to generate CML in the recipient mice suggests that the quiescent LSCs are resistant to the 
antiproliferative effects of imatinib in comparison to the proliferative active progenitors [459-
461]. Therefore, an other possible strategy to sensitize quiescent LSCs in ‘minimal residual 
disease’ such as in CML to antiproliferative agents could be the activation of LSCs and to 
promote their cell-cycle entry by cytokines and other agents known to activate normal stem 
cells, such as G-CSF and IFN-α, as well as arsenic trioxide in combination with the imatinib 
treatment [462]. 
LSCs but also HSCs express a high number of multidrug transporters of the ABC family, 
such as multidrug resistance-1 (MDR1) responsible for the active efflux of different cancer 
drugs and thereby also contributing to the chemoresistance of LSCs [463,464]. Niche 
targeting therapies might also contribute to weaken these cell intrinsic resistance mechanisms. 
Finally, as LSCs and normal HSCs behave in the above-mentioned processes very similar, 
e.g. they share self-renewal pathways, treatments to target LSCs might also have a 
unacceptable toxicity to normal HSCs. The challenge is therefore to discover differences 
between normal HSCs and LSCs that enable the development of drugs, which selectively 
impair the proliferation, survival or self-renewal of LSCs, while sparing normal HSCs. 
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7. Aim of the Thesis 
Kindlin-3 together with talin is required for the activation of integrins on hematopoietic cells. 
The kindlin-3 deficient mouse shows a lethal phenotype shortly after birth. The mice suffer 
from sever hemorrhages, neutrophilia, osteopetrosis and anemia. These multiple phenotypes 
can result from a defective integrin activity in several differentiated hematopoietic cell types 
and/or hematopoietic stem and progenitor cells (HSPCs), which are the origin of all 
hematopoietic cell types. 
Adhesion molecules, especially integrins, are essential for the regulation of HSPCs in the BM 
to ensure a proper production of hematopoietic effector cells for the entire life of an organism. 
Defects in HSPC regulation can lead to a similar phenotype as observed in the kindlin-3 
deficient mice, including pancytopenia, anemia and a reduced survival after BMT. The main 
aim of this thesis was, therefore, to investigate whether a dysfunction of kindlin-3 in early 
HSPCs of the adult hematopoietic system contributes to the observed blood defects. In order 
to investigate effects of kindlin-3 loss in BM HSPCs of adult mice we had to overcome the 
lethal phenotype of kindlin-3 deficient mice shortly after birth. Therefore, we generated fetal 
liver chimeras and investigated the functionality of kindlin-3 deficient HSPCs in a 
comparable approach with HSPCs from wt control chimeras in in vivo experiments under 
homeostasis and hematopoietic stress as well as in ex vivo experiments (paper 1). 
A further aim of this thesis was to study the role of kindlin-3 in mature hematopoietic cell 
types and specific disease models. To investigate the neutrophelia in the kindlin-3 deficient 
mice we used in vitro and in vivo approaches to address the question, if a defective activation 
of not only β1 and β3 integrins, as previous shown on platelets, but also of β1, β2 and β3 on 
neutrophils due to the absence of kindlin-3 can be the reason for the severe neutrophila 
(paper 2). As the kindlin-3 mice also suffer from osteopetrosis, which could be induced by a 
dysfunction of bone resorbing OCLs, we asked if kindlin-3 is involved in activation of 
integrins on OCLs and hence regulate OCL-mediated bone resorption. We therefore, 
compared the function of kindlin-3 deficient OCLs with OCLs lacking different types of 
integrins (paper 3). We also observed that kindlin-3 null mice develop progressive thymus 
atrophy and kindlin-3 deficient chimeras were not able to produce T cells pointing to an 
important role of kindlin-3 in T cell development in the thymus. Thymic T cell development 
depends on the constant repopulation of the organ by T cell progenitors, being first generated 
in the fetal liver and later in the BM. Based on the fact that kindlin-3 deficient HSPCs have a 
severe BM homing defect and kindlin-3 deficient neutrophils show a leukocyte adhesion 
defect, we investigated extravasation and homing efficiency of kindlin-3 deficient T cell 
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progenitors into the pre- and post-vascular thymus with a combination of in vitro and in vivo 
experiments. In addition, we studied intrathymic differentiation of kindlin-3 deficient T cell 
progenitors and their interactions with different cell types within the thymus parenchyma 
(paper 4). In a previous study we showed that entry of autoreactive T cells into brain to 
induce EAE resembling MS in humans requires the activity of α4β1 integrin. We therefore 
investigated if a potential defect in the extravasation of kindlin-3 deficient T cells could also 
have an influence in the development of EAE. To address this question we studied kindlin-3 
deficient mice in different in vivo EAE mouse models as well as in vitro adhesion assays 
(paper 5). 
In another study we asked how much kindlin-3 is required to maintain blood cell functions. 
To address this question we generated hypomorphic kindlin-3 mice expressing different 
amounts of kindlin-3 and analyzed their phenotype as well as the functionality of different 
hematopoietic cells in in vivo and in vitro experiments (paper 6). To investigate the 
interaction between kindlin-3 and β1 integrins in more detail, we used platelets as a model 
system and addressed the following questions. Fist, do β1 integrins play an important role in 
the functionality of platelets? Second, is there also a dose-dependence for the function of β1 
integrins on platelets? And finally, is the interaction of kindlin-3 with β1 necessary for normal 
platelet functions? To address these questions we compared the functions of platelets from β1 
integrin deficient mice, β1 integrin hypomorphic mice (expressing only 3% of β1 integrins) 
and kindlin-3 binding-deficient β1 integrin mutant mice in in vitro and in vivo experiments 
(paper 7). Finally, we tested why kindlin-1 expressed in skin leads to increased tumor 
susceptibility. In a series of in vivo and in vitro experiments we could show that kindlin-1 
influences the activity of cutaneous epithelial stem cells (paper 8). 
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8. Brief Summaries of Publications 
Paper 1: 
Kindlin-3 controls quiescence of hematopoietic stem cells in mice. 
Ruppert R, Moser M, Sperandio M, Rognoni E, Orban M, Oostendorp RAJ, Steffen 
Massberg S, and Fässler R 
 
Adhesion molecules, especially integrins, are responsible for a precise positioning of HSCs in 
the specific BM microenvironment, termed niche, thereby influencing the exposure of HSCs 
to regulatory factors essential to ensure a life-long hematopoietic cell production. HSCs 
express multiple classes of integrins, which are critically important for their homing to and 
function in the BM as well as mobilization from the BM into the blood circulation. The 
functional activity of integrins is controlled by an activation step, which requires binding of 
talin and kindlin-3 to the cytoplasmic domains of β integrin subunits, followed by the 
assembly of a signaling hub at the integrin tails. 
To investigate the role of kindlin-3 in the regulation of HSCs homeostasis, we had to 
overcome the lethal phenotype of the kindlin-3 deficient mice shortly after birth. Therefore, 
we generated chimeric mice by transplanting fetal liver cells into lethally irradiated recipients. 
Loss of kindlin-3 expression in HSCs severely impairs their BM homing potential due to 
defects in adhesion to the microvascular endothelium. Kindlin-3 deficient HSCs (K3-/- HSCs) 
in the BM intersitium are constantly proliferating and spontaneously mobilized into the 
peripheral blood, resulting in a rapid HSC exhaustion and a reduced survival potential of the 
recipient mice. Loss of quiescence is likely caused by defective lodgment into the BM niche, 
leading to the loss of “stemness” in K3-/- HSCs, causing a strongly reduced engraftment 
potential in serial BM transplantation. In mice transplanted with K3-/- and wt BM cells, K3-/- 
HSCs can enter quiescence, but activated K3-/- HSPCs were still reduced and replaced by wt 
HSPCs under homeostatic conditions. However, induction of hematopoietic stress in these 
mix-chimeras leads to the complete displacement of the K3-/- HSCs, demonstrating that 
integrin-mediated HSC adhesion in the BM is essential for active but dispensable for 
quiescent HSCs. The defective engraftment further precluded the development of a chronic 
myeloid leukemia (CML) by BCR-ABL transduced K3-/- BM cells transplanted into 
sublethally irradiated mice. 
In conclusion, the global impairment of integrins shows that they are important for basic HSC 
functions such as homing, mobilization, proper localization in the niche, proliferation, 
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differentiation or the maintenance of stem cell identity during homeostasis and essential in 
situations of hematopoietic stress and malignancies. 
 
Paper 2: 
Kindlin-3 is required for β2 integrin-mediated leukocyte adhesion to 
endothelial cells. 
Moser M, Bauer M, Schmid S, Ruppert R, Schmidt S, Sixt M, Wang HV, Sperandio M, and 
Fässler R 
 
Proper activation of integrins is crucial for the function of all hematopoietic cells. Kindlin-3 is 
a FERM domain-containing protein expressed specifically in hematopoietic cells and 
necessary for activation of β1 and β3 integrins on platelets. Impaired β1 and β3 but also β2 
integrin activation occurs on platelets and leukocytes in patients suffering from a rare 
autosomal recessive disease called leukocyte adhesion deficiency (LAD-III). The LAD-III 
patients display severe hemorrhages and impaired leukocyte adhesion to inflamed endothelia. 
With this work we were able to demonstrate that kindlin-3 is essential for the activation of β2 
integrins and that depletion of kindlin-3 leads to a LAD-III like phenotype in mice. The 
activation of β2 integrins is mediated by a direct binding of kindlin-3 to the membrane distal 
NxxF motif of the cytoplasmic tail of the β subunit. This interaction was proven to be 
fundamental for neutrophil spreading on β2 integrin ligands such as ICAM-1 and binding to 
iC3b, which is the product of complement C3 activation and fibrinogen. In addition, the 
chemokine-triggered adhesion of neutrophils is impaired. Furthermore, in vivo experiments on 
K3-/- BM chimeras revealed that K3-/- neutrophils fail to extravasate into inflamed tissues and 
intravital microscopy on cremaster muscle venules showed that loss of kindlin-3 expression 
leads to loss of firm neutrophil adhesion and arrest on activated endothelial cells, which was 
further confirmed in in vitro adhesion assays. However, we did not observe any defects in 
selectin-mediated rolling. In conclusion, kindlin-3 is a fundamental activator of β1, β3 as well 
as β2 integrins and its deletion leads to a LAD-III-like phenotype in mice. 
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Paper 3: 
Kindlin-3-mediated signaling from multiple integrin classes is required for 
osteoclast-mediated bone resorption. 
Schmidt S, Nakchbandi I, Ruppert R, Kawelke N, Hess MW, Pfaller K, Jurdic P, Fässler R, 
and Moser M 
 
Mutation of the kindlin-3 gene in humans leads to a leukocyte adhesion deficiency type III 
(LAD-III) disorder. Some of the LAD-III patients also suffer from osteopetrosis. The exact 
mechanism of this defective bone turnover is still unclear. In general, bone homeostasis is 
dependant on the balance between bone formation performed by OBs, and bone resorption 
performed by OCLs. With our experiments we could show that loss of kindlin-3 in mice leads 
to severe osteopetrosis due to defects in adhesion and spreading of bone-resorbing OCLs. 
Although long bones of kindlin-3 deficient mice have a severe, early onset osteopetrosis, the 
number of OCLs is even increased. In vitro analysis of the kindlin-3 deficient OCLs revealed 
normal marker gene expression, normal protease activity and only a mild defect in their 
differentiation, which can be overcome by high concentrations of M-CSF. The bone resobing 
function of OCLs is dependant on formation of podosoms, actin rich structures connected to 
the bone matrix trough, mainly, αVβ3 integrins. Mature OCLs organize podosomes into 
sealing zones, which tightly circumvent the active sites of bone resorption and contain high 
concentrations of secreted protons and bone resorbing enzymes. A proper podosome function 
is necessary for formation of sealing zones and bone resorption. We were able to demonstrate 
that the deletion of kindlin-3 leads to impaired activation of integrin β1, β2, and β3 on 
osteoclasts, thereby abrogating the assembly of functional podosomes. In the absence of 
kindlin-3 podosomal actin core formation did occur, however, mature kindlin-3 deficient 
osteoclasts were unable to organize their podosoms in belts (on glass) or sealing zones (on 
bone matrices). In line with these results, we were able to further demonstrate that deletion of 
β1, β2, and β3 integrin classes impairs the development of podosomes, similarly to kindlin-3 
deletion, while the deletion of single integrins classes did not impair the podosom formation 
but rather only their resorptive function. Taken together we were able to show that OCLs 
depend on the kindlin-3 mediated activation of all their specific integrins for maintaining 
bone homeostasis. Until now αvβ3 was considered the most important integrin on osteoclasts.  
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Paper 4: 
Role of kindlin-3 in T cell progenitor homing and thymocyte development. 
Moretti FA, Ruppert R, Fässler R and Moser M 
 
T cell progenitors are generated in the BM but T cell differentiation takes place in the thymus. 
Therefore, a continuous repopulation of the thymus by progenitor cells is essential for an 
appropriate production of T cells. Thymic T cell development depends on interactions with 
various cell types critical for T cell progenitor homing to the thymus anlage and the stepwise 
progression during thymocyte maturation. Hereby the role of integrins is not defined, which 
might be due to functional compensations by different integrin members. To elucidate the role 
of integrins during T cell progenitor homing and subsequent differentiation, we studied T cell 
development in mice lacking the blood cell specific general integrin regulator kindlin-3. We 
observed that kindlin-3 null mice develop a progressive thymus atrophy and could further 
show that this is mainly caused by an impaired homing of T cell progenitors to the 
vascularized thymus in an in vivo homing assay carried out with fetal liver cells from 
wild-type and kindlin-3-null embryos transplanted into RAG-2-null mice lacking mature 
T cells. T cell progenitors, which entered the thymus anlage during development, were able to 
differentiate into single CD4+ and CD8+ T cells and emigrate into the circulation. 
Experiments showed that kindlin-3 deficient fetal liver-derived T cell progenitors colonize the 
avascular thymus primordium, albeit less efficient than wild-type T cell progenitors. Flow 
cytometic analysis of the fetal liver HSPC revealed that kindlin-3 deficient T cell progenitors 
are normally produced but accumulate in the circulation. In vitro assays revealed that the 
kindlin-3 deficient T cell progenitors are functional as they efficiently migrate towards a 
chemokine gradient, produced by the thymus epithelial cells and differentiate into the 
different T cell subsets once they have passed the vasculature. Furthermore, kindlin-3 
deficient thymocytes migrate correctly through distinct thymic regions and show normal 
maturation, in vivo BrdU label assays revealed that they exhibit a reduced proliferation 
capacity due to a weakened crosstalk with a reduced number of thymic antigen-presenting 
cells. Taken together we were able to show that the colonization of the vascularized thymus 
by BM-derived T cell progenitors during late embryogenesis and after birth is kindlin-3 and 
integrin-dependent, while the fetal population of the embryonic thymus anlage by T cell 
progenitors can occur in a kindlin-3 and integrin-independent manner. 
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Paper 5: 
Kindlin-3 regulates integrin activation and adhesion reinforcement of 
effector T cells. 
Moretti FA, Moser M, Lyck R, Abadier M, Ruppert R, Engelhardt B, and Fässler R 
 
The integrin α4β1 heterodimer expressed on activated T cells is necessary for their capture, 
rolling on, and firm adhesion to endothelial cells. Furthermore, activated T cells use the αLβ2 
integrin heterodimer for subsequent crawling and extravasation. Inhibition of α4β1 can block 
extravasation of activated T cells and is, therefore, used as treatment of autoimmune diseases 
such as MS. In this study we investigated if the integrin activator kindlin-3 in T cells is 
required to induce autoimmune diseases in mice. 
By immunization of mice lacking kindlin-3 in T cells with autoantigen we demonstrated that 
deletion of kindlin-3 in effector T cells does not impair their extravasation and consequent 
induction of EAE. Opposite to this, the deletion of kindlin-3 in autoreactive T cells impaired 
their extravasation into the naïve CNS upon adoptive transfer into mice and thereby prevented 
the induction of a passive EAE compared to wt autoreactive T cells. However, kindlin-3 
deficient autoreactive T cells are able to extravasate into inflamed CNS due to a high 
expression of integrin ligands on the brain microvasculature. We were further able to show 
that kindlin-3 null effector T cells can adhere to high concentrations of α4β1 integrins and 
ICAM-1 under conditions of physiological sheer stress in in vitro flow chamber assays, 
although with a reduced efficiency compared to wild type T cells. However, despite the 
ability of few of this arrested T cells to polarize and start crawling, only small number of them 
remained firmly adherent for longer period of time. Therefore, we could conclude that in the 
conditions of low integrin ligand expression, kindlin-3 is essential for activation of α4β1 and 
αLβ2 integrin and subsequent ligand binding as well as stabilization of integrin-ligand bonds, 
while under conditions of high ligand levels kindlin-3 is less crucial. 
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Paper 6: 
Platelets and neutrophils require different Kindlin-3 copy numbers to 
control integrin-mediated functions in vivo. 
Schmidt S, Moretti F, Zeiler M, Ruppert R, Mann M, Sperandio M, Fässler R, and Moser M 
 
Integrins are cell adhesion receptors, which anchor cell to the ECM and regulate numerous 
cellular processes such as cell migration, proliferation, differentiation and survival. Integrin 
activation is regulated by two protein families: talins (talin-1 and -2) and kindlins (kindlin-1, 
-2, and -3). Kindlin-3 and talin-1 are expressed on hematopoietic cells and both control 
integrin activation thought their tightly controlled binding to the β integrin tail, subsequently 
influencing numerous hematopoietic cell functions. Little is known about the signaling 
processes regulating the interaction between both proteins and integrins or if both proteins, 
bind at the same time or sequentially to the β integrin tail. Furthermore it is also unclear if a 
specific stoichiometry of both proteins is critical for the activation of integrins. 
To test how much kindlin-3 is required for a normal function of platelets and neutrophils we 
generated hypomorphic kindlin-3 mouse mutants expressing 50%, 10% and 5% of kindlin-3. 
Despite limited activation of integrins, mice expressing 5% and 10% of kindlin-3 were viable. 
However, these mice had reduced platelet adhesion and aggregation and therefore showed 
severe bleeding during tail-bleeding assay. Interestingly, kindlin-3 hypomorph mice showed 
only mild leukocyte adhesion deficiency in the ear and in the cremaster muscle upon 
inflammation induction, although neutophils isolated from these mice had a sever adhesion 
defect compared to wt cells in a static adhesion assay. Platelets and neutrophils show equal 
levels of both kindlin-3 and talin-1 per cell as shown by absolute quantification. In addition, 
quantification of β2, and β3 integrins revealed that platelets have a 2:1 ratio of kindlin-3 and 
talin-1 in relation to β3 integrin molecules. Neutrophils, however, have a 1:2 ratio of kindlin-3 
and talin-1 in relation to β2 integrin molecules. In conclusion we showed that 5% of kindlin-3 
in mice is sufficient for a normal development and maintenance of hematopoietic 
homeostasis, albeit with increased leukocyte counts. Furthermore, this shows that the normal 
expression of kindlin-3 is necessary for platelet-mediated hemostasis. Contrary to this, 
leukocytes require much lower levels of kindlin-3 as the hypomorphic kindlin-3 neutrophils 
showed efficient adhesion and extravasation. 
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Paper 7: 
β1 integrin-mediated signals are required for platelet granule secretion and 
hemostasis in mouse. 
Petzold T, Ruppert R, Pandey D, Barocke V, Meyer H, Lorenz M, Zhang L, Siess W, 
Massberg S, and Moser M 
 
Platelets depend crucially on integrins for adhesion and aggregation in the process of arterial 
thrombosis as well as during hemostasis. Circulating platelets express integrins in an inactive 
conformation, which are rapidly activated by extracellular stimuli at sites of vascular injury. 
An essential role for the platelet-specific αIIbβ3 integrin is already well understood, while the 
role of β1 integrins expressed on platelets is still controversial. 
Therefore, we used β1-null mice, hypomorph mice expressing 3% of wild-type β1 integrin 
levels, and activation-deficient β1 integrin mutants to analyzed the function of β1 integrins 
during arterial thrombosis. Platelets isolated from all three types of mutants showed a 
deficient adhesion to and spreading on collagen in vitro. The adhesion defects of the three 
mutant platelet types were further confirmed in an in vivo carotid ligation model. Adding of 
Mn2+ and thereby bypassing integrin inside-out signaling, rescued the spreading defect only in 
the activation-deficient β1 integrin mutant platelets. The fact that kindlin-3 is not able to bind 
the cytoplasmic tail of these mutants indicates that a direct interaction between kindlin-3 and 
β1 integrin is not required for integrin outside-in signaling. In a tail-bleeding assay we 
investigated the role of β1 for occlusive thrombus formation and observed that 3% of β1 
integrin is sufficient to enable a normal hemostasis. We next investigated activation of Rac-1, 
actin dynamics and granule secretion in the different mutant platelets, which were only 
affected in the hypomorphic platelets indicating that 3% of β1 expression is sufficient for a 
rapid Rac-1 activation required to remodel the platelet actin cytoskeleton and granule 
secretion in response to fibrous collagen. In summary, we found that β1 integrins on platelets 
function as a signaling receptor rather than as adhesion receptor, and thereby have an essential 
role for platelet granule secretion and hemostasis in mice. This new in vivo role of β1 
intergins makes them a promising antithrombotic target that should be further explored. 
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Paper 8: 
Kindlin-1 controls cutaneous epithelial stem cell proliferation by 
modulating Wnt ligand and TGFβ availability. 
Rognoni E, Widmaier M, Jakobson M, Ruppert R, Ussar S, Katsougkri D, Böttcher RT, Lai-
Cheong JE, Rifkin DB, McGrath J, and Fässler R 
 
Epidermal and hair follicle (HF) keratinocytes express the integrin activating proteins 
kindlin-1 and kindlin-2, which are highly similar in their sequence but cannot compensate for 
each other. In humans, mutations in the kindlin-1 gene leads to an autosomal recessive 
genodermatosis called Kindlier Syndrome (KS), which is characterized by trauma-induced 
skin blisters, premature skin ageing, pigmentation defects, photosensitivity, and increased risk 
for malignancies such as skin cancer. Since compromised integrins protect from skin tumors 
we wanted to investigate how the integrin activator kindlin-1 induces tumor formation. 
To this end we generated a knock-out mouse where the deletion of kindlin-1 is restricted to 
keratinocytes (Kind1-K5 mice) and observed that the phenotype of the mice resembles the 
phenotype of KS patients. In addition, Kind1-K5 mice show a misregulation of the epithelial 
stem cell homeostasis resulting in enlarged and hyperactive stem cell compartments leading to 
hyperthickened epidermis, ectopic hair follicle development and increased skin tumor 
susceptibility. The aberrant hair coat was caused by a kindlin-1 specific and β1 
integrin-independent mechanism, while aberrant keratinocyte adhesion was due to a 
dysfunction of β1-class integrins. 
Under normal conditions the HF bulge harbors dormant stem cells, which have to become 
sequentially active to maintain the hair cycle. The regulation of stem cell activity is mediated 
by a tight interplay between signaling pathways keeping stem cells quiescent such as BMP 
and TGFβ signaling and activating signaling pathways such as canonical Wnt/β-catenin 
signaling. The integrin αvβ6 is important for the release of TGFβ from the latency associated 
protein and thereby suppresses the proliferation of bulge SCs. In vivo and in vitro experiments 
show that kindlin-1 deficient keratinocytes express a higher amount of the αvβ6 integrin but 
that these integrins are functionally inactive resulting in reduced TGFβ release. This finding 
indicates that kindlin-1 is required for activation of αvβ6 and subsequent TGFβ release. We 
also found that loss of kindlin-1 in keratinocytes results in increased nuclear translocation of 
β-catenin/Lef1 and Wnt/β-catenin signaling by in vitro experiments and in vivo by 
intercrossing the Kind1-K5 mouse with the TOPgal reporter mouse. Furthermore, we could 
show that loss of kindlin-3 results in a dysregulated expression of Wnt ligands, which was cell 
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autonomous and integrin-independent. To test whether the decreased TGFβ and augmented 
Wnt signaling in the Kind1-K5 mice increases the skin tumor susceptibility, we treated the 
Kind1-K5 mouse with DMBA and TPA. A single DMBA treatment was sufficient to induced 
tumor development with more and slightly larger tumors in Kind1-K5 animals compared to 
controls, indicating that the hyperproliferative state of Kind1-K5 keratinocytes promotes 
tumor development. In summary, our findings promote a novel and essential function of 
kindlin-1 in control of cutaneous epithelial stem cell homeostasis by balancing TGF-β 
mediated growth inhibitory and Wnt/β-catenin mediated growth-promoting signals. 
 
Paper 9: 
CD98hc facilitates B cell proliferation and adaptive humoral immunity. 
Cantor J, Browne CD, Ruppert R, Féral CC, Fässler R, Rickert RC, and Ginsberg MH 
 
Maintenance of the adaptive immunity is highly dependent on the selective proliferation of 
antigen-specific lymphocytes and consequent clonal expansion. It has been shown that the 
vertebrate membrane protein CD98 heavy chain (hc) is higher expressed on proliferating 
lymphocytes. Initially CD98hc has been described as a lymphocyte-activation antigen but its 
function in the immune system is still not clear jet. This protein has two different functions: 
first it functions as an amino acid transport and second it mediates integrin signaling. 
To address the question if CD98hc is involved in the rapid lymphocyte proliferation required 
for effective adaptive immunity, we generated mice with a B cell specific deletion of the 
Slc3a2 gene (Slc3a2f/fCD19-Cre+ mice), encoding for CD98hc and thereby overcame the 
embryonic lethal phenotype of the CD98hc deficient mice. We observed that resulting 
Slc3a2f/fCD19-Cre+ mice had normal maturation and distribution of peripheral B cells and 
normal morphology of secondary lymphoid organs and concluded that the early B cell 
activation was not affected by the deletion of CD98hc. However, the Slc3a2f/fCD19-Cre+ 
mice had a lower antibody response after immunization compared to control mice, due to a 
complete suppression of B cell proliferation and plasma cell formation by CD98hc-null 
B cells. Viral transfection of CD98hc-deficient BM cells with CD98hc mutants, enabling the 
separation of the transporter function from the integrin dependent signaling functions of 
CD98hc and transplantation into lethally irradiated recipient mice revealed that the a mutant 
form of CD98hc mediating integrin signaling but not amino acid transport supported the 
proliferation of CD98hc-deficient B cells indicating that interaction between CD98hc and 
integrins is important for B cell proliferation. Loss of CD98hc further led to defects in 
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integrin-dependent events such as failure to sustain Erk1/2 activation and impaired down 
regulation of the cyclin-dependent kinase inhibitor p27, which is in common with the 
observed reduced B cell proliferation. Furthermore, mitogenic stimulation of a mixture of 
CD98hc-deficient and CD98hc-sufficient B cells resulted in an increased number of 
CD98hc-sufficient cells, indicating that CD98hc mediates a selective advantage in 
proliferating B cells. In conclusion, CD98hc is necessary for integrin-dependent clonal 
expansion of B cells, which is necessary for adaptive immunity, thereby becoming prevalent 
in vertebrates. 
 
Paper 10: 
The Mechanism of Kindlin-Mediated Activation of Integrin αIIbβ3. 
Ye F, Petrich BG, Anekal P, Lefort CT, Kasirer-Friede A, Shattil SJ, Ruppert R, Moser M, 
Fässler R, and Ginsberg MH 
 
The integrin activation and increased ligand binding has the crucial role in numerous 
processes from development, cell migration, ECM assembly, tumor metastasis, hemostasis, to 
thrombosis. Integrin activation is dependent on talin interaction with integrin β tail and is 
followed by both increased integrin monomer affinity and increased receptor clustering. In 
addition, loss of kindlin also leads to impaired integrin activation. How kindlin and talin 
cooperate in the process of integrin activation is still unclear. It is possible that kindlin 
promotes talin binding to integrin β tail. However, kindlins do not cause an increased 
association of talin with integrins. The kindlins have a high structure similarity to talin head 
domain (THD). 
To test the effect of purified kindlin-3 on individual integrins we compared the effect of 
kindlin-3 and THD on the affinity of purified monomeric αIIbβ3 integrin, inserted in 
phospholipid bilayers (nanodiscs). We observed that kindlin-3, unlike THD, had little effect 
on integrin affinity under this in vitro conditions. In addition, kindlin-3 did not increase the 
activation by THD. We next addressed the question if kindlins differently promote the 
binding affinity of αIIbβ3 integrin to monovalent or multivalent ligands. We observed that 
kindlins enhanced the binding of αIIbβ3 to multivalent but not monovalent ligands and that 
for this effect neither an intact actin cytoskeleton nor myosin II-driven contractility was 
necessary. This was further confirmed by silencing kindlin-2 in Chinese hamster ovary cells 
expressing an active αIIbβ3 mutant, showing that binding of the oligomeric 3FN10 ligand was 
inhibited but not binding of monovalent 3FN10. To investigate the effect of kindlin-3 on 
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mouse platelets in an in vivo experiment, we generated mix-chimera by mixing in a 1:1 ratio 
either kindlin-3 or talin deficient hematopoietic cells with wt DdRed hematopoietic cells and 
injected them into lethally irradiated recipient mice. We observed that kindlin-3 deletion in 
platelets and nucleated cells leads to drastically reduced αIIbβ3 binding to multivalent but not 
monovalent ligands, whereas deletion of talin had major effects on both ligand types. In 
addition, we were able to demonstrate by total internal reflection fluorescence (TIRF) and 
electron microscopy that silencing of kindlins leads to reduced clustering of ligand-bound 
αIIbβ3. In conclusion, unlike talin, kindlins exert little influence on affinity of integrins for 
monovalent ligands but do increase clustering of talin-activated integrins, thereby enhancing 
multivalent ligand binding. Despite our input this finding is highly debated in our laboratory. 
 
Paper 11: 
Knock-down and knockout of β1-integrin in hepatocytes impairs liver 
regeneration through inhibition of growth factor signaling. 
Speicher T, Siegenthaler B, Bogorad RL, Ruppert R, Petzold T, Padrissa-Altes S, Bachofner 
M, Anderson DG, Kotelianski V, Fässler R, and Sabine Werner 
 
Extensive remodeling of cell-cell and cell-matrix contacts is essential for liver regenerative 
capability. Despite this, the roles of integrins, a major class of adhesion molecules, in liver 
regeneration have been poorly studied and still remain unclear. 
In this study, we aspired to determine the functions of β1 integrins in liver regeneration by 
using β1fl/fl-Mx1Cre mice, in which the deletion of β1 integrins is inducible by administration 
of polyinosinic-polycytidylic acid (polyI:C), or mice in which the deletion of β1 integrins is 
mediated by intravenous delivery of siRNAs formulated into nanoparticles, efficiently 
ablating β1-integrin expression in hepatocytes. We were able to demonstrate that in 
non-challenged livers, loss of β1 integrins was not harmfull. However, after partial 
hepatectomy a severe liver necrosis and reduced heptocyte proliferation was observed. The 
deletion of β1 integrins in hepatocytes led to impaired ligand-induced phosphorylation of the 
EGF and HGF receptors and subsequently to defects in down-stream signaling such as 
phosphorylation of Erk, Akt or c-Met both in vitro and in vivo. In summary, we could 
conclude that β1 integrins play a crucial role in liver regeneration. In addition, we were able 
to demonstrate that liver specific gene targeting by nanoparticle-based delivery of siRNAs can 
be a useful tool to study gene functions in the regenerating liver. 
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12. Appendix 
The appendix includes reprints of the paper 1 to 11. The supplementary information as well as 
supplementary movies for each paper can be found on the enclosed CD. 
 
12.1 Paper 1: Kindlin-3 controls quiescence of hematopoietic stem cells in mice. 
12.2 Paper 2: Kindlin-3 is required for β2 integrin-mediated leukocyte adhesion to 
endothelial cells. 
12.3 Paper 3: Kindlin-3-mediated signaling from multiple integrin classes is required for 
osteoclast-mediated bone resorption. 
12.4 Paper 4: Role of kindlin-3 in T cell progenitor homing and thymocyte development. 
12.5 Paper 5: Kindlin-3 regulates integrin activation and adhesion reinforcement of 
effector T cells. 
12.6 Paper 6: Platelets and neutrophils require different Kindlin-3 copy numbers to 
control integrin-mediated functions. 
12.7 Paper 7: β1 integrin-mediated signals are required for platelet granule secretion and 
hemostasis in mouse. 
12.8 Paper 8: Kindlin-1 controls cutaneous epithelial stem cell proliferation by 
modulating Wnt ligand and TGFβ availability. 
12.9 Paper 9: CD98hc facilitates B cell proliferation and adaptive humoral immunity. 
12.10 Paper 10: The Mechanism of Kindlin-Mediated Activation of Integrin αIIbβ3. 
12.11 Paper 11: Knock-down and knockout of β1-integrin in hepatocytes impairs liver 
regeneration through inhibition of growth factor signaling. 
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Figure 4
Ruppert et al.
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Figure 5
Ruppert et al.
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Figure 7
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Kindlin-3 is required for β2 integrin-mediated leukocyte adhesion 
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Kindlin-3 is required for b2 integrin–mediated leukocyte
adhesion to endothelial cells
Markus Moser1, Martina Bauer1, Stephan Schmid2, Raphael Ruppert1, Sarah Schmidt1, Michael Sixt1,
Hao-Ven Wang1, Markus Sperandio2 & Reinhard Fa¨ssler1
Integrin activation is essential for the function of all blood cells,
including platelets and leukocytes1. The blood cell–specific
FERM domain protein Kindlin-3 is required for the activation of
the b1 and b3 integrins on platelets2. Impaired activation of b1,
b2 and b3 integrins on platelets and leukocytes is the hallmark
of a rare autosomal recessive leukocyte adhesion deficiency
syndrome in humans called LAD-III, characterized by severe
bleeding and impaired adhesion of leukocytes to inflamed
endothelia3. Here we show that Kindlin-3 also binds the b2
integrin cytoplasmic domain and is essential for neutrophil
binding and spreading on b2 integrin-dependent ligands such
as intercellular adhesion molecule-1 and the complement C3
activation product iC3b. Moreover, loss of Kindlin-3 expression
abolished firm adhesion and arrest of neutrophils on activated
endothelial cells in vitro and in vivo, whereas selectin-mediated
rolling was unaffected. Thus, Kindlin-3 is essential to activate
the b1, b2 and b3 integrin classes, and loss of Kindlin-3
function is sufficient to cause a LAD-III–like phenotype
in mice.
Leukocyte adhesion to vessel walls and subsequent transmigration into
tissues is mediated through a sequential adhesion cascade, which
allows blood cells to overcome the high shear forces within blood
vessels. The cascade is initiated by transient selectin-carbohydrate
interactions, which trigger leukocyte rolling on the surface of activated
endothelial cells. Rolling leukocytes sense immobilized chemokines,
and chemokine receptor signaling induces activation of b2 integrins.
Activated b2 integrins mediate firm binding to counter-receptors on
the endothelial cell followed by transmigration of leukocytes through
the endothelial layer4. The central role of integrins and selectins in this
multistep process is impressively highlighted by leukocyte adhesion
deficiency (LAD) syndromes in man, which can be caused either by
mutations in the gene encoding b2 integrin (LAD-I)5 or by impaired
glycosylation of selectin ligands (LAD-II)6–8.
In recent years, several groups have identified individuals suffering
from a novel form of LAD syndrome that has been termed LAD-III or
LAD-I variant. LAD-III is inherited in an autosomal recessive manner
and is characterized by a complete inability to induce activation of b1,
b2 and b3 integrins in hematopoietic cells, resulting in severe bleeding
due to impaired platelet aggregation and recurrent infections due to
abrogated leukocyte adhesion to activated endothelial cells3. Activa-
tion of leukocyte integrins can be triggered by various receptor
signaling pathways, including chemokine receptors. These signals
have been proposed to induce the binding of talin to integrin b1, b2
and b3 cytoplasmic domains, resulting in a shift of integrins from a
low-affinity to a high-affinity state for ligands (integrin activation)9.
As talin is ubiquitously expressed, and talin ablation leads to early
embryonic lethality in mice10, it is highly unlikely that mutations in
the gene encoding talin cause LAD-III. One group of researchers
found a mutation in a splice acceptor site of the CALDAGGEF1
(official symbol RASGRP2) gene and loss of CALDAGGEF1messenger
RNA in two subjects with LAD-III (ref. 11). Notably, mice lacking
CALDAG-GEF1 also suffer from defects in platelet and leukocyte
integrin function12. Moreover, CALDAG-GEF1 functions as a guanine
exchange factor for the small GTPase Rap1, which, in turn, activates
leukocyte and platelet integrins downstream of multiple receptors
including receptors for chemokines11. However, other individuals with
LAD-III lack mutations in the CALDAGGEF1 gene (see Svensson
et al.13 and Malinin et al.14 in this issue) and show normal Rap1
activity in platelets and leukocytes15,16, suggesting that mutations in
another gene cause this disease.
We recently showed that the FERM domain–containing, integrin b
tail–binding protein Kindlin-3 (encoded by the Fermt3 gene, called
Kindlin3 here) is required to activate b1 and b3 integrins in platelets2.
Kindlin-3 belongs to a unique family (Kindlin-1, Kindlin-2 and
Kindlin-3) of focal adhesion proteins. Kindlin-1 is expressed in
epithelial cells, and mutations in the gene encoding Kindlin-1 cause
a skin-blistering disease in man called Kindler syndrome17. Kindlin-2
is widely expressed, and gene ablation in mice results in peri-
implantion lethality due to severely compromised function of b1
and b3 integrins18. Kindlin-3 is exclusively expressed in hematopoietic
cells19, and mice lacking Kindlin3 (Kindlin3–/– mice) suffer from fatal
anemia, which is caused by severe bleeding and erythrocytopenia2,20.
Kindlin3–/– mice also show markedly reduced size and cellularity of
spleen and thymus and lack detectable mesenteric lymph nodes
(Supplementary Fig. 1 online).
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To test whether Kindlin-3 deficiency leads to defective leukocyte
adhesion and function, we generated fetal liver cell chimeras from
wild-type (Kindlin3+/+) and Kindlin3–/– embryos to circumvent post-
natal lethality of Kindlin3–/– mice2 and analyzed their polymorpho-
nuclear granulocytes (PMNs) in vitro and in vivo. Peripheral blood
smears 5 weeks after the fetal liver cell transfer indicated that
the number of PMNs was markedly increased in Kindlin3–/– chimeras
(Fig. 1a). This was confirmed by determining the absolute counts of
PMNs in peripheral blood, which reached 3,500 ± 1,000 cells
per ml (mean ± s.d.; n ¼ 9) in Kindlin3+/+ and 31,200 ± 27,000 cells
per ml (n ¼ 9) in Kindlin3–/– fetal liver cell chimeras (counts of other
blood cell types are shown in Supplementary Table 1 online). Despite
the severe granulocytosis, the size and nuclear morphology of PMNs
from peripheral blood or bone marrow as well as the expression
of surface markers such as Gr-1 were similar in Kindlin3+/+ and
Kindlin3–/– chimeras (Fig. 1a,b). Western blot analysis confirmed loss
of Kindlin-3 expression in bone marrow–derived Kindlin3–/– PMNs,
whereas talin amounts were normal (Fig. 1c). Pull-down experiments
with recombinant b1, b2 and b3 integrin cytoplasmic tails incubated
with platelet lysates showed a clear Kindlin-3 interaction with the b2
integrin cytoplasmic tail, although this binding was weaker compared
with binding of Kindlin-3 to b1 or b3 integrin cytoplasmic domains
(Fig. 1d). The cytoplasmic domain of b1 and b3 integrins contains two
NXXY (where X is any amino acid) motifs, whereas the b2 integrin tail
contains two NXXF motifs (Supplementary Fig. 2 online). To test
whether Kindlin-3 shares a similar spatial binding property on the
integrin b2 tail as on b1 and b3 integrin tails, we substituted each
phenylalanine residue in these motifs individually with an alanine
(F755A or F767A) and performed pull-down experiments. Kindlin-3
still bound to the F755A b2 integrin tail mutant but was unable to
interact with the F767A b2 integrin tail mutant (Fig. 1e), indicating
that the binding occurs at the distal NXXF motif and is spatially
conserved among all integrin tails tested so far. FACS analysis revealed
normal amounts of aL and slightly increased amounts of aM and b2
integrin subunits on Kindlin3–/– PMNs (Fig. 1f). Furthermore, the
expression of other surface receptors such as CD43, CD44 and
P-selectin glycoprotein ligand-1 was also not altered in the absence
of Kindlin-3 expression (Supplementary Fig. 3 online). Together
these data indicate that the absence of Kindlin-3 expression permits
the formation and maturation of PMNs. Similar to the granulocytosis
observed in individuals with LAD-I, LAD-II and LAD-III as well as in
b2 integrin–deficient mice21, there is granulocytosis in Kindlin3–/–
chimeric mice, presumably due to a compensatory response to
impaired granulocyte number or function in tissues or both.
Next we tested whether b2 integrins can be activated in the absence
of Kindlin-3 by seeding Kindlin3–/– PMNs on glass surfaces coated
with intercellular adhesion molecule-1 (ICAM-1), the endothelial
counter-receptor for the leukocyte integrins aLb2 and aMb2 that are
crucial for tight adhesion and arrest of rolling PMNs on activated
endothelium. Untreated PMNs did not show substantial adhesion and
spreading (Fig. 2a), indicating that they were not activated during
their isolation. In the presence of phorbol-12-myristate-13-acetate
(PMA), a diacylglycerol analog triggering intracellular signaling events
leading to activation of integrins (‘inside-out’ signaling), PMNs from
Kindlin3+/+ chimeras rapidly adhered and spread on ICAM-1. In
contrast, adhesion and spreading of Kindlin3–/– PMNs on ICAM-1
was completely absent (Fig. 2a). To test whether the defect in b2
integrin activation in Kindlin3–/– PMNs is due specifically to a defect in
‘inside-out’ signaling, we used MnCl2 to induce b2 integrin activation.
We incubated PMNs in suspension with fluorescently labeled fibrino-
gen, a ligand for the aMb2 and avb3 integrins, and measured the extent
of fibrinogen binding by FACS. Notably, Kindlin3+/+ and Kindlin3–/–
PMNs bound comparable amounts of fibrinogen (Fig. 2b). Together,
these findings indicate that Kindlin-3 is a key player in the intracellular
signaling cascade leading to b2 integrin activation.
To corroborate the dependence of b2 integrin activation on
Kindlin-3, we measured PMN adhesion and spreading on immobi-
lized immune complexes, which is triggered by Fcg receptor–mediated
inside-out activation of aMb2 integrin and binding to the activated
complement component iC3b22. Whereas control PMNs adhered
strongly to immune complexes and approximately half of the adherent
PMNs spread, Kindlin-3–deficient PMNs adhered weakly to immune
complexes and did not spread (Fig. 2c,d). The adhesion of mutant
PMNs to immune complexes occurred in an Fcg receptor–dependent
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Figure 1 Characterization of PMNs in Kindlin3–/– chimeric mice.
(a) Peripheral blood smears from control and Kindlin3–/– chimeras. Scale
bar, 20 mm. (b) FACS profile of bone marrow–derived cells from control
and Kindlin3–/– chimeras stained for Gr-1–FITC and CD45.2 (Ly5.2)–
allophycocyanin. PMNs from the boxed area were sorted and used for all
in vitro experiments. (c) Western blot analysis of sorted PMNs from
Kindlin3+/+ and Kindlin3–/– chimeras showing talin and Kindlin-3
expression. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used
as a loading control. (d,e) GST fusions to b1, b2 and b3 (d) and b2, F755A
b2 and F767A b2 (e) integrin cytoplasmic domains were incubated with
platelet cell lysates and used in pulldown assays to assess the binding of
these integrin domains to talin and Kindlin-3. (f) Surface expression of aL,
aM and b2 integrins on PMNs from control and Kindlin3–/– chimeras (black
lines show isotype controls; blue lines show Kindlin3+/+; green lines
show Kindlin3–/–).
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manner, as Fcg receptor blockage abolished Kindlin3–/– PMN cell
adhesion (Fig. 2c). Quantification of cell morphology after plating
revealed that around 60% of Kindlin3+/+ PMNs became flattened on
immobilized immune complexes, whereas no significant spreading
was observed with Kindlin3–/– PMNs (Fig. 2d). For closer inspection,
we followed PMNs contacting the immune complex–coated surfaces
with time-lapse video microscopy using differential interference con-
trast optics. Upon surface contact, Kindlin3+/+ PMNs spread within a
time frame of less than 1 min and subsequently remained flattened
and stationary with a ruffling periphery (Fig. 2e and Supplementary
Video 1 online). In sharp contrast, Kindlin3–/– PMNs showed severely
impaired spreading, despite active surface dynamics with peripheral
ruffling and occasional small lamellae that extended onto the surface
(Fig. 2e and Supplementary Video 1). To characterize spreading
behavior, we quantified the plasma membrane extension rates of
spreading PMNs by kymography. Spreading control PMNs rapidly
increased their diameters within 60 s after contacting the surface,
whereas the diameter of Kindlin3–/– PMNs remained unchanged
(Fig. 2f).
The spreading of preactivated PMNs on adhesive surfaces triggers a
b2 integrin–dependent degranulation and a respiratory burst that can
be measured as free reactive oxygen intermediates (ROIs). Therefore,
we seeded PMNs pretreated with tumor necrosis factor-a (TNF-a) on
immune complexes and quantified the kinetics of ROI release. In line
with findings from PMNs derived from b2 integrin–deficient mice23
and subjects with LAD-I (ref. 24), Kindlin3–/– PMNs were completely
unresponsive, whereas Kindlin3+/+ cells showed a burst of ROI
(Fig. 2g). PMA treatment partially bypasses the adhesion dependency
of the reaction24. Accordingly, under PMA stimulation Kindlin3–/–
PMNs showed a considerable rescue of ROI production, indicating a
constitutive capability to undergo respiratory burst and confirming
the normal differentiation state of these cells (Fig. 2g).
To explore the consequences of abolished b2 integrin activation in
Kindlin3–/– chimeras, we studied leukocyte extravasation into the
perivascular tissue in vivo. Initially, we applied phorbol esters (croton
oil) to the ears of the mice and examined infiltration of PMNs into
perivascular tissue 4 h later by determining PMN distribution in
relation to the vascular basement membrane. In Kindlin3+/+ chimeric
mice, many Gr-1–positive cells transmigrated into the interstitium,
where they became evenly distributed (Fig. 3a). In contrast, in
Kindlin3–/– chimeric mice, Gr-1–positive cells were abolished com-
pletely absent from the perivascular tissue, but were visible within the
vasculature (Fig. 3a). We next investigated rolling, adhesion and
extravasation of PMNs from nonchimeric Kindlin3+/" mice (as a
control) and from Kindlin3+/+ and Kindlin3–/– chimeric mice in
TNF-a–stimulated cremaster muscle venules. In line with the croton
oil experiment, Giemsa staining of treated cremaster tissues revealed a
strong and widespread influx of Kindlin3+/" or Kindlin3+/+ PMNs into
the interstitium 3 hours after TNF-a application, whereas extravasa-
tion of Kindlin3–/– PMNs was markedly reduced (Fig. 3b). Together
these findings indicate that Kindlin3–/– chimeric mice suffer from a
considerable PMN extravasation deficiency as in individuals with
LAD-I, LAD-II or LAD-III.
To determine which step in the extravasation cascade is affected by
the absence of Kindlin-3, we analyzed leukocyte rolling and adhesion
in TNF-a–stimulated cremaster muscle venules of nonchimeric
Kindlin3+/" mice and Kindlin3+/+ and Kindlin3–/– chimeric mice by
intravital microscopy. Microvascular parameters such as vessel dia-
meter, blood flow velocity and wall shear rate were similar among all
three types of mice (Supplementary Table 2 online), despite a
significant elevation of PMN counts in the peripheral blood of
Kindlin3–/– chimeric mice (P o 0.05). In line with previous observa-
tions25 and as shown here, TNF-a treatment markedly lowered
systemic leukocyte counts in Kindlin3+/" mice and in Kindlin3+/+
chimeric mice (Supplementary Table 2). TNF-a–treatment in
Kindlin3–/– chimeric mice also decreased systemic leukocyte counts,
but these counts were significantly higher than in Kindlin3+/" mice or
Kindlin3+/+ chimeric mice (Supplementary Table 2, P o 0.05).
In TNF-a–stimulated cremaster muscle venules of Kindlin3–/–
chimeric mice, the number of adherent leukocytes was significantly
reduced (220 ± 100 cells per mm2) when compared to Kindlin3+/"
mice or Kindlin3+/+ chimeric mice (980 ± 90 cells per mm2 and
Figure 2 Functional properties of Kindlin3–/–
PMNs. (a) Adhesion of neutrophils to coated
ICAM-1. Control and Kindlin3–/– PMNs were
treated with or without PMA (n ¼ 4, each assay
was performed in triplicate). FOV, field of view.
(b) Fibrinogen binding of control and Kindlin3–/–
PMNs, as analyzed by flow cytometry. Cells were
incubated with either EDTA as a negative control
or with MnCl2. (c) Adhesion of PMNs on immune
complexes. Kindlin3+/+ and Kindlin3–/– PMNs
were plated on immune complexes (IC) in the
absence or presence of antibody to Fcg receptor
(Fc block) (n ¼ 3, each assay was performed in
triplicate). (d) Spreading of PMNs on immune
complexes. Kindlin3+/+ and Kindlin3–/– PMNs
were stimulated with TNF-a before plating.
Spreading was analyzed 10, 20 and 30 min after
plating (n ¼ 4). In a and d, graphs show means
± s.d.; Student’s t test was used for comparing
different datasets. (*, P o 0.05; **, P o 0.01;
***, P o 0.001). (e) Differential interference
contrast microscopy of Kindlin3+/+ and
Kindlin3–/– PMNs 20 min after plating on
immune complexes. Scale bar, 25 mm.
(f) Kymographs of a Kindlin3+/+ or a Kindlin3–/– PMN plated on immune complexes and imaged with differential interference contrast microscopy. Scale bar,
10 mm. (g) Oxidative burst after b2 integrin–mediated activation of PMNs. Sorted PMNs from Kindlin3+/+ and Kindlin3–/– chimeras were stimulated with
either TNF-a or PMA and then the production of free ROIs was measured. Data are means ± s.d. of three independent experiments, each conducted in
triplicate. a.u., arbitrary units.
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1,220 ± 80 cells per mm2, respectively, P o 0.05 versus Kindlin3–/–
chimeric mice), indicating that Kindlin-3 is crucial for leukocyte
adhesion in vivo (Fig. 3c). Because leukocyte adhesion is greatly
influenced by the number of available circulating leukocytes, we also
calculated leukocyte adhesion efficiency, which is defined by the ratio
of adherent leukocytes to circulating leukocytes. Owing to the high
systemic leukocyte count in Kindlin3–/– chimeras, the adhesion
efficiency was dramatically reduced in Kindlin3–/– chimeric mice
(0.02 ± 0.01) when compared to Kindlin3+/" mice or Kindlin3+/+
chimeric mice (0.25 ± 0.033 and 0.35 ± 0.03, respectively, P o 0.05
versus Kindlin3–/– chimeric mice; Fig. 3d).
Next, we analyzed leukocyte rolling in TNF-a–stimulated cremaster
muscle venules, which depends on P-selectin and E-selectin in this
model25. We observed a significant increase in the number of rolling
leukocytes in Kindlin3–/– chimeric mice (60 ± 16 cells per min) as
compared to Kindlin3+/" mice or Kindlin3+/+ chimeric mice (12 ± 4
cells per min and 18 ± 3 cells per min, respectively, P o 0.05 versus
Kindlin3–/– mice; Fig. 3e and Supplementary Videos 2 and 3 online).
However, after correcting leukocyte rolling for differences in the total
number of systemic leukocytes (rolling flux fraction), we did not
observe any significant difference in rolling between Kindlin3+/+ and
Kindlin3–/– chimeric mice (Fig. 3f). We also analyzed mean leukocyte
Figure 3 Abrogated leukocyte adhesion
and extravasation in Kindlin3–/– chimeras.
(a) Sections of phorbol ester–treated ears from
Kindlin3+/+ and Kindlin3–/– chimeric mice,
stained with a pan-laminin antibody (green) to
visualize endothelial basement membranes and
Gr-1 (red) to visualize neutrophils. Arrowheads
indicate Gr-1–positive cells within blood vessels
of Kindlin3–/– chimeras. Scale bar, 200 mm.
(b) Quantification of perivascular leukocytes
in whole-mount Giemsa staining of TNF-a–
stimulated cremaster muscles from non-chimeric
Kindlin3+/– mice (15 venules in four mice),
Kindlin3+/+ (15 venules in four mice) and
Kindlin3–/– (21 venules in four mice) chimeras
3 h after cytokine application. Data are
means ± s.e.m. (c) Leukocyte adhesion in
TNF-a–stimulated cremaster muscle venules
assessed in 13 cremaster muscle venules of four
Kindlin3+/" mice, 19 venules of six Kindlin3+/+
chimeric mice and 13 cremaster muscle venules
of four Kindlin3–/– chimeric mice. (d) Leukocyte
adhesion efficiency, given as the number of
adherent leukocytes per mm2 vascular surface area divided by the systemic leukocyte count. (e) Quantification of rolling leukocytes passing an imaginary
perpendicular line over the vessel in 1 min. (f) Leukocyte rolling flux fractions, calculated to account for differences in systemic leukocyte counts between
Kindlin3+/+ mice and Kindlin3–/– mice. All values are given as means ± s.e.m. Significant differences (P o 0.05) between groups are indicated by an asterisk.
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Figure 4 Leukocyte rolling and adhesion under
in vivo and in vitro conditions. (a,b) Mean
leukocyte rolling velocity (a) and the cumulative
frequency distribution (b) of leukocyte rolling
velocities from analysis of TNF-a–stimulated
postcapillary venules of cremaster muscles from
Kindlin3+/+ (n ¼ 54 venules from four mice) and
Kindlin3–/– (n ¼ 111 venules from four mice)
chimeric mice. (c) Top, quantification of
leukocyte rolling in an ex vivo flow chamber
system (P-selectin–coated microglass capillaries)
perfused with whole blood from Kindlin3+/+
(n ¼ 5 chambers from four mice) and Kindlin3–/–
(n ¼ 3 chambers from four mice) chimeric mice.
Bottom, the number of rolling leukocytes was
corrected for differences in systemic leukocyte
counts between Kindlin3+/+ and Kindlin3–/–
chimeric mice. WBC, white blood cell.
(d,e) Assessment of leukocyte adhesion (d) and
leukocyte rolling (e) in unstimulated cremaster
muscle venules of Kindlin3+/+ (n ¼ 4) and
Kindlin3–/– (n ¼ 3) chimeric mice before and
2 min after injection of the arrest chemokine
CXCL1. (f) b1 integrin–dependent adhesion
of leukocytes from Kindlin3+/+ (n ¼ 3) and
Kindlin3–/– chimeric mice (n ¼ 3) ex vivo. Flow chambers were coated with P-selectin only or a mixture of P-selectin, VCAM-1 and CCL2, connected to the
carotid artery, perfused with whole blood for 10 min, and the number of adhered PMNs and mononuclear cells was counted. For each condition, chambers in
at least three mice were used. All data are shown as means ± s.e.m.; significant differences (P o 0.05) are indicated by asterisk.
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rolling velocities and cumulative frequency distribution of leukocyte
rolling velocities and found that they were similar in Kindlin3+/+ and
Kindlin3–/– chimeric mice, suggesting that selectin-mediated rolling is
not disturbed in the absence of Kindlin-3 (Fig. 4a,b). This was further
confirmed in an ex vivo flow chamber assay26, where leukocyte rolling
on immobilized recombinant mouse (rm) P-selectin was indistin-
guishable between leukocytes from Kindlin3+/+ and Kindlin3–/– chi-
meric mice after correction for differences in systemic leukocyte
counts (Fig. 4c). To further confirm the in vivo leukocyte adhesion
defect of Kindlin3–/– chimeric mice, we blocked leukocyte rolling in
TNF-a–stimulated cremaster muscle venules by systemic injection of
blocking antibodies against P- and E-selectin during intravital micro-
scopic observation. The blocking antibodies abruptly abolished leu-
kocyte rolling in Kindlin3+/" mice and in Kindlin3+/+ and Kindlin3–/–
chimeric mice as previously described for wild-type mice27. Five
minutes after antibody injection, a substantial number of adherent
leukocytes were still present in Kindlin3+/" mice and in Kindlin3+/+
chimeric mice (940 ± 80 cells per mm2 and 1,070 ± 90 cells per mm2,
respectively, data not shown), whereas only a few adherent leukocytes
were observed in Kindlin3–/– chimeric mice (230 ± 50 cells per mm2,
data not shown; Supplementary Videos 4 and 5 online). Taken
together, these data indicate that Kindlin-3 is not required for leukocyte
rolling on inflamed endothelium but is essential for their firm adhesion.
To investigate whether Kindlin-3 is also required for chemokine-
induced leukocyte arrest in vivo, we systemically injected the
neutrophil arrest–inducing chemokine CXCL1 (also known as kerati-
nocyte-derived chemokine, KC)25 into Kindlin3+/+ and Kindlin3–/–
chimeric mice and observed leukocyte adhesion and rolling. CXCL1
injection into Kindlin3+/+ mice triggered a significant increase in the
number of adherent leukocytes in postcapillary venules of the exteriori-
zed cremaster muscle, which was accompanied by a marked drop in the
number of rolling leukocytes (Fig. 4d,e and Supplementary Video 6
online). In contrast, injection of CXCL1 into Kindlin3–/– chimeric
mice did not change leukocyte adhesion and rolling (Fig. 4d,e and
Supplementary Video 7 online), showing that chemokine-triggered
leukocyte arrest is also almost completely absent in Kindlin3–/– mice.
Finally, we addressed the role of Kindlin-3 in b1 integrin–mediated
leukocyte adhesion with an autoperfused flow chamber assay26.
Chambers were coated with a mixture of rmP-selectin, rm vascular
cell adhesion molecule-1 (VCAM-1) and rmCCL2 or with rmP-
selectin only and connected to the carotid artery of Kindlin3+/+ or
Kindlin3–/– chimeric mice. Leukocyte adhesion was assessed 10 min
after the start of perfusion with whole blood. In Kindlin3+/+ chimeric
mice, mononuclear cells adhered preferably to the surface coated
with all three proteins compared to the surface coated with rmP-
selectin only, for which adhered cells were almost completely absent
(Fig. 4f). In contrast, in Kindlin3–/– chimeric mice, leukocytes failed to
adhere to the surface coated with all three proteins (Fig. 4f), suggest-
ing that Kindlin-3 is crucial for b1 integrin– and b2 integrin–
dependent adhesion.
Our study demonstrates that Kindlin-3 is essential for the activation
of b2 integrins in PMNs. Consequently, lack of Kindlin-3 expression
prevents adhesion and spreading of PMNs on b2 integrin ligands such
as ICAM-1 and iC3b and results in a severe leukocyte adhesion
deficiency in vivo. The mechanism underlying Kindlin-3–mediated
activation b2 integrin is similar to that underlying its activation of the
b1 and b3 integrins, as Kindlin-3 is capable of binding the distal NXXF
motif of the b2 integrin cytoplasmic domain, albeit with a lower
efficiency than its binding to this motif in the b1 and b3 integrins.
The defects seen in Kindlin3–/– mice—a severe leukocyte adhesion
deficiency and fatal bleeding—bear a striking similarity to the
symptoms observed in individuals with LAD-III. Furthermore, the
gene defect causing LAD-III has been mapped to chromosome 11 in
humans, where the Kindlin3 gene is located. Kindlin3 is thus a prime
candidate to be mutated in LAD-III. However, a recent study identified
a mutation in the CALDAGGEF1 gene, which encodes a RAP-1
guanine exchange factor, to cause LAD-III (ref. 11). Notably, Svensson
et al.13 report in this issue that subjects with LAD-III who have
mutations in CALDAGGEF1 also carry nonsense mutations in their
Kindlin3 gene. Furthermore, reexpression of a Kindlin3 cDNA fully
rescued the adhesion and spreading defect in leukocytes from these
subjects. In contrast, reexpression of CALDAGGEF1 did not rescue
these defects. It will be useful now to clarify whether mutations in
different genes such as CALDAGGEF1 and Kindlin3 can indeed give
rise to the same LAD-III syndrome and how and where they function
in the signaling pathway that leads to b2 integrin activation. Studies
with mouse mutants suggest that deficiencies of either protein can lead
to a LAD-like phenotype2,12, although CALDAG-GEF1-deficient mice
seem to have slightly milder defects than those lacking Kindlin-3. The
reason for this difference could be that Kindlin-3 controls both inside-
out and ‘outside-in’ signaling of integrins2, whereas CALDAG-GEF1
has a role only in Rap-mediated inside-out integrin activation11.
METHODS
Generation of fetal liver cell chimeras. We recently generated Kindlin3-
deficient mice2. We obtained fetal liver cells from embryonic day 15
Kindlin3+/+ or Kindlin3–/– embryos by pushing liver tissue through a cell
strainer (Falcon). We injected 4 # 106 cells into the tail vein of lethally
irradiated (10 Gy) recipient C57BL/6 mice (Charles River Laboratories). Four
to five weeks after transfer, we either isolated PMNs from the bone marrow or
used the mice for intravital microscopy. All mouse experiments were performed
with approval by the District Government of Upper Bavaria.
Intravital microscopy.We injected rmTNF-a (R&D Systems) intrascrotally at a
dose of 500 ng per mouse in a volume of 0.3 ml sterile saline. Two hours later,
we anesthetized the mice as previously described25 and placed them onto a
heating pad to maintain body temperature at 37 1C. After intubation and
carotid artery cannulation for blood sampling and application of antibodies
and chemokines, we surgically prepared the cremaster muscle for intravital
microscopy as previously described28. Briefly, after opening the scrotum, we
exteriorized the cremaster muscle and spread it over a cover glass. We gently
moved the epididymis and testis aside to get microscopic access to the
cremaster muscle microcirculation and its postcapillary venules. We performed
intravital microscopy on an upright microscope (Olympus BX51) with a saline
immersion objective (40# and 0.8 numerical aperture). We recorded experi-
ments via CCD camera (model CF8/1, Kappa) on a Panasonic S-VHS recorder.
We also made recordings with a digital camera (LaVision Biotech) and stored
them on a computer with Imspector software package (LaVision Biotech). We
then used the digital recordings offline to generate movie clips with ImageJ
software (US National Institutes of Health). During the experiment, we
obtained systemic blood samples (10 ml into 90 ml Tu¨rck’s solution, Merck)
to assess systemic white blood cell counts. In some experiments, we stimulated
the postcapillary venules of the exteriorized cremaster muscle by systemic
injection of keratinocyte-derived chemokine (CXCL1, 600 ng per mouse,
Natutec) and assessed leukocyte rolling and adhesion before and 2 min after
injection of CXCL1 as previously described25.
Data analysis of intravital experiments. We measured vessel diameter and
vessel segment length of postcapillary venules with a digital image processing
system29. We obtained centerline red blood cell velocities in microvessels of the
cremaster muscle by a dual photodiode and a digital on-line cross-correlation
program (Circusoft Instrumentation), and we converted them offline to mean
blood flow velocities as previously described28. We assessed wall shear rates as
previously reported30. We defined rolling flux as the number of rolling cells per
min. We defined rolling PMN flux fraction as the percentage of rolling PMNs in
all PMNs passing the same vessel in 1 min28. We considered PMNs that did not
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move for more than 30 s to be adherent. We assessed the number of adherent
leukocytes as the number of adherent cells per mm2 vessel surface area25.
Whole-mount histology. To assess extravasated leukocytes in TNF-a–
stimulated cremaster muscles, we prepared whole mounts of cremaster muscles
as previously described25. Briefly, while the cremaster muscle was still mounted
on the stage for intravital microscopy, we fixed the tissue with 4% parafor-
maldehyde in 0.1 M phosphate buffer (pH 7.4). We removed the cremaster
muscle and mounted it flat on a superfrost glass slide (Menzel), air-dried it for
5"10 min and fixed it in 4% paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4) for 24 h at 4 1C. After fixation, we washed the tissue three times in
0.1 M phosphate buffer with 5% ethanol, stained it with Giemsa (Sigma) at
20 1C for 5 min and developed it in 0.01% acetic acid for contrast. We washed
the developed slides in water, 75% ethanol, 95% ethanol, 100% ethanol and
fresh xylene and then mounted them in mounting medium (AGAR Scientific).
We assessed the number of extravasated leukocytes in Giemsa-stained cremaster
muscles with a Zeiss upright microscope and a 100# and 1.3 numerical
aperture oil immersion objective (Zeiss).
Ex vivo flow chamber assay. We used an autoperfused flow chamber assay as
previously described26. Briefly, we used rectangular microglass capillaries
(VitroCom) as flow chambers. We coated the flow chambers with rmP-selectin
(20 mg ml"1, R&D Systems), rmCCL2 (3 mg ml"1, Natutec) and rmVCAM-1
(15 mg ml"1, R&D Systems). We blocked nonspecific binding by incubating the
flow chambers with 10% casein (Sigma) for 2 h at 20 1C. After blocking, we
rinsed the flow chambers with normal saline and connected them to the mouse
carotid artery via polyethylene tubing. We fixed the flow chamber itself under
an upright fluorescence microscope (BX51 WI, Olympus) with a saline
immersion objective (20# and 0.95 numerical aperture, Olympus). We
observed rolling of leukocytes within the flow chamber for 10 min and
recorded their rolling via a charge-coupled device camera system (CF8HS;
Kappa) on a Panasonic S-VHS recorder. We assessed leukocyte adhesion after a
10-min perfusion by counting adherent mononuclear cells and neutrophils in a
10-mm flow chamber segment; the adherent cells were stained by gentle
flushing of the chamber with Tu¨rck’s stain (Merck).
Statistical analyses. We performed statistical analyses was with the GraphPad
Prism software (version 5.00, GraphPad). Data are presented as means ± s.d. or
means ± s.e.m. We used unpaired Student’s t tests or one-way analysis of
variance followed by a multiple pairwise comparison test (Dunn’s test) as
appropriate to compare datasets. Asterisks indicate significant differences
(*, P o 0.05, **, P o 0.01 and ***, P o 0.005).
Additional methods. Detailed methodology is described in the Supplementary
Methods online.
Note: Supplementary information is available on the Nature Medicine website.
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Introduction
Integrins are ?/? heterodimeric cell surface receptors that bind 
extracellular matrix proteins and cell counter receptors. A hall-
mark of integrins is their ability to reversibly shift between dif-
ferent af!nity states for their ligands. The shift from an inactive 
to an active conformation is triggered by the direct binding of 
talin and kindlin to the cytoplasmic domains of ?1, ?2, and 
?3 integrins, and is called integrin inside-out signaling (Moser 
et al., 2009b). Active integrins recruit and assemble large 
multimolecular complexes at their short cytoplasmic domains 
controlling several cellular processes such as organization of 
the cytoskeleton, migration, proliferation, differentiation, and 
apoptosis (integrin outside-in signaling; Legate et al., 2009).
Kindlins are a family of evolutionary conserved, intra-
cellular FERM (4.1, ezrin, radixin, moesin) domain–containing 
proteins that are recruited to integrin adhesion sites (Moser 
et al., 2009b). Mammals have three members, called kindlin-1, 
-2, and -3. In contrast to the widely expressed kindlin-1 and 
-2, kindlin-3 expression is restricted to hematopoietic cells 
(Weinstein et al., 2003; Ussar et al., 2006). The importance 
of kindlin-3 for integrin activation in vivo was !rst described 
in kindlin-3–de!cient mice, which suffer from bleeding and 
leukocyte adhesion defects (Moser et al., 2008, 2009a). Fur-
ther cellular and molecular analyses of mouse and human 
blood cells revealed that kindlin-3 is required for activation 
of ?IIb?3 on platelets and ?2 integrins on leukocytes (Moser 
et al., 2009b). Based on these !ndings, several groups identi-
!ed mutations in the human kindlin-3 gene in patients with 
leukocyte adhesion de!ciency (LAD) type III syndrome, which 
The blood cell–specific kindlin-3 protein is required to activate leukocyte and platelet integrins. In line with this function, mutations in the KINDLIN-3 gene 
in man cause immunodeficiency and severe bleeding. 
Some patients also suffer from osteopetrosis, but the under-
lying mechanism leading to abnormal bone turnover 
is unknown. Here we show that kindlin-3–deficient mice 
develop severe osteopetrosis because of profound adhe-
sion and spreading defects in bone-resorbing osteoclasts. 
Mechanistically, loss of kindlin-3 impairs the activation of 
?1, ?2, and ?3 integrin classes expressed on osteoclasts, 
which in turn abrogates the formation of podosomes and 
sealing zones required for bone resorption. In agreement 
with these findings, genetic ablation of all integrin classes 
abolishes the development of podosomes, mimicking 
kindlin-3 deficiency. Although loss of single integrin 
classes gives rise to podosomes, their resorptive activity is 
impaired. These findings show that osteoclasts require 
their entire integrin repertoire to be regulated by kindlin-3 
to orchestrate bone homeostasis.
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Results
Kindlin-3–deficient mice develop  
severe osteopetrosis
Kindlin-3–de!cient (kindlin-3?/?) mice die a few days after 
birth because of a severe anemia caused by massive bleeding 
and erythrocyte defects (Krüger et al., 2008; Moser et al., 2008). 
To analyze whether kindlin-3 affects bone development, we 
performed histology and peripheral quantitative computer to-
mography (pQCT) on long bones from kindlin-3?/? mice. At 
postnatal day 4 (P4), kindlin-3?/? bones showed a signi!cant 
increase in trabecular bone accompanied by a marked decrease 
in bone marrow (Fig. 1 A). Van Kossa staining showed increased 
calci!ed bone (Fig. 1 B). pQCT analysis con!rmed a signi!cant 
increase in bone mineral density (BMD; Fig. 1 C). Bone surface 
as determined by static histomorphometry was markedly increased 
in the absence of kindlin-3 (Fig. 1 D).
To de!ne the onset of the osteopetrosis, we compared 
the histology of control and mutant long bones from different 
developmental stages. At embryonic day 14 (E14), long bones 
from kindlin-3?/? embryos showed normal primary ossi!ca-
tion centers surrounded by a normal coat of membranous bone 
(Fig. S1 A). At E16, kindlin-3?/? bones displayed increased 
ossi!cation, and at birth, the bone mass further increased at the 
expense of the bone marrow cavity (Fig. S1 A). Alkaline phos-
phatase (AP) staining of osteoblasts and tartrate-resistant acid 
phosphatase (TRAP)-positive osteoclasts did not signi!cantly 
differ between control and mutant bones at E14, E16, and P1 
(Fig. S1, A and B).
Loss of kindlin-3 leads to severe  
osteoclast dysfunction
It has been proposed that a dysfunction of osteoblasts is respon-
sible for increased bone density in LAD-III patients (Malinin 
et al., 2009). To test whether this is also the case in kindlin-3?/?  
mice, we performed histomorphometric analysis, which showed 
normal osteoblast numbers per unit of bone surface in kindlin-3?/? 
bones (Fig. S2 A). Calvaria-derived osteoblasts isolated from 
wild-type and kindlin-3?/? pups revealed comparable levels of 
gene expression for osteoblastic markers such as AP, osteocalcin, 
and collagen I as well as normal AP activity (Fig. S2, B, D, and E). 
Furthermore, the generation of mineralized bone nodules in vitro 
was similar in osteoblasts from both genotypes. (Fig. S2, F–H). Fi-
nally, and in line with the normal biological activity of kindlin-3?/? 
osteoblasts, wild-type osteoblasts expressed kindlin-2 but neither 
kindlin-3 nor kindlin-1 (Fig. S2 C).
To determine whether osteoclasts are defective, we per-
formed TRAP staining and histomorphometric measurements 
of P4 kindlin-3?/? bones, which revealed that the number of 
TRAP-positive osteoclasts per bone surface was signi!cantly 
increased by more than threefold (Fig. 1, E and F). Despite the 
elevated number of osteoclasts, the surface covered by osteo-
clasts was signi!cantly decreased in kindlin-3?/? bones (Fig. 1 G). 
Consistent with the failure to erode bone, Ca2+ levels in the serum 
of kindlin-3?/? mice were signi!cantly decreased (Fig. 1 H), 
and parathyroid hormone (PTH) levels were increased (Fig. 1 I). 
Indeed, cultured osteoclasts differentiated from wild-type blood 
is characterized by recurrent bacterial and fungal infections 
and severe bleeding (Kuijpers et al., 2009; Malinin et al., 2009; 
Moser et al., 2009a; Svensson et al., 2009). In addition to 
the severe platelet and leukocyte dysfunction, increased bone 
mass was observed in several LAD-III patients (Kilic and 
Etzioni, 2009; McDowall et al., 2010; Sabnis et al., 2010). It 
was recently proposed that the osteopetrosis is caused by in-
creased osteogenic potential of mesenchymal stem cells (Malinin 
et al., 2009).
Bone remodeling depends on a tight interplay of osteo-
blasts that form bone and osteoclasts that resorb bone. 
Osteoblasts are derived from mesenchymal stem cells and 
cluster their integrins in adhesion sites termed focal adhe-
sions (FAs). Osteoclasts are large, multinucleated cells that 
derive from the monocyte lineage and arrange their integrins 
in adhesion structures called podosomes. Podosomes con-
tain a dotlike core of actin !laments, which is perpendicu-
larly oriented to the plasma membrane and surrounded by 
a ringlike arrangement of adhesion, adaptor, and signaling 
molecules such as integrins, paxillin, vinculin, talin, protein 
kinases, and actin-associated molecules (Linder and Kopp, 
2005). Podosomes are found in all cells of the monocytic 
cell lineage (macrophages, dendritic cells, etc.), smooth mus-
cle cells, endothelial cells, src-transformed !broblasts, and 
certain epithelial cells (Linder and Aepfelbacher, 2003). Bone-
resorbing osteoclasts arrange their podosomes by interconnect-
ing the actin cytoskeleton into densely packed rings called 
sealing zones. They delineate the active sites of bone re-
sorption and form a pocket, into which protons and bone-
resorbing proteases are secreted (Luxenburg et al., 2007). 
Sealing zones are attached to the bone matrix via ?v?3 inte-
grin. Although mature osteoclasts express integrins of the ?1, ?2, 
and ?v families, it is believed that ?v?3 integrins are the major 
adhesion proteins in osteoclast biology. This observation is 
largely based on the matrix degradation defects observed in 
Glanzmann patients or mice carrying null mutations in the ?3 
integrin gene. The reduced resorptive activity was thought to 
be caused by loss of ?v?3-mediated signaling that regulates 
cell polarity and cytoskeletal reorganization (McHugh et al., 
2000; Faccio et al., 2003a). It cannot be excluded, however, 
that ?1 and/or ?2 integrins also play a role in osteoclast-
mediated bone resorption in vivo (Helfrich et al., 1996; Rao 
et al., 2006).
Increased bone mineralization has been proposed to be 
the cause for the osteopetrosis in LAD-III patients (Malinin 
et al., 2009). It remains unclear, however, whether loss of 
kindlin-3 is indeed responsible for the increased bone mass and 
whether this bone abnormality is caused by an osteoblast and/or 
osteoclast dysfunction. In this paper, we !nd that kindlin-3– 
de!cient mice develop a severe osteopetrotic phenotype 
caused by osteoclast dysfunctions. We show that kindlin-3–
de!cient osteoclasts fail to activate all their integrin classes, 
which in turn leads to their inability to spread and reorganize 
the actin cytoskeleton, as well as a failure to form podosomes 
and sealing zones and to degrade bone matrix. Our results 
indicate that all integrin classes are required for osteoclast- 
mediated bone resorption.
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osteoprotegerin (OPG), an inhibitor of RANKL, were similar be-
tween wild-type and kindlin-3?/? mice. Treatment of kindlin-3?/? 
osteoclasts with RANKL in vitro induced a strong and sustained 
p38 and JNK phosphorylation that was comparable to wild-type 
osteoclasts (Fig. S3). The high levels of RANKL in the serum and 
the normal response to RANKL by kindlin-3?/? osteoclasts pro-
vides a plausible explanation for the increased osteoclastogenesis 
in kindlin-3?/? bones.
M-CSF and RANKL treatment induced the expression of 
osteoclastogenic markers such as cathepsin K, MMP9, and cal-
citonin receptor in wild-type and kindlin-3?/? fetal liver cells 
(Fig. 2 B). Even though induction of marker gene expression 
was slightly delayed in kindlin-3?/? cells, they nevertheless 
reached wild-type levels 6 d after cytokine treatment (Fig. 2 B). 
It should be noted that the expression of kindlin-3 remained 
stable throughout the differentiation period, and that kindlin-1 
and -2 were expressed in neither wild-type nor kindlin-3?/? cells 
upon cytokine treatment (Fig. 2 C).
Finally, we determined the number of nuclei in the osteo-
clasts as a marker for pre-osteoclast fusion and differentiation. 
Notably, in vitro generated kindlin-3?/? osteoclasts showed a 
lower tendency to form larger (>20 nuclei) polykaryons (Fig. 2 D), 
presumably because of decreased adhesion and cell spread-
ing; however, a signi!cant shift toward more multinucleated 
osteoclasts was detected in bone sections from kindlin-3?/? 
mice (Fig. 2 E). This discrepancy can be explained by the in-
creased number of osteoclast precursors triggered by the ele-
vated RANKL levels in kindlin-3?/? mice.
precursors expressed high levels of kindlin-3 but neither 
kindlin-1 nor -2 (Fig. 2 B and Fig. S2 C).
These data suggest that kindlin-3?/? osteoclasts are func-
tionally impaired. To address this !nding, we tested the resorp-
tive activity of kindlin-3?/? osteoclasts by seeding them on an 
arti!cial calci!ed matrix (osteologic slides) as well as dentin 
discs. Although wild-type osteoclasts resorbed large areas of 
mineralized matrix, kindlin3?/? osteoclasts were incapable of 
doing so (Fig. 1 J and not depicted). Morphometric image analy-
sis of the resorbed areas revealed that resorption by kindlin-3?/?  
osteoclasts was >20-fold lower than wild-type cells (Fig. 1 K). 
The profound resorption defects were not accompanied by dimin-
ished secretion of proteolytic enzymes, as secretion of matrix 
metalloproteinase 2 (MMP2) and -9 and cathepsin K activities 
were indistinguishable between control and kindlin-3?/? osteo-
clasts (Fig. 1, L and M).
Altogether, these !ndings indicate that osteopetrosis in 
kindlin-3?/? mice is caused by a dysfunction of osteoclasts 
rather than osteoblasts.
Kindlin-3 is not required for  
osteoclast differentiation
Osteoclasts originate from monocytic precursors in response to the 
actions of macrophage-colony stimulating factor (M-CSF) and re-
ceptor activator of nuclear factor ?B ligand (RANKL; Teitelbaum 
and Ross, 2003). Although the serum levels of M-CSF were similar 
(unpublished data), circulating levels of RANKL were increased 
eightfold in kindlin-3?/? mice (Fig. 2 A). Serum concentrations of 
Figure 1. Kindlin-3?/? mice develop severe osteopetrosis. (A and B) Histology of tibiae of P4 wild-type and kindlin-3?/? mice stained with hematoxylin 
and eosin (A) and van Kossa (B). (C and D) Quantitative peripheral computer tomography measurements determining bone mineral density (C) and histo-
morphometric analysis to determine bone surface from bones of P4 wild-type and kindlin-3?/? mice (D); n = 3. (E) Histology of tibiae of P4 wild-type and 
kindlin-3?/? mice stained for TRAP activity. (F and G) Histomorphometric analyses determining the number of osteoclasts (F) and surface covered by osteo-
clasts (G) of wild-type and kindlin-3?/? mice; n = 3. (H) Ca2+ levels in serum of P4 wild-type and kindlin-3?/? mice; n = 8. (I) PTH levels in plasma of P3 
wild-type and kindlin-3?/? mice; n = 10. (J and K) Resorption pits (J) and their quantification (K) of wild-type and kindlin-3?/? osteoclasts cultured on calcium 
apatite coated slides; n = 7. (L) Zymography of cell culture supernatants from primary wild-type and kindlin-3?/? osteoclasts. (M) Cathepsin K activity from 
lysates of primary wild-type and kindlin-3?/? osteoclasts; n = 11. Data are presented as mean ± SD (error bars). P-values indicate significant differences 
from wild-type (Student’s t test). n.s., not significant. Bars: (A and B) 250 µm; (E, top) 250 µm; (E, bottom) 25 µm; (J) 100 µm.
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decreases during osteoclast maturation, and ?4?1, ?5?1, 
and ?L?2 were similar in wild-type and kindlin-3?/? cells; 
however, ?M?2 was reduced to ?80% in kindlin-3?/? cells. 
(Fig. 3 B and Fig. S4 C). Next, we addressed the af!nity states 
of integrins by determining the binding of the 9EG7 antibody, 
which recognizes activated mouse ?1 integrins, and the binding 
of a "uorescently labeled FN fragment (FNIII7-10), which is 
bound by active ?v (?v?3 and ?v?5) and ?5?1 integrins. Rest-
ing kindlin-3?/? macrophages failed to bind 9EG7 and showed 
considerably reduced FNIII7-10 binding, whereas MnCl2 treat-
ment, which can bypass inside-out–mediated integrin activa-
tion, markedly increased 9EG7 and FNIII7-10 binding (Fig. 3, 
C and D). Furthermore, adhesion to ICAM-1, a ligand for ?2 
integrins, was strongly diminished in kindlin-3?/? macrophages 
compared with control cells (Fig. 3 E). Manganese treatment 
only partially rescued the adhesion defect of kindlin-3?/? cells, 
which suggests that kindlin-3 also operates in integrin outside-
in signaling.
Collectively, these data indicate that loss of kindlin-3 re-
sults in a severe adhesion defect caused by impaired activation 
and outside-in signaling of ?1, ?2, and ?v integrins.
Osteoclasts require kindlin-3 for integrin 
and growth factor signaling
Biochemical signaling events triggered by integrins and growth 
factor receptors control osteoclast adhesion, spreading, fusion, 
and differentiation (Ross and Teitelbaum, 2005). Wild-type 
osteoclasts generated from fetal liver cells differentiated into 
well-spread, multinucleated osteoclasts within 4–6 d of culture 
(Fig. 4 A). In contrast, kindlin-3?/? fetal liver cells, which also 
Altogether, these data suggest that although osteoclast 
differentiation is slightly delayed in the absence of kindlin-3 
in vitro, it occurs ef!ciently in kindlin-3?/? mice.
Kindlin-3 promotes osteoclast adhesion by 
regulating integrin activation
Kindlin-3 is required for the activation of integrins and integrin-
mediated adhesion (Moser et al., 2008, 2009a). To evalu-
ate osteoclast adhesion, we seeded wild-type and kindlin-3?/? 
osteoclasts on osteopontin, a natural ligand for osteoclasts. 
Although wild-type osteoclasts adhered readily to osteopontin, 
kindlin-3?/? osteoclasts showed signi!cantly reduced adhesion 
(Fig. 3 A). Interestingly, kindlin-3?/? osteoclasts adhered to 
both glass and cell culture plastic, particularly when cultured 
over several days. Because the transmembrane proteoglycan 
CD44 has also been shown to support osteoclast adhesion to 
osteopontin, !bronectin, collagen, and laminin (Goodison et al., 
1999; Ponta et al., 2003), we hypothesized that CD44 might 
mediate the remaining osteoclast adhesion in the absence of 
kindlin-3. To test this hypothesis, we incubated pre-osteoclasts 
with a blocking anti-CD44 antibody and observed that the 
adhesion of kindlin-3?/? cells to !bronectin was further re-
duced, which indeed indicates that CD44 contributes to osteoclast 
adhesion (Fig. S4, A and B).
To determine integrin expression, we measured their 
levels on macrophages, as the large size and strong adhesive 
properties of mature osteoclasts prevented their analysis by "ow 
cytometry. Indeed, kindlin-3?/? macrophages express ?76% 
and 63% of ?1 and ?3 integrins, respectively, when compared 
with wild-type macrophages. The expression of ?v?5, which 
Figure 2. Differentiation of kindlin-3?/? osteoclasts. (A) RANKL/OPG ratio in plasma of P3 wild-type and kindlin-3?/? mice; n = 11. (B) RT-PCR of osteo-
clastogenic markers upon M-CSF and RANKL treatment of wild-type and kindlin-3?/? fetal liver cells. (C) RT-PCR of kindlin-1 and -2 expression during 
in vitro osteoclast differentiation. RNA from keratinocytes served as positive control. (D) Number of nuclei per osteoclast 5 d after induction of differentiation; 
1,004 cells of each genotype obtained from five independent experiments were analyzed. (E) Osteoclast nuclear numbers determined from histological 
sections of P4 tibiae. 63 and 252 osteoclasts from wild-type and kindlin-3?/? bone sections were analyzed, respectively. Data are presented as mean ± SD 
(error bars). P-values indicate significant differences from wild-type (Student’s t test).
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osteoclasts. Notably, expression of integrin-binding mutant 
EGFP–kindlin-3 (EGFP–kindlin-3–QA; Moser et al., 2008) did 
not rescue osteoclast spreading, whereas fusion signi!cantly 
improved compared with cells infected with a control virus 
(Fig. S5, A and B).
Next, we analyzed whether integrin-mediated adhesion 
signaling can still occur in the absence of kindlin-3. Adhesion 
on vitronectin triggered phosphorylation of c-Src and focal ad-
hesion kinase (FAK) in wild-type pre-osteoclasts, but induced 
only a weak phosphorylation in kindlin-3?/? pre-osteoclasts 
produced multinucleated TRAP-positive cells, failed to spread 
(Fig. 4 A). Phalloidin staining showed an actin belt beneath the 
plasma membrane of control osteoclasts, whereas kindlin-3?/? 
osteoclasts displayed randomly distributed actin patches in their 
cytoplasm (Fig. 4 B). Mn2+-mediated activation of integrins 
was unable to improve the spreading defect, suggesting that 
kindlin-3 is also required for integrin outside-in signaling, 
which is central in organizing the osteoclast cytoskeleton (un-
published data). Retroviral expression of EGFP–kindlin-3 into 
kindlin-3?/? fetal liver cells rescued the formation of well-spread 
Figure 3. Integrin defects in kindlin-3?/? osteoclasts. (A) Adhesion of primary wild-type and kindlin-3?/? osteoclasts to osteopontin. Number of adherent 
cells per field of view (FOV) is shown. (B) Surface expression of ?1, ?3, ?5, and ?V integrins on wild-type (green) and kindlin-3?/? (red) macrophages. Iso-
type control staining is shown in dark blue. Numbers above graphs indicate integrin expression on kindlin-3?/? cells (mean ± SD) relative to wild-type cells 
(n = 6). (C) 9EG7 binding on wild-type and kindlin-3?/? macrophages in the presence or absence of 2 mM MnCl2. (D) Binding of Alexa Fluor 647–labeled 
FNIII7-10 by wild-type and kindlin-3?/? macrophages in the presence or absence of 3 mM MnCl2. Data show mean ± SD of four independent experiments 
and were subtracted by background binding of the isotype and EDTA control, respectively. (E) Wild-type and kindlin-3?/? macrophages plated on ICAM-1 
in the presence or absence of 1 mM MnCl2. P-values indicate significant differences from wild-type (Student’s t test).
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on glass or bone matrix. Wild-type pre-osteoclasts were able to 
form typical podosomes consisting of a central actin core sur-
rounded by a ring of adhesion molecules including ?v(?3) and 
?1 integrins, vinculin, paxillin, and talin (Fig. 6, A, C, and D; and 
not depicted). Kindlin-3?/? cells formed small, actin core–like 
structures surrounded by a diffuse actin cloud. Vinculin, talin, 
and paxillin colocalized with the actin cloud, whereas ?v and 
?1 integrins were diffusely distributed throughout the plasma 
membrane (Fig. 6, A, C, and D; and not depicted). Fluorescence 
intensity pro!ling through actin-core units revealed that actin 
cores alternate with vinculin rings in wild-type podosomes, 
whereas this alternating pattern of actin and vinculin staining 
was lost in kindlin-3?/? cells (Fig. 6 B). Approximately half 
(59.9% ± 11.1%) of the actin dots from kindlin-3?/? cells were 
depleted of vinculin and considered to be podosome structures 
even though a discrete vinculin ring was rarely observed. 
Re-expression of GFP–kindlin-3 into kindlin-3?/? pre-osteoclasts 
restored the size of the F-actin dots and the ringlike distribu-
tion of vinculin around the F-actin cores (Fig. S5 C). On the 
contrary, the integrin-binding mutant EGFP–kindlin-3–QA did 
not rescue podosome formation in kindlin-3?/? pre-osteoclasts 
and showed a diffuse distribution throughout the cell membrane 
when expressed in control pre-osteoclasts (Fig. S5 C). The 
percentage of cells that form normal podosomes was similar 
in EGFP–kindlin-3–expressing control and kindlin-3?/? cells, 
whereas re-expression of the EGFP–kindlin-3–QA resulted in 
signi!cantly fewer podosome-forming cells (Fig. S5 D). Re- 
expression of the integrin-binding mutant kindlin-3 did just 
partially improve the diffuse vinculin and F-actin localization in 
kindlin-3?/? cells (Fig. S5 C). In line with the normal podosome 
formation in EGFP–kindlin-3–expressing kindlin-3?/? cells, 
?v integrins colocalized with vinculin to podosome rings, 
whereas ?v integrins were diffusively distributed in the mem-
brane of kindlin-3?/? cells expressing an EGFP–kindlin-3–QA 
construct (Fig. S5 E). Finally, the resorptive activity of kindlin-3?/? 
osteoclasts expressing an EGFP–kindlin-3–QA was !ve times 
less compared with kindlin-3–de!cient osteoclasts expressing 
wild-type EGFP–kindlin-3 (Fig. S5 F).
High-resolution scanning electron microscopy con!rmed 
that kindlin-3?/? osteoclasts were able to form small actin 
patches, which were surrounded by a loose network of radial 
actin !bers (Fig. 7 A). In sharp contrast, control osteoclasts 
formed large actin cores within podosome clusters, which were 
extensively interconnected by thick actin bundles (Fig. 7 A). 
Despite their smaller size, the actin cores of kindlin-3?/? cells 
colocalized with cortactin, Arp2/3, and Wiskott-Aldrich syn-
drome protein (WASp), which are known core components of 
podosomes (Linder and Aepfelbacher, 2003), indicating that 
podosomal actin core formation occurs in the absence of 
kindlin-3 and activated integrins (Fig. 7, B–D).
Mature osteoclasts arrange their podosomes into differ-
ent higher ordered structures. On glass, they form a ring at 
the periphery of the cell called the podosomal belt (Fig. 8 A); 
whereas on mineralized matrices, they form several smaller 
ringlike adhesion structures called sealing zones (Fig. 8 B; 
Jurdic et al., 2006). Kindlin-3?/? osteoclasts were not able to 
form podosomal rings on glass surfaces or on sealing zones 
(Fig. 5 A), further corroborating the !nding that integrin- 
mediated signaling is severely compromised in the absence of 
kindlin-3. This weak activation is either triggered by integrin-
independent signaling processes or by some residual integrin 
activity that exists even in the absence of kindlin-3.
A previous study demonstrated that loss of ?v?3 integrin 
function in osteoclasts can be compensated by high concentra-
tions of M-CSF (Faccio et al., 2003b). To test whether kindlin-3 
loss can also be overcome by high levels of cytokines, we treated 
wild-type and mutant fetal liver cells with RANKL and different 
concentrations of M-CSF. Wild-type fetal liver cells differenti-
ated within 4 d into large, multinucleated osteoclasts when cul-
tured at low M-CSF levels (20 ng/ml), whereas kindlin-3?/? fetal 
liver cells rarely fused into polykaryons. High levels of M-CSF 
(100 ng/ml) rescued polykaryon formation but not the spreading 
defect of kindlin-3?/? cells (Fig. 5 B). Moreover, although low 
levels of M-CSF failed to induce normal phosphorylation of Erk, 
Akt, and Syk in kindlin-3?/? osteoclasts, high levels were able 
to induce normal phosphorylation of these signaling proteins 
(Fig. 5 C), which suggests normal differentiation of kindlin-3?/? 
osteoclasts in the presence of high M-CSF levels.
Altogether, these !ndings show that kindlin-3 recruitment 
to integrins is required for their activation, actin reorganization, 
and cell spreading, as well as ampli!cation of growth factor sig-
naling in osteoclasts.
Kindlin-3 is required for the formation and 
arrangement of podosomes
Osteoclast adhesion is mediated by the formation of specialized 
adhesion structures called podosomes when they are cultured 
Figure 4. Defective spreading of kindlin-3?/? osteoclasts. (A) Wild-type 
and kindlin-3?/? osteoclasts grown on glass coverslips and stained for 
TRAP. (B) F-actin (stained with phalloidin, green) and nuclei (DAPI, blue) in 
wild-type and kindlin-3?/? osteoclasts. Bars, 100 µm.
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led us to hypothesize that additional integrins contribute to the 
kindlin-3?/? osteoclast defect. To test this, we established os-
teoclast cultures from mice lacking the ?1, ?2, or ?v integrin 
genes, respectively, and from mice lacking a combination of 
two or all three integrin genes. In addition, we generated osteo-
clasts from ?3 integrin–de!cient mice to test whether other 
?v integrins in addition to ?v?3 play a signi!cant role in osteo-
clast biology. Bone marrow cells with a single or ?v/?1 or 
?1/?2 double integrin-null mutation differentiated into multi-
nucleated, spread, and TRAP-positive osteoclasts. Osteoclasts 
lacking both ?v and ?2 integrins formed polykaryons but 
were less ef!cient in spreading and localizing their nuclei to 
the cell periphery (Fig. 9 A). Bone marrow cells lacking 
?1/?2/?v integrins were only able to form a few mono- and 
binucleated cells with TRAP activity, which suggests that loss 
of all integrin classes severely impairs osteoclastogenesis in vitro 
(Fig. 9 A). Notably, although these cells did not spread, they 
weakly adhered on glass.
Individual podosomes, podosome clusters, and podo-
some belts of ?1, ?2, and ?1/?2 double integrin-null cells 
were indistinguishable from wild-type cells. ?v- and ?3-de!cient 
cells showed smaller podosome clusters with irregular distrib-
uted podosome units (Fig. 9 B). Deletion of ?v together with 
?1 or ?2 integrins abolished cluster formation completely, and 
typical podosomes with a discrete vinculin ring were rarely 
on bone matrices. F-actin and vinculin often colocalized in 
patches and were usually localized to the cell periphery (Fig. 8, 
A and B). The formation of podosomal belts and sealing zones 
requires an intact microtubule network (Destaing et al., 2003, 
2005). We therefore analyzed microtubule organization and 
acetylation by immuno"uorescence microscopy and Western 
blot analysis. Both the total and acetylated microtubule pools 
were similar between kindlin-3?/? and wild-type osteoclasts 
(Fig. 8, C and D). Furthermore, phosphorylation and the total 
amount of Pyk2, which is required for microtubule stability 
and acetylation in osteoclasts (Gil-Henn et al., 2007), were 
not altered in kindlin-3?/? cells (Fig. 5 A), an observation that 
was also made in ?3 integrin–de!cient osteoclasts (Faccio 
et al., 2003a).
These data indicate that kindlin-3 is not required for initial 
actin core formation. However, actin core maturation and inter-
connection, podosome formation, and their subsequent assem-
bly into belts and sealing zones depend on kindlin-3.
?1, ?2, and ?v integrin classes are required 
for normal osteoclast function
?v?3 integrin is considered the major functional integrin on 
osteoclasts. In contrast to the severe osteopetrotic phenotype of 
kindlin-3–de!cient mice, however, loss of ?v?3 leads to a mild 
and protracted osteopetrosis in mice and humans. This discrepancy 
Figure 5. Impaired adhesion and M-CSF sig-
naling in kindlin-3?/? pre-osteoclasts. (A) Wild- 
type and kindlin-3?/? pre-osteoclasts either 
maintained in suspension (S) or replated on 
vitronectin (A). Western blotting for kindlin-3, 
p-FAK, FAK, p-src, Src, p-Pyk2, and Pyk2. 
GAPDH and actin served as loading controls. 
(B) TRAP staining of wild-type and kindlin-3?/? 
osteoclasts treated with 40 ng/ml RANKL 
together with either 20 ng/ml or 100 ng/ml 
M-CSF. Bar, 250 µm. (C) Starved wild-type 
and kindlin-3?/? osteoclasts treated with either 
10 ng/ml or 100 ng/ml M-CSF. Western 
blotting for activated Erk and Akt. Activated 
Syk was determined by immunoprecipitation 
followed by immunoblotting with anti-phospho-
tyrosine (4G10) antibody.
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observed (Fig. 9 B). Similar to loss of kindlin-3, cells lack-
ing ?1/?2/?v integrins formed small actin dots lacking an 
adhesion ring (Figs. 9 B and 6 A). In agreement with these 
observations, we found that the diameter of the actin core 
was signi!cantly smaller (?650 nm) in podosomes from 
kindlin-3?/?, ?1/?2/?v triple-null, and ?v/?1 and ?v/?2 double- 
null pre-osteoclasts when compared with wild-type cells 
(?800 nm) or cells with a single integrin or a double ?1/?2 
integrin gene ablation (Fig. 9 C). Podosome belts of ?v- 
de!cient cells often failed to surround the entire cell and were 
signi!cantly thinner than belts from ?3-de!cient cells, which 
showed a belt size that was intermediate between control 
and ?v-de!cient osteoclasts (Fig. 9, D and E). ?v/?1 as well 
as ?v/?2 integrin–de!cient osteoclasts showed even thinner 
Figure 6. Impaired podosome formation 
in kindlin-3?/? osteoclasts. (A) Vinculin (red) 
and F-actin staining (phalloidin, green) 
of pre-osteoclasts plated on glass cover-
slips and observed by confocal microscopy. 
(B) Fluorescence intensity profile through 
three actin-core units (indicated by the white 
lines in A) of wild-type and kindlin-3?/? pre-
osteoclasts. (C and D) vinculin (red) and F-actin 
staining (phalloidin, blue) together with ?v 
integrin (green; C) or ?1 integrin (green; D). 
Bars (A and C) 5 µm; (D) 10 µm.
actin belts, which contained fewer and irregularly localized 
actin dots (Fig. 9, D and E).
Finally, we differentiated bone marrow–derived cells on 
a calci!ed matrix and evaluated their sealing zones and their 
capability to resorb matrix. The absence of a single integrin or 
the simultaneous loss of ?1 and ?2 still allowed sealing zone 
formation (Fig. 10 A), whereas the absence of ?v together with 
either ?1 or ?2 integrins abolished the formation of a distinct ring 
(Fig. 10 A). The resorptive activity of ?v/?1- and ?v/?2-de!cient 
osteoclasts was reduced to 30% of the wild-type level. Despite 
the presence of sealing zones in single integrin-null osteoclasts, 
their resorptive activity was diminished by 50%, indicating that 
each individual integrin family member contributes to functional 
sealing zone formation and bone degradation (Fig. 10 B).
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detect was a signi!cantly elevated RANKL/OPG ratio in the 
serum of kindlin-3?/? mice. RANKL secretion by osteoblasts is 
triggered in response to PTH, which is released by the parathy-
roid gland when serum Ca2+ levels decrease because of dimin-
ished bone resorption (Grant et al., 1990; Suda et al., 1999). An 
immediate consequence of high RANKL levels is enhanced dif-
ferentiation of osteoclasts, which derive from the monocytic 
lineage and express high levels of kindlin-3. Indeed, we found 
reduced levels of Ca2+ and markedly increased levels of PTH in 
the blood of kindlin-3?/? mice. Consistent with the high circu-
lating RANKL levels, we found a dramatic increase in the num-
ber of multinucleated osteoclasts in bones of kindlin-3?/? mice. 
These osteoclasts, however, completely failed to degrade bone 
matrix in vitro. In search for a mechanistic explanation for the 
dysfunction of kindlin-3?/? osteoclasts, we identi!ed several 
cellular defects that could be ascribed to kindlin-3’s principal 
task to activate several classes of integrins and subsequently 
mediate their outside-in signaling properties.
Our !ndings show that differentiation of kindlin-3?/?  
osteoclasts is slightly delayed and that fusion into multinu-
cleated polykaryons is less ef!cient under in vitro conditions. 
However, the number of large polykaryons is signi!cantly 
higher in kindlin-3?/? bones. This is most likely caused by in-
creased RANKL-induced osteoclastogenesis that compensates 
Discussion
Several LAD-III patients have displayed increased bone min-
eral density (Kilic and Etzioni, 2009; Malinin et al., 2009; 
McDowall et al., 2010; Sabnis et al., 2010), which points to the 
possibility that kindlin-3 plays a role in bone homeostasis. 
In search for an explanation of this observation, Malinin et al. 
(2009) reported that mesenchymal stem cells isolated from 
LAD-III patients produced signi!cantly higher amounts of car-
tilage and bone in transplantation experiments, and concluded 
that the increased bone mass was caused by increased matrix de-
position by hyperactive osteoblasts. Although kindlin-3 is highly 
and exclusively expressed in hematopoietic cells, osteoblasts ex-
press kindlin-2 but lack kindlin-3 expression, which suggests that 
the increased bone mass in LAD-III patients either developed 
independently of kindlin-3 or was caused by a dysfunction of a 
cell type other than osteoblasts. In this paper, we tested this hy-
pothesis by analyzing bone formation in mice lacking kindlin-3.
Kindlin-3?/? mice develop a severe osteopetrosis that is 
already apparent at birth. When we !rst analyzed the osteoblasts 
of kindlin-3–de!cient mice in vivo and in vitro, we found that 
they appeared normal in terms of their numbers, morphological 
appearance, localization to the bone, expression of marker 
genes, and matrix production. The only abnormality we could 
Figure 7. Podosomal actin core formation is not abolished in kindlin-3?/? cells. (A) Scanning electron microscopy of basal membrane preparations of 
wild-type and kindlin-3?/? osteoclasts. (B–D) Colocalization of cortactin (red) and F-actin (phalloidin, green; B), F-actin (red) and Arp2/3 (green; C), and 
WASp (red) and F-actin (green; D) in podosome clusters of wild-type and kindlin-3?/? pre-osteoclasts analyzed by confocal microscopy. Bars: (A, left) 1 µm; 
(A, right) 500 nm; (B–D) 10 µm.
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platelet integrins and that binding to ?2 tails is required to 
activate leukocyte integrins (Moser et al., 2008, 2009a). Our 
!ndings here demonstrate that this essential function of kindlin-3 
is also conserved in osteoclasts. Osteoclasts require kindlin-3 
to mediate ?1 and ?v integrin binding to !bronectin and osteo-
pontin and ?2 integrin binding to ICAM-1. This suggests that 
?v?3 integrins, considered the most important integrin class 
the fusion defects in vivo. Although TRAP-positive, multinucle-
ated kindlin-3?/? osteoclasts are present at very high numbers 
in kindlin-3?/? mice, their shape and ability to adhere to bone 
surfaces is severely impaired. Similarly, adhesion to and binding 
of several extracellular matrix proteins and to ICAM-1 is also 
almost completely abrogated. We have previously shown that 
kindlin-3 interaction with ?1 and ?3 tails is required to activate 
Figure 8. Abnormal F-actin distribution but normal microtubule organization and acetylation in kindlin-3?/? osteoclasts. (A) Vinculin (red) and F-actin 
staining (phalloidin, green) of wild-type and kindlin-3?/? osteoclasts plated on glass coverslips. (B) Vinculin (red) and F-actin staining (phalloidin, green) 
of wild-type and kindlin-3?/? osteoclasts plated on mineral surface of osteologic slides. DAPI (blue) shows nuclei (A and B). (C) Wild-type and kindlin-3?/? 
osteoclasts were labeled with phalloidin (blue), anti-acetylated tubulin (green), and anti-tubulin antibodies. (D) Cell lysates from wild-type and kindlin-3?/? 
osteoclasts were immunoblotted with antibodies against kindlin-3, acetylated tubulin, and tubulin. Antibodies against actin and GAPDH were used as load-
ing controls. Bars: (A) 25 µm; (B) 100 µm; (C) 10 µm.
Figure 9. Podosomes and actin belts in integrin-deficient osteoclasts. (A) Wild-type and single, double, and triple integrin-deficient osteoclasts stained for 
TRAP. (B) Vinculin (red) and F-actin staining (phalloidin, green) of wild-type and integrin-deficient pre-osteoclasts plated on glass. (C) Diameters of actin dots 
in pre-osteoclasts with indicated genotypes measured using MetaMorph software; n = 6/5/5/8/9/6/6/6/8/9 different cells from each genotype taken 
to measure the actin core size. (D) Vinculin (red) and F-actin staining (phalloidin, green) of wild-type and integrin-deficient osteoclasts plated on glass. DAPI 
(blue) shows nuclei. (E) Diameter of podosomal belts of wild-type and integrin-deficient osteoclasts plated on glass. Data are presented as mean ± SD (error bars). 
P-values indicate significant differences from wild-type (Student’s t test). Bars: (A) 100 µm; (B) 2 µm; (D, top) 25 µm; (D, bottom) 5 µm.
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to assume that loss of all three integrin classes leads to a fur-
ther impairment. These !ndings provide an explanation for the 
much more severe osteopetrotic phenotype of kindlin-3?/? mice 
compared with ?3 integrin mutants. Interestingly, in contrast to 
the failure of osteoclast differentiation in the absence of ?1, ?2, 
and ?v integrins, kindlin-3 de!ciency does not impair osteo-
clast differentiation both in vivo and in vitro. The reason for this 
observation is not clear. Because kindlins and talins shift the 
equilibrium of integrins toward their activation state, it is pos-
sible that certain processes such as cell fusion can proceed with 
just a few activated integrins and thus do not require the kindlin-
3–mediated equilibrium shift, whereas other processes such 
as adhesion and podosome formation require a larger number 
of activated integrins. These questions can be addressed with 
osteoclasts of engineered mice carrying hypomorphic alleles 
for ?1, ?2, and ?v integrins. If true, very low levels of integrins 
Figure 10. Sealing zones of integrin- 
deficient osteoclasts. (A) Vinculin (red) and 
F-actin staining (phalloidin, green) of wild-
type and integrin-deficient osteoclasts plated 
on a mineral surface. DAPI staining (blue) 
shows nuclei. Bar, 25 µm. (B) Resorption 
activity of wild-type and integrin-deficient 
osteoclasts plated on calcium apatite-coated 
slides quantified with MetaMorph. Number 
of analyzed slides per genotype: n = 26/6/ 
6/6/6/3/3/3/8. Data are presented as 
mean ± SD (error bars). P-values indicate 
significant differences from wild-type (Stu-
dent’s t test).
of osteoclasts, are just one of several integrin players during 
osteoclast-mediated bone resorption. This !nding was corrobo-
rated by a series of genetic experiments in which we ablated 
several integrin genes either individually or in combination 
in osteoclasts. The experiments revealed an already strongly 
reduced resorptive activity of osteoclasts when the ?1, ?2, or 
?v integrin genes were individually ablated, and a further func-
tional decline when two integrin classes were absent from 
osteoclasts. The !nding that ?v-de!cient osteoclasts show a sig-
ni!cantly more pronounced defect in matrix degradation com-
pared with ?3-de!cient osteoclasts corroborates our hypothesis 
that other integrins beside ?v?3 also play an important role in 
osteoclast function. The ablation of all three integrin classes 
does not permit osteoclast development in vitro. This made it 
impossible to test their resorptive activity. In light of the severe 
defects in osteoclasts lacking two classes of integrins, it is fair 
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Mice
Kindlin-3?/? and integrin ?3?/? mice have been described previously 
(Hodivala-Dilke et al., 1999; Moser et al., 2008). Multiple integrins were 
deleted by intercrossing mice carrying conditional null mutations in the ?v 
(?vflox/flox) and ?1 (?1flox/flox) genes (Potocnik et al., 2000), a constitutive 
null mutation in the ?2 (?2?/?) gene (Scharffetter-Kochanek et al., 1998), 
and the Mx1Cre transgene (Kühn et al., 1995). All mice were from a 
mixed 129/SvJxC57BL/6 background. Cre expression in the hematopoi-
etic system was induced by a single intraperitoneal injection of 250 mg 
polyI/C (GE Healthcare). 7 d after polyI/C treatment, bone marrow cells 
were isolated and checked for integrin surface expression via FACS. All 
animals were kept under specific pathogen-free conditions at the animal 
facility of the Max Planck Institute of Biochemistry.
Antibodies
The following antibodies were used for immunostaining of cells: mouse anti-
vinculin antibody, mouse anti-talin, mouse anti-cortactin, rabbit anti-actin, and 
mouse anti-acetylated tubulin (all from Sigma-Aldrich); rat anti-tubulin, rat 
anti-integrin ?1, and rat anti-integrin ?v (all from Millipore); mouse anti– 
p-Tyrosine (clone pY99) and mouse anti-WASp (both from Santa Cruz Bio-
technology, Inc.); rabbit anti-p16 subunit of Arp2/3 complex (Abcam); and 
FITC and Cy3-labeled secondary antibodies (Jackson ImmunoResearch 
Laboratories, Inc.). Phalloidin dyes were obtained from Invitrogen.
The following antibodies were used for flow cytometry: hamster IgG 
anti-integrin ?1, isotype control hamster IgG, and isotype control mouse 
IgG1 (all from Biolegend); rat IgG2a anti-integrin ?2, rat IgG2a anti- 
integrin ?7, rat IgG2a anti-integrin ?4, rat IgG2a anti-integrin ?5, rat 
IgG2a anti-integrin ?L, rat IgG1 anti-integrin ?v, isotype control rat IgG1, 
isotype control rat IgG2a, and rat anti-integrin ?1 clone 9EG7 (all from 
BD); and hamster IgG anti-integrin ?3, mouse IgG1 anti-integrin ?5, and rat 
IgG2b anti-integrin ?M, isotype control rat IgG2b (all from eBioscience).
The following antibodies were used for Western blotting: mouse 
anti–glyceraldehyde 3-phosphate dehydrogenase (anti-GAPDH; Merck); 
rabbit anti-actin and mouse anti-talin (both from Sigma-Aldrich); rabbit 
anti-JNK, rabbit anti-pJNK Thr183/Tyr185, rabbit anti-p38, rabbit anti-
pp38 Thr180/Tyr182, rabbit anti-pSrc Tyr418, rabbit anti-Pyk2, rabbit 
anti-pPyk2 Tyr402, rabbit anti-P42/44 MAPK, rabbit anti-pP42/44 MAPK 
Thr202/Tyr204, rabbit anti-Akt, and rabbit anti-pAkt Ser473 (all from Cell 
Signaling Technology); rabbit anti-FAK and rat anti-tubulin (both from Milli-
pore); rabbit anti-pFAK Tyr397 and rabbit anti-src (both from Invitrogen); 
and mouse anti-Syk (Abcam).
Histology
Long bones were dissected, freed from soft tissue, and either embedded in 
plastic (Osteo-Bed Bone Embedding kit, Polysciences Inc.) or decalcified in 
10% EDTA/PBS and embedded in paraffin. Paraffin sections were stained 
with hematoxylin and eosin and for TRAP activity using a commercial kit 
(Sigma-Aldrich). AP and van Kossa staining were performed according to 
standard protocols. The number of nuclei in osteoclasts was determined in 
plastic embedded bone sections from three different 4-d-old animals.
Pictures were taken by bright field microscopy with a microscope 
(Axioskop; Carl Zeiss, Inc.) equipped with a camera (DC500; Leica), 10× 
NA 0.3, 20× NA 0.50, and 40× NQ 0.75 objectives, and IM50 soft-
ware. Pictures were edited with Photoshop (Adobe).
Measurement of RANKL, OPG, and PTH concentrations
Blood was collected from P2–P5 mice after decapitation using a microvette 
(CB 300 LH; Sarstedt); samples were then centrifuged for 3 min at 7,000 g 
and the plasma was harvested. The concentrations of RANKL and OPG 
were determined with ELISA kits from R&D Systems, and the intact PTH con-
centration was determined with an ELISA kit from Immutopics International.
Osteoclast culture
Osteoclasts were differentiated in vitro either from fetal liver cells or from 
bone marrow. E14.5 wild-type and kindlin-3?/? fetal liver cells were ob-
tained by pushing the fetal liver through a 70-µm cell strainer (BD). The 
cells were kept in ?-MEM supplemented with 20 ng/ml M-CSF overnight 
(ON). Nonadherent cells were collected after 24 h. Leukocytes were 
isolated from the interface after centrifugation at 1,000 g for 20 min in 
leukocyte separation medium (Laboratoires Eurobio), then washed with 
?-MEM medium and seeded at a concentration of 2,000 cells/mm2 in osteo-
clast differentiation medium (?-MEM containing 10% heat inactivated 
FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin with 50 ng/ml 
M-CSF and 40 ng/ml RANKL). Cells were cultured at 37°C in 5% CO2 for 
5–8 d, and medium was changed every second day. Staining for TRAP 
should allow cell fusion but not bone resorption to proceed. An 
alternative scenario could be that cells that are plated for several 
days in the presence of serum and integrin ligands can activate 
integrins from outside and trigger integrin signaling even with-
out ef!cient inside-out signaling. This is obviously not possible 
in the absence of all integrin classes.
Loss of kindlin-3 expression or a triple knockout of the 
?1, ?2, and ?v integrin genes is also accompanied by impaired 
podosome formation. Podosomes consist of an integrin ring 
and a central actin core. Interestingly, small actin cores con-
taining core proteins such as cortactin, Arp2/3, and WASp form 
in kindlin-3–de!cient osteoclasts. Similarly, ?1/?2/?v-integrin 
de!cient macrophages also form actin cores with a reduced 
diameter, indicating that the induction of actin polymerization 
occurs independently of integrin action, whereas their matu-
ration requires an integrin signaling program. This observation 
is in agreement with previous studies showing that actin core 
formation and osteoclast adhesion to the substratum can also 
be mediated by the transmembrane proteoglycan CD44 in an 
integrin-independent manner (Chabadel et al., 2007). Actin 
cores lacking an adhesion ring are also found in c-src–de!cient 
osteoclasts, which suggests that c-src activity is central for their 
maturation and acts as an upstream signaling molecule required 
for the assembly of integrins and cytoplasmic adhesion proteins 
(Destaing et al., 2008; Saltel et al., 2008).
Treatment of kindlin-3?/? osteoclasts with Mn2+ signi!cantly 
improved integrin-mediated adhesion but restored neither the de-
fective F-actin reorganization nor podosome organization and 
assembly. This !nding is in agreement with several reports demon-
strating that kindlins mediate both inside-out as well as outside-in 
integrin signaling (Larjava et al., 2008; Moser et al., 2009b; Plow 
et al., 2009). Moreover, this interesting observation also indicates 
that integrin arrangement around F-actin cores cannot be accom-
plished solely by an active integrin; kindlin-3 and/or kindlin-3–
associated proteins are required in addition. Another consequence 
of the abrogated integrin outside-in signaling in kindlin-3?/? osteo-
clasts includes diminished FAK and Syk activation upon adhesion 
to extracellular matrix and impaired Erk and Akt phosphorylation 
that is seen only upon treatment with low concentrations of 
M-CSF, whereas high M-CSF levels are associated with normal 
Erk and Akt phosphorylation, indicating that integrin outside-in sig-
nals represent an ampli!er of M-CSF–induced c-Fms signaling.
This study shows for the !rst time that osteoclast- 
mediated bone resorption depends on multiple integrin classes, 
which are under control of kindlin-3. Further work will be 
required to elucidate the individual contributions of each inte-
grin subclass during podosome maturation and assembly, and 
whether certain signaling pathways that control the organiza-
tion of the cytoskeleton and the formation of sealing zones are 
directed by speci!c integrins in osteoclasts.
Materials and methods
Reagents
Recombinant murine M-CSF and receptor activator of NF-?B ligand 
(RANKL) were obtained from R&D Systems and PeproTech, respectively. 
Osteopontin was purified from bovine plasma (provided by D. Heinegard, 
University of Lund, Lund, Sweden; Franzén and Heinegård, 1985).
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legs of newborn wild-type and kindlin-3?/? mice were minced and rotated 
for 1 h at 37°C in ?-MEM containing 10% FCS. Afterward, the freed cells 
were seeded onto the coated-glass slides for 1 h and the slides were care-
fully washed with medium to remove nonadherent cells. The adherent cells 
were allowed to spread ON and were then TRAP-stained.
Macrophage adhesion on ICAM-1 was performed as described 
previously (Chavakis et al., 2008). In brief, 96-well plates were coated 
with 4 µg/ml recombinant human ICAM-1 (R&D Systems) in coating buffer 
(150 mM NaCl, 20 mM Tris-HCl, and 2 mM MgCl2, pH 9) ON at 4°C, 
blocked with 3% BSA in PBS for 1 h at RT, then incubated with 50,000 
macrophages for 30 min in a tissue culture incubator in the presence or 
absence of 1 mM MnCl2. Each condition was assayed in quadruplet. After 
washing with PBS containing 1% BSA, adherent cells were fixed in 4% 
PFA for 10 min and stained with 5 mg/ml crystal violet in 2% ethanol for 
30 min. After washing, the remaining dye was dissolved in 2% SDS. Stain-
ing intensity was measured in an ELISA plate reader at 550 nm.
Resorption assay
Osteoclasts isolated from bones of P2–P4 wild-type and kindlin-3?/? mice 
or in vitro differentiated from fetal liver cells or bone marrow were plated 
in osteoclast differentiation medium on osteologic slides (BD) for 1 wk. 
To quantify matrix resorption, cells were removed from the slides by treat-
ing them with 1% Triton X-100 and mechanical agitation, pictures were 
obtained with a microscope (Axioskop; 20× NA 0.50 objective, see His-
tology), and the resorbed area was measured using MetaMorph software. 
Alternatively, cells were cultured on dentin discs (Immunodiagnostic Sys-
tems) and resorption pits were visualized by staining with 1% toluidine 
blue in 0.5% sodium tetraborate for 3 min.
Immunofluorescence
Cells were plated on 12-mm coverslips coated with FCS for 1 h at 37°C, 
fixed with 4% PFA in PBS for 10 min or with 4% PFA for 1 min followed by 
a methanol fixation for 10 min at ?20°C, and permeabilized with 0.25% 
Triton X-100 in PBS for 20 min. Blocking was performed for 1 h with 3% 
BSA in PBS. Cells were then incubated with the primary antibody in block-
ing solution for 3 h at RT or at 4°C ON. F-actin was visualized with Alexa 
Fluor 488–Phalloidin or Alexa Fluor 647–Phalloidin. Cells were imaged at 
RT with a SP2 confocal microscope (DMIRE2; Leica) using Leica Confocal 
Software (version 2.5 Build 1227) with 40× NA 1.25 and 100× NA 1.40 
oil objective lenses. Single channels were imaged sequentially. All pictures 
were processed with Photoshop (Adobe).
Actin core size was measured in the actin channel by using Meta-
Morph software from at least six cells of each genotype. 50 actin dots were 
measured from each individual cell. The podosome belt size was obtained 
by measuring the thickness of the vinculin ring of at least 20 belts from 
osteoclasts that were differentiated in three or more independent prepara-
tions. Actin cores from at least 10 different pre-osteoclasts were analyzed. 
From each cell, 25 actin cores were analyzed.
Retroviral infections
EGFP–kindlin-3 and EGFP–kindlin-3–QA constructs (Moser et al., 2008) 
were amplified and directionally cloned using the EcoRI and BamHI 
sites of the pCLMFG retroviral vector (Naviaux et al., 1996). Vesicu-
lar stomatitis virus G–pseudotyped retroviral vectors were produced by 
transient transfection of 293T (human embryonic kidney) cells. Viral 
particles were concentrated from cell culture supernatant as described 
previously (Pfeifer et al., 2000) and used for infection of fetal liver cells. 
Fetal liver cells were prepared for differentiation into osteoclasts as de-
scribed. Cells were cultured in medium containing 10 ng/ml M-CSF 
and 40 ng/ml RANKL for 5 d, and were used for TRAP and immuno-
fluorescence staining and matrix degradation assays, or were lysed for 
Western blotting.
Gelatin zymography
Osteoclasts were isolated from bones of P2–P4 wild-type and kindlin-3?/? 
mice, plated in osteoclast differentiation medium in a single 24 well for 
about 1 wk, and washed and incubated with serum-free ?-MEM for 24 h. 
The conditioned medium was harvested, concentrated in Centricon filter 
units (10 kD cut-off; Millipore), mixed with nonreducing SDS sample buffer, 
and run on an SDS gel with a 4% stacking gel and a 12% running gel con-
taining 0.2% gelatin. Gels were incubated twice for 15 min at RT in 
0.2% Triton X-100 in ddH2O and then for several days at 37°C in MMP re-
action buffer (50 mM Tris-HCl, pH 7.5, 0.2 M NaCl, 5 mM CaCl2, and 
0.02% NaN3). The bands of gelatinolytic activity were revealed after stain-
ing with Coomassie blue.
activity was performed after 5 d in culture. Pictures were taken with a 
microscope (Axioskop) using a 20× NA 0.50 objective (see Histology).
For pre-osteoclast generation, 5 × 106 interface cells were plated 
on a 10-cm dish and cultured in osteoclast differentiation medium for 2 d. 
Cells were washed with PBS and lifted with 10 mM EDTA in PBS. Adherent 
cells that were treated with osteoclast differentiation medium for at least 2 d 
but had yet not fused into polykaryons were defined as pre-osteoclasts.
Isolation and functional assays with primary osteoblasts
Mouse calvarial osteoblasts were isolated from newborn mice as described 
previously (Wu et al., 1992). 8 × 104 primary osteoblasts were cultured 
in ?-MEM in a 12-well plate until confluence. Osteoblastogenic medium 
(?-MEM, 10% FCS, 5 mM ?-glycerophosphate, and 10 mg/ml ascorbic 
acid) was added to induce osteoblast differentiation. Osteoblast identity 
was confirmed at day 4 of differentiation by RT-PCR for AP, osteocalcin, 
and collagen I expression.
AP staining was performed on osteoblasts fixed in 4% PFA for 15 min 
and stained with DIG III solution (0.4% nitro-blue tetrazolium chloride 
[NBT]/5-bromo-4-chloro-3?-indolyphosphate p-toluidine salt [BCIP], 0.4 M 
Tris-HCl, pH 9.5, 0.4 M NaCl, and 0.2 M MgCl2). To determine AP activ-
ity, osteoblasts from 12-well plates were collected in 500 µl lysis buffer 
(10 mM Tris-HCl, pH 7.5, 0.5 mM MgCl2, 0.1% Triton X-100, and 1× 
protease inhibitors) and homogenized by sonication for 20 s followed by 
centrifugation. 50 µl of the supernatant was mixed with 50 µl of 10 mM 
p-nitrophenylphosphate (Sigma-Aldrich) in 0.1 M glycine, 1 mM MgCl2, 
and 1 mM ZnCl2, pH 10.4, and incubated for 30 min at 37°C. 50 µl 
1 M NaOH was added to stop the reaction, and absorption at 405 nm 
was measured. Assays were performed in triplicate and the AP activity was 
normalized to the initial protein content.
Alizarin red S (ARS) staining and quantification of in vitro mineral-
ization of osteoblasts was performed at day 21 after induction of osteoblast 
differentiation as described previously (Gregory et al., 2004). In brief, 
cells were fixed in 4% PFA for 15 min at RT, washed twice with ddH2O, 
and incubated with 2% ARS, pH 4.2 (adjusted with NH4OH) for 20 min 
while shaking. Cells were washed five times with ddH2O for 5 min each 
and pictured. Bound ARS was dissolved in 10% acetic acid for 30 min 
at RT. The cell layer was scraped from the plate, transferred to a reaction 
tube, and vigorously shaken for 30 s. The suspension was overlayed with 
mineral oil, heated to exactly 85°C for 10 min, and kept on ice for 5 min. 
After centrifugation at 20,000 g for 15 min, two equivalents of 10% 
NH4OH were added to five equivalents of ARS solution to get a pH of 
4.1–4.5. This solution was measured at 405 nm in triplicate.
Pictures were obtained using a stereomicroscope (MZ FLIII; Leica) 
equipped with a Plan-Apochromat 1.0× objective, a ProgRes C14 camera, 
and Photoshop (Adobe) software.
RT-PCR
RT-PCR was used to examine the expression levels of osteoclast and osteo-
blast marker genes. Osteoclasts were obtained as described; cells at time 
point day 0 were taken immediately after performing the gradient centrifu-
gation, cells at time point day 1 were cultured for 24 h in differentiation 
medium containing RANKL and M-CSF, and so on.
Total RNA was isolated using an RNeasy kit (QIAGEN). cDNA was 
obtained using the SuperScriptTM III Reverse transcription kit (Invitrogen). 
The following primers were used: calcitonin receptor 1b forward, 5?-TTTACC-
GACGAGCAACGCCTACGC-3?, and reverse, 5?-CATGTAGGACTCG-
GCCTCGTGGG-3?; cathepsin K forward, 5?-GCTATATGACCACTGCTTTC-
CAATACG-3?, and reverse, 5?-ACTGCATGGTTCACATTATCACGGTC-3?; 
GAPDH forward, 5?-TCGTGGATCTGACGTGCCGCCTG-3?, and reverse, 
5?-CACCACCCTGTTGCTGTAGCCGT-3?; collagenI forward, 5?-AAGAG-
GCGAGAGAGGTTTCC-3?, and reverse, 5?-ATCACCAGGTTCACCTTTCG-3?; 
kindlin-3 forward, 5?-AGCTGTCTCTGCTGCGTGCTC-3?, and reverse, 
5?-ATACCTTGCTGCATGAGGCAC-3?; MMP9 forward, 5?-CGAGTGGAC-
GCGACCGTAGTTGG-3?, and reverse, 5?-CAGGCTTAGAGCCACGACCAT-
ACAG-3?; kindlin-1 forward, 5?-CTACACCTTCTTTGACTTG-3?, and reverse, 
5?-AGGGATGTCAGTTATGTC-3?; kindlin-2 forward, 5?-GTACCGAAGTAG-
ACTGCAAGG-3?, and reverse, 5?-CATACGGCATATCAAGTAGGC-3?; AP 
forward, 5?-CCTTTGTGGCTCTCTCCAAG-3?, and reverse, 5?-CTGGCCTTCT-
CATCCAGTTC-3?; and osteocalcin forward, 5?-AAGCAGGAGGGCAATA-
AGGT-3?, and reverse, 5?-AGCTGCTGTGACATCCATAC-3?.
Adhesion assays
12-mm glass slides were coated for 6 h at RT with 5 µg/ml bovine osteo-
pontin in PBS or with 3% BSA. The adhesion assay was performed with 
osteoclasts, which were directly isolated from long bones as described 
previously (Flores et al., 1992; Ek-Rylander et al., 1994). In brief, all four 
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ON at 4°C on a rotator, then protein G–Sepharose beads (Sigma-Aldrich) 
were added to the lysates, incubated for 3 h at 4°C on a rotator, washed 
three times in lysis buffer, and boiled in 3× SDS sample buffer for 5 min. 
After centrifugation, proteins were separated by 10% SDS-PAGE, Western 
blotted, and probed using an HRP-labelled 4G10 antibody (Millipore).
Electron microscopy
Primary osteoclasts were cultured on glass coverslips and then “unroofed” 
as described previously (Heuser, 2000; Luxenburg et al., 2007). In brief, 
cells were exposed to hypotonic buffer (20% PHEM, 6 mM Pipes, 5 mM 
Hepes, 0.4 mM Mg2SO4, and 2 mM EGTA) and broken by brief sonication 
for 2 s. The resulting ventral membrane preparations were fixed with 2.5% 
(vol/vol) glutaraldehyde in 0.1 M phosphate buffer (pH 7.4, 1 h at RT), 
postfixed with 1% (wt/vol) aqueous OsO4, dehydrated, critical-point dried, 
and sputter-coated with 10 nm Au-Pd. Samples were viewed at 5 kV with 
a scanning electron microscope (DSM 982-Gemini; Carl Zeiss, Inc.).
Statistical analysis
A Student’s t test was used to analyze histomorphometric data, osteoblast 
data, ELISA assays, ?1 integrin activation, osteoclast fusion, belt thickness, 
resorption, and adhesion. P < 0.05 was considered to be statistically sig-
nificant. All graphs include standard deviation error bars.
Online supplemental material
Fig. S1 shows histological sections of control and kindlin-3?/? long bones 
from different developmental stages indicating progressive ossification in 
kindlin-3?/? mice. Fig. S2 shows normal biological activity of kindlin-3?/? 
osteoblasts. Fig. S3 shows normal p38 and JNK phosphorylation of 
kindlin-3?/? osteoclasts upon RANKL treatment in vitro. Fig. S4 shows that 
CD44 contributes to the residual adhesion of kindlin-3?/? pre-osteoclasts 
and integrin surface expression levels on control and kindlin-3?/? macro-
phages. Fig. S5 shows that retroviral-expressed EGFP–kindlin-3 rescues cell 
spreading, podosome formation, and matrix degradation in kindlin-3?/?  
osteoclasts, whereas expression of an integrin-binding mutant EGFP–kindlin-3 
construct fails to do so.
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Cathepsin K activity measurement
Functional cathepsin K concentration was measured in protein lysates of 
cultured osteoclasts using a Cathepsin K Activity Assay kit (BioVision, Inc.). 
The assay was performed according to the manufacturer’s instructions 
using 50 µg protein lysate per measurement.
Bone mineral density and histomorphometric measurements
pQCT of the distal femur was performed with XCT Research SA+ (StraTec 
Medizintechnik). Bone density was measured exactly in the middle of the 
bone length using peel mode 2 with the threshold set at 100. Calcein 
labeling was performed as follows: 50 µl of 5 mg/ml calcein (Sigma- 
Aldrich) in 0.9% NaCl and 50 mM NaHCO3 was injected at P0 and 
exactly 24 h later intraperitoneally. Mice were sacrificed 15 h after the 
second injection and long bones were dissected, fixed in 70% ethanol, 
and embedded in polymethylmethacrylate. 3-µm sections of the distal 
femur were deplasticized and stained for Masson-Goldner with hema-
toxylin (Gill II; Carl Roth), acid fuchsin-ponceau xylidine, and phospho-
molybdic acid-orange G for visualizing cells, and osteoid and light green 
for visualizing mineralized matrix. Cancellous bone was examined in the 
1-mm band below the growth plate, whereas primary cancellous bone 
was examined in the first 200 µm and secondary cancellous bone in 
the remaining 800 µm. Data presented were combined for both types. 
Histomorphometric analysis was performed according to the standards 
set forth by the American Society for Bone and Mineral Research (Parfitt 
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(OS), bone surface (BS), osteoblast number (Ob.N), osteoclast number 
(Oc.N), and osteoclast surface (Oc.S). Measurements were performed by 
a person blinded to the genotype of the mice.
Flow cytometry
Fetal liver cell–derived macrophages and pre-osteoclasts were incubated 
with Fc receptor–blocking antibody (Millipore) and then with the appropri-
ate fluorophore-conjugated monoclonal antibodies for 30 min on ice. 
Analysis was performed with a FACSCalibur (BD). ?1 integrin activation 
was induced with 2 mM Mn2+ and analyzed with the 9EG7 antibody and 
a fluorophore-conjugated anti–rat antibody. 9EG7 binding was normal-
ized to ?1 integrin surface levels.
FNIII7-10 binding assay
Human FNIII7-10 fragment was subcloned into pET15b plasmid (Invitro-
gen), expressed in bacteria, and subsequently labeled with Alexa Fluor 
647 carboxylic acid via a succinimidyl ester (Invitrogen) as described pre-
viously (Czuchra et al., 2006). To assess ligand-binding properties, fetal 
liver–derived macrophages were harvested and incubated with Alexa Fluor 
647–coupled FNIII7-10 fragment in TBS in the presence or absence of 
10 mM EDTA or 2 mM MnCl2, respectively, and then subjected to flow 
cytometry analysis. Mean fluorescence of EDTA-treated cells was consid-
ered unspecific signal and was subtracted from all values.
Blocking of CD44-mediated adhesion
Osteoclast precursors were lifted using 10 mM EDTA in PBS and were first 
incubated for 15 min with an Fc receptor–blocking antibody followed by a 
15 min incubation with either an anti-CD44–blocking antibody (BD) or rat 
IgG2b (eBioscience) before seeding on a fibronectin-coated surface. After 
adhesion for 30 min, cells were carefully rinsed with PBS and fixed with 
4% PFA. Pictures were obtained using a microscope (Axiovert 40C; Carl 
Zeiss, Inc.) with a camera (Prosilica), a 10× objective lens, and FireWire 
Recorder software.
RANKL- and M-CSF-signaling
Mature osteoclasts were serum starved in ?-MEM for 3–4 h and treated with 
either recombinant M-CSF (100 ng/ml or 10 ng/ml) or recombinant RANKL 
(100 ng/ml) for the times indicated. Cells were washed in cold PBS, lysed on 
ice with modified RIPA lysis buffer (50 mM Tris-HCl, pH7.3, 150 mM NaCl, 
2 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 1× protease in-
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For detection of Syk phosphorylation, 500 µg of lysate was used for 
immunoprecipitation. Lysate was incubated with 3 µg of primary antibody 
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ABSTRACT 
 
T cell development depends on interactions with various cell types, which are critical for 
T cell progenitor homing to the thymus anlage and the stepwise progression during 
thymocyte maturation. During these processes the role of integrins is not defined, which 
might be due to functional compensations by different integrin members. To elucidate 
the role of integrins during T cell progenitor homing and subsequent differentiation, we 
studied T cell development in mice lacking the blood cell specific general integrin 
regulator kindlin-3. Kindlin-3 null mice develop a progressive thymus atrophy, which is 
mainly caused by an impaired homing of T cell progenitors to the vascularized thymus. 
Interestingly, during early thymus development kindlin-3 deficient fetal liver-derived T 
cell progenitors can home to the avascular thymus primordium, albeit less efficiently 
than wild-type T cell progenitors. We further show that those T cell progenitors, which 
managed to enter the thymus anlage, further develop into single positive CD4+ and 
CD8+ T cells and emigrate into the circulation. Although kindlin-3 deficient thymocytes 
migrate correctly through distinct thymic regions and show normal maturation, they 
exhibit a reduced proliferation capacity, which is due to a weakened crosstalk with a 
reduced number of thymic APCs. 
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INTRODUCTION 
In contrast to most hematopoietic lineages, which develop within the bone marrow (BM), T 
cells complete their development within the specialized environment of the thymus. Since the 
hematopoietic stem cells and T cell progenitors are generated in the BM, T cell development 
depends on the continuous repopulation of the thymus by blood-born T cell progenitors 
(Jotereau 1987; Foss 2001; Cai 2007). T cell progenitor homing starts before the thymus is 
vascularized, which occurs at embryonic day (E) 15. Initial colonization of the thymic anlage 
can be already observed at E11.5 by fetal liver  (FL)-derived progenitors, which leave the 
adjacent pharyngeal vessels and migrate towards and enter the thymic primordium. Upon 
thymus vascularization, T cell progenitors can directly enter the thymus anlage, where direct 
interactions with thymic epithelial cells (TECs), macrophages and dendritic cells (DCs) 
coordinate their proliferation, differentiation and selection before they are released into the 
periphery.  
T cell progenitor homing to the thymus requires their adhesion and transmigration through the 
pharyngeal vessels at the pre-vascular stage and the post-capillary venules at the cortico-
medullary junction (CMJ) of the vascularised thymus. Although the molecular mechanisms 
controlling T cell progenitor extravasation have not been investigated in detail, it is assumed 
that they follow the classical multistep leukocyte adhesion cascade consisting of initial 
selectin-mediated rolling, activation by chemokines, and integrin-dependent adhesion, 
adhesion strengthening and crawling before the leukocyte transmigrates through the 
endothelium (Ley 2007). In line with this assumption, mouse mutants lacking P-selectin 
glycoprotein ligand-1 (PSGL-1) and studies with function-blocking antibodies against ?4 
and/or ?2 integrin revealed fewer thymic progenitors in the adult thymus indicating that both 
selectin-mediated rolling and integrin-mediated adhesion are important for T cell progenitor 
homing to the adult thymus (Rossi 2005; Scimone 2006). However, genetic ablation of 
various integrins, such as ?4 (Arroyo 1996), ?L (Schmits 1996), ?6 (Georges-Labouesse 
1996), ?2 (Scharffetter-Kochanek 1998), ?7 (Wagner 1996; Bungartz 2006) as well as the 
integrin ligand ICAM-1 (Sligh 1993; Xu 1994) had no effect on thymic colonization. In 
addition, the molecular events forming the basis of T cell progenitor homing to the pre-
vascular thymus has not yet been addressed.  
Once within the thymus, progenitors then follow a defined route through distinct regions 
within the thymus, where specific interactions with different thymic antigen presenting cell 
(APC) subsets trigger proliferation and differentiation and the formation of self-tolerant T 
cells (Wood 1985; Lorenz 1989a; Lorenz 1989b; Jayaraman 1992; Sebzda 1999; Wu 2005; 
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Mackay 2001; Li 2009). Whether T cell progenitor extravasation and homing to the pre- and 
post-vascular thymus as well as intrathymic differentiation are integrin dependent or whether 
a functional compensation by different receptors occurs in vivo is not known yet.  
In this study, we investigated the role of integrins during T cell progenitor homing and 
subsequent differentiation by analysing kindlin-3 deficient mice. Kindlins, like talins, are 
intracellular proteins that directly bind to the cytoplasmic domain of integins and thereby 
control the ligand-binding affinity state of the integrin. Kindlin-3 is one member of the kindlin 
gene family, which is exclusively expressed in the hematopoietic system (Weinstein 2003; 
Ussar 2006). The paramount importance of kindlin-3 in controlling the three major integrin 
classes, ?1, ?2 and ?3 integrins, in different hematopoietic cells is demonstrated by the severe 
phenotype of kindlin-3-deficient mice. These mice die postnatally with severe haemorrhages, 
structural defects of the erythrocyte membrane skeleton, a leukocyte adhesion defect and a 
severe osteopetrosis (Moser 2008, Krüger 2008, Schmidt 2011, Moser 2009). Importantly, 
mutations in the human kindlin-3 gene cause a rare leukocyte adhesion deficiency type-III 
(LAD-III) syndrome, which is characterized by the same disease pattern as observed in the 
kindlin-3 knockout mice (Mory 2008; Kuijpers 2009; Malinin 2009; Svensson 2009). 
Surprisingly, LAD-III patients show a lymphocytosis suggesting that T cell development does 
not require kindlin-3-mediated integrin regulation (Alon 2003; Pasvolsky 2007). Based on 
this finding, we investigated T-lymphopoiesis in kindlin-3-deficient mice. 
Here we show that kindlin-3-deficient mice develop a progressive thymus atrophy, which is 
caused by impaired colonization of the vascularised thymus by the bone marrow (BM)-
derived T cell progenitors during late embryogenesis and after birth. In strong contrast, 
colonization of the non-vascularized thymic primordium by kindlin-3-deficient FL-derived 
progenitors does occur indicating that T cell progenitor homing to the early thymus does not 
critically depend on integrins. Progenitors that managed to enter the thymus differentiate into 
mature single positive CD4 and CD8 T cells. Nevertheless, their proliferation is markedly 
decreased, which might be due to the reduced presence and a weakened interaction with 
macrophages and dendritic cells within the thymus parenchyma and a disturbed crosstalk with 
TECs. 
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RESULT 
Mice lacking kindlin-3 develop progressive thymus atrophy 
We have previously reported that kindlin-3-deficient (kindlin-3-/-) mice show a reduced 
cellularity of the postnatal thymus (Moser, 2009). To study this in more detail, we first 
analyzed thymopoiesis during embryonic and postnatal development. As shown in Fig. 1A 
and B, thymi from both wild-type and kindlin-3-/- mice grow in size until postnatal day 3 (P3). 
Thereafter, kindlin-3-/- thymi became atrophic. In line with this macroscopic observation, an 
increase in thymus cellularity of both genotypes was measured until P3, even though the 
kindlin-3-/- thymus cellularity remained significantly reduced compared to controls at all time 
points. While the cell number of wild-type thymi subsequently increased, the thymus 
cellularity of kindlin-3-/- mice decreased (Fig 1C). Kindlin-3-/- mice usually die within the first 
week after birth (Moser 2008) excluding an analysis later then P8. 
Next, we evaluated the thymic cyto-architecture on thymus sections by standard hematoxylin 
& eosin stainings (Fig. 1D). Despite the difference in size, both wild-type and mutant thymi 
were organized into a cortex and a medulla. P0 thymi showed numerous medullary islets 
interspersed within the cortex, which subsequently enlarged and fused to give a mature central 
medulla at P3. A regular formation of a cortico-medullary junction (CMJ), with separation of 
CD4/CD8-double positive (DP) T cells in the cortex from CD4- and CD8-single positive (SP) 
T cells in the medulla, can also be observed in kindlin-3-/- thymi by immunofluorescence 
stainings at P3. Furthermore, a normally organized thymic epithelial meshwork and vascular 
system is present in kindlin-3 mutant thymi (Supplementary Fig. 1A). However, the atrophic 
thymi of kindlin-3-/- mice at P6 and P8 showed a progressive enlargement of the medulla in 
relation to a strong reduction of the cortex, suggesting a biased development towards CD4- 
and CD8-SP T cells (Fig. 1D). This trend was indeed confirmed by flow cytometry (Fig. 1E, 
F and G). Importantly, at both P3 and P6 the CD4/CD8-double negative (DN) cell 
populations, which contain the most immature intrathymic T cells, were significantly reduced 
in their frequencies in kindlin-3-/- thymi (Fig. 1F and G). Despite the shift towards SP T cell 
populations in kindlin-3-/- thymi, all T cell subsets were significantly reduced in cell number 
compared to controls (Supplementary Fig. 1B and C); however, T cell maturation, which 
depends on a functional T cell receptor (TCR)/CD3 complex and a regulated expression of 
certain co-stimulatory glycoproteins, such as CD5 and CD24 (Fehling 1997; Michie 2002; 
Punt 1994; Azzam 1998; McKean 2001), was not affected by the absence of kindlin-3 
(Supplementary Fig. 1D). 
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Importantly, expression of kindlin-3 in different T cell subsets and complete absence of 
kindlin-3 without a compensatory up-regulation of kindlin-1 and -2 expression in the thymus 
of kindlin-3-deficient mice was confirmed by Western-blot analysis (Supplementary Fig. 1E 
and F). 
Taken together, these findings clearly indicate that kindlin-3 is dispensable for intrathymic T 
cell migration, differentiation and maturation, but T cell numbers and distribution critically 
depend on kindlin-3. 
 
Kindlin-3-/- BM-derived T cell progenitors do not extravasate to the postnatal thymus 
Next we wanted to investigate why kindlin-3-/- thymi contain significantly less immature T 
cells (Fig. 1F and G). Therefore, we depleted P3 and P6 thymi from all mature cells resulting 
in a population enriched in DN1-4 cells (referred to as lineage negative, Linneg), which was 
significantly reduced in kindlin-3-/- thymi (Fig. 2A and B). Further gating for cKIT and CD44 
separated DN1-2 from DN3-4 cell populations and revealed the complete absence of DN1 and 
DN2 cells in kindlin-3-/- thymi (Fig. 2A and C). As DN1 and DN2 cells are the immediate 
intrathymic descendants of circulating T cell progenitors, we investigated whether these T cell 
progenitors are present in the circulation of kindlin-3-/- mice. Interestingly, a strong 
accumulation of myeloid (Linneg, cKIT+, SCA-1-) and lymphoid (Linneg, cKIT+, SCA-1+) 
hematopoietic progenitor cells (HPCs) was detectable in the peripheral blood of kindlin-3-/- 
mice suggesting an impaired extravasation from the blood into the thymus (Fig. 2D and E). 
In order to study T cell progenitor homing to the adult thymus in a different system, we 
transferred fetal liver cells from E14.5 wild-type and kindlin-3-/- embryos into RAG-2 knock-
out (RAG-2-/-) mice, in which T cell development is blocked at the DN3 stage due to loss of 
V(D)J rearrangement (Shinkai 1992). Thymus size, weight, cellularity (Fig. 3A-C) and 
peripheral blood (Supplementary Fig. 2) of these chimeras were then analyzed 8 to 10 weeks 
later. Injection of control FL cells resulted in the complete reconstitution of the thymus and 
the repopulation of all DN populations in RAG2-/- mice, whereas kindlin-3-/- FL cells failed to 
do so (Fig. 3A-F). Nevertheless, like in kindlin-3 null mice, an accumulation of kindlin-3-/- 
HPCs was detected in the chimeras (data not shown). Notably a few kindlin-3-/- progenitors 
managed to enter the thymus and differentiated into DN4 cells (Fig. 3D and F). These cells 
further differentiated into a moderate number of CD4-and CD8-SP T cells, which were then 
released into the circulation (Supplementary Fig. 2A and B). 
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Altogether, these results indicate a crucial role of kindlin-3 for T cell progenitor homing to the 
adult thymus, but once within the thymus, the progenitor’s differentiation into mature T-cells 
proceeds in a kindlin-3 independent fashion. 
 
Diminished fetal thymus colonization in embryos lacking kindlin-3-/- 
Since thymi of newborn kindlin-3-/- mice lack DN1 and DN2 cells but contained DN3 and 
DN4 cells we assumed that these cells must have been entered the thymus during fetal 
development. To address this issue, we studied the presence and immigration of CD45+ 
hematopoietic progenitor cells into the thymic primordium by immunofluorescence stainings 
on embryonic sections (Fig. 4A). In line with previous reports (Douagi 2000; Itoi 2001) the 
first wave of hematopoietic progenitors can be observed in the perithymic mesenchyme at 
E11.5 and subsequently enter the primordium (E12) and proliferate (E12.5). At these time 
points, the number of progenitors in the proximity and within the thymus primordium was 
markedly reduced in kindlin-3-/- mice (Fig. 4B). However, despite the reduced efficiency in T 
cell progenitor homing to the kindlin-3-/- thymus primordium, the thymus was fully packed by 
thymocytes at E13.5 (Fig. 4A), of which a significant number was identified as DN1 and DN2 
cells (Fig. 4C). Strikingly, a dramatic drop in the DN1-2 population of kindlin-3-/- thymi was 
observed at E16.5 (Fig. 4D and E), exactly at a developmental stage when thymus 
vascularisation takes place (Liu 2006). Taken together, T cell progenitor homing to the pre-
vascularized thymic primordium can occur in a less efficient manner in the absence of 
kindlin-3. 
 
Kindlin-3-/- FL-derived T cell progenitors do not efficiently cross the vasculature 
Since the reduced number of kindlin-3-/- progenitors, which migrate and enter the embryonic 
thymus primordium, might be due to a reduced number of progenitors in the embryonic 
circulation we investigated their production and release from the fetal liver by flow 
cytometry. The cellularity of kindlin-3-/- FL cells is reduced (data not shown) causing an 
increased frequency of kindlin-3 null progenitors compared to control FL. Nevertheless, the 
absolute numbers of T cell progenitors (Linneg, cKIThi, CD45+ and PIR+) (Kawamoto 2000; 
Masuda 2005) in kindlin-3-/- FL were similar to that in kindlin-3+/+ FL (Fig. 5A, B and C). In 
addition, a gradual abnormal accumulation of FL-derived myeloid/erythroid (Linneg, cKIThi, 
PIR-) and T-lymphoid (Linneg, cKIThi, PIR+) HPCs (Katsura 2002) was detected in the 
circulation of kindlin-3-/- fetuses suggesting that progenitor extravasation out of the 
pharyngeal vessels is affected in the absence of kindlin-3 (Fig. 5D and E). 
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In order to exclude the possibility that kindlin-3-/- progenitors are lost either in the circulation 
or in the perithymic interstitium because of an inability to sense the chemokine gradient 
generated by the thymic primordium, we monitored progenitor migration and thymus 
colonization in vitro by time-lapse video microscopy. In this assay, alymphoid 
deoxyguanosine (dGuo)-treated thymic lobes from wild-type E15.5 SJL embryos (CD45.1+) 
were positioned in close proximity to FL-derived hematopoietic precursor cells (Linneg cells) 
from either kindlin-3+/+ or kindlin-3-/- E14.5 C57BL/6 (CD45.2+) embryos and progenitor 
migration towards the thymic lobes was then monitored for 36 to 48 hours. As shown in Fig. 
5F and in the Movies S3A and S3B (Supplementary Fig. 3), both kindlin-3-/- and kindlin-3+/+ 
FL cells moved directionally towards the thymic lobe, while no progenitor cells showed a 
directed migration in the absence of a chemokine-producing thymic lobe (Movie S3C). 
To confirm that FL cells, which have successfully entered the thymic lobes, have the potential 
to develop into mature T cells, the lobes were recovered from the collagen matrix and 
cultured for additional 18 days under conventional fetal thymus organ culture (FTOC) 
conditions. Importantly, both CD45.2+ kindlin-3-/- and kindlin-3+/+ donor cells developed into 
DP, CD4- and CD8-SP cells (Fig. 5G). 
Taken together, these data indicate that kindlin-3-/- T cell progenitors are normally produced 
in the fetal liver and accumulate in the circulation. Importantly, once kindlin-3-/- progenitors 
have passed the vasculature, they efficiently migrate towards the chemokine gradient 
produced by the thymus epithelial cells and differentiate into different T cell subsets. 
 
Intrathymic vessels strongly express VCAM-1 and ICAM-1 
In order to find an explanation for the difference in T cell precursor homing to the pre- and 
post-vascular thymus, we analysed the expression of adhesion molecules known to be 
involved in leukocyte extravasation (Ley 2007). No difference in the expression of ?4, ?L, ?1, 
?2, ?3 and ?7 integrins on FL-derived HPCs (Linneg, cKIT+) and T cell-specific progenitor 
cells (Linneg, cKIT+, PIR+) was detected on control and kindlin-3-/- cells using flow cytometry 
(Fig. 6A). Moreover, immunofluorescence staining for VCAM-1 and ICAM-1, which are the 
vascular ligands for ?4?1 (VLA-1) and ?L?2 (LFA-1) integrins, respectively, showed strong 
expression on intrathymic blood vessels and stromal cells of an E18.5 fetal thymus (Fig. 6B). 
In contrast, a rather weak expression of VCAM-1 and ICAM-1 was detected in the lumen of 
pharyngeal vessels of E12.5 embryos (Fig. 6C). These observations further support the 
hypothesis that integrin-mediated adhesion plays a crucial role for the extravasation process 
via the intrathymic microvasculature (Lepique 2003). 
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Reduced proliferation of Kindlin-3 thymocytes 
In addition to impaired T cell progenitor homing, a reduced proliferation or an increased cell 
death of thymocytes might contribute to the decreased thymus cellularity and progressive 
thymus atrophy of kindlin-3-deficient mice.  
Therefore, we determined the number of apoptotic cells within the P3 thymus by 
immunohistochemistry against cleaved caspase-3 (Fig. 7A) and by annexin V staining using 
flow cytometry (Fig. 7B). Both number (Fig. 7C) and frequency (Fig. 7D) of thymic apoptotic 
cells were not altered in kindlin-3-/- compared to control mice. A more detailed analysis, 
which allowed discrimination between different T cell subsets, revealed that none of these 
populations showed increased annexin V staining in kindlin-3-/- cells compared to wild-type 
cells (Fig.7E). In contrast, thymocyte proliferation, which was determined by in vivo 
bromodeoxyuridine (BrdU) labeling was significantly reduced in P3 kindlin-3-/- thymi as 
shown by both immunohistochemistry (Fig. 7F and H) and flow cytometry (Fig. 7G and I). 
Reduced proliferation was detected in both DP and SP T cell populations (Fig 7L). 
Reduced T cell proliferation might be a consequence of a disrupted thymic microenvironment. 
Therefore, we first analysed the presence and organisation of cortical (cTECs) and medullary 
(mTECs) thymic epithelial cells (Van Vliet 1984). Despite the absence of the DN1-2 
population in kindlin-3-/-mice, both cortical and medullary TECs were present and properly 
organized in a three-dimensional-meshwork at P0 and P3 (Fig. 8A and B). However, at later 
time points, particularly mTECs showed a tendency to cluster leading to the formation of 
cysts at P6 (Fig 8B). Even more expanded thymic cysts are visible in thymus sections at P8 
(Fig 1D) suggesting an impaired thymic crosstalk between thymocytes and TECs in the 
absence of kindlin-3. Next we investigated the presence of macrophages and dendritic cells in 
kindlin-3-deficient thymi. Strikingly, significant reductions in the amount of both kindlin-3-/- 
M?s (CD11bhi, CD11clow) and DCs (CD11chi, CD11blow) were detected in the thymus of 
kindlin-3-/- mice, including the kindlin-3-/- FL cell chimeras, by flow cytometry (Fig. 8C, D 
and E). This observation indicates that blood-borne myeloid progenitors show a similar 
homing defect like the T cell progenitors.  
Finally, we tested T cell proliferation upon contact with antigen presenting cells (APC). To 
this end we used T cells from mice with a T cell specific deletion of the kindlin-3 gene 
(kindlin-3fl/fl / CD4-Cre), which express T cell receptors specific for the MOG35-55 peptide 
(2D2 mice) (Moretti, 2013). Naïve CD4+ T splenocytes were isolated from these kindlin-
3fl/fl/2D2+/CD4-Cre mice and control kindlin-3fl/fl/2D2+ animals, labelled with 
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carboxyfluorescein diacetate succinidyl ester (CSFE) and co-cultured with MOG35-55-loaded 
dendritic cells. After 3 days T cells were harvested and their proliferative response was 
tracked by CSFE dye dilution. Interestingly, kindlin-3 deficient T cells, which were in contact 
with DCs loaded with high concentration of MOG35-55 peptide (10ug/ml), showed a similar 
proliferative response compared to control cells, whereas kindlin-3-deficient T cells showed a 
significant reduction in proliferation at lower MOG35-55 concentrations (0.1 and 1.0ug/ml) 
(Fig ). Altogether, these results suggest that thymus atrophy of kindlin-3-deficient mice is also 
caused by a reduced proliferation of thymocytes due to a defective crosstalk with APCs. 
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DISCUSSION 
During thymopoiesis T cells and their progenitors undergo a series of defined and coordinated 
developmental stages beginning with the initial homing of lymphoid progenitor cells 
originated from the fetal liver or bone marrow followed by proliferation, differentiation and 
selection steps at certain environments within the thymus, which finally lead to self tolerant 
mature T cells. In recent years significant progress has been made in the understanding which 
chemokine cues guide thymic progenitors from the bloodstream to the thymus and position 
developing T cells within the thymus (Takahama 2006). In addition, much is known about the 
transcriptional networks, which control T cell fate specification (Koch and Radtke 2011). In 
contrast, the molecular details of thymus homing have not been elucidated fully. It is assumed 
that similar to the extravasation process of leukocytes, T cell progenitors follow a defined 
cascade of chemoattraction, selectin-mediated rolling and integrin-dependent adhesion and 
transmigration (Ley 2007). In line with this assumption, mouse mutants of the selectin ligand 
PSGL-1 show reduced progenitor homing to the thymus (Rossi 2005); however, mice with 
defects in individual integrins, such as ?4 or ?2 integrins, revealed no defect in T cell 
development, which might be caused by a functional compensation by different integrins.  
In the present study, we investigated the role of integrins during T cell homing and 
subsequent T cell maturation within the thymus in mice lacking the general integrin regulator 
kindlin-3. In contrast to LAD-III patients, which develop a lymphocytosis suggesting a minor 
role of kindlin-3 for T cell development, Kindlin-3 null mice exhibit progressive thymus 
atrophy. The reason for the difference between mice and humans are unclear, since both 
species suffer from the same severe bleeding and leukocyte adhesion defects confirming the 
essential role of this protein for integrin regulation in various hematopoietic cell types. On the 
contrary, while kindlin-3 null mice developed a profound osteopetrosis, an increased bone 
mass have not been detected in all LAD-III patients indicating clear differences in the 
phenotypes of mice and man. We have excluded that other kindlin members compensate for 
the loss of kindlin-3 in murine T cells, as those are neither expressed in wild-type cells nor is 
their expression induced in kindlin-3 null cells. Studies on kindlin-1 or 2 expressions in 
human T cells from LAD-III patients have not been conducted. 
During development two different pathways mediate the seeding of the thymus with T cell 
progenitors. Before thymus vascularization, T cell progenitors leave the pharyngeal vessels 
and migrate through mesenchymal tissue before they reach the epithelial thymic anlage. Once 
the thymus has become vascularized during late gestation, fetal liver and bone marrow (BM)-
derived lymphoid progenitors directly enter the thymus at large post-capillary venules at the 
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thymus cortico-medullary junctions. Our study clearly shows that T cell progenitor homing to 
the vascularized thymus critically depend on kindlin-3. Kindlin-3 is required for stable 
adhesion mediated by at least the three major integrin classes (?1, ?2 and ?3 integrins) 
(Schmidt 2011). Since loss of individual integrins or studies with function-blocking 
antibodies showed no or only a partial reduction in T lymphocyte homing (Scimone 2006), 
our study demonstrate that kindlin-3-dependent regulation of integrins are essential for T 
lymphoid progenitor homing to the vascularized thymus and loss of one integrin member can 
be functionally compensated by other integrins. 
To our surprise we observed a rather efficient homing of T cell progenitors to the non-
vascularized thymus anlage, which occurs as early as E11.5. Our data indicate that integrins 
are also involved in this process, since homing is slightly delayed and fewer progenitors find 
their way to the thymus primordium of kindlin-3 null embryos. In support of this assumption, 
we found an accumulation of progenitors in the circulation of mutant embryos. However, the 
reduced number of progenitors around or within the thymus at these early developmental 
stages is neither caused by an impaired production of progenitors in the fetal liver nor by 
differences in the integrin expression on the progenitors of kindlin-3 null mice. Furthermore, 
in vitro homing assays of FL-derived hematopoietic precursor cells to alymphoid thymic 
lobes confirmed the histological observations that T cell progenitors from kindlin-3 null mice 
can sense the chemokine gradient produced by the thymic epithelial cells and can efficiently 
migrate towards the thymic lobules.   
Why can T cell progenitors extravasate the pharyngeal vessel at early developmental stages 
but fail to leave the post-capillary venules at the cortico-medullary junctions of the 
vascularized thymus? Several reasons are conceivable. Differences in the adhesive properties 
of T cell progenitors derived from the fetal liver versus the bone marrow are possible. 
However, since a sharp decline in the DN1 and DN2 populations of kindlin-3 deficient thymi 
occurs before a functional bone marrow has been formed, it is rather unlikely that the 
progenitors differ in their adhesive properties. Two other reasons are more plausible. An 
immunohistological analysis revealed that intrathymic vessels at the cortico-medullary 
junction express high levels of the integrin ligands VCAM-1 and ICAM-1 confirming that 
integrin-mediated adhesion plays a central role. On the contrary, since pharyngeal vessels 
show only weak VCAM-1 and ICAM-1 expression, it is fair to speculate that other adhesion 
receptors, such as CD44, might play a role in early T cell progenitor adhesion as well. The 
hypothesis that the different vessels have different adhesive features is also promoted by the 
drop of DN1 and DN2 populations of the thymus at E16.5, when T cell progenitor homing is 
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shifted towards the intrathymic vessel pathway. A further important parameter, which may 
influence the homing capabilities of T cell progenitors, is the difference in the hydrodynamic 
forces that these cells are exposed to during development. It can be assumed that the blood 
pressure rises during maturation of the cardio-vascular system and that less adhesive forces 
are required for the adhesion of blood cells to capillaries during early developmental stages 
compared to later stages. Integrin-mediated adhesion of cells depends on conformational 
changes of the integrin heterodimer leading to a high ligand-binding affinity state, which is 
triggered by the direct binding of talin and kindlin proteins to the ? integrin cytoplasmic tail 
(Moser 2009). More recently, progress in the understanding of the molecular mechanisms of 
talin and kindlin-mediated integrin regulation has been made. In vivo studies on talin-1 and 
kindlin-3-deficient neutrophils suggested the model that initial activation of integrins towards 
an intermediate, ligand-binding competent state requires only talin-1, while the shift towards 
the high affinity state requires additional kindlin-3 binding (Lefort, 2012). Similarly, studies 
on effector T cells and on the platelet ?IIb?3 integrin indicated that kindlin-3 is required for 
stabilizing the integrin-ligand interaction by promoting integrin clustering (Moretti 2013; Ye 
2013). Taken this into account, it is possible that a weak adhesion of kindlin-3 deficient T cell 
progenitors to pharyngeal vessels is sufficient for their extravasation, whereas firm kindlin-3 
dependent adhesion to intrathymic capillaries is required for progenitor extravasation when 
vascular flow rates are higher. In addition, an interesting phenomenon is the specific effect, 
which kindlin-3 exerts on ?L?2 versus ?4?1 integrins. While ?L?2 integrin mediated 
adhesion to ICAM-1 is very sensitive to kindlin-3 deficiency, ?4?1 mediated adhesiveness is 
less affected even under shear flow conditions (Manevich-Mendelson 2009). Thus, a 
primarily ?4?1 integrin-driven adhesion might be responsible for the initial seeding of the 
non-vascularized thymus with lymphoid progenitor cells. 
Despite the severe defect in kindlin-3-deficient T cell progenitor homing to the vascularized 
thymus, those T cell progenitors, which were able to enter the thymus either during early 
developmental stages or to the adult thymus of RAG2-null mice, undergo well-characterized 
sequential developmental maturation steps to produce mature T cells within defined thymic 
areas. Histological and immunohistological analyses revealed a normal thymus architecture of 
kindlin-3 deficient mice consisting of the four major compartments, the subcapsular zone, the 
cortex, the medulla and the cortico-medullary junction. Importantly, both cortical and 
medullary TECs were present and organized in a three dimensional meshwork, which was not 
distinguishable from wild-type thymi. The presence of DP thymocytes in the cortex and SP 
CD4 and CD8 T cells in the medulla of kindlin-3 deficient postnatal thymi, indicates that the 
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positioning of developing T cells within the thymus, which is guided by chemokines produced 
by thymic stromal cells is not impaired. Nevertheless, already at P6 medullary TECs show a 
tendency to form cysts indicating a defective communication between thymocytes and thymic 
stroma cells in the absence of kindlin-3.  
We also detected a reduction in the number of macrophages and dendritic cells in kindlin-3 
deficient thymi. Since the earliest T cell progenitors still retain the potential to give rise to 
DCs, natural killer cells and macrophages, it is not surprising that due to the homing defect 
the number of macrophages and DCs is reduced in the thymus of kindlin-3 null mice. In 
addition, we observed a reduced proliferative response of kindlin-3 deficient naïve T cells 
upon priming with low concentration of antigens presented by a DC. Altogether, our data 
suggest that the reduced number of APCs and the weakened crosstalk with thymic epithelial 
cells and APCs also contribute to the thymus atrophy of kindlin-3 deficient mice. 
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MATERIALS AND METHODS 
Mice and chimeras 
Kindlin-3-/- mice have been described previously (Moser 2008). All mice were from a mixed 
129/SvJ x C57BL/6 background.  
The day on which a vaginal plug was first observed was designated as embryonic day 0.5 
(E0.5).  
Fetal liver (FL) cell chimeras were generated as previously described (Tulunay 1975; 
Prümmer 1986). Briefly, 5-6 x106 of whole kindlin-3-/- or kindlin-3+/+ E14.5 FL cells were 
injected per mouse through the tail vain of sub-lethally irradiated (1x 6 Gy) RAG2-/- mice 
(Shinkai 1992). Chimeras were analyzed 8 to 10 weeks after repopulation. 
Pictures of dissected thymi were taken with a ProgRes C14 camera (JenOptic) connected to 
the Leica MZ FLIII stereomicroscope. 
Thymic single cell suspensions were counted using a counting chamber and the total viable 
cell numbers identified by the trypan blue dye exclusion method. 
Relative frequencies of diverse cell populations were obtained by flow-cytometry analysis. 
All animals were mated and maintained under specific pathogen-free conditions at the animal 
facility of the Max Planck Institute of Biochemistry. 
 
Western blot analysis 
Identical protein amounts (~20 ?g) were run on a 10% SDS-PAGE and analyzed by Western 
blot with rabbit anti-mouse polyclonal antibodies kindlin-1 and kindlin-3 (home made), 
kindlin-2 (Sigma) or with mouse anti-GAPDH monoclonal antibody (Calbiochem). Serial 
ECL expositions of the membranes were performed to determine the optimal linear range with 
a LAS-4000 imager (Fujifilm). 
 
Multi-color flow cytometry analysis and cell sorting 
Multi-color flow-cytometric analysis and cell sorting were performed using FACS-Calibur 
and FACS-Aria flow cytometers, respectively. Data for viable cells, which were determined 
by forward light scatter and propidium iodide exclusion, were obtained with Cell Quest 
software. All antibodies we used were purchased from eBioscience or DB Pharmingen.  
Removal of mature cells from organ single-cell suspensions to obtain cells of the lineage 
negative (Linneg) was performed using the following cocktails of biotinylated antibodies:  
Anti-B220, anti-CD19, anti-TER119, anti-NK1.1, anti-CD11b (Mac-1), anti-Gr-1, anti-CD8?, 
anti-CD3e, anti-TCR?, anti-TCR?? and anti-CD11c for fetal and adult thymi. Anti-TER119, 
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anti-B220, anti-CD11b, anti-Gr-1, anti-CD11c, anti-NK1.1, anti-CD4 and-CD8? for postnatal 
peripheral blood. Anti-B220, anti-CD19, anti-TER119, anti-NK1.1, anti-Gr-1 and anti-Thy1.2 
for fetal liver and fetal blood.  
Biotinylated cells were then stained either with PerCP-Cy5.5-coniugated or FITC-coniugated 
Streptavidin and excluded by FL3 or FL1 FACS channels. The resulting Linneg cell population 
was further gated with anti-CD25-FITC, anti-CD44-PE and anti-cKIT-APC for thymocytes; 
with anti-SCA1-PE and anti-cKIT-APC for postnatal peripheral blood cells; with anti-CD45-
FITC, anti-PIR-PE and anti-cKIT-APC or anti-cKIT-PerCP, anti-PIR-APC and anti-Integrin-
PE for fetal liver cells; with anti-PIR-PE and anti-cKIT-APC for fetal blood cells. 
Mature T cells were analyzed for surface receptor expression with anti-CD4-FITC, anti CD8-
APC, anti-CD3-PE, anti-CD5-PE, anti-CD24-PE and TCR?-PE. 
Linneg FL-cells used for generating chimeras and for the time-lapse visualization of thymus 
attraction were obtained by negative selection through MACS separation columns after 
staining biotinylated cells with anti-Biotin-coupled magnetic beads according to the 
manufacturer’s instructions (MACS Miltenyi Biotec). 
 
Immunofluorescience analysis of embryos and thymi 
4% PFA prefixed, frozen embryos and thymi embedded in Shandon Cryomatrix compound 
(Thermo Scientific) were first sliced into 8-10 ?m thick sections and stained with the 
following antibodies:  
For the embryos: rabbit anti-Fibronectin polyclonal antibody (Chemicon), mouse anti-
panCytokeratin monoclonal antibody (Sigma), rat anti-CD45-FITC (eBioscience), goat anti-
CD106 (VCAM-1, R&D Systems), hamster anti-CD54 (ICAM-1, Pharmingen) and rat anti 
CD31 (PECAM-1, Pharmingen) followed by Alexa-Fluor-647-conjugated anti-rabbit IgG, 
Alexa-Fluor-546-conjugated anti-mouse IgG, Alexa-Fluor-488-conjugated anti-rat IgG, 
Alexa-Fluor-647-conjugated anti-mouse IgG, Fluor-546-conjugated anti-goat IgG, and Fluor-
546-conjugated anti-hamster IgG antibodies (Invitrogen).  
For the thymus: rabbit anti-panLaminin polyclonal antibody (gift from Rupert Timpl), mouse 
anti-pan-FITC-Cytokeratin monoclonal antibody (Sigma), rat anti-CD31 (PECAM-1, 
Pharmingen), rat anti-CD4-FITC (eBioscience), rat anti CD8-Biotin (eBioscience), anti-
CD106 (VCAM-1, R&D Systems), hamster anti-CD54 (ICAM-1, Pharmingen), rat anti-ER-
TR4 and anti-ER-TR5 polyclonal antibodies (gift from Eric Vroegindeweij) followed by 
Alexa-Fluor-647-conjugated anti-rabbit IgG, Alexa-Fluor-647-conjugated anti-rat IgG, Alexa-
Fluor-488-conjugated anti-Fluorescein/Oregon green IgG, Cy3-coniugated Streptavidin 
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(Jackson), Alexa-Fluor-488-conjugated anti-rat IgG, Fluor-546-conjugated anti-goat IgG, and 
Fluor-546-conjugated anti-hamster IgG antibodies (Invitrogen). Thymic sections were fixed 
with acetone instead of PFA only for the anti-ER-TR4 and anti-ER-TR5 staining. 
The stained sections were mounted with a fluorescence mounting medium (Elvanol). The 
images were acquired with a fluorescence microscope (Imager.Z1, Zeiss) and analyzed by the 
Axio Vision 40 (version 4.8.2.0) software (Zeiss), utilizing 10x, 20x and 40x magnification. 
 
Immunohistologic analysis of the thymus 
4% PFA fixed and paraffin-embedded thymi were sliced into 8 ?m tick sections and stained 
with antibodies. The sections were then counterstained with Mayer’s haematoxylin (Merck), 
mounted in Entellan (Merck), and coverslipped. Haematoxylin and Eosin (H/E) staining was 
performed according to a standard protocol. Images were acquired with the light microscope 
Axioskop (Zeiss) and analyzed with the adobe ImageReady/TWAIN software.  
 
Apoptosis assays 
Thymocytes from P3 mice were stained with PE-labeled Annexin V and 7-AAD according to 
the manufacturer’s instructions (BD Pharmingen Apoptosis Detection Kit). T cells were 
additionally stained for anti-CD4-FITC and anti-CD8-APC and FACS analyzed. 
Paraffin-embedded thymus sections were stained with rabbit anti-mouse cleaved caspase-3 
antibody (Cell Signalling). Apoptotic cells were detected by DAB staining after treatment 
with the immunoperoxidase Vectastain ABC system (Vector Laboratories).  
 
Proliferation assays 
P3 mouse newborns were given intraperitoneal injections of 50 ?g of bromodeoxyuridine 
(BrdU) per each gram of body weight. At 1 hour after injection, thymocytes were isolated and 
stained with FITC-labeled anti-BrdU monoclonal antibody (BD Pharmingen BrdU Flow Kit), 
anti-CD4-PerCP and anti-CD8-PE antibodies, and analyzed by flow cytometry.  
Alternatively, paraffin-embedded thymus sections were DAB stained after incubation with a 
POD-coupled anti-BrdU antibody (Roche). 
 
Time-lapse visualization of thymus attraction 
Time-lapse imaging of horizontal cell migration to fetal thymus lobes was recorded as 
described previously (Ueno 2005; Liu 2005). Briefly, 10 µL freshly neutralized collagen 
solution (1.72 mg/mL PureCol, Advanced BioMatrix, in RPMI 1640-based culture medium) 
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containing 1-2 x105 fetal liver cells (Linneg) from either kindlin-3+/+ or kindlin-3-/- C57BL/6 
(CD45.2+) animals was placed in a 35 mm plastic dish and solidified at 37°C for 10 minutes. 
An E15.5 fetal thymus lobe from wild-type SJL (CD45.1+) mouse, pre-treated for 6 days with 
1.35 mM 2-deoxyguanosine (dGuo; Sigma) was positioned approximately 0.5 mm away from 
the cell spot. The culture was submerged in 1.72 mg/mL collagen medium and solidified at 
37°C for 30 minutes. The dish was placed in 5% CO2 under an Axiovert 40 CFL microscope 
(Zeiss) equipped with a digital CCD camera. The culture was time-lapse monitored for 36 to 
48 hours using a home-written software. After colonization, fetal thymus lobes were removed 
from the collagen gel, rinsed, and further cultured for 18 days under conventional organ 
culture conditions. Thymi were than pooled and squeezed and the resulting single cell 
suspensions were stained with anti-CD45.2 to isolate the donor-derived thymocytes and 
further gated for anti-CD4-FITC and anti-CD8-APC. 
 
Fetal Thymus Organ Culture 
Seeded thymus lobes were cultured on 0.8 ?m isopore membrane filters (Millipore) supported 
by a Gelfoam sponge (Pfizer) at an interface between 5% CO2-humidified air and RPMI 
1640-based culture medium containing 10% FCS, 100 U/ml penicillin and 100 ?g/ml 
streptomycin (PAA), 2 mM L-glutamine (PAA), 1X non-essential amino acids (Gibco), 1 mM 
sodium pyruvate (Gibco), 10 mM HEPES, 50 ?M 2-mercaptoethanol (Sigma). Details have 
been described (Ueno 2005). 
 
Reaggregate thymus organ culture (RTOC) 
Wild-type E15.5 SJL (CD45.1+) thymi were digested in RPMI 1640 culture medium 
containing 2% FCS, 25 mM HEPES, 1 mg/ml collagenase Type II (Worthington Biochemical 
Corporation) and 25 ?g/ml DNase I (Boehringer Mannheim) for 30 min at 37°C. Cell-cell 
complexes were disrupted by addition of 0.5 M EDTA (1:100) for 5 min at 37°C. Leukocytes 
were MACS depleted using anti-Biotin-coupled magnetic beads according to the 
manufacturer’s instructions (MACS Miltenyi Biotec), after prestaining with a biotinylated 
anti-CD45.1 antibody. The negatively sorted TECs (~5 x105) were then mixed 1.1, 1:3 and 
1:5 with kindlin-3-/- or kindlin-3+/+ DP cells to reform a thymus lobe-like structure as 
previously described (Ueno 2005). Reaggreates were cultured for 7 days in a 5% CO2, 37°C 
incubator and FACS analyzed for CD3, CD4 and CD8. DP cells were positively MACS 
sorted from E17.5 fetuses with anti-CD4 and anti-CD8 antibodies. 
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Isolation and FACS analysis of thymic dendritic cells (DCs) and macrophages (M?s) 
during mouse ontogeny 
Isolation of myeloid cells from the thymus was carried out as previously described with 
modifications (Vremec 1992; Vremec 2000; Shortman 1989). Briefly, 3 to 5 thymi from 
E14.5, E19.5 and P3 animals were pooled, cut into small fragments and digested with 
frequent mixing for 30 min at room temperature (~25°C) in modified RPMI 1640-FCS 
medium containing collagenase (1 mg/ml; type II; Worthington Biochemical Corporation) 
and DNase I (0,1 mg/ml; Boehringer Mannheim). To disrupt DC/T cell and M?/T cell 
complexes, EDTA pH 7.2 (0.01 M final conc.) was added, and mixing continued for 5 min. 
Undigested fibrous material was then removed by filtration through a cell-strainer (BD 
Falcon). All subsequent steps were at 4°C using a divalent balanced salt solution containing 
EDTA pH 7.2 and FCS (EDTA-BSS-FCS). Cells were recovered from the digest by 
centrifugation, the pellet was washed with cold EDTA-BSS-FCS and then incubated (not for 
E14.5 thymi) for 30 min at 4°C with the following biotinylated mAbs (eBioscience): anti-
CD19, anti-erythrocyte (TER-119), anti-TCR? and anti-TCR?? (BD Pharmingen). All mAb 
were titrated and used at near-saturating concentrations. The cells coated with biotinylated 
mAbs were then removed using anti-Biotin-coupled magnetic beads according to the 
manufacturer’s instructions (MACS Miltenyi Biotec). The DC/M? enriched population was 
stained with anti-CD11c-FITC (BD Pharmingen) and anti-CD11b-PE (eBioscience) and 
analyzed by flow cytometry.  
 
Statistic analysis 
Means, standard deviations and statistical comparisons with Student’s t-test (*P<0.05, 
**P<0.01, ***P<0.001) were made using Microsoft Excel software.  
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FIGURE LEGEND 
 
Figure 1. Cellular characterization of the kindlin-3-/- thymus. (A and B) Pictures of 
kindlin-3+/+ (upper panel) and kindlin-3-/- (lower panel) E14.5 to E18.5 fetal thymi, and P0 to 
P8 postnatal thymi. (C) Single-cell suspensions isolated from individual thymi of indicated 
time points (E14.5 to P6) were counted and values expressed in a logarithmic scale. (D) 
Haematoxylin and Eosin (H/E) staining of paraffin-embedded thymus sections. (E) 
Representative FACS profiles for CD4 and CD8 of thymocytes isolated from P3 and P6 
thymi. Numbers within the FACS plots represent percentages of CD4/CD8 double negative 
(DN), CD4/CD8 double positive (DP), CD4 and CD8 single positive populations. (F and G) 
The frequency of each thymocyte population was measured by flow cytometry as shown in 
panel E. Bars indicate means ± standard errors. n = numbers of animals. *P < 0.05; **P < 
0.01; ***P < 0.001; NS, not significant. 
 
Figure 2. Cellular characterization of the kindlin-3-/- thymus and blood lineage negative 
populations. (A) Thymocytes from kindlin-3-/- and kindlin-3+/+ thymi of indicated time points 
were three-color stained for Lin (B220, CD19, TER119, NK1.1, Mac-1, Gr-1, CD11c, CD8?, 
CD3e, TCR?, and TCR??), cKIT and CD44 to identify the DN1-2 (Linneg, cKIThi, CD44hi) and 
the DN3-4 (Linneg, cKITlow, CD44low) populations. (B and C) Frequencies and absolute cell 
numbers of P3 Linneg and DN1-2 thymocytes were calculated from the flow cytometric 
analysis as shown in panel A. (D) Peripheral blood cells from P3 animals was first ACK-lysed 
and then three-color stained for Lin (TER119, B220, CD11b, Gr-1, CD11c, NK1.1, CD4 and 
CD8?), cKIT and SCA-1. (E) Frequencies of the hematopoietic progenitor cell (HPC) 
populations: whole HPCs (Linneg, cKIT+), potential myeloid (Linneg, cKIT+, SCA1-) and 
lymphoid (Linneg, cKIT+, SCA1+) progenitor subsets. Numbers within the representative 
FACS plots indicate cell percentages. Bars indicate means ± standard errors. n = numbers of 
animals. *P < 0.05; **P < 0.01; ***P < 0.001. 
 
Figure 3. Analysis of the fetal liver cell chimeras. (A) Images, (B) weights and (C) cell 
numbers of thymi from the indicated adult mice (WT and RAG2-/-) and 10-week-old 
chimeras. (D) Thymocytes from controls and chimeric thymi were four-color stained for Lin 
(B220, CD19, TER119, NK1.1, Mac-1, Gr-1, CD11c, CD8?, CD3e, TCR?, and TCR??), 
cKIT, CD44 and CD25 to identify the DN1-2 (Linneg, cKIThi, CD44hi) and the DN3-4 (Linneg, 
cKITlow, CD44low) populations (upper panel), and DN1 (Linneg, CD44hi, CD25-), DN2 (Linneg, 
CD44hi, CD25+), DN3 (Linneg, CD44low, CD25+) and DN4 (Linneg, CD44low, CD25-) single 
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subsets (lower panel). (E and F) Frequencies of DN1-2 and DN4 thymocytes were calculated 
from the flow cytometric analysis as shown in panel D. Numbers within the representative 
FACS plots indicate cell percentages. Bars indicate means ± standard errors. n = numbers of 
animals. *P < 0.05; **P < 0.01; ***P < 0.001. 
 
Figure 4. Fetal thymus colonization in kindlin-3-/- mice during development. (A and B) 
Sagittal sections of frozen embryos at the indicated ages were stained for fibronectin to 
visualize the perithymic mesenchyme (blue), for cytokeratin to identify the thymic 
primordium (green) and for CD45 to label potential T cell progenitor cells. Plotted in panel B 
are the means ± standard errors of the numbers of CD45+ cells in and surrounding the thymic 
primordium. Representative images are shown in panel C, and the numbers of sections 
analyzed (N) are indicated in panel B. (C) Fetal thymocytes from kindlin-3-/- and control 
thymi at the indicated time points were three-color stained for Lin (B220, CD19, TER119, 
NK1.1, Mac-1, Gr-1, CD11c, CD8?, CD3e, TCR?, and TCR??), cKIT and CD44 to identify 
the DN1-2 (Linneg, cKIThi, CD44hi) and the DN3-4 (Linneg, cKITlow, CD44low) populations. 
Representative FACS plots are shown. (D and E) Frequencies and total numbers of DN1-2 
were extrapolated from the flow cytometric analysis as shown in panel C. Bars indicate means 
± standard errors. n = numbers of animals. *P < 0.05; **P < 0.01; ***P < 0.001. 
 
Figure 5. Cellular characterization of fetal liver-derived T cell progenitors. (A) Single 
cell suspensions from kindlin-3-/- and control fetal livers at the indicated time points were 
four-color stained for Lin (B220, CD19, TER119, NK1.1, Gr-1 and Thy1.2), cKIT, CD45 and 
PIR. Representative FACS plots are shown. (B and C) Frequencies and total numbers of PIR+ 
T cell progenitors per fetal liver were extrapolated from the flow cytometric analysis as 
shown in panel A. (D) Blood from indicated embryos were collected and three-color stained 
for Lin (B220, CD19, TER119, NK1.1, Gr-1 and Thy1.2), cKIT and PIR. Representative 
FACS plots are shown. (E) Frequencies of circulating PIR+ T cell progenitors were 
extrapolated from the flow cytometric analysis as shown in panel D. (F) Representative 
images (10x magnification) of TLVA at indicated time points. The edge of a drop of 2x 105 
Linneg fetal liver cells (from kindlin-3-/- or control C57BL/6 CD45.2+ embryos) is shown at the 
right side of the panels, in the absence (top panels) or presence of a dGuo-treated fetal thymus 
lobe (from wild-type SJL CD45.1+ embryos), shown at the left side of the panels. (G) dGuo-
treated fetal thymus lobes seeded with FL cells as in panel G were further cultured for 18 days 
under conventional organ culture conditions as shown in panel F. Cells were 4-color stained 
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for CD45.1, CD45.2, CD4, and CD8. Shown are representative FACS profiles. Bars indicate 
means ± standard errors. n = numbers of animals. *P < 0.05; **P < 0.01; ***P < 0.001; NS, 
not significant. 
 
Figure 6. Fetal liver (FL)-derived T cell progenitor adhesion assays. (A) Expression of 
integrins on HPCs (Linneg, cKIT+) and T cell progenitors (Linneg, cKIT+, PIR+). FL cells from 
E13.5 kindlin-3-/- and control embryos were four-color stained for Lin (B220, CD19, TER119, 
NK1.1, Gr-1 and Thy1.2), cKIT, PIR and one of the indicated integrins. (B) Cryostat sections 
of the vascularized fetal thymus from wild-type E18.5 fetuses were stained for the endothelial 
adhesion receptors VCAM-1 and ICAM-1 (red), and PECAM-1 (green) to identify the 
intrathymic microvasculature. (C) Cryostat sections of E12 embryos were stained for VCAM-
1, ICAM-1 (red), PECAM-1 (green) and pan-Cytokeratin (blue) to identify the thymic 
primordium. A, atrium; T, thymus; PV, pharyngeal vessel.  
 
Figure 7. Apoptosis and proliferation assays. (A and C) Paraffin-embedded sections of 
kindlin-3-/- and kindlin-3+/+ P3 thymi were stained for the apoptotic cell marker cleaved 
caspase-3 and counterstained with Mayer´s haematoxylin (blue). Representative images are 
shown in panel A, and the numbers of apoptotic cells and sections (N) analyzed are indicated 
in panel C. (B, D and E) Single cell suspensions of thymocytes from kindlin-3-/- and control 
P3 thymi were in-vitro stained for Annexin V, 7-AAD, the apoptotic and dead cell markers 
respectively, CD4 and CD8, and FACS analyzed. Representative FACS plots showing the 
total amount of thymic apoptotic cells (Annexin V+, 7-AAD-) are shown in panel B and 
plotted in panel D. Frequencies of apoptotic cells in each T cell subpopulation are shown in 
panel E. (F and H) Paraffin-embedded sections of thymi from kindlin-3-/- and kindlin-3+/+ P3 
mice that received intraperitoneally a dose of the cell proliferation marker BrdU were stained 
with an antibody anti-BrdU and counterstained with Mayer´s haematoxylin (blue). 
Representative images are shown in panel F, and the numbers of BrdU+ cells and sections (N) 
analyzed are indicated in panel H. (G, I and L) Single cell suspensions of thymocytes from 
BrdU+ thymi were in-vitro stained for BrdU, CD4 and CD8, and FACS analyzed. 
Representative FACS plots showing the total amount of thymic proliferating cells (BrdU+) are 
shown in panel G and plotted in panel I. Frequencies of BrdU+ cells in each T cell 
subpopulation are shown in panel E. Bars indicate means ± standard errors. n = numbers of 
animals. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
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Figure 8. Analysis of the thymic stromal cells in kindlin-3-/- mice during development. (A 
and B) Cryostat sections (20x magnification) of thymi from kindlin-3-/- and kindlin-3+/+ P0, 
P3 and P6 animals were stained for anti-CD4 (green), anti-CD8 (blue) and anti-ER-TR4 (red, 
panel A) or ER-TR5 (red, panel B), markers for the cortical (cTECs) and medullary (mTECs) 
thymic epithelial cells, respectively. Cells in cyan indicate the co-expression of CD4 and 
CD8, therefore being CD4/CD8 double positive cells. mTEC-lined cysts are visible in the 
medulla of kindlin-3-/- P6 thymus. C, cortex; M, medulla. (C, D and E) Single cell suspensions 
from a pool of four E14.5, three E19.5 fetal thymi and one P3 thymus, enriched for 
macrophages (CD11bhi, CD11clow) and dendritic cells (CD11chi, CD11blow), were two-color 
stained for anti-CD11b and anti-CD11c. Representative FACS plots at the indicated time 
points are shown in panel C and cell percentages are plotted in panel D and E. Bars indicate 
means ± standard errors. N = numbers of experiments. *P < 0.05; **P < 0.01; ***P < 0.001; 
NS, not significant. 
 
Supplementary Figure 1. (A) Cryostat sections of P3 kindlin-3+/+ and kindlin-3-/- thymi were 
stained with anti-pan-Laminin (red), anti-CD4 (green) and anti-CD8 (blue) (left panel), and 
with anti-pan-Cytokeratin (green), anti-PECAM-1 (red) and DAPI (blue) (right panel). Cells 
in cyan indicate the co-expression of CD4 and CD8, therefore being CD4/CD8 double 
positive cells. M, medulla; C, cortex; Ca, capsule; V, vessel; CMJ, cortico-medullary junction. 
(B and C) Quantification of the absolute numbers of thymocytes present in each T cell 
subpopulation (DN, DP, CD4-SP, CD8-SP) of P3 and P6 thymi. Bars indicate means ± 
standard errors. n = numbers of animals. *P < 0.05; **P < 0.01; ***P < 0.001. (D) FACS 
analysis of surface receptor expression on thymocytes isolated from P3 kindlin-3-/- and 
kindlin-3+/+ thymi. Isotype matched controls (blue histograms); kindlin-3+/+ cells (green 
histograms); kindlin-3+/+ cells (red histograms). (E) Cell lysates from the whole P3 kindlin-3-/- 
and kindlin-3+/+ thymi was analyzed by Western blot for expression of kindlin-1, -2 and -3. 
Keratinocyte and embryonic stem cell (HSC) lysate were used as positive controls for kindlin-
1 and -2, respectively. The protein load was controlled by detecting GAPDH in the same 
extracts. (F) Western blot of protein lysates from sorted DN, DP, CD4+ and CD8+-SP cells. 
 
Supplementary Figure 2. (A) Representative FACS plots showing peripheral blood T-
lymphocytes (PBL) in adult mice (WT and RAG2-/-) and chimeras. (B) Frequencies of 
circulating CD4+ and CD8+ T cells were calculated from the flow cytometric analysis as 
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shown in panel D. Numbers within the FACS plots indicate cell percentages. Bars indicate 
means ± standard errors. n = numbers of animals. *P < 0.05; **P < 0.01; ***P < 0.001. 
 
Supplementary Figure 3. (A) In vitro proliferation of kindlin-3fl/fl/2D2+/CD4Cre+ 
(K3/Cre2D2) or control kindlin-3fl/fl/2D2+ (WT2D2) T cells was analyzed by flow cytometry 
after priming with MOG35-55 peptide-loaded DCs (left panel) or antibodies (right panel). 
CFSE staining from one representative kindlin-3-null and control sample are shown. Red-
lined histograms represent control samples that received DCs without MOG35-55 peptide or no 
stimulating antibodies. The percentage of dividing cells (B), the division (C) and proliferation 
(D) index and the cell counts (E) were calculated from the generation sizes (n = 5). 
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FIGURE 8
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Suppl. Fig 2
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Activated T cells use very late antigen-4/α4β1 integrin for capture,
rolling on, and ﬁrm adhesion to endothelial cells, and use leuko-
cyte function-associated antigen-1/αLβ2 integrin for subsequent
crawling and extravasation. Inhibition of α4β1 is sufﬁcient to pre-
vent extravasation of activated T cells and is successfully used to
combat autoimmune diseases, such as multiple sclerosis. Here we
show that effector T cells lacking the integrin activator Kindlin-3
extravasate and induce experimental autoimmune encephalomy-
elitis in mice immunized with autoantigen. In sharp contrast, adop-
tively transferred autoreactive T cells from Kindlin-3–deﬁcient mice
fail to extravasate into the naïve CNS. Mechanistically, autoreactive
Kindlin-3–null T cells extravasate when the CNS is inﬂamed and the
brain microvasculature expresses high levels of integrin ligands.
Flow chamber assays under physiological shear conditions con-
ﬁrmed that Kindlin-3–null effector T cells adhere to high concentra-
tions of vascular cell adhesion molecule-1 and intercellular adhesion
molecule-1, albeit less efﬁciently than WT T cells. Although these
arrested T cells polarize and start crawling, only few remain ﬁrmly
adherent over time. Our data demonstrate that the requirement of
Kindlin-3 for effector T cells to induce α4β1 and αLβ2 integrin ligand
binding and stabilization of integrin–ligand bonds is critical when
integrin ligand levels are low, but of less importance when integrin
ligand levels are high.
integrin afﬁnity | EAE
In experimental autoimmune encephalitis (EAE), autoreactiveCD4+ Th cells, which recognize components of the myelin
sheath of nerve ﬁbers, extravasate into the CNS and induce
breakdown of the blood–brain barrier and severe inﬂammation,
leading to the destruction of brain tissue (1). Integrins play
pivotal roles during this process. P-selectin–mediated rolling and
α4β1 (VLA4)-VCAM-1 (vascular cell adhesion molecule-1)–
mediated capture of encephalitogenic T cells on the brain en-
dothelium is followed by αLβ2 (LFA-1)-ICAM-1/2 (intercellular
adhesion molecule-1/2)–mediated T-cell polarization, crawling,
and diapedesis (2). Once the T cells have passed the circula-
tion, they become reprimed by antigen-presenting cells, which
expose self-antigens of the myelin to further stimulate T-cell pro-
liferation (3).
A hallmark of integrins is their ability to shift from an inactive
to an active state (i.e. inside-out signalling), which is associated
with an allosteric change of the integrin ectodomain and trans-
membrane domains and results in adhesion, sensing of substrate
stiffness, and signal transduction (i.e. outside-in signalling) (4, 5).
The allosteric modulation of the afﬁnity state of integrins is
regulated by talin and kindlin binding to the cytoplasmic domain
of the β subunit (6) and is of particular importance for circulating
platelets and leukocytes, which require fast attachment to blood
vessel walls to seal leaks or react to inﬂammation. In addition to
chemical allostery, integrin afﬁnity also can be regulated by in-
creasing the lifetime of integrin–ligand bonds, which can be
achieved by integrin clustering, also known as avidity modulation
(7, 8), and/or by application of tension (by, e.g., myosin II motors)
to the adhesive bonds, resulting in the formation of catch bonds
(9, 10). Whether kindlins are involved in bond lifetime regulation
is not known.
Kindlins are evolutionary conserved and consist of three
members (11). Hematopoietic cells express Kindlin-3 (11), the
deletion of which in mice abrogates integrin activation, resulting
in hemorrhages, leukocyte adhesion defects, and osteopetrosis
(12–14). A human disease with similar abnormalities, leukocyte
adhesion deﬁciency type III (LADIII), is also caused by null
mutations of the Kindlin-3 (FERMT3) gene (15–17). The severe
LADIII defects lead to perinatal lethality, hindering the analysis
of Kindlin-3 in speciﬁc blood cell lineages. We used conditional
gene targeting to circumvent the problem of lethality and in-
vestigated the role of Kindlin-3 in effector T cells using EAE as
model for T-cell–induced inﬂammation (18, 19). We report that
autoreactive T cells lacking Kindlin-3 cannot extravasate and
induce EAE when transferred into healthy mice. Interestingly,
however, a high density of integrin ligands on inﬂamed vascular
endothelial cells is sufﬁcient to enable autoreactive T-cell extrav-
asation and disease induction, and also to induce α4β1- and αLβ2-
mediated effector T-cell adhesion and αLβ2-mediated crawling
even under physiological shear conditions. These ﬁndings indicate
that increased ligand concentrations can partially substitute
Kindlin-3–mediated inside-out signaling, and that Kindlin-3 reg-
ulates both the activation of β1 and β2 integrins and the stabili-
zation of integrin–ligand bonds.
Signiﬁcance
T cells use integrins for adhesion to endothelial cells and ex-
travasation. Thus, their blocking with Abs prevents T cell ex-
travasation and ameliorates autoimmune diseases, such as
multiple sclerosis (MS). Given the side effects of these Abs, we
explored the integrin activator Kindlin-3 as potential thera-
peutic target. Mice lacking Kindlin-3 in T cells were immunized
with an autoantigen to induce experimental autoimmune en-
cephalitis (EAE), a model of MS. Although these mice developed
EAE, adoptively transferred autoreactive T cells from Kindlin-3–
deﬁcient mice to healthy recipients failed to induce EAE. We
found that autoreactive Kindlin-3–null T cells extravasate only
when the brain microvasculature expresses high integrin ligand
levels. Thus, blockage of Kindlin-3 is not a viable alternative ap-
proach to treating MS.
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Results
Kindlin-3 Is Not Required to Induce Active EAE. To analyze the role
of Kindlin-3 in T cells, we backcrossed mice carrying a ﬂoxed
Kindlin-3 gene 11 times with C57BL/6 mice (Kindlin-3ﬂ/ﬂ, re-
ferred to as controls) and subsequently deleted the Kindlin-3
gene with C57BL/6 mice carrying the CD4Cre transgene (20).
Western blot analysis demonstrated that CD4+ and CD8+ T cells
isolated from the spleen of conditional Kindlin-3ﬂ/ﬂ/CD4Cre
(hereinafter, K3/Cre) mice lack Kindlin-3 expression (Fig. S1A).
Kindlin-3 loss still allows the production of normal numbers of
CD4+ and CD8+ T cells in the thymus, peripheral blood, and
spleen of K3/Cre mice, suggesting that homeostatic T-cell pro-
liferation, differentiation, and distribution in peripheral hema-
topoietic organs occur independent of Kindlin-3 (Fig. S1 B–D).
We next investigated whether effector T cells require Kindlin-3
for extravasation and induction of an inﬂammatory disease. To
this end, we immunized mice with the encephalitogenic MOG35–55
peptide to induce active EAE (aEAE) (19). K3/Cre mice and
control littermates exhibited a similar EAE onset (Fig. 1A) with
such clinical symptoms as weight loss (Fig. 1B) and paralysis (Fig.
1C). Immunostaining of the lumbar region of spinal cords
revealed that diseased K3/Cre and control animals contained
similar numbers of CD45high inﬂammatory cells and CD45medium
microglial cells, Mac-1–positive monocytes/macrophages, and Gr-
1-expressing granulocytes and macrophages. Furthermore, the
subarachnoidal space and the spinal cord parenchyma of K3/Cre
and control mice contained a comparable inﬁltrate of autoreactive
CD4+ T cells (Fig. 1D). Importantly, isotype control Ab staining
veriﬁed the speciﬁcity of the immunostaining. FACS sorting of T
cells from K3/Cre CNS inﬁltrates revealed normal numbers of
CD4+ T cells (Fig. S1E), and Western blot analysis conﬁrmed the
loss of Kindlin-3 expression (Fig. 1E). Taken together, these ﬁnd-
ings suggest that Kindlin-3–deﬁcient T cells are able to extravasate
and induce EAE.
Kindlin-3 Is Required to Induce Passive EAE. The development of
aEAE and the presence of Kindlin-3–deﬁcient T cells in brain
inﬁltrates of K3/Cre mice suggest that Kindlin-3 is not required
for effector T-cell extravasation. To corroborate this ﬁnding, we
tested whether Kindlin-3–deﬁcient encephalitogenic T-cell blasts
are able to induce passive EAE (pEAE) (18) in WT C57BL/6
mice. To this end, we crossed K3/Cre and littermate control mice
with 2D2 mice, which express an MHC-II–restricted T-cell re-
ceptor (TCR) that speciﬁcally recognizes the MOG35–55 peptide
(21). We isolated naïve CD4+ T splenocytes from Kindlin-3ﬂ/ﬂ/
2D2+/CD4Cre+ (hereinafter, K3/Cre2D2) and control Kindlin-
3ﬂ/ﬂ/2D2+ (hereinafter, Co2D2) mice and primed them for sev-
eral days in vitro with MOG35–55-loaded dendritic cells (DCs)
to induce proliferation and differentiation into memory (i.e.,
CD62Lhi/CD44hi) and effector (i.e., CD62Llow/CD44hi) T cells
(Fig. 2A). The differentiated T-cell populations derived from K3/
Cre2D2 mice expressed normal levels of integrins and T-cell–
speciﬁc maturation and activation markers (Fig. S2A), and
lacked Kindlin-3 protein expression (Fig. 2B). Importantly, en-
cephalitogenic T cells did not express α9β1 integrins (Fig. S2B),
which can bind VCAM-1 as well.
To test whether Kindlin-3 affects T-cell differentiation into Th1,
Th2, or Th17 cells, we performed intracellular FACS staining for
IL-2, IFN-γ, TNF-α, IL-4, and IL-17. In these experiments, most
Co2D2 and K3/Cre2D2 cells were positive for IFN-γ and TNF-α,
indicating that they are Th1-polarized rather than Th17-polarized
(Fig. S2C). Consistent with the essential role of Kindlin-3 in
integrin activation, resting and phorbol 12-myristate 13-acetate
(PMA)-stimulated K3/Cre2D2 effector T cells showed signiﬁcantly
reduced levels of 9EG7 epitope, which is induced in activated β1
integrins. Bypassing cellular activation by the addition of manga-
nese resulted in comparable 9EG7 binding of Co2D2 and K3/
Cre2D2 effector T cells (Fig. S2D). Similarly, binding assays with
soluble VCAM-1 revealed that both resting and PMA-stimulated
K3/Cre2D2 effector T cells bound signiﬁcantly less VCAM-1 than
control cells, which was rescued with manganese (Fig. S2E).
We next transferred the encephalitogenic T-cell blasts into
sublethally irradiated WT C57BL/6 mice. As expected, the trans-
fer of Co2D2 T-cell blasts induced EAE pathology with T-cell
inﬁltration into the spinal cord, weight loss, and paralysis at ap-
proximately 11 d after the adoptive cell transfer (Fig. 2 C–E).
Unexpectedly, however, none of the recipient mice that received
K3/Cre2D2 T-cell blasts developed EAE (Fig. 2 C–E), and in all
recipients, Kindlin-3–deﬁcient encephalitogenic 2D2+ T cells
were detectable in the circulation for more than 3 wk after K3/
Cre2D2 T-cell transfer (Fig. S2F). Thus, in contrast to aEAE,
the adoptive T-cell transfer experiments indicate that loss of
Kindlin-3 protein in T-cell blasts prevents entry into a healthy
CNS and thus induction of EAE.
Kindlin-3 Regulates Initial Arrest and Firm Adhesion to VLA-4 and LFA-1.
Why can Kindlin-3–deﬁcient encephalitogenic T cells enter the
brain parenchyma to induce aEAE, but not pEAE? Induction of
aEAE was achieved by immunization with antigens and the si-
multaneous treatment with complete Freund’s adjuvant (CFA)
and pertussis toxin (PT), which induces elevated expression of
VCAM-1 and ICAM-1 on endothelial cells (Fig. 3 A and B) (22,
23). In contrast, in pEAE, T-cell blasts encounter naïve en-
dothelial cells expressing low levels of ICAM-1 and VCAM-1.
Thus, we hypothesized that high surface levels of endothelial
cell adhesion molecules overcome compromised adhesive prop-
erties of Kindlin-3–deﬁcient effector T cells and subsequent dis-
ease induction, whereas low integrin-ligand expression permits
Fig. 1. aEAE in mice lacking Kindlin-3 expression in T cells. (A) Median day of
disease onset in Kindlin-3ﬂ/ﬂ/CD4Cre+ (K3/Cre) and control (Co) mice with aEAE.
(B and C) Relative weight normalized to day 0 (B) and clinical disease score (C)
of mice with aEAE. Data points indicate means of 16 Co mice and 9 K3/Cre mice
from two independent experiments. (D) Healthy control (PBS-treated) and dis-
eased (MOG peptide-treated) mice with ongoing aEAE (clinical disease score 4)
were killed, and spinal cord white matter was analyzed by immunostaining.
Inﬁltrating leukocytes were stained with anti-CD45, anti-CD4, anti-Mac-1, or
anti-Gr-1 Abs (green); blood vessels were stained with a pan-laminin Ab (red);
and nuclei were stained with DAPI (blue). (Scale bar: 200 μm.) (E) Western blot
analysis of protein lysates of FACS-sorted CD4+ cells from the CNS of K3/Cre and
Co mice with ongoing aEAE. GAPDH served as a loading control.
17006 | www.pnas.org/cgi/doi/10.1073/pnas.1316032110 Moretti et al.
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adhesion and extravasation only after Kindlin-3–mediated
integrin activation.
To test this hypothesis, we generated an inﬂamed, activated
brain endothelium by inducing aEAE (clinical disease score 2)
and injected either carboxyﬂuoresceine diacetate, succinimidyl
ester (CFSE)-labeled Co2D2 or K3/Cre2D2 T-cell blasts into the
diseased mice. Immunohistology of spinal cords at 18 h after
transfer revealed that Kindlin-3–null CFSE-labeled CD4+ T
cells, like WT cells, were indeed present in vessels, meninges,
and brain parenchyma of these animals (Fig. 3 C and D). The
quantiﬁcation of CFSE-labeled T-cell numbers in spinal cord
sections from mice injected with Co2D2 or K3/Cre2D2 T-cell
blasts revealed similar T-cell numbers in the spinal cord paren-
chyma (Fig. 3E).
To further validate whether the quantity of endothelial cell
adhesion molecules can indeed modulate integrin-mediated ad-
hesion of Kindlin-3–deﬁcient effector T cells, we tested the ﬂow-
resistant binding of Co2D2 or K3/Cre2D2 T-cell blasts to recom-
binant mouse VCAM-1 (rmVCAM-1) or recombinant mouse
ICAM-1 (rmICAM-1) immobilized at different concentrations
(24). In the same manner as for pEAE induction, T cells were
isolated from spleen and lymph nodes and activated with
MOG35–55-loaded DCs. The activated T cells were allowed to
accumulate on immunoglobulin cell adhesion molecules (IgCAMs)
at very low shear forces (0.1 dyn/cm2) and then exposed to an in-
creased shear force of 1.5 dyn/cm2 to wash away nonbound effector
T cells (i.e., arrested T cells) and to assess for continuous shear-
resistant ﬁrm adhesion (i.e., ﬁrmly adherent T cells). The numbers
of arrested T cells per ﬁeld of view (FOV) were counted when the
laminar ﬂow was reached at 15 s after shear enhancement, and the
numbers of ﬁrmly adherent T cells per FOV were determined after
5, 10, and 15 min of continuous laminar ﬂow. The experiments were
controlled by coating the ﬂow chambers with a nonintegrin ligand
[100 nM Delta and Notch-like Epidermal growth factor-related
Receptor precursor (DNER)-Fc] that demonstrated no T-cell ad-
hesion. In agreement with our previous ﬁndings (25), Co2D2 T cells
arrested and spread on immobilized rmVCAM-1 (Movie S1), but
failed to crawl perpendicular and against the shear, which requires
LFA-1–ICAM-1/2 interactions (25). The number of arrested Co2D2
T cells was approximately twofold higher than the number of K3/
Cre2D2 T cells on 100 nM rmVCAM-1 (Fig. 3F). The numbers of
arrested Co2D2 and K3/Cre2D2 T cells relative to the arrested T cells
on 100 nM rmVCAM-1 decreased with decreasing concentrations
(40 nM and 10 nM) of rmVCAM-1 (Fig. 3G). However, in relation
to control cells, signiﬁcantly fewer K3/Cre2D2 T cells were arrested
on 40 nM and 10 nM rmVCAM-1 (Fig. 3G). Notably, after expo-
sure to physiological shear force on 100 nM rmVCAM-1 for 15 min,
approximately 80% of the Co2D2 T cells remained ﬁrmly attached,
whereas the proportion of ﬁrmly attached K3/Cre2D2 T cells de-
creased to 60% after 5 min of continuous shear force and to 40%
after 15 min of shear force (Fig. 3H). Thus, during continuous
laminar ﬂow, a signiﬁcant number of K3/Cre2D2 T cells main-
tained adhesive contact with rmVCAM-1, although at signiﬁ-
cantly lower numbers compared with Co2D2 T cells (Movie S2).
Importantly, preincubation of T cells with an anti-α4β1 Ab
blocked T-cell adhesion to VCAM-1, verifying the speciﬁcity of
the T-cell interaction with rmVCAM-1.
We also analyzed LFA-1–mediated T-cell adhesion, polarity,
and crawling on 10 nM, 40 nM, and 100 nM rmICAM-1 in
ﬂow experiments. The number of arrested Co2D2 T cells on 100
nM rmICAM-1 at 15 s after shear enhancement was fourfold
higher than the numbers of K3/Cre2D2 effector T cells (Fig. 3I).
Fig. 2. Adoptively transferred autoreactive Kindlin-
3–deﬁcient T cells fail to induce EAE. (A) FACS
analysis of in vitro-generated autoreactive T cells.
Anti-CD4 and anti-CD8 Abs were used to identify
CD4+ T helper cells (Left), anti-Vα3.2 and anti-Vβ11
were used to identify 2D2+ cells (Center), and anti-
CD62L and anti-CD44 were used to identify memory
(CD62Lhi/CD44hi) and effector (CD62Llow/CD44hi) T
cells (Right). (B) Western blot analysis of in vitro-
primed and MACS-sorted Kindlin-3ﬂ/ﬂ/2D2+/CD4Cre+
(K3/Cre2D2) and control Kindlin-3ﬂ/ﬂ/2D2 (Co2D2) T
cells. GAPDH served as a loading control. (C and D)
Relative weight normalized to day 0 (C) and clinical
disease score (D) of naïve WT C57BL/6 mice injected
with encephalitogenic K3/Cre2D2 and Co2D2 T cells.
Data points represent means from three indepen-
dent Co2D2 (n = 13) and K3/Cre2D2 (n = 20) T-cell
transfer experiments. (E) Immunostaining of the
lumbar spinal cord white matter from C57BL/6 mice
injected with either PBS or in vitro-generated en-
cephalitogenic Co2D2 or K3/Cre2D2 T cells. Inﬁltrating
lymphocytes were stained with anti-CD4 Ab (green),
blood vessels were stained with a pan-laminin Ab
(red), and nuclei were stained with DAPI (blue).
(Scale bar: 200 μm.)
Moretti et al. PNAS | October 15, 2013 | vol. 110 | no. 42 | 17007
IM
M
U
N
O
LO
G
Y
______________________________________________________________________________________________________________
231
Appendix
Interestingly, 85% of arrested Co2D2 effector T cells and 71% of
arrested K3/Cre2D2 effector T cells rapidly polarized and began
crawling on 100 nM rmICAM-1 (Fig. 3J and Movies S3 and S4).
Although the proportions of arrested Co2D2 effector T cells were
decreased on 40 nM and 10 nM rmICAM-1 (to 68% and 23%,
respectively) almost no K3/Cre2D2 effector T cells were arrested
on 40 nM and 10 nM ICAM-1 (4% and 2%, respectively) (Fig. 3K).
After exposure to physiological shear force, 90% of Co2D2 T cells
remained ﬁrmly attached during the entire 15-min shear force
exposure, compared with only 18% of K3/Cre2D2 T cells (Fig.
3L). Treatment with an anti–LFA-1 Ab prevented adhesion of
effector T cells to ICAM-1–coated ﬂow chambers, underscoring
the speciﬁcity of our assay.
Taken together, these ﬁndings indicate that high levels of
VCAM-1 allow the arrest and adhesion of a signiﬁcant number
of Kindlin-3–deﬁcient effector T cells under ﬂow, whereas high
levels of ICAM-1 enabled adhesion of a few Kindlin-3–deﬁcient
effector T cells, which polarized and crawled before they also
ﬁnally detached.
T Cell Spreading and Adhesion on Brain Microvascular Endothelium
Requires Kindlin-3. To investigate how Kindlin-3 affects effector
T-cell adhesion and crawling in an ex vivo system, we performed
live cell imaging with primary mouse brain microvascular endo-
thelial cells (pMBMECs) (25, 26) stimulated with TNF-α to in-
duce a proinﬂammatory phenotype with up-regulated expression
of VCAM-1 and ICAM-1. After a ﬂow chamber was mounted
on the pMBMECs, the chamber was perfused with Co2D2 or K3/
Cre2D2 T cells at low shear force (0.1 dyn/cm2), to allow accu-
mulation of T cells within a 4-min period. Subsequently, effector
T cells were exposed to shear force (0.7 dyn/cm2) for 10 min, and
the interactions of dynamic effector T cells with the brain en-
dothelium were imaged and quantiﬁed. The experiments re-
vealed that after 15 s of shear force exposure, both Co2D2 T cells
and K3/Cre2D2 T cells were able to arrest on activated endo-
thelial cells and were immediately polarized (Movies S5 and S6);
however, the number of arrested K3/Cre2D2 T cells was reduced
to 48% of Co2D2 T cells (Fig. 4A). After 5 min and 10 min of
laminar ﬂow, the number of adherent K3/Cre2D2 T cells further
decreased to 29% and 21%, respectively, whereas the number of
Fig. 3. Kindlin-3 controls ﬁrm adhesion of T cells to
VCAM-1 and ICAM-1. (A and B) Spinal cords from
untreated and pertussis toxin (PT)-treated animals
were stained with anti–VCAM-1 (A) and anti–ICAM-
1 (B) Abs (green). Blood vessels were stained with
PECAM-1 Ab (red), and nuclei were stained with
DAPI (blue). (Scale bar: 200 μm.) (C and D) Autor-
eactive CFSE+-labeled (green) Co2D2 T cells (C) and
K3/Cre2D2 T cells (D) injected into recipient C57BL/6
animals with ongoing aEAE (clinical disease score 2).
Sections from lumbar spinal cords were stained with
an anti-CD4 Ab (red) to identify inﬁltrating T lym-
phocytes. Blood vessels were stained with a pan-
laminin Ab (blue). Arrowheads indicate CSFE+ CD4+
T cells within or in close proximity to blood vessels,
and arrows indicate peripheral T cells in the paren-
chyma or meninges. (Scale bar: 100 μm.) (E) Num-
bers of CFSE+-labeled Co2D2 and K3/Cre2D2 T cells in
the lumbar region of the spinal cord at 18 h after
transfer into mice with aEAE (clinical disease score
2). (F) Number of T cells arrested on surfaces coated
with 100 nM rmVCAM-1 (n = 4 movies for Co; 4
movies for K3/Cre) per FOV. (G) Number of arrested
T cells determined on surfaces coated with 100 nM
(n = 4; 4), 40 nM (n = 4; 4), or 10 nM (n = 4; 4)
rmVCAM-1, expressed as percent of arrested T cells
on 100 nM VCAM-1. (H) Numbers of attached T cells
determined at 5, 10 and 15 min of laminar ﬂow at
1.5 dyn/cm2, expressed as percent of arrested T cells
determined at 15 s after shear increase. (I) Number
of T cells arrested on surfaces coated with 100 nM
rmICAM-1 (n = 4; 4). (J) Percentage of arrested T cells
with crawling activity on 100 nM rmICAM-1 (n = 3;
3). (K) Number of arrested T cells determined on
surfaces coated with 100 nM (n = 4; 4), 40 nM (n = 4;
4), and 10 nM (n = 4; 4) rmICAM-1 and expressed as
percent of arrested T cells on 100 nM ICAM-1. (L)
Percentage of ﬁrmly attached T cells on 100 nM (n =
3; 3) rmICAM-1. Numbers of attached T cells were
determined at 5, 10, and 15 min of laminar ﬂow at
1.5 dyn/cm2 and expressed as percent of arrested T
cells determined at 15 s after shear increase. *P <
0.05; **P < 0.01; ***P < 0.001; NS, not signiﬁcant.
Data are mean ± SD.
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Co2D2 T cells remained unchanged (Fig. 4A). Although the ad-
herent K3/Cre2D2 T cells polarized on the endothelial cell layer,
this polarization was less efﬁcient. Co2D2 T cells polarized and
adopted a mean cell length of 15.50 ± 3.8 μm, whereas K3/
Cre2D2 T cells polarized with a mean cell length of 11.9 ± 2.3 μm
(Fig. 4 B and C). Importantly, approximately 50% of the ad-
herent and polarized K3/Cre2D2 T cells initiated crawling on the
brain endothelium before ﬁnally detaching within the 10 min of
shear exposure (Fig. 4 D and E). Interestingly, ﬂow chamber
assays on TNF-α–treated pMBMECs isolated from ICAM-1null/
ICAM-2−/− mice (25) conﬁrmed the important role of VCAM-1
(Fig. 3E) in the arrest and ﬁrm adhesion of K3/Cre2D2 T cells
at 15 s after shear enhancement (Fig. 4F) and after 10 min of
laminar ﬂow (Fig. 4G).
Discussion
Inhibition of α4β1 with blocking Abs ameliorates the course of
MS and thus has become a powerful therapy for MS (3). Like-
wise, genetic ablation of β1 in mice inhibits EAE (27), a widely
used model for MS in rodents. Because EAE is triggered by
autoreactive CD4+ T cells, we used this model to examine the role
of the integrin-activating adaptor protein Kindlin-3 for effector
T-cell adhesion and crawling on brain endothelial cells, and to test
whether Kindlin-3 is required to induce this inﬂammatory disease.
Stable integrin–ligand interactions require the conversion of
the integrin conformation toward a high-afﬁnity state and the
subsequent stabilization of integrin–ligand bonds (4, 6). Conse-
quently, it can be assumed that a loss of integrin activation in
autoreactive T cells should abrogate α4β1 function and thus also
prevent EAE. In line with this expectation, transfer of autor-
eactive T cells lacking the essential integrin activator Kindlin-3
prevented the development of EAE in recipient mice. In sharp
contrast to these ﬁndings, however, Kindlin-3–deﬁcient T cells ef-
ﬁciently induced active EAE, despite efﬁcient and complete
Kindlin-3 gene deletion. A likely explanation for the different
outcomes is the different integrin ligand levels expressed on en-
dothelial cells at the time of EAE induction. This hypothesis is
supported by the efﬁcient extravasation of adoptively transferred
Kindlin-3–deﬁcient effectorT-cell blasts into an inﬂamed brain that
expresses high levels of VCAM-1 and ICAM-1 on endothelial cells.
Why are Kindlin-3–deﬁcient T-cell blasts able to adhere, ar-
rest, and extravasate at sites of high integrin–ligand expression,
despite their reduced VCAM-1 and 9EG7 binding? Our ﬂow
chamber experiments revealed that Kindlin-3–deﬁcient effector
T cells can adopt an afﬁnity state for α4β1 integrin that allows
remarkably efﬁcient T-cell capture and transient arrest on re-
combinant VCAM-1. In contrast, transient effector T-cell adhe-
sion to recombinant ICAM-1 was much more strongly impaired,
indicating that αLβ2 integrins critically depend on Kindlin-3 for
adoption of a high-afﬁnity state. Interestingly, however, increasing
levels of VCAM-1 as well as ICAM-1 increased the arrest of
Kindlin-3–deﬁcient effector T cells under shear force. Despite this
efﬁcient arrest of Kindlin-3–deﬁcient effector T cells at high
VCAM-1 levels, ﬁrm adhesion on recombinant VCAM-1 and
endothelial cells was reduced. These ﬁndings are in line with
a previous report showing that chemokine-stimulated Kindlin-3–
deﬁcient LAD-III effector T cells show transient adhesion, but not
stable adhesion, to VCAM-1 under ﬂow conditions (28). Fur-
thermore, these ﬁndings suggest that α4β1 on Kindlin-3–deﬁcient
effector T cells can adopt an afﬁnity state sufﬁcient for the pro-
duction of weak α4β1–VCAM-1 interactions. The number of weak
α4β1–VCAM-1 interactions on activated brain endothelial cells
may increase to a level that enables sufﬁcient numbers of T-cell
blasts to ﬁrmly adhere, extravasate, and induce disease.
A similar mechanism also operates with αLβ2 on Kindlin-3–
deﬁcient effector T cells and has been suggested for Kindlin-3–
deﬁcient neutrophils, on which αLβ2 can adopt an intermediate
conformation allowing slow leukocyte rolling on endothelial cells
(29). This intermediate conformation of αLβ2 requires Talin-1,
suggesting that the initial contact with ICAM-1 is Kindlin-3–
independent, whereas further conformational changes associated
with the high-afﬁnity state are Kindlin-3–dependent (29). A simi-
lar ﬁnding also has been reported for αIIbβ3 integrin binding to
ﬁbrinogen, which occurs in the presence of Talin-1 alone (30).
A further striking ﬁnding of the present study is that a small
but signiﬁcant number of Kindlin-3–deﬁcient T cells adhered to
recombinant ICAM-1– or TNF-α–treated endothelial cells and
began to polarize and crawl, albeit less efﬁciently than WT T
cells. This clearly indicates that β2 integrins induce outside-in
signals even in the absence of Kindlin-3 and before reaching
a fully active conformation. In contrast, the majority of Kindlin-
3–deﬁcient T cells attached to VCAM-1, ICAM-1, or TNF-
α–treated endothelial cells are unable to resist higher shear
forces, indicating that strengthening of integrin interactions with
these ligands requires further changes in α4β1 and αLβ2 that are
mediated by Kindlin-3 (31, 32). It is possible that these changes
represent conformational changes of the integrin ectodomain
induced by tension and resulting in the formation of catch bonds
that increase bond lifetimes. It is also possible that Kindlin-3
increases bond lifetimes by clustering integrins, thereby enabling
avidity that combines the strength of multiple integrin–ligand
bonds (33). The mechanism regulated by Kindlin-3, and whether
Fig. 4. Kindlin-3 promotes ﬁrm adhesion of T cells to primary brain mi-
crovascular endothelial cells. T-cell crawling and ﬁrm arrest on WT pMBMECs
was analyzed by live cell imaging in a ﬂow chamber experimental setup. (A)
Numbers of arrested and ﬁrmly adherent T cells per FOV on WT pMBMECs
determined 15 s, 5 min, and 10 min after onset of a 0.7-dyn/cm2 shear (n = 7;
8). (B) Arrested K3/Cre2D2 T cells are more roundish and less polarized
compared with Co2D2 T cells on WT pMBMECs. Arrows indicate stationary
and more roundish cells, and arrowheads indicate polarized and migratory
cells. (C) Mean cell lengths of Co2D2 and K3/Cre2D2 T cells (n = 105; 110). (D)
Percentage of arrested (determined at 15 s after shear enhancement) Co2D2
and K3/Cre2D2 T cells with crawling activity on WT pMBMECs (n = 3 movies
for Co; 3 movies for K3/Cre). (E) Percentage of arrested T cells able to resist
10 min of shear of 0.7 dyn/cm2 on pMBMECs (n = 3; 3). (F) Number of
arrested T cells per FOV on ICAM-1/-2 double KO pMBMECs at 15 s after
onset of a 0.7-dyn/cm2 shear (n = 4; 4). (G) Percentage of arrested T cells from
ICAM-1/-2 double KO pMBMECs after 10 min of laminar ﬂow at 0.7 dyn/cm2
(n = 4; 4). *P < 0.05; **P < 0.01; ***P < 0.001. NS, not signiﬁcant. Data are
mean ± SD.
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this pathway can be exploited to combat inﬂammation, remain to
be identiﬁed and tested.
Materials and Methods
Animals. Kindlin-3 ﬂoxed (Kindlin-3ﬂ/ﬂ) mice, in which exons 3–6 of the
Kindlin-3 gene is ﬂanked with loxP sites, were backcrossed more than 11
times with C57BL/6 mice, then intercrossed with C57BL/6 mice carrying a CD4
promoter-driven Cre recombinase transgene (20). To obtain MOG35–55-spe-
ciﬁc TCR transgenic mice deﬁcient for the Kindlin-3 gene, Kindlin-3ﬂ/ﬂ/
CD4Cre+mice were intercrossed with 2D2 transgenic mice (21). All mice were
bred in the animal facilities at the Max Planck Institute of Biochemistry. All
EAE experiments were performed in accordance with the license of the
government of Oberbayern.
Induction of aEAE and pEAE. aEAE was induced by s.c. administration of
MOG35–55 peptide as described previously (34). pEAE was induced by an i.v.
transfer of 2 × 106 encephalitogenic T cells into WT sex-matched C57BL/6
mice sublethally irradiated with 3.5 Gy. To obtain encephalitogenic T cells,
spleen and axillary, brachial, inguinal, and paraaortal lymph nodes were
isolated from Kindlin-3ﬂ/ﬂ/2D2+/CD4Cre+ and control Kindlin-3ﬂ/ﬂ/2D2+ mice.
Single-cell suspensions were obtained, and after ammonium-chloride-
potassium lysis of RBCs, cells from two mice were cocultured with 4 × 106 DCs
loaded for 2 h with 20 μg/mL MOG35–55 peptide. After 4 d of coculture, the
cell suspensions were split 1:2 into medium containing 5 ng/mL IL-2 (R&D
Systems). After another 6 d of culture, dead cells were removed by density
gradient centrifugation (Nycoprep 1.077; Axis-Shield). A total of 2 × 106 cells
per well were incubated overnight in 24-well plates coated with 1 μg/mL anti-
mouse CD3e and CD28 Abs (both from eBioscience) and in the presence of
recombinant murine IL-18 (20 ng/mL; MBL) and IL-12 (25 ng/mL) and IL-23
(10 ng/mL; both from R&D Systems). The cells were then washed three times
with PBS and transferred i.v. into recipient mice. Clinical disease score and
weight of the mice with aEAE and transfer EAE were checked daily. Scoring of
the mice was as follows: 0, healthy; 1, limp tail; 2, hind leg weakness; 3, one
paralyzed hind leg; 4, two paralyzed hind legs; 5, moribund.
Live Cell Imaging Under Flow Conditions. Live cell imaging on TNF-α–stimulated
pMBMECs isolated from WT or ICAM-1null/ICAM-2−/− C57BL/6 mice, or on
immobilized recombinant mouse ICAM-1 (rmICAM-1), VCAM-1 (rmVCAM-1),
or DNER (rmDNER; all from R&D Systems) was performed as described pre-
viously (25, 26). CD3e- and CD28-activated T cell blasts (2 × 106/mL) were
allowed to accumulate for 3–4 min at low shear force (0.1 dyn/cm2). Then,
dynamic T cell interactions with pMBMECs or immobilized rmICAM-1 and
rmVCAM-1 were recorded under physiological shear force (1.5 dyn/cm2) for
15 s (deﬁned as arrested T cells) and for 5, 10, and 15 min (deﬁned as ﬁrmly
adherent T cells). Speciﬁc integrin-mediated adhesion to ICAM-1 and VCAM-1
was tested by pretreating T cells with rat mAbs speciﬁc for mouse α4 integrin
(PS/2) and mouse LFA-1 (FD448.1). An anti-human CD44 (9B5) Ab was used as
negative control. All Abs were incubated with the T cells for 20 min at
a concentration of 10 μg/mL
Flow Cytometry. Single-cell suspensions of hematopoietic organs were pre-
pared and staining for FACS analysis was done as described previously (34)
and detailed in SI Materials and Methods. For intracellular cytokine stain-
ings, T-cell blasts were stimulated for 4 h with 50 ng/mL PMA, 500 ng/mL
ionomycin, and 10 μg/mL brefeldin A (Sigma-Aldrich), and cytokine expres-
sion was analyzed as described previously (27).
For analysis of soluble VCAM-1–Fc binding, 0.5 × 106 effector T cells were
incubated with 100 μg/mL VCAM-Fc (R&D Systems) for 15 min at 37 °C in
HBSS binding media supplemented with 0.2% BSA, Ca2+ and Mg2+ (1 mM
each), Mn2+ (2 mM), or PMA (100 ng/mL). Cells were then washed once,
incubated with PE-donkey anti-human IgG (Jackson ImmunoResearch) for an
additional 20 min on ice, washed twice, and analyzed by FACS.
Statistical Analysis. Means, SDs, and statistical comparisons with the Student
t test (*P < 0.05; **P < 0.01; ***P < 0.001) were performed using Microsoft
Excel software.
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ABSTRACT 
Many of the diverse functions of blood cells depend on integrins and the cytoplasmic 
proteins kindlin-3 and talin-1. To relate specific functions of platelets and 
polymorphonuclear neutrophils (PMNs) to specific kindlin-3 levels we generated mouse 
strains expressing 50%, 10% and 5% of kindlin-3. We report that in contrast to Kindlin-3 
null mice, which die of severe bleeding and leucocyte adhesion deficiency, mice 
expressing as little as 5-10% of kindlin-3 were viable, although only a limited number of 
integrins could be activated on platelets and neutrophils. Interestingly, tail wounding led to 
a severely prolonged bleeding tendency due to reduced platelet adhesion and aggregation 
but leukocyte adhesion to endothelial cells in the inflamed ear and the cremaster muscle 
was rather mildly impaired. Absolute quantification of protein copy numbers revealed 
similar kindlin-3 and talin-1 copy numbers in platelets and neutrophils. Interestingly, the 
ratio of the copy number of kindlin-3 and talin-1 relative to β3 integrin in platelets was 2:1, 
whereas in neutrophils the ratio relative to β2 integrins was 1:2. These data indicate that 
platelet-mediated hemostasis requires high kindlin-3 levels to ensure full-fledged integrin 
activation, whereas leukocyte adhesion and extravasation require lower levels of active 
integrins. 
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INTRODUCTION 
Integrins are cell adhesion receptors that consist of α and β subunits. They anchor cells to 
the extracellular matrix and assemble large signaling hubs, with which they regulate 
essential cellular processes including cell adhesion, migration, proliferation, survival and 
differentiation. A hallmark of integrins is their ability to reversibly switch between an active 
and an inactive conformation. In their inactive conformation they have low affinity for 
ligands, while upon activation (inside-out signaling) the affinity increases, which leads to 
ligand binding, integrin clustering and finally signaling (outside-in signaling). Two principal 
protein families are known to regulate integrin affinity, the talins (talin-1 and -2) and 
kindlins (kindlin-1, -2, -3). They both bind directly β integrin tails and thereby induce the 
allosteric change in the integrin ectodomain (Moser et al., 2009b). 
A fast allosteric change and rapid integrin-ligand interaction is particularly important for 
blood cells such as platelets and leukocytes, whose surface integrins continuously 
encounter ligands in plasma or on the vascular endothelium, respectively. Therefore, it is 
of fundamental importance for these cells to maintain integrins in an inactive state and 
rapidly activate them on demand, for example during bleeding when platelet aggregation is 
needed to seal vascular injuries, or during infection when leukocytes need to extravasate 
and kill microbial invaders. Blood cells express talin-1 and kindlin-3 whose binding to β 
integrin tails is tightly controlled by mechanism(s) that are largely unknown. Furthermore, it 
is also unclear whether a specific stoichiometry is critical for the integrin activation 
process. 
In the present study, we engineered several mouse strains expressing different kindlin-3 
protein levels. This allowed testing how different talin-1/kindlin-3 ratios influence integrin-
mediated functions. We found that 5% of kindlin-3 in blood cells is sufficient for embryonic 
and postnatal development. However, upon exposure to stress the low levels of kindlin-3 
impair adhesive functions of platelets and polymorphonuclear neutrophil (PMNs). 
Furthermore, platelets possess more kindlin-3 and talin-1 relative to their integrin levels 
than PMNs suggesting that rapid and full-fledged integrin activation is required for platelet 
functions, while only a limited number of integrins are activated during leukocyte 
extravasation. 
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RESULTS AND DISCUSSION 
Generation of conditional and hypomorphic kindlin-3 mouse mutants 
Kindlin-3 deficient mice die shortly after birth of anemia caused by bleeding and 
erythrocyte defects (Kruger et al., 2008; Moser et al., 2009b). To enable the disruption of 
the kindlin-3 gene at later stages or in specific blood cells, we generated a conditional 
kindlin-3 mouse by flanking exon 3-6 with loxP sites (suppl. Fig. 1). An intercross of these 
kindlin-3 floxed (K3fl/fl) mice with a deleter Cre strain produced offspring lacking exon 3-6 
and the frt-flanked neomycin cassette, and as expected, with the same defects observed 
in constitutive kindlin-3 null mice (Moser et al., 2009a; Moser et al., 2009b) (suppl. Fig. 
1D,E). We noticed that the presence of the neomycin cassette in intron 6 of the floxed 
kindlin-3 gene (suppl. Fig. 1A; K3+/n mice) significantly reduced kindlin-3 protein levels 
(Figure 1A,B). Intercrossing these mice to homozygosity (K3n/n) or with mice carrying a 
kindlin-3 null allele (K3n/-) further reduced kindlin-3 protein levels in spleen and thymus to 
around 10% and 5%, respectively (Figure 1A,B). Sequence analysis of kindlin-3 mRNA 
revealed aberrant splicing into the neomycin cassette as the major cause for reduced 
protein levels (data not shown). Thus, the introduction of a neomycin cassette into intron 6 
of the kindlin-3 gene produced a hypomorphic kindlin-3 allele and by intercrossing these 
mice with wild type or kindlin-3 null mice we could differently reduce kindlin-3 protein 
levels. 
Surprisingly, the different hypomorphic mouse strains including the K3n/- mice developed 
and aged normally, were fertile and showed normal cellularity in spleen and thymus (suppl. 
Fig. 2A-C). Furthermore, their erythroid counts in blood were normal indicating that they 
did not suffer from microbleedings or erythrocyte defects. However, the total number of 
white blood cells (WBC), in particular PMNs and lymphocytes, was significantly increased 
in K3n/n and K3n/- mice suggesting that low kindlin-3 levels compromise leukocyte 
extravasation and tissue patrolling (supplementary table 1).  
 
Kindlin-3 hypomorphic mice show a bleeding tendency 
Kindlin-3 deficiency causes fatal bleedings in mice and man (Kuijpers et al., 2009; Malinin 
et al., 2009; Moser et al., 2008; Svensson et al., 2009). Although platelets from K3n/n and 
K3n/- mice expressed around 10% and 5% of kindlin-3 levels, respectively, compared to 
wild type controls (Fig. 2A), they did not suffer from spontaneous hemorrhages during 
development or postnatal life (Fig. 2B, and data not shown). However, bleeding assays 
revealed that wild type and K3+/n mice stopped bleeding within 5 min, while K3n/n mice 
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suffered from a similar bleeding tendency as kindlin-3 null mice (Fig. 2C). Interestingly, 
thrombin treatment of wild type and K3+/n platelets robustly induced binding of fibrinogen 
by platelet αIIbβ3, while fibrinogen binding was reduced to less than 20% in K3n/n and 
K3n/- platelets and almost entirely lost in K3-/- platelets (Fig. 2D). Consistently, thrombin-
induced activation of αIIbβ3 integrins measured by flow cytometry using the JON/A-PE 
antibody decreased concomitantly with lowering levels of kindlin-3 in platelets (Fig. 2E). 
Adhesion and spreading of platelets from K3n/n and K3n/- mice on a fibrinogen-coated 
surface was severely impaired (Fig. 2F). Since treatment of platelets with manganese, 
which can bypass integrin activation (Mould et al., 2002) rescued fibrinogen binding (not 
shown) and platelet adhesion but not platelet spreading (Fig. 2F), we conclude that the 
diminished kindlin-3 levels in K3n/n and K3n/- platelets impaired both integrin activation 
and outside-in signaling leading to actin reorganization. These findings were corroborated 
with in vitro aggregation assays, in which platelets from K3n/n and K3n/- mice produced 
much smaller aggregates (Fig. 2G) and displayed a biphasic aggregation response (Fig. 
2H); the platelet shape change was followed by a rapid initial aggregation, while the 
second phase of aggregation, which depends on secreted auto- and paracrine factors, 
was significantly reduced in K3n/n and K3n/- platelets. Addition of fibrinogen normalized 
the second aggregation phase suggesting that indeed integrin-triggered platelet 
degranulation and release of secondary agonists is impaired and/or delayed in kindlin-3 
hypomorphic platelets (Fig. 2G). Furthermore, thrombin-induced platelet clot retraction was 
delayed with platelets from K3n/n and K3n/- mice in platelet-rich plasma; however, addition 
of manganese normalized the clot retraction times indicating that acto-myosin induced 
pulling forces are induced by active integrins independent of kindlin-3 (Fig. 2I), while actin 
reorganization and platelet spreading require active integrins and depend on kindlin-3 (Fig. 
2F). 
Altogether, these data indicate that lowering kindlin-3 in platelets to 5-10% of wild type 
levels allows them to activate a limited number of integrins, which is sufficient to fulfill 
basal functions but insufficient to scope with stress conditions. 
 
K3n/n and K3n/- mice suffer from leukocyte adhesion defects 
Absence of Kindlin-3 also impairs β2 integrin functions on leukocytes resulting in leukocyte 
adhesion deficiency in mouse and man (Moser et al., 2009a). PMNs from the bone marrow 
of wild type, K3n/+, K3n/n and K3n/- mice displayed reduced kindlin-3 levels ranging from 
50% in K3n/+, to 10% in K3n/n and 5% in K3n/- mice (Fig. 3A). With these different mouse 
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strains we investigated in several experiments to which extent leukocyte adhesion, 
extravasation and phagocytosis become compromised when kindlin-3 drops below a 
certain threshold. First, stimulation of K3n/n and K3n/- PMNs with phorbol-12-myristate-13-
acetate (PMA) showed diminished adhesion to ICAM-1, although adhesion levels were still 
significantly higher than for K3-/- PMNs (Fig. 3B). Next, we treated earflaps with phorbol 
ester (crotoin oil) for 1 h and observed a delay in the extravasation of K3n/n and K3n/- 
PMNs compared to wild type and K3+/n PMNs. Notably, 4 h after treatment K3n/n and 
K3n/- PMNs have crossed the vascular wall and distributed in the interstitium like wild type 
PMNs, while K3-/- PMNs failed to extravasate (Fig. 3C). In order to study leukocyte 
adhesion and extravasation more quantitatively we analysed TNFα-stimulated cremaster 
muscle venules in vivo using intravital microscopy. The experiments revealed that 
leukocyte adhesion was normal in wild type and K3n/+ mice, decreased by about 20% in 
K3n/n mice and by about 50% in K3n/- mice (Fig. 3D). Concomitantly with the reduced in 
vivo adhesion of leukocytes, the numbers of rolling leukocytes were increased in K3n/- 
mice (Fig 3E). Similarly, β2 integrin-mediated phagocytosis of serum-opsonized bacteria 
was reduced in K3n/n and K3n/- PMNs and abolished in K3-/- PMNs (Fig. 3F). Altogether, 
these findings indicate that the low kindlin-3 levels in K3n/n and K3n/- PMNs impairs 
phagocytosis and adhesion. However, the compromised adhesion still allows a rather 
efficient leukocyte extravasation in inflammatory models. 
 
Kindlin-3, talin-1 and integrin copy numbers in platelets and PMNs 
The basal functions of platelets and PMNs from K3n/n and K3n/- mice are efficiently 
executed in vivo. However, upon stress exposure the functions of platelets and PMNs 
become compromised. Interestingly, stress situations affect K3n/n and K3n/- derived 
platelets more severely than leukocytes. To test whether this difference could be due to 
different copy number ratios of kindlin-3 and talin-1 proteins in platelets versus leukocytes 
we performed Western blot analysis with purified blood cell populations. In comparison 
with various white blood cells platelets contain high levels of kindlin-3 and talin-1 (Fig. 4A). 
Analysis of the platelet proteome by high resolution mass spectrometry (MS) (Cox and 
Mann, 2011) confirmed that kindlin-3, talin-1 and β3 integrins are among the most 
abundant platelet proteins (Fig. 4B).  
To determine the stoichiometry of kindlin-3, talin-1, β2 and β3 integrins in platelets and 
PMNs, we used a recently developed MS method to quantify absolute protein numbers by 
expressing parts of the target protein sequence in a heavy labeled form (Zeiler et al.). 
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Specifically, short protein fragments of approximately 150 amino acids from murine kindlin-
3, talin-1, β3 and β2 integrins were fused to the albumin-binding protein (ABP) and 
expressed in the presence of 13C615N2-lysine (Lys8) and 13C615N4-arginine (Arg10) in an 
auxotrophic Escheria coli strain, which labeled them with heavy isotopes. A precisely 
quantified cocktail of different stable isotope labeled protein standards from kindlin-3, talin-
1, β2 and β3 integrins was then mixed with platelet and PMN lysates and their absolute 
copy numbers per cell were calculated after determining the heavy to light ratio by MS (Fig 
4C; for details see material and methods and Zeiler et al., 2012). Kindlin-3 expression in 
platelet lysates from wild type, K3+/n, K3n/n and K3n/- mice revealed a stepwise 
decrease, while talin-1 and β3 integrin levels were similar in the different platelet 
populations (Fig. 4D). The measurements also revealed that a wild type platelet contained 
between 260,000 and 290,000 copies of talin-1 and kindlin-3, respectively, and about 
130,000 copies of β3 integrin molecules (Fig. 4D). The PMNs also contained a 
stoichiometric number of kindlin-3 and talin-1 molecules of about 420,000 molecules per 
cell each. Furthermore, the total numbers of β2 integrins were approximately 800,000 
molecules per cell, and hence was twice the number of talin-1 and kindlin-3 (Fig. 4E). 
These data indicate that platelets have an excess of talin-1 and kindlin-3 over integrins, 
whereas PMNs have an excess of integrins over talin-1 and kindlin-3. 
  
Integrin-dependent functions of blood cells are strictly controlled by kindlin-3. In this study 
kindlin-3 hypomorphic mice were generated to address which levels of kindlin-3 are 
required for basal and stress induced platelet and PMNs functions. The results allow 
drawing interesting conclusions; first, expression of 5 to 10% of kindlin-3 in blood cells is 
sufficient for survival. Second, the steady state functions of platelets and PMNs with 5-
10% of normal kindlin-3 levels are maintained, although the elevated WBC counts indicate 
reduced tissue patrolling. Third, low kindlin-3 expression allows activation of only a 
reduced number of integrins leading to decreased ligand binding and adhesion. This 
shows that kindlin-3 does not act in a catalytic manner. Fourth, under stress conditions 
such as bleeding or inflammation the low levels of kindlin-3 limit platelet functions more 
than PMN functions indicating that platelets require a higher threshold of kindlin-3 to cope 
with their demands. Fifth, although kindlin-3 is required for integrin-dependent intracellular 
signalling controlling platelet spreading and degranulation, it is not required for acto-
myosin pulling and platelet contraction, which is in contrast to talin-1 (Haling et al., 2011).  
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Why are decreased kindlin-3 levels affecting platelets more than PMNs? The integrin-
mediated adhesion machinery is highly expressed in platelets indicating that it is of 
paramount importance for the organism. The binding of plasma fibrinogen might require 
more functional integrins than the binding of PMNs to insoluble ICAM-1, which is 
upregulated and clustered on inflamed endothelial cells allowing a fast rebinding of broken 
integrin-ligand bonds. We determined the absolute numbers of kindlin-3, talin-1, β2 and β3 
integrins in platelets and PMNs and found stoichiometric expression of both integrin 
activators, which further corroborates their cooperativeness during integrin regulation. In 
addition, surface density of β3 integrins on platelets (approximately 20,000 copies per µm2 
platelet surface area based on a total surface area of 8 µm2) and the corresponding 
concentration of talin-1 and kindlin-3 in platelets (40,000 copies each per fL platelet 
volume; total platelet volume appr. 7fL (von Hundelshausen et al., 2007)) are much higher 
than the corresponding values in PMNs (3,000 copies of β2 integrins per µm2 neutrophil 
surface area and 1,500 copies of talin-1 and kindlin-3 per fL PMN volume; based on 250 
µm2 surface area and 300fL volume for PMNs (Ting-Beall et al., 1993)). These values may 
very well reflect differences in mechanical stress, platelets and neutrophils are exerted to 
(platelet adhesion in arteries versus neutrophil adhesion in venules). Furthermore, the 
twofold excess of talin-1 and kindlin-3 over β3 integrins in platelets ensuring rapid and full-
fledged integrin activation critical for primary hemostasis. On the contrary, PMNs express 
only half as much integrin activators than β2 integrins suggesting that only a limited 
number of β2 integrins is activated. Remarkably, even neutrophils from kindlin-3 
hypomporphic mice can efficiently adhere and leave the inflamed vasculature. Probably 
because a highly dynamic and strongly restricted number of active β2 integrins on 
leukocytes is sufficient to control the dynamic interaction with the inflamed endothelium 
and subendothelial tissue. In this regard, studies on leukocyte adhesion deficiency type I 
patients also showed that the severity of clinical infectious complications is directly related 
to the degree of β2 integrin deficiency. Severely immune deficient patients have 
essentially undetectable β2 integrin expression on leukocytes, whereas moderate 
phenotypes are found in patients expressing 2.5 to 6% of β2 integrins on PMNs (Anderson 
et al., 1985; Anderson and Springer, 1987). The clinical data mentioned above, together 
with our results, indicate that integrin activation and function is regulated in a large part by 
the precise control of the stoichiometry of integrin activators relative to integrin levels, thus 
enabling different blood cells to achieve their diverse biological functions. 
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MATERIAL AND METHODS 
Animals: 
Kindlin-3−/− mice have been described previously (Moser et al., 2008). To generate 
conditional kindlin-3 mouse mutants (kindlin-3 fl/fl) a targeting vector was cloned, in which 
exons three to six of the kindlin-3 gene were flanked by loxP sites. This vector was 
electroporated into 129 ES cells. A Neo-cassette flanked by frt sites allowed G418 
selection. Several homologous recombinant clones were injected into C57BL/6 blastocysts 
and resulted in germ line chimeras. The presence of the Neo-cassette within the kindlin-3 
genomic locus resulted in strongly reduced kindlin-3 expression giving rise to a 
hypomorphic kindlin-3 allele. Mating with mice carrying a wild type, hypomorphic or kindlin-
3 null (K3-/-) allele resulted in offspring with different levels of kindlin-3. In parallel, the 
Neo-cassette was removed from the kindlin-3 genomic locus by mating kindlin-3 
hypomorphic mice with a strain expressing a deleter flipase resulting in conditional kindlin-
3 mice. Finally, conditional kindlin-3 mice were crossed with a deleter Cre mouse strain 
(Betz et al., 1996) to obtain K3-/- mice. 
All mouse experiments were performed with the approval of the District Government of 
Bavaria. 
 
Generation of fetal liver cell chimeras: 
Fetal liver cells were obtained from embryonic day 15 K3+/+ or K3-/- embryos by pushing 
liver tissue through a cell strainer (Falcon). 4 x 106 cells were then injected into the tail vein 
of lethally irradiated (twice 6.5 Gy) recipient C57BL/6 mice. Mice were used not before 6 
weeks after transfer.  
 
Antibodies: 
The following antibodies were used for immunostaining of cells: mouse anti-vinculin 
antibody, (from Sigma-Aldrich); Cy3-labeled secondary antibody (Jackson 
ImmunoResearch Laboratories, Inc.). Phalloidin-488 dye was obtained from Invitrogen.  
The following antibodies were used for flow cytometry: hamster IgG anti-integrin β1, 
isotype control hamster IgG, and isotype control mouse IgG1 (all from Biolegend); rat 
IgG2a anti-integrin β2, rat IgG2a anti-integrin β7, rat IgG2a anti-integrin α4, rat IgG2a anti-
integrin α5, rat IgG2a anti-integrin αL, rat IgG1 anti-integrin αv, isotype control rat IgG1, 
and isotype control rat IgG2a (all from BD); hamster IgG anti-integrin β3, mouse IgG1 anti-
integrin β5, rat IgG2b anti-integrin αM and isotype control rat IgG2b (all from eBioscience).  
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The following antibodies were used for Western blotting: mouse anti-glyceraldehyde 3-
phosphate dehydrogenase (anti-GAPDH; Merck); rabbit anti-actin and mouse anti-talin 
(both from Sigma-Aldrich); rabbit anti-P42/44 MAPK, rabbit anti-pP42/44 MAPK 
Thr202/Tyr204, rabbit anti-Akt, and rabbit anti-pAkt Ser473 (all from Cell Signaling 
Technology); rabbit anti-kindlin-3 antibody is home made (Ussar et al., 2006).  
 
Peripheral blood cell counts: 
Mice were bled from the retro-orbital sinus into EDTA-coated tubes. Blood cell counts were 
determined using a Hemavet 950 analyzer (Drew Scientific Inc., Oxford, CT). 
 
Cell preparation: 
CD4-positive T-cells were isolated from spleen using the CD4+ T cell Isolation Kit II from 
Miltenyi Biotech (Bergisch Gladbach, Germany). PMNs (polymorphonuclear neutrophils) 
were FACS sorted from whole bone marrow for high expression of Gr1 using a FITC-
labeled antibody (eBioscience). B220-positive B-cells were FACS-sorted from whole 
spleen. Macrophages and dendritic cells (DCs) were derived from whole bone marrow by 
culturing in medium containing M-CSF and GM-CSF. 
 
Platelet analyses: 
Integrin activation studies were performed with blood samples washed twice with modified 
Tyrode´s HEPES buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 
20 mM HEPES, pH 7.0) containing 5 mM glucose, 0.35% bovine serum albumin (BSA) 
and 1 mM CaCl2, which then were activated with 0.1 U/ml thrombin (Sigma Aldrich) and 
either stained with fluorophore-labeled anti-activated αIIbβ3 (JON/A, Emfret Analytics) or 
fibrinogen (Molecular Probes).  
Platelet adhesion and spreading was analysed on fibrinogen-coated (1mg/ml; Sigma 
Aldrich) glass bottom dishes blocked with 3% BSA. Washed platelets were re-suspended 
at a concentration of 0.5x 106 platelets/ml and then further diluted 1:10 in Tyrode’s-HEPES 
buffer. Shortly before plating, platelets were activated with 0.01 U/ml thrombin. Platelets 
were allowed to spread for 10 min and imaged by differential interference contrast (DIC) 
microscopy. Additionally, washed platelets were allowed to adhere to fibrinogen in the 
presence of 3 mM Mn2+ without thrombin stimulation. 
Platelet aggregation was measured with 2 x 108/ml washed platelets stimulated with 0.1 
U/ml Thrombin in the absence or presence of 100 ug/ml human fibrinogen. Light 
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transmission was recorded on a ChronoLog aggregometer over 15 min and was 
expressed as arbitrary units with the transmission through buffer defined as 100% 
transmission. 
Platelet clot retraction was measured in platelet-rich plasma (PRP) obtained from blood 
drawn into 1/10 volume of 3.8% sodium citrate. Platelets were diluted to 1x 108/ml with 
platelet-poor plasma obtained from wild type mice. PRP was added to siliconized glass 
cuvettes containing a paperclip, and clot retraction was initiated after addition of 2 mM 
CaCl2 and 1 U/ml thrombin (Sigma Aldrich). In parallel, samples were also treated with 0.5 
mM MnCl2. Samples were incubated at 25°C for 2 hrs and clot retraction was analysed by 
weighing the residual serum to calculate the percentage of serum extruded from the clot at 
the indicated time points. 
 
Skin inflammation model: 
Croton oil (Sigma-Aldrich) was diluted to 1% in acetone and topically applied to the ventral 
and the dorsal sides (20µl each) of ears from K3+/+, K3n/n, K3n/- and K3-/- chimeric mice. 
After 1 and 4 h, mice were sacrificed and the earflaps were split into two halves by 
carefully separating the dorsal and ventral skin. For histological analysis, dorsal and 
ventral ear halves were subjected to whole-mount immunostaining. After fixation in 
paraformaldehyde (PFA), ear halves were blocked with 1% BSA (PAA Laboratories) in 
PBS for 1h at room temperature, probed with biotin-labeled anti-Gr-1 (RB6-8C5; BD 
Biosciences-Pharmingen) to identify PMNs and anti-pan-laminin (L9393; Sigma-Aldrich) to 
visualize vessels, diluted in 1% BSA in PBS overnight at 4°C (wile shaking), and finally 
washed with 1% BSA in PBS. Antibodies were detected with a repeated cycle of staining 
with anti-rabbit Alexa Fluor 488 (Invitrogen) and anti-rat Cy3 (Dianova) before tissue was 
embedded in elvanol and representative images taken with a Zeiss Axio Imager equipped 
with an ApoTome (Zeiss). 
 
Intravital microscopy: 
rmTNF-α (R&D Systems) was injected intrascrotally at a dose of 500 ng per mouse in a 
volume of 0.15 ml sterile physiological NaCl solution. Two hours later, the mice were 
anesthesized (Frommhold et al., 2008) and placed onto a heating pad to maintain body 
temperature at 37 °C. After intubation and carotid artery cannulation for blood sampling 
and application of antibodies and chemokines, the cremaster muscle was surgically 
prepared for intravital microscopy as previously described (Sperandio et al., 2006). 
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Intravital microscopy was performed on an upright microscope (Olympus BX51) with a 
saline immersion objective (40x and 0.8 numerical aperture). Experiments were recorded 
via CCD camera (model CF8/1, Kappa) on a Panasonic S-VHS recorder and with a digital 
camera (LaVision Biotech), and stored on a computer with Imspector software package 
(LaVision Biotech). The digital recordings were used offline to generate movie clips with 
ImageJ software (US National Institutes of Health). During the experiment, systemic blood 
samples were obtained (10 µl into 90 µl Türck's solution, Merck) to assess systemic white 
blood cell counts. Rolling flux was defined as the number of rolling cells per min and rolling 
PMN flux fraction as the percentage of rolling PMNs in all PMNs passing the same vessel 
in 1 min (Sperandio et al., 2006). PMNs that did not move for more than 30 s were 
considered to be adherent. The number of adherent leukocytes was assessed as the 
number of adherent cells per mm2 vessel surface area (Frommhold et al., 2008). 
 
Adhesion assays: 
For PMN adhesion to ICAM-1, 96-well plates were coated with 4 µg/ml recombinant 
human ICAM-1 (R&D Systems) in coating buffer (150 mM NaCl, 20 mM Tris-HCl, and 2 
mM MgCl2, pH 9) ON at 4°C and blocked with 3% BSA in PBS for 1 h at RT. PMNs sorted 
from bone marrow were either left untreated, or treated either with 33 ng/ml PMA (Phorbol-
12-Myristate-13-Acetate; Calbiochem) or 1 mM MnCl2. The adhesion assay was 
performed with 50.000 cells per well for 30 min. Adherent cells were fixed with 4% PFA 
after washing. The number of adherent cells was determined by acquisition of 3 phase 
contrast pictures from each well. 
 
Phagocytosis assay: 
Phagocytosis was measured using the pHrodoTM Red E.coli BioParticle Phagocytosis Kit 
for Flow cytometry (invitrogen) according to the manufacturer´s instructions. Blood was 
collected from the retro-orbital sinus and each blood sample was measured in triplicates. 
Granulocytes were identified by their position in a forward vs. side scatter plot. 
 
Absolut quantification of proteins in platelets and neutrophils: 
We produced two protein standards spanning over different regions of talin-1, b3 and b2 
integrins, and 3 standards for kindlin-3. The protein standards were designed with an 
approximate length of 150 amino acids and with as many unique tryptic cleavage sites as 
possible. They covered in kindlin-3 the aminoacids 114-276, 304-477 and 522-605; in 
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talin-1 1752-1948 and 2021-2188; in β3 integrin 34-162 and 589-714; and in β2 integrin 
176-325 and 334-480. Subsequently they were fused to the albumin binding protein (ABP), 
whose cDNA was was inserted into the expression vector pET28a(+) then fused with the 
gene sequences of interest using HindIII and XhoI. In a next step the proteins fused to 
ABP were expressed in an auxotrophic E. coli strain and labeled with 'heavy' isotopes 
(13C615N2-lysine and 13C615N4-arginine). The labeled proteins were purified via His6-Tag 
using spin columns from Qiagen (Hilden, Germany). 
The proteins of interest were quantified as previously described (Zeiler et al.). In brief, 
unlabeled ABP was quantified beforehand with amino acid analysis. These measurements 
were used to quantify the 'heavy' protein standards via SILAC ratios. The different protein 
standards with known concentration were then mixed. The platelets or neutrophils were 
lysed and the 'protein standard mix' was spiked in at approximately endogenous level. The 
mixture was further processed using the filter-aided sample preparation (FASP) method 
(Wisniewski et al., 2009), in which proteins were captured on a 30 kDa filter and SDS was 
removed with an urea-containing buffer. Proteins were alkylated with iodoacetamide and 
typsinized. The peptides were measured by MS, and peptide ratios between endogenous 
and labeled peptides were extracted.  
For the platelet proteome FASP peptides were further fractionated with strong anion 
exchange chromatography. Six fractions of pH 11, 8, 6, 5, 4 and 3 were obtained. 
All samples were measured using the LTQ-Orbitrap Elite or Q Exactive proteomic pipeline 
(Michalski et al., 2012). Raw mass spectrometric data were analyzed using the MaxQuant 
software (Cox and Mann, 2008). Detailed description of the MS analysis as well as the 
data analysis can be found in the supplementary material. 
For calculation of the absolute copy number per cell we used the peptide ratios and 
converted the ratios to pmol. We took the median of all peptides amounts (derived from 
different protein standards) to calculate the copy number. We required at least 3 peptides 
for the quantification of each protein. 
 
Statistical analysis 
All data are shown as mean ± SD or mean ± SEM as indicated in the figure legends. To 
test significance level an unpaired student t-Test was performed.  
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Supplementary Material 
Liquid chromatography and mass spectrometry analysis. The peptides were 
separated on a 20 cm column packed with Reprosil-Pur 1.9 µm resin (Dr. Maisch GmbH, 
Ammerbuch-Entringen, Germany) using an UPLC system (Thermo Fisher Scientific). A 
linear gradient 180 min 5–25% buffer B (80% acetonitrile, 0,5 % acetic acid) at a constant 
flow rate of 300nl/min was applied. The UPLC was coupled via nanoelectrospray ion 
source (Proxeon Biosystems) to an LTQ-Orbitrap Elite mass spectrometer (Michalski et 
al., 2012). The data was acquired with a data-dependent top10 method, automatically 
selecting the most abundant precursor ions for fragmentation. Full scans, 300-1750m/z, 
were measured with a target value 1e6 at a resolution of 60,000 followed by 
10 fragmentation spectra using higher energy collisional dissociation also measured in the 
Orbitrap using 5e4 ions at a resolution of 15,000. The injection time for MS spectra was 
restricted to 100 ms and for MS/MS spectra to 150 ms. 
The platelet proteome was measured on a QExactive instrument (Michalski et al., 
2011)Thermo Scientific) using the same liquid chromatography setup as described above. 
A linear gradient 180 min 5–35% buffer B at a constant flow rate of 300 nl/min was 
applied. Full scans, 300-1650m/z, were measured with a target value 3e6 at a resolution 
of 70,000 followed by 20 fragmentation spectra using higher energy collisional dissociation 
and measured in the Orbitrap using 1e6 ions at a resolution of 17,500. The injection time 
for MS spectra was restricted to 20 ms and for MS/MS spectra to 60 ms. 
Data analysis. The raw files were analyzed using MaxQuant (version 1.3.7.4; (Cox and 
Mann, 2008). For peptide identification Andromeda search engine incorporated into 
MaxQuant (Cox et al., 2011) was used to search fragmentation spectra against the 
UniProtKB mouse database (downloaded on 16 June 2012), which contains 54,232 
entries. 247 common contaminants were added to this database. A time-dependent mass 
recalibration algorithm was used for recalibration to improve the mass accuracy of 
precursor ions. Peptide identification was based on a search with an initial mass deviation 
of the precursor ion of up to 6 ppm and the allowed fragment mass deviation was set to 20 
ppm. The search included cysteine carbamidomethylation as a fixed modification and N-
terminal acetylation and methionine oxidation as variable modifications. Enzyme specificity 
was set to trypsin allowing N-terminal cleavage to proline. Two mis-cleavages were 
allowed and a minimum of seven amino acids per identified peptide was required. The 
second peptide identification option in Andromeda was enabled. For statistical evaluation 
of the data obtained, the posterior error probability and false discovery rate (FDR) were 
______________________________________________________________________________________________________________
249
Appendix
 15 
used. The false discovery rate was determined by searching a reverse database and was 
set to 0.01 for peptide and protein identification. Additional peptides were identified by the 
“match between run” option in MaxQuant, which matches precursor masses in a 2 min 
retention time window (after realignment of the runs) based on the accurate mass. 
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FIGURE LEGENDS 
 
Figure 1: Kindlin-3 protein levels in spleen and thymus. (A) Western blot analyses of 
kindlin-3 in spleen and thymus lysates from K3+/+, K3n/n, K3n/- mice. GAPDH served as 
loading control. (B) Densitometric quantification of (A). 
 
Figure 2: Function of platelet integrins is kindlin-3 dose dependent. (A) Densitometric 
quantification of kindlin-3 levels in K3+/+, K3n/n, K3n/- and K3-/- platelets (N=5;5;4;4). 
GAPDH served as loading control. (B) Kindlin-3 K3+/+, K3n/n, K3n/- E14.5 embryos are 
free bleedings. (C) Tail bleeding times of K3+/+, K3n/n, K3n/- and K3-/- chimeric mice. (D) 
Binding of fibrinogen to platelets after treatment with 0.1 U/ml thrombin. Resting platelets 
were used as control. N=5;5;5;5;3. (E) Activation of αIIbβ3 integrin on platelets upon 
stimulation with 0.1 U/ml thrombin. N=5;5;5;5;3. (F) Washed platelets were stimulated with 
0.01 U/ml thrombin and allowed to adhere to coated fibrinogen for 10 min in the presence 
or absence of 3 mM Mn2+. (G) Aggregates of K3+/+, K3n/n and K3n/- platelets in response 
to 0.1 U/ml thrombin. (H) Platelet aggregation assays with K3+/+, K3n/n, K3n/- platelets in 
response to thrombin in the absence and presence of 100 µg/ml fibrinogen. (I) Clot 
retraction of platelets from K3+/+, K3n/n, K3n/- and K3-/- mice in the absence or presence 
of 0.5 mM Mn2+. N=7;4;6;6;7. Values are given as mean ± SD. Significant differences are 
indicated by asterisk (*: p<0.05; **: p<0.01; ***p<0.001). 
 
Figure 3: Leukocyte adhesion is Kindlin-3 modulated. (A) Densitometric quantification 
of kindlin-3 levels in K3+/+, K3n/n, K3n/- and K3-/- PMNs (N=3). GAPDH served as 
loading control. (B) Static adhesion of PMNs to ICAM-1 upon PMA stimulation. N=4. (C) 
Whole mounts of ears treated with phorbol ester for 1 (left) and 4 h (right) stained with a 
pan-laminin antibody (LN; green) to visualize endothelial basement membranes and a Gr-
1 antibody (red) to visualize PMNs. Scale bar: 200 µm. (D-E) Leukocyte adhesion and 
rolling in TNFα-stimulated cremaster muscle venules assessed in 12 venules of 4 K3+/+ 
mice, in 19 venules of 4 K3n/n mice and in 17 venules of 3 K3n/- mice. (D) Leukocyte 
adhesion efficiency determined as number of adherent leukocytes per mm2 vascular 
surface area divided by the systemic leukocyte count. (E) Leukocyte rolling flux fraction 
determined as rolling leukocytes passing an imaginary perpendicular line over the vessel 
corrected by the total number of passing leukocytes. Values are mean ± SEM. (F) 
Phagocytosis of fluorescently labeled E.coli particles by K3+/+, K3n/n, K3n/- and K3-/- 
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PMNs. N=3;5;4;4;3. Significant differences are indicated by asterisk (*: p<0.05; **: p<0.01; 
***p<0.001). 
 
Figure 4: Quantification of kindlin-3, talin-1 and integrin protein levels in platelets 
and PMNs. (A) Western blot of kindlin-3 and talin-1 from different blood cell lysates. 
GAPDH and actin served as loading controls. (B) Copy number counts of platelet proteins 
were estimated with intensity based absolute quantification. (C) Schematic representation 
of the workflow for quantification of protein copy numbers in platelet lysates. Heavy 
labeled protein standards with known concentration were spiked into platelet lysates and 
peptide ratios were determined by mass spectrometry. (D) Mass spectrometry-based 
absolute quantification of the copy numbers of kindlin-3, talin-1, β3 integrin and β2 integrin 
in K3+/+, K3n/n and K3n/- platelets. (wt N=3; +/n, n/n and n/- N=2) . Values are given as 
median ± range. (E) Mass spectrometry-based absolute quantification of the copy 
numbers of kindlin-3, talin-1 and β2 integrin in wild type PMNs. N=3. Values are given as 
median ± range. 
 
Supplementary Figure 1: Generation of mutant Kindlin-3 mice. (A) Targeting strategy 
of kindlin-3. Partial map of the kindlin-3 gene and the targeting vector carrying a loxP sites 
flanking exons 3 to 6 of the kindlin-3 gene. A frt flanked neomycin resistance cassette was 
inserted into intron 6. Exons are indicated as rectangles and restriction enzymes by name. 
Probe used for Southern blotting is shown as red rectangle. (B) Southern blot on DNA 
samples from R1 ES cells electroporated with the targeting construct. The genomic DNA 
was digested with HindIII and hybridized with the probe indicated in A. (C) Genomic PCR 
performed with primers indicated as red arrows in A to identify mice carrying the K3+/+, 
K3n/n, K3n/- and K3-/- alleles. (D) Deletion of the kindlin-3 gene by crossing conditional 
kindlin-3 mice with deletor Cre mice. (E) Western blots of thymus lysates from K3+/+ and 
K3-/- mice. 
 
Supplementary Figure 2: Normal development of K3+/n, K3n/n, K3n/- mice. (A) Weight 
gains. (B) Cellularity of the thymus and spleen. (C) Differentiation of precursor cells into 
CD4- and CD8-positive T-cells. 
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Supplementary Table 1: 
Blood counts of K3+/+, K3+/n, K3n/n, K3n/- and K3-/- chimeras. Values are shown as 
mean ± SD. WBC, white blood cell; NE, neutrophil; LY, lymphocyte; RBC, red blood cell; 
Hb, hemoglobin; PLT, platelet. 
 
 
  +/+ 
[n=9] 
   +/n  
[n=8] 
  n/n 
[n=9] 
  -/n  
[n=9] 
  -/-
chimera 
[n=4] 
  
  mean SD mean SD mean SD mean SD mean SD 
[103/µl] WBC 5,70 (± 2,45) 6,38 2,05 13,30 2,58 9,76 4,01 18,23 2,97 
[103/µl] NE 1,01 (± 0,49) 1,21 0,46 4,15 1,48 2,53 2,38 13,97 2,99 
[103/µl] LY 4,32 (± 2,09) 4,72 1,49 8,37 2,27 6,62 3,68 3,33 0,55 
[106/µl] RBC 9,44 (± 1,27) 9,19 0,82 8,35 1,21 8,35 0,95 2,44 0,47 
[g/dL] Hb 13,93 (± 2,29) 13,56 1,19 12,56 2,12 12,71 1,53 5,78 0,77 
[106/µl] PLT 603,44 (± 138,5) 452,0 61,8 593,2 112,5 695,3 216,4 648,0 167,1 
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12.7 Paper 7: 
 
 
 
 
 
 
 
 
 
β1 integrin-mediated signals are required for platelet granule 
secretion and hemostasis in mouse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                     1 
______________________________________________________________________________________________________________
263
Appendix
doi:10.1182/blood-2013-06-508721
Prepublished online September 4, 2013;
2013 122: 2723-2731
 
 
 
 
Lorenz, Lin Zhang, Wolfgang Siess, Steffen Massberg and Markus Moser
Tobias Petzold, Raphael Ruppert, Dharmendra Pandey, Verena Barocke, Hannelore Meyer, Michael
 
and hemostasis in mouse
mediated signals are required for platelet granule secretion!1 integrin"
 http://bloodjournal.hematologylibrary.org/content/122/15/2723.full.html
Updated information and services can be found at:
 (659 articles)Thrombosis and Hemostasis    
 (423 articles)Platelets and Thrombopoiesis    
Articles on similar topics can be found in the following Blood collections
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
 http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
 Copyright 2011 by The American Society of Hematology; all rights reserved.
Washington DC 20036.
by the American Society of Hematology, 2021 L St, NW, Suite 900, 
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly
 
 
 
 
 For personal use only. at UBM Bibliothek Grosshadern on January 27, 2014. bloodjournal.hematologylibrary.orgFrom 
______________________________________________________________________________________________________________
264
Appendix
Regular Article
PLATELETS AND THROMBOPOIESIS
b1 integrin2mediated signals are required for platelet granule secretion
and hemostasis in mouse
Tobias Petzold,1-3 Raphael Ruppert,1 Dharmendra Pandey,1 Verena Barocke,2 Hannelore Meyer,1 Michael Lorenz,2,3
Lin Zhang,2,3 Wolfgang Siess,3,4 Steffen Massberg,2,3 and Markus Moser1
1Department of Molecular Medicine, Max Planck Institute of Biochemistry, Martinsried, Germany; 2Medizinische Klinik und Poliklinik I, Klinikum der
Universita¨t Mu¨nchen, Munich, Germany; 3Munich Heart Alliance, Munich, Germany; and 4Institute for Prevention of Cardiovascular Diseases, Universita¨t
Mu¨nchen, Munich, Germany
Key Points
• Platelet b1 integrin2mediated
signals control granule
secretion and hemostasis
• b1 integrin2mediated
outside-in signaling is
independent of direct
kindlin-integrin interaction
Integrins are critical for platelet adhesion and aggregation during arterial thrombosis
and hemostasis. Although the platelet-specific aIIbb3 integrin is known to be crucial
for these processes, the in vivo role of b1 integrins is a matter of debate. Here we
demonstrate that mice expressing reduced levels of b1 integrins or an activation-
deficientb1 integrin show strongly reduced platelet adhesion to collagen in vitro and in
a carotis ligation model in vivo. Interestingly, hypomorphic mice expressing only 3% of
b1 integrins on platelets show normal bleeding times despite reduced platelet adhesion.
The residual 3% of b1 integrins are able to trigger intracellular signals driving Rac-12
dependent granule release required for platelet aggregation and hemostasis. Our
findings support a model, in which platelet b1 integrins serve as an important signaling
receptor rather than an adhesion receptor in vivo and therefore promoteb1 integrins as a promising and so far clinically unemployed
antithrombotic target. (Blood. 2013;122(15):2723-2731)
Introduction
The rupture of atherosclerotic plaques leads to the exposure of
matrix proteins, which in turn trigger arterial thrombosis, leading
to stroke and cardiac infarction. Different platelet receptors sense
the exposed matrix and induce platelet activation and secretion of
prothrombotic molecules, leading to further platelet recruitment
and ﬁnally thrombus formation. Integrins represent the major family
of cell-adhesion receptors on platelets. They are heterodimeric trans-
membrane molecules consisting of a and b subunits. The aIIbb3
integrin is exclusively expressed on platelets and can bind von
Willebrand factor (vWF), ﬁbrinogen, and ﬁbronectin. In addition to
aIIbb3, platelets express threeb1 integrins, a2b1,a5b1, anda6b1,
albeit at lower levels, which bind to collagen, ﬁbronectin, and
laminin, respectively. Circulating platelets express integrins in a
conformation with a low afﬁnity for the ligand. At sites of vascular
injury, extracellular stimuli, such as collagen binding to glycopro-
tein VI (GPVI), induce the formation of active integrins with high
afﬁnity for ligands. This process is termed integrin activation or integrin
inside-out signaling and requires the direct interaction of talin and
kindlins with the cytoplasmic domain of the b integrin subunit.1,2
Although the fundamental role of the aIIbb3 integrin for platelet-
mediated hemostasis is indisputable, the in vivo relevance of b1
integrins on platelets remains controversial because of either different
approaches to target b1 integrin function in platelets, including the
use of a2 or b1 integrin-deﬁcient mice,3,4 b1 integrin2blocking
antibodies, synthetic collagen-derived peptides, or small-molecule
inhibitors,5-7 or to the different experimental methods used to model
arterial thrombosis8,9 and to assay bleeding tendency.3,10 Depending
on the assay, b1 integrins have been reported to be both crucial and
dispensable for platelet accumulation in vivo. Several in vitro studies
indicated an important role of a2b1 integrin in the activation of
various signaling molecules that are known to induce integrin aIIbb3
activation, platelet spreading, and aggregation.11,12 In one study with
two patients, investigators reported that the loss of a2b1 integrin is
associated with minor bleeding13,14 attributable to defective a2b1
integrin function, resulting in impaired platelet adhesion and aggre-
gation to collagen or collagen-derived peptides under shear condi-
tions.10,15 Overall, the exact role of b1 integrins remains a matter
of debate.
In the present study we therefore investigated the role of b1
integrins on platelets during arterial thrombosis by using mouse
mutants that express different levels of b1 integrins or an activation-
deﬁcient b1 integrin. We report that b1-null mice or an activation-
deﬁcient b1 integrin mutant show prolonged bleeding times because
of insufﬁcient activation of Rac-1, actin dynamics, granule secretion,
and platelet aggregation. Interestingly, platelets expressing 3% of
wild-type b1 integrin show reduced adhesion to sites of vascular
injury; however, bleeding times, Rac-1 activation, and degranulation
are not affected. The relevance of these ﬁndings is discussed.
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Materials and methods
Reagents and antibodies
Thrombin and heparin were purchased from Sigma-Aldrich and convulxin
(CVX), adenosine 59-diphosphate, and U46619 were from Alexis. Horm-
collagen was purchased from Nycomed. The following antibodies were
used for ﬂow cytometry: PE-integrin b1 (CD29), PE-IgG hamster isotype
(Biolegend), PE-integrin b3 (CD61; eBioscience), FITC-integrin a2
(CD49b; Emfret), PE-integrin a5 (CD49e) and PE-integrin a6 (CD49f;
PharMingen), FITC-9EG7 (active integrin b-1), IgG1 rat isotype control
(BD Biosciences); FITC-GPIa, FITC-GPVI, FITC-GPIX, PE-CD62P,
PE-JON/A (active Integrin aIIbb3; all from Emfret), FITC-IgG2a rat
isotype control, FITC-IgG2b rat isotype control (NatuTec), and PE-
IgG2a rat isotype control (PharMingen).
The following antibodies were used for western blotting: antikindlin-
3,16 anti-Talin-1 (Sigma-Aldrich), antiﬁbrinogen (g-chain) (Abcam),
antithrombospondin-1, anti-VEGF, anti-vWF (Santa Cruz Biotechnologies,
Inc), anti-GAPDH (Calbiochem), anti-Rac-1 (Cell Biolabs), anti-PAK1
(phosphorylated-Thr432)/PAK2 (phosphorylated-Thr402), anti-MLC
(phosphorylated-Ser19), anti-MLC (Cell Signaling), anti-FAK (phosphorylated-
Y397; Biosource), anti-FAK (Upstate), and anti-b1 integrin (Millipore).
Mice
Conditional integrin b1 mice (b1ﬂ/ﬂ), kindlin-32/2, integrin b1 hypomor-
phic (b1Hpm/ﬂ) mice, and Mx1-Cre transgenic mice have been described
previously.1,17-19 Bone marrow chimeras were generated by injecting 63 106
bone marrow cells into the tail vein of lethally irradiated 8-week-old C57BL/6
mice. Three weeks later, Cre expression in the hematopoietic system was
induced by two intraperitoneal injections of 250 mg of polyI/C (Amersham
Biosciences) with a time lag of 2 days.
Platelet preparation
Heparinized whole blood was centrifuged to isolate platelet-rich plasma.
Platelets were washed in Tyrodes buffer, pH 6.5 (134 mM NaCl, 2.9 mM
KCl, 12 mM NaHCO3, 10 mM N-2-hydroxyethylpiperazine-N9-2-ethane-
sulfonic acid) containing 5 mM glucose and 0.35% bovine serum albumin
(BSA) and were kept at 37°C. For experiments ex vivo, platelets were
resuspended in Tyrodes buffer, pH 7.4, containing 5 mM glucose, 0.35%
BSA, 1 mM CaCl2, and 1 mM MgCl2.
Flow cytometry
Heparinized blood was diluted 1:50 in Tyrodes buffer, pH 7.4, containing
5 mM glucose, 0.35% BSA, 1 mM CaCl2, and 1 mM MgCl2. To quantify
surface receptor expression level, blood samples were incubated with
ﬂuorophore-conjugated antibodies for 15 minutes at room temperature and
analyzed on a FACScalibur ﬂow cytometer (Becton Dickinson, Heidelberg,
Germany). For integrin activation assays, washed platelets were stimulated
for 15 minutes with the indicated agonists and incubated with ﬂuorophore-
conjugated conformation sensitive antibodies.
Platelet spreading
Coverslips were coated with 1 mg/mL ﬁbrinogen (Sigma-Aldrich) or 25 mg/mL
acid soluble collagen I (Sigma-Aldrich) overnight, washed and blocked
with 1% BSA. Washed platelets (1 3 106) were suspended in 150 mL
of Tyrodes buffer (pH 7.4; 1 mM CaCl2, 1 mM MgCl2), stimulated with
0.01U/mL thrombin, and seeded on coated coverslides in the presence or
absence of 0.75 mMMn21. After 45 minutes at 37°C, differential interference
contrast microscopy was performed with a Zeiss Axiovert 200M microscope
with a Plan-NEOFLUAR, 3100, 1.45 oil objective (Zeiss, Jena, Germany).
Pictures were acquired via the use of Metamorph software (Molecular
Devices). Platelet spreading area was analyzed using ImageJ software
(http://rsbweb.nih.gov/ij/).
Carotid ligation model
Experiments were performed as described byMassberg et al.20 In brief, carotid
arteries of anesthetized mice were dissected and ligated by the use of a small
suture for 5 minutes. To visualize platelet adhesion, ﬂuorescently 29,79-
dichloroﬂuorescein (Molecular Probes)-labeled platelets (200 3 106/250
mL) from control and mutant mice were infused, and the number of adherent
platelets at the lesion site was quantiﬁed by video-ﬂuorescence microscopy
with a high-speed, wide-ﬁeld ﬂuorescent microscope with a long distance
condenser and a 203 (NA 0.95) water immersion objective and a coupled
camera (ORCA-ER; Hamamatsu Photonics). Images were acquired and
analyzed using a Cell^R software (Olympus). The number of adherent
platelets per mm2 is represented as percentage of adherent b11/1 platelets
at the 5-minute time point.
Analysis of bleeding time
Ten- to twelve-week-old mice were anesthetized by constant isoﬂurane gas-
narcosis and subcutaneous application of weight-adapted fentanyl (0.05 mg/kg;
CuraMed Pharma GmbH) and placed on a 37°C heating pad. An 8-mm
segment of the tail tip was cut off, and the bleeding tail was immediately
placed into 37°C warm physiological saline solution. Time until bleeding
vanished was measured. All experiments were stopped latest after 15 minutes
by cauterization to prevent excessive blood loss.
Aggregation
To determine platelet aggregation, light transmission was measured over
10 minutes in a two-channel aggregometer (CHRONO-LOG) and was ex-
pressed as arbitrary units. Washed platelets (23 108/mL) were stimulated with
different agonists in Tyrodes buffer (pH 7.4, 1 mM CaCl2, 1 mM MgCl2) in
the presence or absence of ﬁbrinogen (100 mg/mL) or Mn21 (0.75 mM),
respectively.
Evaluation of adenosine triphosphate (ATP) release
A luciferin-luciferase detection kit (CHRONO-LOG) was used to quantify the
release of ATP platelets. For these experiments, platelets were stimulated in
a lumino-aggregometer (CHRONO-LOG) under stirring conditions, in the
presence of luciferase and luciferin. Emitted luminescence was recorded as
arbitrary units, and values were expressed as signal ratio of collagen and
CVX-stimulated platelets.
Serotonin and PF-4 release assays
Platelets were stimulated in an aggregometer (CHRONO-LOG) under
stirring conditions for 8 minutes. Platelets were pelleted by centrifugation
for 30 seconds. The serotonin and PF-4 contents within the supernatants
were determined using the Serotonin ELISA (LDN, Germany) and PF-4
ELISA (Abcam) Kits following the manufacturer’s instructions.
Granule protein release
Platelets were stimulated in an aggregometer in the absence of BSA as
described previously. After 8 minutes, platelets were pelleted by centri-
fugation (20 000 3 g for 30 seconds) and immediately lysed in Laemmli
buffer (60 mM Tris-Cl, pH 6.8; 2% sodium dodecyl sulfate; 10% glycerol; 5%
b-mercaptoethanol; 0.01% bromophenol blue). Lysates were subjected to
immunoblotting and probed with the indicated antibodies.
Rac-1 activity assay
Rac-1 activity was analyzed with a Rac-1 Activation-Assay-Kit (Cell Biolabs).
Platelets were stimulated with 5 mg/mL ﬁbrillar collagen for 60 seconds in an
aggregometer as described and then lysed by addition of 23 lysis buffer (125
mMHEPES, pH 7.5; 750mMNaCl; 5%NP-40; 50mMMgCl2; 5 mMEDTA;
10% glycerol) on ice. Cleared lysates were incubated with PAK-PBD agarose
and processed according to the manufacturer’s protocol. Rac-1-GTP binding
was determined by western blot analysis.
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Measurement of filamentous actin content
Platelets were stimulated with 5 mg/mL ﬁbrillar collagen in an ag-
gregometer under stirring conditions in the presence of 0.5 mM RGDS
(Sigma-Aldrich). At indicated time points, platelets were ﬁxed in 1.8%
parformaldehyde, permeabilized in 0.02% Triton X-100 phosphate-
buffered saline, and stained with FITC-phalloidin (Invitrogen). F-actin
content was quantiﬁed using ﬂow cytometry.
Statistical analysis
All data are shown as mean 6 SEM. To test signiﬁcance level, an unpaired
Student t test was performed, and a value of P , .05 was considered sig-
niﬁcant. If indicated, one-way analysis of variance followed by a Tukey
multiple comparison test was performed.
Ethics statement
All animal experiments were performed with approval by the District
Government of Bavaria (Munich, Germany).
Results
Genetic targeting of b1 integrin
To address the role of platelet b1 integrins for platelet activation,
adhesion, and aggregation, we generated mouse strains with dif-
ferent b1 integrin expression levels and an activation-deﬁcient b1
integrin mutant. We derived platelets from offspring (b1ﬂ/ﬂ Mx1-
Cre; b11/ﬂ Mx1-Cre) of intercrosses between ﬂoxed b1 integrin
mice and the inducible Mx1-Cre strain,18 from b1 integrin
hypomorphic mice,17 and from Kindlin binding2deﬁcient mice
carrying the TT788/789AA substitutions in the b1 integrin cyto-
plasmic domain.21 Because homozygous hypomorphic b1 integrin
(b1hpm/hpm) mice expressing very low levels of functional b1 integrin
and homozygous b1TTAA/TTAA mice die at peri-implantation, we
crossed b11/hpm and b11/TTAA mice, respectively, with ﬂoxed b1
integrin andMx1-Cre mice to generate b1hpm/ﬂMx1-Cre andb1TTAA/ﬂ
Mx1-Cre mice. Injection of poly-IC induced the expression of the Cre-
recombinase, leading to the deletion of the ﬂoxed b1 integrin gene
predominantly in hematopoietic cells resulting in blood cell-restricted
b1-null (KO), heterozygous (HT), hypomorphic (Hpm), and b1TTAA
(TTAA)mice. To prevent off-target effects of theMx1-Cre2mediated
gene deletion described in other tissues,we restricted the deletion to the
hematopoietic system by using bone marrow chimeras for in vivo
experiments.18
Differential b1 integrin expression in mutant mice
We ﬁrst quantiﬁed the surface expression of platelet b1, a2, a5, and
a6 integrins by using ﬂow cytometry. Poly-IC treatment resulted in
a loss of b1 integrin surface levels on platelets from b1ﬂ/ﬂMx1-Cre
mice, reduced the levels by approximately 51% in b11/ﬂ Mx1-Cre
mice, approximately 82% in b1TTAA/ﬂMx1-Cre, and approximately
97% in b1hpm/ﬂ Mx-Cre mice (Figure 1A-B). The differences in b1
integrin expression levels were conﬁrmed by western blot analysis
(Figure 1C). A similar reduction in the surface expression of the b1
integrin2associated a2, a5, and a6 integrin subunits was measured
in the different platelet populations (supplemental Table 1A; see the
Figure 1. Characterization of platelets from b1
integrin mouse mutants. Platelet b1 integrin surface
expression of wild-type (WT; b11/1), HT (b11/2), KO
(b12/2), TTAA (b1TTAA), and Hpm (b1Hpm) b1 integrin
mice were analyzed by flow cytometry. (B) Geometric
mean values of b1 integrin expression shown in panel A
were corrected for isotype control and expressed as %
of WT b1-integrin surface levels (n 5 6 per group). (C)
Platelet lysates were subjected to immunoblotting for
b1-integrin, talin-1, kindlin-3, and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). (D) Surface ex-
pression of b3 integrin, GPVI, and GPIX on platelets of
indicated mouse strains. (E) Platelet b1 integrin acti-
vation was determined with the conformation-specific
9EG7 antibody via the use of flow cytometry upon
stimulation with 50 ng/mL CVX, 0.1 U/mL thrombin, or
5 mM U46619. Acquired mean fluorescence intensity
values were normalized to total b1 integrin expression
levels and are shown as arbitrary unit (n 5 3 for TTAA
and Hpm, n 5 4 for all other groups; bars represent
mean values 6 SEM; significance levels are indicated;
*P , .05; **P , .01; n.s., not significant). (F) Active b3
integrins were determined with JON/A antibody after
platelet stimulation with indicated stimuli. No significant
difference between all tested groups was determined
(n 5 5 for HT and WT, n 5 4 for all other groups; bars
represent geometric mean values 6 SEM).
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Blood Web site). Furthermore, we analyzed the distribution of b1
integrin expression on hypomorphic platelets, which showed a mean
expression of 3% compared with wild-type platelets. Fluorescence-
activated cell sorting analysis revealed that 80% of the platelets from
hypomorphic mice express ,8.5% of b1 integrins, whereas only
5% express more than 25% of b1 integrins compared with controls
(supplemental Table 1B). It has been previously shown that the
reduced expression of b1TTAA integrin was caused by increased
degradation.21 Expression of talin-1 (for quantiﬁcation, see supple-
mental Figure 1) and kindlin-3was similar in platelets of all genotypes
(Figure 1C). Furthermore, surface levels of b3 integrin, GPVI, and
GPIX also were unaffected by the different b1 levels (Figure 1D).
b1 integrin inside-out signaling depends on an intact
kindlin-binding site
We then analyzed the b1 integrin activation state on platelets from
the different mice. Active b1 integrins were quantiﬁed by ﬂow
cytometry by use of the conformation-speciﬁc 9EG7 antibody that
recognizes the active conformation of b1 integrins and the measured
values were then corrected for the different b1 integrin expression.
Treatment with CVX, the thromboxane A analog U46619, and
thrombin led to a similar b1 integrin activation on platelets from
wild-type, heterozygous, and hypomorphic mice. In sharp contrast,
all three agonists failed to activate the kindlin binding2deﬁcient
b1TTAA integrin (Figure 1E). Importantly, the activation of aIIbb3
integrins was not affected by b1 integrin surface levels or the
kindlin binding mutation (Figure 1F). These data show that an
intact kindlin-3 binding site in b1 integrins is required for their
activation in vivo and that an intact binding site for talin-1 alone
is not sufﬁcient to activate b1 integrins.
b1 integrin2mediated outside-in signaling and spreading is
independent of kindlin-integrin interaction
Next, we analyzed platelet adhesion and spreading on acidic soluble
collagen. Acidic soluble collagen I is bound by a2b1 integrin via
a repetitive GFOGER motif. This motif is not recognized by GPVI,
which binds GPOn exposed on ﬁbrillar collagen.5,22 In contrast to
human platelets that can bind soluble collagen and generate intrinsic
signaling without previous activation, mouse platelets require a
weak intrinsic activation to spread on soluble collagen.23 Taking this
into account, we stimulated washed mouse platelets with 0.01 U/mL
thrombin in the presence or absence of 0.75 mMMn21. As depicted
in Figure 2A, b1Hpm and b1-null platelets showed a severe spreading
defect on soluble collagen I both in the presence or absence of Mn21.
Furthermore, they formed elongated ﬁlopodia and only occasionally
small lamellipodia. Activation of b1TTAA platelets also failed to
form lamellipodia and showed a signiﬁcantly reduced spreading
(Figure 2A-B). Notably, spreading of b1Hpm platelets was not
improved by increasing the coating concentration of collagen
(supplemental Figure 2A). Interestingly, however, bypassing integrin
inside-out signaling by Mn21-treatment rescued the spreading
defect in b1TTAA platelets (Figure 2A-B). In light of our previous
observation showing that Mn21-induced platelet spreading is
abolished in kindlin-32deﬁcient platelets,1 we conclude that a
direct interaction between kindlin-3 and b1 integrin is not required
for integrin outside-in signaling.
To further corroborate this ﬁnding we analyzed autophosphor-
ylation of focal adhesion kinase (FAK) at position Tyr397 as an
immediate effect of collagen-bound b1 integrin signaling. Indeed,
b1TTAA platelets showed robust FAK phosphorylation in the
presence of Mn21, which was neither seen in b1-null nor Kindlin-32
null platelets (Figure 2C). Of note, platelet adhesion and spreading
on the a6b1 ligand laminin was similarly affected (supplemental
Figure 2B). In contrast, adhesion and spreading on theaIIbb3 ligands
ﬁbrinogen (Figure 2A) and ﬁbronectin or on the GPVI substrate
collagen-related peptide (supplemental Figure 2B) was not altered
in any of the genotypes examined here. Because Mn21 treatment
of b1TTAA platelets show normal spreading, these ﬁndings indicate
that a direct interaction between the integrin cytoplasmic domain and
kindlin-3 is required for inside-out signaling, but this interaction
is dispensable for integrin-mediated, outside-in signaling and
cytoskeletal reorganization during platelet spreading.
b1 integrins are important for platelet adhesion and hemostasis
We next investigated whether the in vitro defects have consequences
in vivo. The reduced b1 integrin expression in b1hpm mice and the
expression of b1TTAA integrins had no impact on thrombopoiesis
Figure 2. b1 integrin2mediated spreading and
outside-in signaling is independent of kindlin-integrin
interaction. (A) Spreading of thrombin-stimulated
platelets on soluble collagen in the absence or presence
of 0.75 mM Mn21 and on fibrinogen. Representative
pictures are shown 45 minutes after platelet seeding
(scale bar represents 5 mm). (B) Spreading area of
mutant platelets on soluble collagen is shown relative
to wild-type (WT) platelets at 45 minutes (bars represent
mean values 6 SEM; significance level are indicated;
*P , .05; **P , .01). (C) Integrin outside-in signaling
was evaluated by FAK autophosphorylation at Tyr379.
Washed platelets fromwild-type (WT),b1 knockout (KO),
and TTAA mice as well as from kindlin-32deficient
mice (K3(2/2)) were stimulated with 5 mg/mL fibrillar
collagen and seeded on soluble collagen-coated surfaces
in the absence or presence of Mn21. To analyze basal
FAK phosphorylation, unstimulated platelets were seeded
onBSA.Cells were lysed after 30minutes and subjected to
immunoblotting for FAK Y397 phosphorylation and total
FAK.
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because platelet counts were similar to control animals (data not
shown). For studying platelet adhesion to vascular lesions in vivo,
we used the in vivo carotid ligation model, in which platelets
accumulate in a collagen-dependent manner20 and which allows
monitoring single-platelet adhesion to a deﬁned subendothelial
vessel wound by intravital microscopy over time. Consistent with an
important role of collagen for platelet adhesion, we observed that b1
integrin2deﬁcient platelets as well as hypomorphic and b1TTAA
mutant platelets, but not platelets from heterozygous b1 integrin
knockout mice, showed a strong decrease in platelet adhesion to
the wounded vessel wall 5 to 60 minutes after vascular injury
(Figure 3A). These ﬁndings indicate that b1 integrins signiﬁcantly
contribute to primary adhesion to subendothelial lesions and that 50%
but not the 3% of wild-type b1 integrins (present on b1 hypomorphic
platelets) are sufﬁcient to mediate this task. The reduced adhesion of
b1TTAA platelets is likely attributable to the activation defect of the b1
integrins, although we cannot fully rule out that the expression level of
approximately 18% compared with wild-type platelets also contrib-
utes to the observed adhesion defect.
Next, we tested whether b1 integrins also play a role for occlusive
thrombus formation and hemostasis using the tail-bleeding assay.
Although wild-type, heterozygous, and animals carrying a ﬂoxed b1
integrin allele but no Mx1-Cre allele (b1ﬂ/ﬂ, b1TTAA/ﬂ, b1Hpm/ﬂ)
showed similar bleeding times of 2 to 3 minutes,b1 integrin knockout
and b1TTAA mice showed signiﬁcantly prolonged tail bleeding times
of 8 to 9minutes (Figure 3B), and kindlin-32 deﬁcient mice exhibited
the most severe bleeding defect as the result of impaired b1 and
aIIbb3 integrin activation.1 Surprisingly, hypomorphic mice showed
normal bleeding times. Taken together, these data indicate that b1
integrins play a crucial role for stopping bleeding and as little as 3% of
them are sufﬁcient enabling a normal hemostasis.
Defective aggregation and granule secretion in b1TTAA
and b1-null mice
Occlusive thrombus formation requires a second wave of platelet
recruitment, activation, and subsequent aggregation, which is trig-
gered by the release of paracrine factors stored in platelet a and
dense granules. To ﬁnd an explanation for the normal tail bleeding
times of b1 hypomorphic mice, we investigated platelet aggregation
in more detail. In brief, washed platelets were activated with either
5 mg/mL ﬁbrillar collagen or with 50 ng/mL CVX, which activates
GPVI by inducing GPVI receptor dimerization and downstream
signaling.24 CVX induced aggregation of platelets of all genotypes
(Figure 4A; supplemental Figure 3A). In contrast, b1-deﬁcient and
b1TTAA platelets failed to aggregate after stimulation with ﬁbrillar
collagen, whereas b1hpm platelets showed an intermediate response
(Figure 4A). Exogenous activation of b1TTAA platelets by Mn21
resulted in normal aggregation, but this did not occur in b1-
deﬁcient platelets (Figure 4B). This latter ﬁnding further supports
the concept that the double threonine motif within the b1 integrin
cytoplasmic domain is required for integrin inside-out but not for
integrin outside-in signaling.
Unexpectedly, the addition of exogenous ﬁbrinogen to washed
platelets rescued the aggregation defect of b1TTAA and b1-null
platelets (Figure 4B). Platelets contain substantial amounts of
Figure 3. Reduced platelet adhesion and aggregate
formation onto injured vessel walls of b1-null,
b1TTAA, and b1hpm mice, whereas tail bleeding
times of b1hpm mice are normal. (A) Number of
adherent fluorescently labeled platelets to the injured
vessel wall was quantified after 5, 10, 15, and 60minutes.
Values are expressed as percentage of adherent wild-
type (WT) platelets (n/mm2) at 5 minutes (WT, n5 9; HT,
n 5 6; knockout [KO], n 5 6; TTAA, n 5 4; Hpm, n 5 8;
bars represent mean values 6 SEM in percent, signifi-
cance level are indicated; *P, .05; **P, .01 by one-way
analysis of variance followed by a Tukey multiple com-
parison test). (B) Tail-bleeding times of chimeric mice
carrying the bonemarrow of the indicated genotype (WT,
n5 19; fl/fl, n5 6; HT, n5 10; KO, n5 9; TTAA, n5 15;
TTAA/fl, n5 6; Hpm, n5 13; Hpm/fl, n5 6; Kindlin-32/2,
n 5 4; cross line represents mean bleeding time and
bars represent SEM, significance level are indicated;
**P , .01).
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ﬁbrinogen within their granules, which they release upon stimula-
tion (eg, by collagen). Hence, the ﬁnding that exogenous ﬁbrinogen
is able to rescue defective aggregation of b1TTAA and b1-null
platelets suggests a novel role of b1 integrin in the regulation of
ﬁbrinogen release from a granules in platelets. We therefore tested
whether b1 integrin-mediated signals are important for granule
secretion in general. Dense granule secretion was quantiﬁed by
measuring ATP release after addition of luciferin/luciferase reagent
in an aggregometer. Platelets were stimulated either with 50 ng/mL
CVX or 5 mg/mL ﬁbrillar collagen, and values were calculated as
a ratio between ﬁbrillar collagen- and CVX-induced luminescence.
Although b1-null and b1TTAA platelets showed a severe defect in
dense granule secretion after ﬁbrillar collagen stimulation, b1hpm
platelets showed an almost-normal exocytosis of dense granules
upon collagen stimulation (Figure 4C; supplemental Figure 3B).
Furthermore, the defect in dense granule secretion of b1-null and
b1TTAA platelets was corroborated by reduced secretion of serotonin
(Figure 4D). To analyze plateleta-granule secretion, we determined the
cellular level of the a-granule cargo ﬁbrinogen (Figure 4E; supple-
mental Figure 3C) before and 8 minutes after agonist treatment
(5 mg/mL ﬁbrillar collagen or 50 ng/mL CVX) by immunoblotting.
Our data show that stimulationwithﬁbrillar collagen led to a decrease in
cellular ﬁbrinogen in wild-type and hypomorphic platelets but not in
b1-null and b1TTAA platelets. Importantly, the total ﬁbrinogen content
was similar in unstimulated platelets of all groups (supplemental
Figure 3D), and exocytosis of other a-granule cargo proteins such as
thrombospondin, vWF or PF-4 were also b1 integrin–dependent,
suggesting that b1 integrin2mediated signals control platelet granule
release (Figure 4F-G; supplemental Figure 3E).
b1 integrins control platelet actin polymerization and Rac-1
activation upon collagen stimulation
How does b1 integrin control platelet granule secretion? Platelet
granule fusion with the outer platelet membrane requires the reorga-
nization of the actin cytoskeleton.25,26 Therefore, we analyzed F-actin
dynamics after collagen stimulation by ﬂow cytometry. Indeed b1-
null platelets failed to increase their F-actin content after 60 seconds,
whereas ;3% of b1 integrin were sufﬁcient to rescue F-actin poly-
merization in hypomorphic platelets (Figure 5A).
The small GTPase Rac-1 is a central regulator of actin poly-
merization and granule secretion in platelets and is activated rapidly
after platelet stimulation.27 Previous studies showed that genetic and
pharmacologic inhibition of Rac-1 efﬁciently blocks collagen-induced
platelet granule secretion and reduces the stability of platelet aggre-
gates under ﬂow.28 Moreover, it has also been shown that a2b1
integrins regulate actin dynamics and lamellipodia formation in plate-
lets spread on soluble collagen in a Rac-12dependent manner.29
Hence, we next examined the formation of active, GTP-bound Rac-1
within 60 seconds after collagen exposure. Hypomorphic and wild-
type platelets showed robust Rac-1 activation within 60 seconds,
which was not observed in b1 integrin2null platelets (Figure 5B-C).
In line with the reduced Rac-1 activity, phosphorylation of the Rac-1
target proteins PAK1/2 was strongly reduced in b1-null platelets 90
and 240 seconds after collagen treatment. Importantly, also hypo-
morphic platelets showed signiﬁcant PAK phosphorylation. In contrast,
phosphorylation of MLC in b1 integrin–null platelets was not
different (Figure 5D). These results show that 3% of b1 integrin
expression is sufﬁcient for rapid Rac-1 activation required to
Figure 4. Collagen-induced platelet aggregation and granule secretion requires b1 integrins. (A) Washed platelets were stimulated with 5 mg/mL fibrillar collagen (black
curves) or 50 ng/mL CVX (gray curves) and aggregation was recorded for 600 seconds. (B) Aggregation of b1-null (KO) and b1TTAA (TTAA) platelets in the presence of
100 mg/mL fibrinogen (gray curves) or 0.75 mM Mn21 (black curves). (C) ATP release from platelet dense granules after stimulation of platelets with collagen. ATP was
measured by luminescence after addition of luciferase luciferin reagent using the Lumi-aggregometer (Chronolog, Havertown, PA). Platelets were stimulated with either 5 mg/mL
fibrillar collagen or 50 ng/mL CVX for 10 minutes. The relative luminescence after 8 minutes (ratio of collagen to CVX stimulated cells) is shown (bars represent mean
values 6 SEM of n 5 3 independent experiments). (D) Serotonin release after stimulation with collagen. Platelets were stimulated with either 5 mg/mL fibrillar collagen or
50 ng/mL CVX for 8 minutes. The relative serotonin level (ratio of collagen to CVX stimulation) is shown (bars represent mean values 6 SEM of n $ 3 independent
experiments). (E) Quantification of the cellular fibrinogen content in resting platelets or 8 minutes after stimulation with either fibrillar collagen (5 mg/mL) or CVX (50 ng/mL; bars
represent mean values 6 SEM; significance levels are indicated; *P , .05; wild-type (WT), n 5 3; knockout (KO), n 5 3; TTAA, n 5 3; hypomorphic (Hpm), n 5 3;
representative blots are shown in supplemental Figure 4B). (F) Platelet content of the a-granule cargo proteins vWF and thrombospondin-1 (TSP-1) in wild-type (WT) and
b1-null (KO) platelets upon collagen and stimulation with CVX. (G) Ratio of PF-4 release from platelets stimulated with either 5 mg/mL fibrillar collagen or 50 ng/mL CVX
for 8 minutes (bars represent mean values 6 SEM of n $ 3 independent experiments).
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remodel the platelet actin cytoskeleton and granule secretion in
response to ﬁbrous collagen.
Discussion
Previous authors have investigated platelet-collagen interactions by
using various knockout mouse mutants, pharmacologic inhibitors,
and disease models in arterial thrombosis and hemostasis. Despite
conﬂicting results, the current model suggests that both GPVI and
integrin a2b1 play signiﬁcant roles as adhesion receptors; however,
whether a2b1 plays an additional crucial role in platelet intracellular
signaling controlling platelet aggregation and thrombus formation
has not been elaborated. To address the molecular role of b1 in-
tegrins for these processes, we generated mice expressing either very
low levels of functional (wild-type) b1 integrin or an activation-
deﬁcient b1 integrin, which harbors a mutation in the binding site
for the essential integrin activating protein kindlin. Our studies
reveal critical and distinct roles for b1 integrins in thrombosis
and hemostasis dependent on their expression levels: (1) high b1
integrin levels critically contribute to platelet adhesion at sites of
vascular injury; (2) b1 integrins assemble signaling platforms
required to initiate full-ﬂedged platelet activation and platelet
granule secretion in response to ﬁbrillar collagen; and (3) the
level of b1 integrins can decrease to as little as 3% for sufﬁcient
activation of Rac-1 and its downstream effector molecules to
ﬁnally promote F-actin formation and initiate platelet granule
secretion.
Despite robust Rac-1 activation, hypomorphic platelets fail
to spread on plates coated with high concentrations of soluble
collagen I, suggesting that a certain number of b1 integrins (.3%)
are required for platelet adhesion during spreading. Furthermore,
the efﬁcient release of dense granule cargo such as ATP or
serotonin and a-granule cargo proteins such as ﬁbrinogen is con-
trolled by b1 integrin outside-in signaling and cannot be com-
pensated by GPVI in the absence of b1 integrins. More potent,
although rather nonphysiologic, stimuli such as CVX may mask the
contribution of b1 integrin signaling and thereby underestimate its
role during thrombotic processes. However, our experimental con-
ditions might not account for complex in vivo situations, in which
additional platelet-collagen interactions through vWF and b3 integrin
as well as mechanical forces or soluble stimuli might contribute
to platelet activation in the presence of plasma proteins such as
ﬁbrinogen.
In addition, our data on platelets expressing an activation-
deﬁcient b1 integrin are in line with the proposed model that
a2b1 integrins directly participate in collagen signaling in an
Figure 5. Normal actin polymerization, Rac activation, and PAK phosphorylation in b1 hypomorphic platelets. (A) Platelets from wild-type (WT), b1-null (KO), and
hypomorphic (Hpm) mice were stimulated with 5 mg/mL fibrillar collagen for 60 seconds in the presence of 0.5 mM RGDS peptide, and the relative F-actin content was
measured by flow cytometry. Curves represent mean 6 SEM increase in FITC phalloidin MFI (n 5 3, significance level are indicated). (B) Same platelet populations were
stimulated with 5 mg/mL fibrillar collagen for 30 and 60 seconds lysed and subjected to Rac-1 GTP pulldown experiments. Total Rac-1 loading is shown below. (C)
Quantification of GTP-bound active Rac-1 pulldown experiments at 60 seconds (bars represent mean values 6 SEM; significance level are indicated; *P , .05; **P , .01;
wild-type (WT), n 5 4; b1-null (KO), n 5 3; hypomorphic (Hpm), n 5 4). (D) Platelets from WT, KO, and Hpm mice were stimulated with 5 mg/mL fibrillar collagen for the
indicated time points, lysed and subjected to immunoblotting for p-Thr432/402 PAK1/2 and p-Ser19 myosin light chain (pMLC). Total MLC is shown as loading control.
BLOOD, 10 OCTOBER 2013 x VOLUME 122, NUMBER 15 PLATELET b1 INTEGRIN CONTROLS GRANULE SECRETION 2729
 For personal use only. at UBM Bibliothek Grosshadern on January 27, 2014. bloodjournal.hematologylibrary.orgFrom 
______________________________________________________________________________________________________________
271
Appendix
activation-dependent manner.10 Inside-out activation by a2b1 integrin
is probably triggered by signals generated by GPVI. These signals
can be overcome by external integrin activation by manganese, which
rescues the defects in platelet adhesion, spreading, and aggregation
of b1TTAA platelets. Thus, upon GPVI-mediated a2b1 activation,
collagen-bound a2b1 integrin generates GPVI independent outside-
in signals that are sufﬁcient to trigger the release of secondary
agonists to fully activate platelets.
Our ﬁndings also revealed that b1 integrins on platelets require
an intact kindlin binding motif for their activation. This important
ﬁnding further corroborates previous studies by showing that a
direct interaction between kindlin-3 and the b1 integrin cytoplasmic
domain is required for platelet b1 integrin activation in vivo.21
However, we also observed that the direct interaction of kindlin-3
with the b1 tail is not required for integrin outside-in signaling and
for achieving platelet spreading, FAK phosphorylation, and platelet
aggregation. A similar observation has been reported recently for b2
integrins, which form a trimeric complex together with kindlin-3
and Rack-1 in T cells, and that kindlin-3 binding to b2 integrin tails
can even occur to a kindlin binding-deﬁcient b2 integrin tail.30
Thus, kindlins need to directly bind the integrin tails for inducing
inside-out signaling but a direct contact is either not required or does
not occur for triggering outside-in signals. In such a scenario the
dissociation of kindlin-3 from the integrin tail after activation has
occurred will enable binding of other cytoplasmic proteins to the
integrin tail.
Because high levels of b1 integrins are required for primary
platelet adhesion to exposed matrix at sites of vascular disease but
very low levels are already sufﬁcient to trigger platelet signals
required for normal hemostasis, the use of novel therapeutic agents
targeting b1 integrins might be a worthwhile approach to reduce
arterial thrombosis without increasing the risk for bleeding.
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12.8 Paper 8: 
 
 
 
 
 
 
 
 
 
Kindlin-1 controls cutaneous epithelial stem cell proliferation by 
modulating Wnt ligand and TGFβ availability. 
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Kindlin-­‐1	   controls	   cutaneous	   epithelial	   stem	   cell	   proliferation	   by	  modulating	  Wnt	   ligand	  
and	  TGFβ	  availability	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ABSTRACT	  
Kindlin-­‐1	  is	  an	  integrin	  tail	  binding	  protein	  that	  controls	  integrin	  activation.	  Mutations	  in	  the	  
Kindlin-­‐1	   gene	   lead	   to	   Kindler	   Syndrome	   in	  man,	  which	   is	   characterized	  by	   skin	   blistering,	  
premature	   skin	   ageing	   and	   skin	   cancer	   of	   unknown	   etiology.	   Here	   we	   show	   that	   loss	   of	  
Kindlin-­‐1	   in	  mouse	  keratinocytes	  recapitulates	  Kindler	  Syndrome,	  and	   in	  addition	  produces	  
enlarged	  and	  hyperactive	  stem	  cell	  compartments,	  which	  lead	  to	  hyperthickened	  epidermis,	  
ectopic	   hair	   follicle	   development	   and	   increased	   skin	   tumor	   susceptibility.	  Mechanistically,	  
Kindlin-­‐1	   controls	   keratinocyte	   adhesion	   through	   β1-­‐class	   integrins	   and	   proliferation	   and	  
differentiation	  of	  cutaneous	  epithelial	  stem	  cells	  by	  promoting	  αvβ6	  integrin-­‐mediated	  TGFβ	  
activation	   and	   by	   inhibiting	   Wnt-­‐β-­‐catenin	   signaling	   through	   an	   integrin-­‐independent	  
regulation	   of	  Wnt	   ligand	   expression.	   Our	   findings	   assign	   Kindlin-­‐1	   the	   novel	   and	   essential	  
task	   to	   control	   cutaneous	   epithelial	   stem	   cell	   homeostasis	   by	   balancing	   TGFβ	   mediated	  
growth	  inhibitory	  and	  Wnt-­‐β-­‐catenin	  mediated	  growth-­‐promoting	  signals.	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INTRODUCTION	  
Kindler	   Syndrome	   (KS)	   is	   an	   autosomal-­‐recessive	   disease	   caused	   by	   loss	   of	   function	  
mutations	   in	  the	  FERMT-­‐1	  gene,	  which	  encodes	  Kindlin-­‐1.	  The	  skin	   is	  the	  principal	  affected	  
organ	   of	   individuals	   with	   KS	   and	   displays	   trauma-­‐induced	   blisters,	   photosensitivity,	  
pigmentation	  defects,	  and	  increased	  risk	  for	  malignancies1,2.	  
The	   Kindlins	   belong	   to	   a	   family	   of	   evolutionary	   conserved	   proteins,	   which	   are	   primarily	  
found	   at	   cell-­‐matrix	   adhesion	   sites	   where	   they	   bind	   β	   integrin	   tails	   and	   increase	   integrin	  
affinity	  for	  ligand	  (also	  called	  integrin	  activation)3–5.	  In	  addition,	  they	  are	  also	  present	  at	  cell-­‐
cell	   adhesion	   sites,	   in	   the	   cytoplasm	   and	   in	   the	   nucleus	   where	   their	   functions	   are	  
unknown6,7.	   Epidermal	   and	   hair	   follicle	   (HF)	   keratinocytes	   express	   Kindlin-­‐1	   and	   Kindlin-­‐2.	  
However,	  despite	   the	   striking	   sequence	   similarity,	  Kindlin-­‐1	  and	   -­‐2	   cannot	   compensate	   for	  
each	  other	  indicating	  that	  they	  have	  specialized	  functions3,8.	  
Epidermal	  keratinocytes	  express	  several	  integrins,	  most	  notably	  members	  of	  the	  β1	  integrin	  
subfamily9.	   Keratinocytes	   of	   the	   HF	   bulge	   express	   high	   levels	   of	   β1	   integrins	   and	   αvβ6	  
integrin10.	  The	  HF	  bulge	  harbors	  dormant	  stem	  cells	  (SCs)	  that	  periodically	  become	  activated	  
to	   sustain	   the	   hair	   cycle	   (HC)11,12.	   The	   alternation	   of	   bulge	   SC	   activation	   and	   dormancy	   is	  
regulated	  by	  a	  tight	  interplay	  of	  antagonistic	  signaling	  pathways.	  SC	  dormancy	  is	  achieved	  by	  
BMP	   and	   TGFβ	   signaling,	   while	   SC	   activation	   is	   elicited	   by	   shutting	   down	   BMP	   and	   TGFβ	  
signaling	   and	   activating	   canonical	   Wnt-­‐β-­‐catenin	   signaling.	   Perturbations	   of	   these	   cell	  
growth	   regulating	   signaling	   pathways	   or	   of	   integrin	   signaling	   can	   profoundly	   alter	   SC	  
homeostasis	   and	   tumor	   incidence13–16.	   	   It	   has	   been	   shown	   for	   example,	   that	   increased	  
integrin	   expression	   or	   activity	   is	   associated	   with	   an	   increased	   risk	   for	   squamous	   cell	  
carcinoma16–18.	   Conversely,	   loss	   of	   β1	   integrin	   expression	   in	   skin	   (M.	   Sibilia,	  manuscript	   in	  
preparation)	   or	   other	   tissues	   such	   as	   mammary	   gland	   markedly	   reduces	   tumor	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susceptibility19.	  Moreover,	   it	  has	  recently	  been	  shown	  that	  Kindlin-­‐2	  can	  stabilize	  β-­‐catenin	  
and	   induce	   Wnt	   signaling	   in	   certain	   tumor	   cell	   lines20.	   It	   is	   therefore	   enigmatic	   why	   KS	  
patients	   suffer	   from	  an	   increased	   tumor	   risk2,21,22	   despite	   Kindlin-­‐1	   loss	   and	   compromised	  
integrin	   functions	   in	   their	   keratinocytes3,23,24.	   This	   discrepancy	   suggests	   that	   Kindlin-­‐1	  
harbors	  potent	  tumor	  suppressor	  function(s)	  in	  keratinocytes	  that	  operate	  independently	  of	  
the	   abundant	   and	   oncogenic	   β1	   integrins.	   In	   this	   paper	   we	   identified	   oncogenic	   signaling	  
pathways	  that	  are	  tightly	  controlled	  by	  Kindlin-­‐1.	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RESULTS	  	  
Kindlin-­‐1	  loss	  in	  epidermis	  and	  HFs	  leads	  to	  KS-­‐like	  defects	  
To	   circumvent	   the	   lethal	   ulcerative	   colitis	   of	   a	   constitutive3	   Fermt-­‐1	   gene	   ablation,	   we	  
efficiently	  deleted	  the	  Fermt-­‐1	  gene	  in	  keratinocytes	  by	  breeding	  floxed	  Kindlin-­‐1	  mice	  with	  
Keratin-­‐5	  (K5)-­‐Cre	  transgenics25	  (Kind1-­‐K5;	  Fig.	  1a–c	  and	  Supplementary	  Fig.	  1a–c).	  Kindlin-­‐1	  
loss	  persisted	  and	  did	  not	  affect	  Kindlin-­‐2	  expression	  (Supplementary	  Fig.	  1b).	  Heterozygous	  
Kind1-­‐K5	   or	   homozygous	   floxed	   Kindlin-­‐1	   mice	   used	   as	   control	   strains	   (Control)	   had	   no	  
apparent	  phenotype.	  Homozygous	  Kind1-­‐K5	  mice	  were	  born	  within	  the	  expected	  Mendelian	  
ratio,	  were	  fertile	  and	  gained	  weight	  normally	  (Supplementary	  Fig.	  1d).	  
The	   first	   histologic	   phenotype	   emerged	   around	   P21	   in	   Kind1-­‐K5	   back	   skin	  with	   basement	  
membrane	   (BM)	   splitting,	   small	   blisters	   at	   the	   dermal-­‐epidermal	   junction	   and	   aberrant	  
accumulation	   of	   F-­‐actin	   and	   cell-­‐cell	   adhesion	   proteins	   at	   the	   basal	   side	   of	   basal	  
keratinocytes	  (Fig.	  1d,e	  and	  Supplementary	  Fig.	  1e).	  The	  same	  defects	  were	  also	  observed	  in	  
mice	   expressing	   Kindlin-­‐binding	   deficient	   β1	   integrins	   in	   keratinocytes	   (Fig.	   1a)	   due	   to	  
threonine-­‐788/789	   to	   alanine	   substitutions	   in	   the	   β1	   cytoplasmic	   domain	   (TTAA-­‐K5)
26	  
indicating	  that	  they	  are	  caused	  by	  malfunctioning	  β1	  integrins	  (Fig.	  1f).	  The	  blisters	  and	  BM	  
defects	  triggered	  a	  regenerative	  response	  with	  granulocyte,	  monocyte	  and	  T	  cell	  infiltrates	  in	  
the	  dermis	  of	  the	  back	  skin	  of	  Kind-­‐K5	  as	  well	  as	  TTAA-­‐K5	  mice	  (Supplementary	  Fig.	  1f–h).	  
At	  postnatal	  age	  60	   (P60)	  Kind1-­‐K5	  mice	  showed	  progressive	  melanin	  deposits,	   first	   in	   the	  
tail	   and	   then	   in	   the	   entire	   back	   skin	   (Fig.	   1g,h	   and	   Supplementary	   Fig.	   1i)	   resembling	  
poikiloderma	  in	  KS.	  At	  around	  3	  months	  Kind1-­‐K5	  mice	  developed	  an	  irregular	  hair	  coat	  with	  
small	  patches	  of	  densely	  clustered	  hair	  (Fig.	  1b)	  that	  increased	  in	  size	  with	  age	  and	  appeared	  
as	  meanders	  on	  the	  shaved	  back	  skin	  (Fig.	  1c).	  At	  6–8	  months	  of	  age	  Kind1-­‐K5	  mice	  began	  to	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lose	  hair	  and	  patches	  with	  dense	  hair	  and	  alopecia	  alternated	  (Supplementary	  Fig.	  1j).	  TTAA-­‐
K5	   mice	   developed	   neither	   pigmentation	   defects	   nor	   densely	   packed	   hairs	   (Fig.	   1b,c,e).	  
Kind1-­‐K5	  mice	  also	  developed	  areas	  of	  atrophy	  next	  to	  areas	  of	  hyperkeratosis	  in	  the	  tail	  and	  
back	   skin,	   while	   TTAA-­‐K5	   mice	   displayed	   hyperkeratotic	   areas	   only	   (Fig.	   1e	   and	  
Supplementary	  Fig.	  2a).	  While	  the	  number	  of	  Ki67-­‐positive	  cells	  was	  higher	  in	  the	  Kind1-­‐K5	  
and	   TTAA-­‐K5	   epidermis,	   especially	   in	   hyperkeratotic	   areas	   (Supplementary	   Fig.	   2b–d),	  
keratinocyte	   differentiation	   and	   apoptosis	   was	   unaffected	   in	   both	   mouse	   strains	  
(Supplementary	  Fig.	  2e–i).	  
These	  results	  show	  that	  Kindlin-­‐1	  deletion	  in	  mouse	  epidermis	  recapitulates	  human	  KS	  and	  
additionally	   induces	   an	   aberrant	   hair	   coat,	   which	   does	   not	   develop	   in	   TTAA-­‐K5	   mice	  
indicating	   that	   the	  aberrant	  hair	  coat	   is	   caused	  by	  a	  Kindlin-­‐1	  specific	  and	  β1	   integrin-­‐	  and	  
inflammation-­‐independent	  mechanisms.	  
Kindlin-­‐1	  loss	  disturbs	  HC	  and	  induces	  ectopic	  HFs	  
Back	  skin	  histology	  of	  6	  months	  old	  Kind1-­‐K5	  mice	  revealed	  two	  different	  HF	  abnormalities;	  
(i)	   areas	  with	   isolated	   and	   densely	   packed	   HFs	   (Fig.	   1g)	   separated	   by	   1–15	   interfollicullar	  
epithelium	   (IFE)	   cells	   compared	   to	  37	  ±10	   IFE	   cells	   between	   control	  HFs,	   and	   (ii)	  HFs	  with	  
multiple	  hair	  shafts	  and	  bulges	  that	  clustered	  together	  and	  contained	  hair	  strands	  exiting	  the	  
skin	  through	  a	  single	  hair	  canal	  (Fig.	  1h).	  
A	  detailed	  HC	  analysis	  revealed	  that	  HF	  morphogenesis	  and	  the	  first	  HC	  proceeded	  normally	  
in	  Kind1-­‐K5	  mouse	  skin	  (Supplementary	  Fig.	  3a).	  At	  P50,	  HFs	  from	  control	  and	  Kind1-­‐K5	  mice	  
entered	  telogen	  (resting	  phase	  of	  the	  HC).	  While	  HFs	  from	  control	  mice	  remained	  in	  a	  long	  
telogen	   until	   P80	   before	   a	   new	   HC	   was	   initiated	   (Supplementary	   Fig.	   3a),	   Kind1-­‐K5	   HFs	  
immediately	  re-­‐entered	  anagen	  (growth	  phase	  of	  the	  HC)	  (Fig.	  2a–c)	  visible	  by	  the	  formation	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of	   a	   hair	   germ	   (HG)	   and	   the	   expression	   of	   the	   transcription	   factor	   CCAAT	   displacement	  
protein	   (CDP)27.	   We	   never	   observed	   premature	   anagen	   induction	   in	   TTAA-­‐K5	   mice	  
(Supplementary	  Fig.	  3b).	  
Whole	   mount	   staining	   of	   P80	   tail	   epidermis	   showed	   control	   mouse	   HFs	   with	   prominent	  
sebaceous	  glands	  (SGs),	  normal	  sized	  keratin-­‐15	  (Krt-­‐15)-­‐positive	  bulges	  and	  small	  HGs	  with	  
few	   CDP+	   cells	   (Fig.	   2d).	   The	   tail	   skin	   of	   Kind1-­‐K5	   mice	   contained	   small	   ectopic	   HFs	  
originating	  from	  pre-­‐existing	  HFs	  and	  the	  IFE	  (Fig.	  2d,e).	  Ectopic	  HF-­‐	  and	  IFE-­‐derived	  Kind1-­‐
K5	  HFs	  were	  also	  present	  in	  the	  back	  skin	  and	  expressed	  the	  dermal	  papilla	  marker	  alkaline	  
phosphatase	   (Supplementary	  Fig.	  3c,d).	  Of	  note,	  while	  HF	  numbers	   increased	  after	  P50	   in	  
the	  murine	  Kind1-­‐K5	  back	   skin	   their	  number	  began	  declining	  at	  older	  age	   (Supplementary	  
Fig.	  3i).	  
These	   findings	   show	   that	   Kindlin-­‐1	   deficiency	   leads	   to	   a	   premature	   onset	   of	   anagen,	   the	  
formation	  of	  ectopic	  HFs	  in	  the	  IFE	  and	  from	  pre-­‐existing	  HFs	  and	  a	  decline	  in	  HF	  numbers	  at	  
old	  age.	  
Kindlin-­‐1	  regulates	  cutaneous	  epithelial	  SC	  homeostasis	  
The	   ectopic	   HFs	   in	   Kind1-­‐K5	  mice	   pointed	   to	   a	   perturbed	   SC	   homeostasis.	   The	   epidermis	  
contains	  different	  SC	  populations	  that	  reside	   in	  different	  niches11.	  While	  bulge	  SCs	  express	  
CD34,	  Krt-­‐15,	  nephronectin	  (Npnt)28	  and	  high	   levels	  of	  α6	   integrin	  (Fig.	  3a),	   reliable	  murine	  
IFE	   SC	   markers	   are	   still	   missing11,39.	   Immunostaining	   revealed	   higher	   numbers	   of	   CD34+	  
bulge	   cells	   in	  back	   skin	   (Supplementary	   Fig.	   3e)	   and	  enlarged	  Krt-­‐15+	  bulges	   in	   tail	  whole	  
mounts	  of	  P80	  old	  Kind1-­‐K5	  mice	  compared	  to	  controls	  (Fig.	  3b	  and	  Supplementary	  Fig.	  3f).	  
Krt-­‐15+	  cells	  were	  also	  present	  in	  the	  Kind1-­‐K5	  infundibulum	  and	  IFE	  (arrowheads	  in	  Fig.	  3b),	  
but	  never	  in	  control	  mice.	  Npnt	  expression	  expanded	  into	  the	  SG,	  the	  infundibulum	  and	  the	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outer	   root	  sheath	   (Fig.	  3b,c)	  and	  Npnt	  mRNA	   levels	  were	  higher	   in	  FACS-­‐sorted	  bulge	   (Bu)	  
and	   interfundibulum-­‐junctional	   zone	   (IJ)	   cells	   of	   Kind1-­‐K5	   mice	   compared	   to	   controls	  
(Supplementary	   Fig.	   3h).	   Also	   the	   Lrig1-­‐positive	   SC	   population	   of	   the	   IJ	   zone30	   extended	  
towards	   the	   infundibulum	  and	   lower	  hair	   shaft	  of	  back	  and	   tail	   skin	  HFs	   of	  Kind1-­‐K5	  mice	  
(Fig.	  3d	  and	  Supplementary	  Fig.	  3g).	  
Despite	   normal	   HCs	   and	   hair	   counts	   until	   P50	   (Supplementary	   Figs.	   3a,i),	   FACS	  
quantifications	   of	   keratinocytes	   from	   P40	   mouse	   skin	   revealed	   significantly	   more	   SCs	   in	  
bulge,	  upper	   isthmus	   (UI)	  and	   IJ	  of	  Kind1-­‐K5	  mice	  compared	   to	  controls	   (Fig.	  3e,f).	  A	   time	  
course	  analysis	  showed	  that	  the	  SC	  compartments	  were	  already	  elevated	  at	  P21,	  peaked	  at	  
P50–80	  and	  then	  began	  declining	  to	  become	  significantly	  smaller	  in	  12	  months	  old	  Kind1-­‐K5	  
mice	   (Fig.	   3g).	   In	   line	   with	   a	   normal	   hair	   coat	   development	   SC	   subpopulations	   were	  
unaffected	  in	  TTAA-­‐K5	  mice,	  at	  least	  until	  one	  year	  of	  age	  (Supplementary	  Fig.	  3j).	  	  
To	   test	   if	   elevated	   proliferation	   caused	   the	   enlarged	   bulges,	   we	   performed	   5-­‐bromo-­‐2'-­‐
deoxyuridine	   (BrdU)	   label-­‐retaining	   cell	   (LRC)	   assays.	   After	   10	   days	   of	   chase	   significantly	  
more	  bulge	  cells	  were	  BrdU+	   in	   tail	  whole	  mounts	  of	  Kind1-­‐K5	  mice	  compared	  to	  controls,	  
while	  after	  32,	  70	  days	  and	  5.5	  months	  significantly	  fewer	  bulge	  cells	  were	  BrdU+	  in	  Kind1-­‐K5	  
mice	  (Fig.	  3h,i).	  
These	   findings	   demonstrate	   that	   Kindlin-­‐1	   deficiency	   elevates	   cutaneous	   epithelial	   SC	  
proliferation,	  numbers	  and	  compartments	  in	  a	  β1	  integrin-­‐independent	  manner.	  
Kindlin-­‐1	  triggers	  αvβ6	  integrin-­‐mediated	  TGFβ	  release	  in	  skin	  
To	   determine	   whether	   Kindlin-­‐1	   loss	   alters	   integrin	   surface	   levels	   we	   analyzed	   integrin	  
profiles	  on	  primary	  keratinocytes	  using	  FACS.	  Levels	  of	  β1	  and	  β4	  integrins	  were	  slightly	  lower	  
and	  levels	  of	  β5,	  β8	  slightly	  higher	  in	  Kind1-­‐K5	  cells	  compared	  to	  controls.	  β3	  integrin	  was	  not	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detectable	   in	   either	   genotype.	   β6	   integrin	   levels	   were	   significantly	   elevated	   in	   Kindlin-­‐1	  
deficient	   keratinocytes	   (Fig.	   4a),	   as	   was	   the	   β6	   mRNA	   in	   FACS-­‐sorted	   cutaneous	   SCs	  
(Supplementary	  Fig.	  4a).	  Immunostaining	  showed	  β6	  integrin	  expression	  extending	  from	  the	  
bulge	  and	  outer	  root	  sheath	  to	  the	  infundibulum	  and	  IFE	  of	  Kind1-­‐K5	  mice	  (Fig.	  4b).	  
Next,	  we	   investigated	   β6	   integrin	   dependent	   cell	   spreading	   and	   focal	   adhesion	   formation.	  
While	  keratinocytes	  from	  Kind1-­‐K5	  mice	  spread	  normally	  on	  fibronectin	  (FN),	  they	  displayed	  
severely	  impaired	  adhesion,	  spreading,	  clustering	  of	  paxillin	  in	  focal	  adhesion-­‐like	  structures	  
and	   assembly	   of	   F-­‐actin	   stress	   fibers	   when	   plated	   on	   surfaces	   coated	   with	   anti-­‐αvβ6	  
antibodies	   or	   αv-­‐specific	   peptidomimetic	   cyclic	   RGD	   (cRGD)	   (Fig.	   4c,d	   and	   Supplementary	  
Fig.	   4b,c)	   indicating	   that	   αvβ6	   on	   Kind1-­‐K5	   keratinocytes	   is	   non-­‐functional.	  We	   confirmed	  
αvβ6	   specificity	   of	   these	   defects	   by	   treating	   keratinocytes	   from	   control	   mice	   with	   the	   β6	  
blocking	  antibody	  10D5,	  which	  phenocopied	  the	  spreading	  defects	  of	  Kindlin-­‐1	  deficient	  cells	  
on	  cRGD	  surfaces	  (Supplementary	  Fig.	  4d).	  
Active	  αvβ6	  integrins	  can	  release	  TGFβ	  from	  the	  latency	  associated	  protein	  (LAP)
31,	  which	  in	  
turn	   suppresses	   proliferation	   of	   bulge	   SCs10,12,32,33.	   We	   tested	   the	   αvβ6-­‐dependent	   TGFβ	  
release	   by	   seeding	   keratinocytes	   together	   with	   transformed	   mink	   lung	   epithelial	   cells	  
(tMLEC)	   able	   to	   report	   TGFβ-­‐induced	   luciferase	   on	   a	   latent	   TGFβ	   binding	   protein-­‐1-­‐LAP-­‐
TGFβ-­‐1	   rich	   matrix34	   (Fig.	   4e).	   Keratinocytes	   from	   control	   mice	   efficiently	   induced	   the	  
luciferase	   reporter,	  which	   could	   be	   inhibited	  with	   the	  αvβ6	   blocking	   antibody	   10D5	  or	   the	  
TGFβ	  neutralizing	  antibody	  1D11.	  In	  sharp	  contrast,	  keratinocytes	  from	  Kind1-­‐K5	  mice	  were	  
unable	   to	   release	  TGFβ	  confirming	   that	   their	  αvβ6	   integrins	  are	  non-­‐functional	   (Fig.	  4e).	   In	  
line	  with	  this	  in	  vitro	  result,	  TGFβ	  signaling	  was	  also	  severely	  impaired	  in	  bulge	  cells	  of	  Kind1-­‐
K5	   mice	   in	   vivo,	   in	   which	   pSmad2/3	   was	   detectable	   neither	   before	   nor	   after	   premature	  
anagen	   induction	   (Fig.	   4f	   and	   Supplementary	   Fig.	   4g).	   Signaling	   by	   BMP	   via	   pSmad1/5/8,	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which	  also	  suppresses	  bulge	  cell	  proliferation35,36,	  	  was	  unaffected	  (Supplementary	  Fig.	  4h).	  
Treatment	   of	   Kindlin-­‐1	   deficient	   keratinocytes	  with	   soluble	   TGFβ-­‐1	   induced	   robust	   Smad2	  
phosphorylation	   and	   reduced	   cell	   proliferation	   (Supplementary	   Fig.	   4e,f)	   indicating	   that	  
TGFβ-­‐1	  signals	  are	  efficiently	   transduced.	  The	  severe	  dysfunction	  of	  αvβ6	   integrins	  was	  not	  
compensated	   by	   Kindlin-­‐2	   due	   to	   the	   inability	   of	   Kindlin-­‐2	   to	   bind	   β6	   tails	   (Fig.	   4g).	  Most	  
importantly,	  subjects	  with	  KS	  showed	  a	  similar	  TGFβ	  defect	  as	  Kind1-­‐K5	  mice	  with	  elevated	  
expression	  of	  β6	   integrin	  and	   reduced	  nuclear	  pSmad2/3	   in	   large	  areas	  of	  basal	  epidermal	  
keratinocytes	  (Fig.	  4h,i),	  while	  pSmad1/5/8	  was	  unaffected	  (Supplementary	  Fig.	  4i).	  
These	  findings	  indicate	  that	  Kindlin-­‐1	  is	  essential	  for	  β6	  integrin-­‐mediated	  cell	  adhesion,	  cell	  
spreading	  and	  TGFβ	  release	  required	  for	  SC	  quiescence.	  
Kindlin-­‐1	  curbs	  Wnt-­‐β-­‐catenin	  signaling	  in	  skin	  
Premature	  anagen	   induction,	   ectopic	  HF	  development	  and	  expansion	  of	   SC	   compartments	  
also	   develop	   in	   mice	   with	   elevated	   Wnt-­‐β-­‐catenin	   signaling	   in	   keratinocytes37–40,	   while	  
reduced	  HF	  spacing	  and	  aberrant	  hair	  orientation	  occur	  in	  mice	  overexpressing	  the	  β-­‐catenin	  
cofactor	   Lef141	   or	  mice	  with	   increased	  Notch	   signaling42.	   In	   skin	   of	   control	  mice	   β-­‐catenin	  
levels	  were	  high	  at	  cell-­‐cell	  junctions,	  low	  in	  the	  nucleus	  and	  absent	  at	  the	  basal	  side	  of	  basal	  
keratinocytes.	  In	  contrast,	  in	  epidermis	  of	  Kind1-­‐K5	  mice	  β-­‐catenin	  also	  accumulated	  at	  basal	  
sides	   of	   basal	   keratinocytes	   (Fig.	   5a,	   arrowheads	   top	   left	   panel),	   in	   the	   nucleus	   of	   a	   large	  
number	   of	   IFE	   cells	   (Fig.	   5a,	  middle	   panel)	   and	   catagen	  HFs	   (Fig.	   5a,	   lower	   left	   panel	   and	  
Supplementary	   Fig.	   5d,	   left).	   Furthermore,	   Kind1-­‐K5	   mice	   showed	   β-­‐catenin	   in	   nuclei	   of	  
developing	   HGs	   during	   premature	   anagen	   induction	   (Supplementary	   Fig.	   5a	  upper	   panel,	  
5b),	  and	  an	  extended	  Lef1	  expression	  from	  the	  normal	  site	  in	  HGs	  to	  the	  bulge	  and	  IFE	  at	  all	  
stages	  analyzed	  (Fig.	  5a	  right	  panel	  and	  Supplementary	  Figs.	  5a,c,d	   left	  panel).	  Notably,	  at	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P50	  shortly	  before	  bulges	  from	  Kind1-­‐K5	  mice	  induced	  premature	  anagen	  they	  showed	  high	  
nuclear	  Lef1	  levels	   indicating	  a	  premature	  onset	  of	  Wnt	  signaling.	   In	  control	  mice	  Lef1	  was	  
absent	  in	  telogen	  bulges	  and	  became	  highly	  expressed	  in	  nuclei	  of	  HG	  cells	  and	  weakly	  in	  the	  
cytoplasm	  of	  IFE	  cells	  (Fig.	  5a	  right	  panel	  and	  Supplementary	  Fig.	  5a	  lower	  panel).	  Numbers	  
of	   nuclear	   Notch	   effector	   Notch	   intracellular	   domain	   (NICD)-­‐containing	   cells	   and	   NICD-­‐
induced	  Hes1	  mRNA	  were	  unaltered	  in	  HG	  and	  pericortex,	  but	  higher	  in	  the	  IFE	  of	  Kind1-­‐K5	  
mice	  compared	  to	  controls	  at	  all	  time	  points	  analyzed	  (Fig.	  5b	  and	  Supplementary	  Fig.	  5e–g).	  
Next	   we	   determined	   Wnt-­‐β-­‐catenin	   signaling	   by	   intercrossing	   Kind1-­‐K5	   and	   control	   mice	  
with	   TOPgal	   reporter	   mice,	   which	   express	   β-­‐galactosidase	   under	   a	   TCF-­‐Lef	   controlled	  
minimal	   cfos	   promotor43.	   In	   HFs	   from	   control	   mice	   TOPgal	   activities	   were	   high	   in	   the	  
pericortex	  during	  anagen,	  low	  during	  catagen	  and	  lost	  in	  telogen	  with	  some	  residual	  activity	  
in	  club	  hairs.	  In	  Kind1-­‐K5	  mice,	  the	  high	  TOPgal	  activity	  in	  the	  pericortex	  and	  bulb	  of	  anagen	  
HFs	   persisted	   throughout	   catagen,	   decreased	   in	   telogen	   (Fig.	   5c	   left	   panel	   and	  
Supplementary	   Fig.	   5i)	   and	   was	   strongly	   re-­‐induced	   in	   the	   following	   anagen	   stage	  
(Supplementary	   Fig.	   5h).	   Furthermore,	  we	   observed	   a	   patch-­‐like	   distribution	   of	   TOPgal	   in	  
the	  IFE	  of	  Kind1-­‐K5	  mice,	  which	  was	  absent	  in	  controls	  (Fig.	  5c	  right	  panel).	  Importantly,	  the	  
IFE	  of	  humans	  with	  KS	  showed	  similar	  abnormalities	  in	  β-­‐catenin-­‐LEF1	  expression	  with	  weak	  
nuclear	   β-­‐catenin	   in	   the	   basal	   cell	   layer	   and	   a	   patch-­‐like	   distribution	   of	   nuclear	   LEF1,	  
whereas	  normal	  human	  skin	  contained	  β-­‐catenin	  exclusively	  in	  cell-­‐cell	  contacts	  and	  LEF1	  in	  
the	  cytoplasm	  (Fig.	  5d	  and	  Supplementary	  Fig.	  5j).	  
These	  findings	  demonstrate	  that	  loss	  of	  Kindlin-­‐1	  induces	  nuclear	  translocation	  of	  β-­‐catenin-­‐
Lef1	   in	   KS	   and	   mouse	   skin	   leading	   to	   elevated	   Wnt-­‐β-­‐catenin	   signaling	   and	   premature	  
anagen	  onset	  of	  Kind1-­‐K5	  mouse	  HFs.	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Kindlin-­‐1	  regulates	  Wnt	  ligand	  expression	  
To	  find	  an	  explanation	  for	  the	  increased	  Wnt-­‐β-­‐catenin	  signaling	  in	  the	  absence	  of	  Kindlin-­‐1	  
we	  compared	  the	  skin	  transcriptome	  between	  healthy	  individuals	  and	  subjects	  with	  KS	  using	  
microarray.	   As	   expected,	   FERMT-­‐1	   was	   absent	   in	   skin	   from	   subjects	   with	   KS	   and	   mRNAs	  
encoding	   inflammatory	   proteins	   were	   high	   (Fig.	   5e,	   for	   complete	   list	   see	   Supplementary	  
Table	  2).	  Unexpectedly,	  several	  Wnt	  signaling	  components,	  most	  notably	  WNT5A	  were	  high	  
in	   individuals	   with	   KS	   (Fig.	   5e).	   Immunostaining	   confirmed	   the	   aberrant	   expression	   of	  
WNT5A	  in	  basal	  keratinocytes	  of	  individuals	  with	  KS	  (Fig.	  5f).	  qPCR	  and	  in	  situ	  hybridization	  
of	   tail	  whole	  mounts	   from	   Kind1-­‐K5	  mice	   corroborated	   high	  Wnt5a	  mRNAs	   levels	   in	   HBs,	  
ectopic	  HFs	   and	   patches	   of	   IFE,	  which	   overlapped	  with	   high	   TOPgal	   activities	   (Fig.	   5g	   and	  
Supplementary	   Fig.	   6a–c).	   qPCR	   of	   all	   known	   Wnt	   ligands	   and	   receptors	   revealed	   that	  
several	   canonical	   (Wnt1,	   2b,	   3a,	   9b)	   and	   non-­‐canonical	   Wnts	   (Wnt6	   and	   2)	   were	   also	  
significantly	  higher	  in	  keratinocytes	  from	  Kind1-­‐K5	  mice	  compared	  to	  controls,	  while	  Wnt4,	  
7a,	  9a,	  10a	  and	  16	  were	  significantly	  lower	  (Fig.	  5g	  and	  Supplementary	  Table	  3).	  Expression	  
of	  several	  Frizzled	  (Fzd)	  receptors	  was	  higher,	  most	  notably	  Fzd4	  and	  Fzd5,	  and	  to	  a	   lesser	  
extent	  the	  Fzd	  co-­‐receptor	  Lrp6.	  qPCR	  of	  FACS	  sorted	  bulge	  cells	  and	  in	  situ	  hybridization	  of	  
tail	  whole	  mounts	  from	  Kind1-­‐K5	  mice	  confirmed	  the	  high	  Fzd4	  mRNA	  levels	  and	  patch-­‐like	  
expression	  in	  their	  IFE	  (Supplementary	  Fig.	  6d,e).	  
Transfection	  of	  Kindlin-­‐1	  deficient	  keratinocytes	  with	  SuperTOPFlash	  reporter	  revealed	  that	  
the	   elevated	  Wnt	   signaling	  was	   cell	   autonomous	   (Fig.	   5h,i)	   and	   that	   Lef1	  was	   limiting	   the	  
extent	   of	  Wnt	   signaling	   (Supplementary	   Fig.	   6f).	   Overexpression	   of	  Wnt4,	   which	   triggers	  
translocation	  of	  β-­‐catenin	  to	  cell-­‐cell	  junctions,	  thereby	  preventing	  nuclear	  accumulation	  of	  
β-­‐catenin	   and	   Wnt-­‐β-­‐catenin	   signaling44,	   decreased	   SuperTOPFlash	   activity	   in	   Kindlin-­‐1	  
deficient	   keratinocytes	   compared	   to	   GFP-­‐transfected	   controls	   (Fig.	   5h).	   Overexpression	   of	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Wnt5a,	  which	  together	  with	  Lrp5	  and	  Fzd4	  efficiently	  activates	  the	  canonical	  Wnt-­‐β-­‐catenin	  
signaling	  pathway45,	  further	  increased	  the	  SuperTOPFlash	  reporter	  in	  Kindlin-­‐1	  deficient	  cells	  
but	   not	   in	   control	   cells	   where	   Fzd4	   expression	   was	   low	   (Fig.	   5h	   and	   Supplementary	   Fig.	  
6d,e).	  	  
Re-­‐expression	  of	  similar	  quantities	  of	  Kindlin-­‐1-­‐GFP	  or	  an	  integrin	  binding-­‐deficient	  Kindlin-­‐1-­‐
QW611/612AA-­‐GFP,	  but	  not	  Kindlin-­‐2	  attenuated	  the	  increased	  SuperTOPFlash	  activities	  and	  
levels	   of	  Wnt4	   and	  Wnt5a	   in	   Kindlin-­‐1	   deficient	   keratinocytes	   (Fig.	   5i	   and	  Supplementary	  
Fig.	  6g–j)	   indicating	  that	   inhibition	  of	  Wnt-­‐β-­‐catenin	  signaling	   is	  Kindlin-­‐1	  specific	  and	  does	  
not	  require	  integrin	  binding.	  To	  exclude	  a	  role	  for	  nuclear	  Kindlin-­‐1,	  we	  expressed	  Kindlin-­‐1-­‐
GFP	  fused	  to	  two	  SV40	  nuclear	  localization	  signals	  (NLS)	  in	  Kind1-­‐null	  cells.	  Although	  most	  of	  
the	  protein	   localized	   to	   the	  nucleus	   the	  elevated	  SuperTOPFlash	  activity	  was	  only	  partially	  
rescued	  (Fig.	  5i),	   likely	  due	  to	  Kind1-­‐NLS-­‐GFP	  spillovers	  into	  the	  cytoplasm	  (Supplementary	  
Fig.	  6j).	  	  
To	   corroborate	   that	   elevated	   Wnt	   protein	   secretion	   and	   high	   Wnt-­‐β-­‐catenin	   signaling	  
underlies	  premature	  HF	  anagen	  induction	  in	  Kind1-­‐K5	  mice,	  we	  treated	  them	  at	  P49,	  shortly	  
before	   telogen	   onset	   (Fig.	   5j	   and	   Supplementary	   Fig.	   7a)	   with	   IWP-­‐2,	   which	   blocks	   Wnt	  
protein	  secretion	  by	   inhibiting	  porcupine-­‐mediated	  palmitylation	  of	  Wnts46,	  or	  with	   IWR-­‐1,	  
which	   inhibits	   tankyrases	   thereby	   stabilizing	   the	   β-­‐catenin	   destruction	   complex46,47.	   Both	  
compounds	  efficiently	  blocked	  premature	  anagen	  induction	  in	  Kind1-­‐K5	  mice	  and	  decreased	  
SuperTOPFlash	  activities	  in	  vitro	  (Fig.	  5j	  and	  Supplementary	  Fig.	  7a,b).	  In	  line	  with	  previous	  
reports42,	   inhibition	   of	   Wnt	   signaling	   also	   reduced	   aberrant	   Notch	   activities	   in	   Kind1-­‐K5	  
keratinocytes	   in	   vitro	   and	   in	   vivo,	  which	   in	   turn	  normalized	  Wnt4	   levels48	   (Supplementary	  
Fig.	  7c–g).	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Together	   these	   findings	   demonstrate	   that	   Kindlin-­‐1	   inhibits	   Wnt-­‐β-­‐catenin	   signaling	   by	  
regulating	   transcription	   of	  Wnt	   ligands	   and	   receptors	   in	   a	   cell	   autonomous	   and	   integrin-­‐
independent	  manner.	  
Loss	  of	  Kindlin-­‐1	  increases	  skin	  tumor	  susceptibility	  
The	  low	  TGFβ	  and	  augmented	  Wnt	  signaling	  in	  humans	  with	  KS	  and	  Kind1-­‐K5	  mice	  represent	  
oncogenic	   threats49,50.	   To	   test	   this	   hypothesis,	   we	   used	   the	   two-­‐stage	   carcinogenesis	  
protocol	   and	   treated	   mice	   with	   7,12-­‐dimethylbenz[a]anthracene	   (DMBA)	   and	   12-­‐O-­‐
tetradecanoylphorbol-­‐13-­‐acetate	   (TPA)	   for	   25	   weeks.	   Kind1-­‐K5	   mice	   developed	   tumors	  
earlier	   and	   had	  more	   tumors	   than	   control	   mice	   (Fig.	   6a–c).	   Of	   note,	   the	   tumor	   size	   was	  
similar	  between	  Kind1-­‐K5	  and	   control	  mice	   (Fig.	   6d),	  which	   could	  be	  due	   to	  different	   skin	  
lesion	   subtypes.	   Indeed,	   histology	   of	   the	   tumor	   lesions	   revealed	   that	   hyperkeratotic	   and	  
exophytic	   papillomas	   dominated	   in	   control	   mice,	   while	   HF-­‐derived	   trichofolliculoma-­‐like	  
lesions,	  sebaceous	  papillomas,	  mixed	  papillomas	  and	  basal	  cell	  carcinoma	  (BCC)-­‐like	  lesions	  
dominated	  in	  Kind1-­‐K5	  mice	  (Fig.	  6e	  and	  Supplementary	  Fig.	  8a).	  In	  line	  with	  uncurbed	  Wnt	  
signaling,	  we	  observed	  more	  cells	  with	  nuclear	  β-­‐catenin	  and	  Lef1	  in	  tumors	  from	  Kind1-­‐K5	  
mice	  (Supplementary	  Fig.	  8b–d).	  
A	   single	   DMBA	   treatment	   induced	   more	   and	   slightly	   larger	   tumors	   in	   Kind1-­‐K5	   mice	  
compared	  to	  controls	  (Fig.	  6f–i)	  indicating	  that	  the	  hyperproliferative	  state	  of	  keratinocytes	  
in	  Kind1-­‐K5	  mice	  was	  sufficient	  to	  promote	  tumor	  development.	  Furthermore,	  their	  tumors	  
primarily	  originated	  from	  HFs	  and	  SGs	  containing	  hyperactive	  SCs.	  
	  
______________________________________________________________________________________________________________
288
Appendix
15 
 
DISCUSSION	  
Loss-­‐of-­‐function	  mutations	   in	   the	   FERMT-­‐1	   gene	   cause	   KS,	   which	   is	   characterized	   by	   skin	  
blistering	   at	   birth,	   premature	   skin	   aging,	   pigmentation	   defects	   and	   increased	   incidence	   of	  
skin	   cancer.	   The	   ability	   of	   Kindlin-­‐1	   to	   activate	   integrins	   and	   link	   them	   to	   the	   F-­‐actin	  
cytoskeleton	   explains	   the	   development	   of	   skin	   blisters	   and	   BM	   splitting	   followed	   by	   an	  
inflammatory	  response.	  However,	  the	  notion	  that	  skin	  tumor	  development	   is	  promoted	  by	  
hyperactive	   integrins	   and	   inhibited	   by	   compromised	   integrins	   indicates	   that	   Kindlin-­‐1	   loss	  
activates	  oncogenic	  and/or	  inhibits	  tumor	  suppressor	  functions.	  The	  task	  of	  this	  study	  was	  to	  
identify	  such	  pathway(s).	  
Deletion	   of	   Kindlin-­‐1	   in	   skin	   epithelial	   cells	  with	   the	   K5-­‐Cre	   driver	   line	   leads	   to	   small	   skin	  
blistering,	  BM	  defects,	  chronic	  skin	  inflammation,	  progressive	  pigmentation	  defects	  and	  skin	  
atrophy	   and	   hence	   is	   alike	   KS.	   Unexpectedly,	   the	   Kind1-­‐K5	   mice	   also	   develop	   enlarged	  
cutaneous	   epithelial	   SC	   compartments,	   hyperactive	   bulge	   SCs,	   distorted	   HF	   cycles	   and	  
ectopic	  HF	  (Supplementary	  Fig.	  8e).	  In	  line	  with	  the	  high	  SC	  proliferation,	  DMBA-­‐TPA	  as	  well	  
as	  DMBA	  only	  treatment	  induces	  a	  significantly	  higher	  tumor	  incidence	  and	  tumor	  burden	  in	  
Kind1-­‐K5	   mice.	   Moreover,	   the	   majority	   of	   the	   tumors	   are	   BCC-­‐	   and	   trichofolliculoma-­‐like	  
lesions	  suggesting	  that	  the	  tumors	  predominantly	  originate	  from	  HF	  bulge	  SCs.	  
In	  search	  for	  a	  mechanistic	  explanation	  for	  the	  dysregulated	  SC	  and	  tumor	  cell	  proliferation	  
in	   Kind1-­‐K5	  mice,	  we	   identified	   two	   Kindlin-­‐1	   regulated	   signaling	   pathways	  with	   opposing	  
functions	   on	   bulge	   SC	   quiescence	   (Fig.	   6j).	   Kindlin-­‐1	   binding	   to	   the	   cytoplasmic	   tail	   of	   β6	  
integrin51	  triggers	  αvβ6	  integrin	  binding	  to	  the	  RGD	  motif	  of	  LAP	  thereby	  liberating	  TGFβ	  and	  
inducing	  TGFβ	  receptor	  signaling	  and	  cutaneous	  epithelial	  SC	  quiescence.	  These	  findings	  are	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supported	   by	   report	   showing	   that	   loss	   of	   β6	   integrin	   impairs	   TGFβ	   signaling	   and	   elevates	  
bulge	  SC	  activity	  in	  vivo32.	  
Despite	   the	   sequence	   similarities	   of	   Kindlin-­‐1	   and	   -­‐252	   and	   their	   expression	   in	   control	   and	  
Kind1-­‐K5	  keratinocytes,	  Kindlin-­‐2	   can	  only	  partially	   compensate	   for	  Kindlin-­‐1	  at	  β1	   integrin	  
adhesion	  sites.	  Furthermore,	  Kindlin-­‐2	  is	  unable	  to	  bind	  β6	  tails,	  which	  prevents	  it	  to	  release	  
TGFβ-­‐1	  and	  to	  suppress	  SC	  proliferation.	   Interestingly,	  other	  TGFβ	  isoforms	  such	  as	  TGFβ-­‐2	  
activate	  HF	  stem	  cells	  by	  antagonizing	  BMP	  in	  the	  bulge53.	  In	  contrast	  to	  LAP1	  however,	  LAP2	  
lacks	  the	  αvβ6-­‐binding	  RGD	  motif
54	  and	  hence	  the	  release	  of	  TGFβ-­‐2	  and	  BMP	  signaling	  are	  
not	  affected	  by	  Kindlin-­‐1	  loss.	  
It	   is	   particularly	   interesting	   that	   high	   Kindlin-­‐1	   levels	   have	   also	   been	   associated	  with	   high	  
TGFβ-­‐1	   signaling	   in	   metastatic	   breast	   cancers55.	   Although	   it	   was	   not	   investigated	   how	  
Kindlin-­‐1	   regulates	   TFGβ-­‐1	   signaling,	   this	   together	  with	   our	   findings	   suggest	   that	   different	  
tumor	   stages	  may	   benefit	   from	   different	   Kindlin-­‐1	   levels;	   in	   early	   stage	   tumors	   low	   TGFβ	  
signaling	   supports	   tumor	  growth,	  while	   in	   late	   stage	   tumors	  high	  TGFβ	  signaling	  promotes	  
epithelial	   to	  mesenchymal	   transition	   and	  metastatic	   progression56.	   If	   so,	   subjects	   with	   KS	  
suffering	  from	  an	  increased	  tumor	  risk	  may	  be	  protected	  from	  metastasis.	  
We	  also	  found	  elevated	  Wnt-­‐β-­‐catenin	  signaling	  in	  Kind1-­‐K5	  mice	  and	  KS	  epidermis,	  which	  is	  
inevitably	  associated	  with	  a	  high	  tumor	  risk	  and	  severe	  SC	  and	  HC	  defects13,50.	   	  The	  defect	  
leads	  to	  ectopic	  HF	  formation	  and	  aberrant	  HCs,	  and	  is	  due	  to	  aberrant	  expression	  of	  several	  
Wnt	  ligands,	  most	  notably	  Wnt5a,	  which	  probably	  act	  in	  an	  autocrine	  manner.	  Importantly,	  
chemical	   compounds	   that	   inhibit	  Wnt	  protein	   secretion	  or	  Wnt-­‐β-­‐catenin	   signaling	   the	  HC	  
and	  Wnt	  signaling	  defects	  in	  keratinocytes	  from	  Kind1-­‐K5	  mice.	  
Wnt5a	   is	   best	   known	   for	   the	   ability	   to	   activate	   the	   non-­‐canonical	  Wnt	   signaling	   pathway.	  
However,	   Wnt5a	   can	   also	   elicit	   canonical	   Wnt-­‐β-­‐catenin	   signaling.	   The	   decision	   which	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signaling	  pathway	  is	  induced,	  is	  dictated	  by	  the	  type	  of	  cell	  surface	  receptor	  to	  which	  Wnt5a	  
is	   binding;	  Wnt5a	   binding	   to	   the	  Ror2	   receptor	   tyrosine	   kinase	   inhibits	   the	   transcriptional	  
activity	  of	  β-­‐catenin	  and	   thus	  canonical	   signaling,	  whereas	  Wnt5a	  binding	   to	  Fzd4	  and	   the	  
Lrp5/6	   co-­‐receptors	   leads	   to	   β-­‐catenin	   stabilization	   and	   canonical	   Wnt	   signaling45.	  
Interestingly,	   Wnt-­‐β-­‐catenin	   signaling	   can	   activate	   Notch42,	   which	   is	   also	   elevated	   in	  
keratinocytes	  from	  Kind1-­‐K5	  mice	  and	  may,	  at	  least	  in	  part	  contribute	  to	  the	  Kind-­‐K5	  mouse	  
phenotype,	  e.g.	  by	  suppressing	  Wnt4	  expression48	  and	  the	  recruitment	  of	  β-­‐catenin	  to	  cell-­‐
cell	   junctions44.	  Clearly,	  the	  dysregulated	  expression	  of	  Wnt	  proteins	  and	  their	  receptors	   in	  
Kind1-­‐K5	   mice	   strongly	   suggests	   that	   Kindlin-­‐1	   safeguards	   the	   skin	   and	   HFs	   against	   an	  
overshooting	  activation	  of	  the	  important	  and	  at	  the	  same	  time	  potentially	  harmful	  canonical	  
Wnt-­‐β-­‐catenin	  signals.	  	  	  
In	  summary	  our	  results	  show	  that	  Kindlin-­‐1	  loss	  results	  in	  a	  combination	  of	  defects	  caused	  by	  
the	  dysregulation	  of	  distinct	  pathways;	   the	  compromised	  β1	   integrins	   impair	  adhesion	  and	  
induce	   an	   inflammatory	   response;	   the	   impaired	   TGFβ	   liberation	   from	   LAP	   leads	   to	   HF	   SC	  
hyperproliferation;	  and	  the	  increased	  Wnt	  signaling	  abrogates	  the	  resting	  phase	  of	  the	  HC,	  
expands	   the	   SC	   compartments	   and	   together	   with	   the	   impaired	   TGFβ	   signaling	   and	  
inflammation	   contributes	   to	   the	   increased	   tumor	   risk.	   The	   high	   epithelial	   SC	   activity	  
eventually	  leads	  to	  SC	  exhaustion	  and	  skin	  atrophy	  later	  in	  life,	  which	  is	  another	  hallmark	  of	  
KS.	  It	  is	  also	  conceivable	  that	  the	  ability	  of	  Kindlin-­‐1	  to	  shuttle	  between	  integrin	  sites	  where	  
it	  mediates	  adhesion,	  migration	  and	  TGFβ	  release,	  and	  the	  cytoplasm	  where	  it	  curbs	  Wnt-­‐β-­‐
catenin	  signaling	  may	  also	  contribute	   to	  physiologic	  SC	  homeostasis	  and	  hair	  development	  
(Fig.	  6j);	  mobilization	  of	  bulge	  SC	  have	  little	  or	  no	  integrin-­‐ligand	  engagement	  and	  therefore,	  
use	  Kindlin-­‐1	  to	  prevent	  Wnt-­‐β-­‐catenin	  signaling	  and	  their	  activation.	  Once	  they	  move	  to	  the	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HG	  they	  engage	  integrins	  to	  ensure	  downward	  growth	  and	  therefore,	  have	  less	  Kindlin-­‐1	  in	  
the	  cytoplasm	  to	  inhibit	  Wnt-­‐β-­‐catenin	  signaling.	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METHODS	  
Mouse	  Strains	  
The	   conditional	   Kind1fl/fl	  mice	   carry	   a	   loxP-­‐flanked	  ATG-­‐containing	   exon	   2	   (Supplementary	  
Fig.	   1a)	   and	   were	   generated	   via	   electroporation	   of	   R1	   embryonic	   stem	   (ES)	   cells	   using	  
standard	   procedures57.	   Homologous	   recombination	   was	   verified	   with	   southern	   blots	   and	  
positive	  ES	  clones	  were	  used	  to	  generate	  chimeric	  mice.	  Mice	  were	  crossed	  with	  transgenics	  
carrying	  a	  deletor-­‐flp	  recombinase	  to	  remove	  the	  neomycin	  cassette	  and	  with	  mice	  carrying	  
deleter-­‐Cre	   (to	   confirm	   the	   null	   phenotype)	   or	   K5-­‐Cre	   transgenes,	   respectively58.	   For	   all	  
animal	   studies	   transgenic	   mice	   were	   backcrossed	   eight	   times	   to	   C57BL/6.	   The	   TTAA-­‐K5	  
transgenic	  mice	  were	  obtained	  through	  an	  intercross	  of	  mice	  carrying	  alanine	  substitutions	  
of	   TT788/789	   in	   the	   cytoplasmic	   domain	   of	   β1	   integrin
26	   with	   β1	   floxed	   mice	   and	   K5-­‐Cre	  
transgenics.	   The	   TOPgal	  Wnt	   reporter	  mice43	  were	   intercrossed	  with	   Kind1-­‐K5	  mice.	  Mice	  
were	   housed	   in	   a	   special	   pathogen	   free	   mouse	   facility	   and	   all	   animal	   experiments	   were	  
carried	  out	  according	  to	  the	  rules	  of	  and	  approved	  by	  the	  government	  of	  Upper	  Bavaria.	  
DMBA/TPA	  tumor	  experiment	  
Cutaneous	  two	  stage	  chemical	  carcinogenesis	  was	  performed	  as	  previously	  described59	  using	  
topical	  applications	  of	  100	  nmol	  (25	  µg)	  DMBA	  (Sigma)	  in	  100	  µl	  of	  acetone	  and	  twice	  weekly	  
applications	   of	   10	   nmol	   (6.1	   µg)	   TPA	   (Sigma)	   in	   200	   µl	   of	   acetone	   or	   only	   acetone	   for	   25	  
weeks.	   The	   tumor	  model	  was	   terminated	  after	  25	  weeks	  of	  TPA	  promotion	  due	   to	   critical	  
skin	  health	  condition	  of	  Kind1-­‐K5	  mice.	  For	  tumor	  experiment	  control	  animals	  were	  treated	  
with	  acetone	  or	  TPA	  only.	  For	  all	  animal	  studies	  seven	  week	  old	  mice	  were	  randomized	  after	  
genotyping	   and	   sample	   size	   was	   estimated	   by	   non-­‐parametric	   Wilcoxon	   Test	   (U-­‐Test).	  	  
Number	  and	  size	  of	  tumors	  were	  recorded	  once	  per	  week	  after	  the	  start	  of	  promotion	  (week	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0).	   All	   mice	   were	   sacrificed	   at	   the	   end	   of	   the	   experiment.	   Skin	   lesions	   were	   analyzed	   by	  
histology	  and	  graded	  as	  described	  previously59–61.	  
Subjects	  with	  KS	  
Individuals	   with	   KS	   gave	   their	   informed	   written	   consent	   under	   protocols	   approved	   by	   St	  
Thomas’	   Hospital	   Ethics	   Committee	   (COREC	   number	   06	   ⁄Q0702	   ⁄154)	   and	   the	   study	   was	  
conducted	  according	  to	  the	  Declaration	  of	  Helsinki	  Principles.	  For	   IF	  analysis	  biopsies	  were	  
taken	   from	   age	   and	   site	   matched	   controls	   (NHS)	   and	   subjects	   with	   KS	   with	   following	  
mutations:	   KS	   patient	   1	   (3-­‐year-­‐old	   Indian	   girl;	   homozygous	   nonsense	   mutation	   +/+	  
p.Glu516X)	   and	   KS	   patient	   2	   (22	   year	   old	   Panamanian	   woman;	   homozygous	   nonsense	  
mutation	  +/+	  p.Arg271X).	  
RNA	   for	   microarray	   analysis	   was	   isolated	   from	   upper	   arm	   biopsies	   taken	   from	   three	   KS	  
subjects;	   KS	   patient	   A,	   22	   year	   old	   Omani	   woman,	   homozygous	   nonsense	   mutation	   +/+	  
p.Arg271X;	   KS	   patient	   B,	   7	   year	   old	   Indian	   girl,	   homozygous	   nonsense	   mutation	   +/+	  
p.Try616X	  and	  KS	  patient	  C,	  19	  year	  old	  Omani	  woman,	  nonsense	  mutation	  +/+	  p.Try616X.	  
Control	  skin	  RNA	  was	  isolated	  from	  four	  age-­‐,	  site	  -­‐	  and	  sex-­‐matched	  biopsies.	  
Gene	  expression	  micro	  array	  	  
Total	  RNA	  was	  extracted	  using	  the	  RNeasy	  Fibrous	  Tissue	  Mini	  kit	  (Qiagen)	  and	  quantity	  and	  
quality	   were	   measured	   on	   a	   Nanodrop	   spectrophotometer	   (Nanodrop,	   Wilmington,	   DE,	  
U.S.A.).	  For	  whole-­‐genome	  Illumina	  expression	  analysis,	  total	  RNA	  from	  each	  skin	  biopsy	  was	  
hybridized	   to	   an	   Illumina	  Human-­‐Ref-­‐6	   v2	  BeadChip	  expression	  array	   (Illumina,	   San	  Diego,	  
CA,	   U.S.A.).	   The	   Illumina	   HumanRef-­‐6	   v2	   BeadChips	   were	   scanned	   with	   an	   Illumina	   Bead	  
Array	  Reader	  confocal	  scanner.	  
______________________________________________________________________________________________________________
294
Appendix
21 
 
The	   microarray	   data	   analysis	   was	   performed	   using	   Illumina’s	   BeadStudio	   Data	   Analysis	  
Software	  (Illumina).	  The	  expression	  signal	  for	  all	  genes	  from	  each	  individual	  were	  grouped	  in	  
KS	  and	  NHS	  and	  averaged.	  In	  order	  to	  identify	  statistically	  significant	  differentially	  regulated	  
genes,	  a	  prefiltering	  set	  was	  determined	  for	  significantly	  higher	  (≥	  2-­‐fold	  change)	  and	  lower	  
expression	   (≤	   0.5-­‐fold	   change)	   intensity	   between	   KS	   and	   NHS	   skin	   samples.	   Bonferroni’s	  
correction	  was	  applied	  to	  each	  P-­‐value	  to	  obtain	  an	  adjusted	  P-­‐value	  to	  identify	  differentially	  
expressed	   mRNAs	   with	   high	   statistical	   significance	   (see	   Supplementary	   Table	   2).	   The	  
microarray	  has	  been	  submitted	  to	  NCBI	  under	  the	  GEO	  accession	  number	  GSE47642.	  
FACS	  analysis	  
FACS	  analysis	  and	  sorting	  was	  performed	  as	  previously	  described62.	  A	  suspension	  of	  primary	  
keratinocyte	  in	  FACS-­‐PBS	  (PBS	  with	  1%	  BSA)	  were	  incubated	  for	  1	  h	  with	  primary	  antibodies	  
on	   ice	   and	   then	   washed	   twice	   with	   FACS-­‐PBS.	   Cell	   viability	   was	   assessed	   by	   7-­‐
aminoactinomycin	  (7-­‐AAD)	  labeling	  (BD	  Biosciences)	  or	  ethidium	  monoazide	  (EMA)	  staining	  
(Invitrogen).	   FACS	   analysis	   was	   carried	   out	   using	   a	   FACSCantoTMII	   Cytometer	   (BD	  
Biosciences)	   and	   cell	   sorting	   with	   an	   AriaFACSII	   high-­‐speed	   sorter	   (BD	   Biosciences),	   both	  
equipped	  with	  FACS	  DiVa	  software	  (BD	  Biosciences).	  Purity	  of	  sorted	  cells	  was	  determined	  by	  
post	  sort	  FACS	  analysis	  and	  typically	  exceeded	  95%.	  Integrin	  surface	  FACS	  analysis	  of	  primary	  
keratinocytes	  was	  carried	  out	  as	  previously	  described63.	  Data	  analysis	  was	  conducted	  using	  
the	  FlowJo	  program	  (Version	  9.4.10).	  
Real	  Time	  PCR	  and	  Notch	  target	  gene	  inhibition	  
Total	   RNA	   from	   total	   skin	   or	   FACS	   sorted	   keratinocytes	   was	   extracted	   with	   RNeasy	   Mini	  
extraction	   kit	   (Qiagen)	   following	   manufacturer’s	   instructions.	   For	   Notch	   target	   gene	  
inhibition	  analysis	  cells	  were	  plated	  on	  FN/collagen	  I	  coated	  6-­‐well	  plates	  (1.2	  ×	  106	  cells	  per	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well)	   and	   the	   next	   day	   treated	   with	   2.5	   µM	   N-­‐[N-­‐(3,5-­‐Difluorophenacetyl)-­‐L-­‐alanyl]-­‐S-­‐
phenylglycine	   t-­‐butyl	  ester (DAPT;	  Selleckchem;	  CatNo:	  S2215)	   in	   full	   keratinocyte	  growth	  
medium	  (KGM)	  for	  24	  h	  before	  total	  RNA	  isolation.	  cDNA	  was	  prepared	  with	  a	  	  iScript	  cDNA	  
Synthesis	  Kit	   (Biorad).	  Real	  Time	  PCR	  was	  performed	  with	  an	   iCycler	   (Biorad).	  Each	  sample	  
was	  measured	  in	  triplicates	  and	  values	  were	  normalized	  to	  Gapdh.	  PCR	  primers	  are	  listed	  in	  
Supplementary	  Table	  4.	  
Antibodies	  and	  inhibitors	  
The	   following	   antibodies	   or	   molecular	   probes	   were	   used	   at	   indicated	   concentration	   for	  
Western	  blot	  (W),	  immunofluorescence	  (IF),	  immunohistochemistry	  (IHC)	  or	  flow	  cytometry	  
(FACS):	   Kindlin-­‐13	   (W:	   1:5000,	   IF	   of	   tissue:	   1:1000),	   Kindlin-­‐2	   (Sigma;	   CatNo:	   K3269;	   W:	  
1:1000),	  Talin	  (Sigma;	  clone	  8D4;	  W:	  1:1000),	  GAPDH	  (Calbiochem;	  clone	  6C5;	  W:	  1:10000),	  
Phalloidin-­‐Alexa488	  (Invitrogen;	  CatNo:	  A12379;	  IF	  tissue:	  1:500;	  IF	  of	  cells:	  1:800),	   integrin	  
αM	   (Mac-­‐1)	   (eBioscience;	   clone	  M1/70;	   IF	  of	   tissue:	   1:200),	  GR1	   (Ly6g)	   (eBioscience;	   clone	  
RB6-­‐8C5;	   IF	   of	   tissue:	   1:200),	   CD4	   (PharMing;	   clone	   H129.19;	   IF	   of	   tissue:	   1:200),	   CD19	  
(PharMing;	  clone	  1D3;	  IF	  of	  tissue:	  1:200),	  integrin	  αx	  (CD11c)	  (BD	  Bioscience;	  clone	  HL3;	  IF	  
of	   tissue:	   1:200),	   	   Desmoplakin	   (Fritzgerald	   Industries	   International;	   CatNo:	   20R-­‐DP002;	   IF	  
tissue	  1:500),	  α6	  integrin	  (Itga6)	  (PharMingen;	  clone	  GoH3;	  IF	  of	  tissue:	  1:200,	  FACS:	  1:500),	  
Laminin-­‐332	   (a	  gift	   from	  Monique	  Aumailley,	  University	  of	  Cologne,	  Germany;	   IF	  of	   tissue:	  
1:500),	  Keratin10	  (Krt-­‐10)	  (Covance;	  CatNo:	  PRB-­‐159P;	  IHC:	  1:600),	  Keratin	  15	  (Krt-­‐15)	  (a	  gift	  
from	   Rudolf	   Grosschedl;	   MPI	   Immunobiology,	   Freiburg,	   Germany),	   IF:	   1:500),	   Lef1	   (a	   gift	  
from	   Rudolf	   Grosschedl,	   MPI	   Immunobiology,	   Freiburg,	   Germany;	   IF	   of	   tissue:	   1:500),	  	  
Loricrin	   (Lor)	   (Covance;	   CatNo:	   PRB-­‐145P;	   IF:	   1:500),	   Ki67	   (Dianova;	   CatNo:	   M7249;	   IHC:	  
1:100),	   cleaved	   caspase-­‐3	   (Asp175,	   cCaspase3)	   (Cell	   Signaling;	   CatNo:	   9661;	   IF	   of	   tissue:	  
______________________________________________________________________________________________________________
296
Appendix
23 
 
1:200),	   CD34	   (BD	   Bioscience;	   clone	   RAM34;	   IF	   of	   tissue:	   1:200,	   FACS:	   1:100),	   Sca1	  
(BioLegend;	  clone	  D7;	  IF	  of	  tissue	  1:200,	  FACS:	  1:200),	  Lrig1	  (R&D	  Systems,	  CatNo:	  AF3688;	  
IF:	  1:500),	  BrdU	  (Abcam;	  CatNo:	  ab6326;	   IF:	  1:500),	  Keratin5	  (Krt-­‐5)	   (Covance;	  CatNo:	  PRB-­‐
160P;	   IF:	   1:1000),	   Keratin6	   (Krt-­‐6)	   (Covance;	   CatNo:	   PRB-­‐169;	   IF:	   1:500),	   CDP	   (Santa	   Cruz;	  
CatNo:	   sc-­‐13024;	   IF:	   1:500),	   β1	   integrin	   (BD	   Biosciences;	   clone	   Ha2/5;	   FACS:	   1:200);	   β3	  
integrin	  (BD	  Bioscience;	  clone	  2C3.G2;	  FACS:	  1:200),	  β4	  integrin	  (BD	  Biosciences;	  clone	  346-­‐
11A;	  FACS:	  1:200),	   	  β6	   integrin	  CH2A1	  (Itgb6)	  (a	  gift	   from	  Shelia	  Violette,	  Biogen	  Idec;	   IF	  of	  
mouse	  tissue:	  1:500);	  β6	  	  integrin	  (Itgb6)	  (Chemicon;	  clone	  10D5;	  IF	  of	  human	  tissue:	  1:200,	  
FACS:	  1:200,	  IF	  of	  cells:	  1:500),	  β5	  integrin	  (Itgb5)	  (a	  gift	  from	  Dean	  Sheppard,	  University	  of	  
California,	  USA	  ;	  FACS:	  1:200),	  β8	  integrin	  (Itgb8)	  (Santa	  Cruz;	  CatNo:	  sc-­‐25714;	  FACS	  1:200),	  
paxillin	  (BD	  Bioscience;	  CatNo:	  610051;	  IF:	  500);	  pSMAD2/3	  (Santa	  Cruz,	  CatNo:	  sc11769;	  	  IF:	  
1:200),	   pSmad2	   (Millipore;	   W:	   1:2000);	   total	   Smad2/3	   (Santa	   Cruz;	   catNo:	   sc-­‐8332;	   W:	  
1:1000),	   pSMAD1/5/8	   (Millipore;	   CatNo:	   AB3848;	   IF	   of	   tissue:	   1:200),	   Sox9	   (a	   gift	   from	  
Michael	  Wegner,	  University	  of	  Erlangen,	  Germany;	   IF	  of	   tissue:	  1:500),	  Trichohyalin	   (AE15)	  
(Abcam;	   CatNo:	   ab58755;	   IF	   of	   tissue:	   1:500),	   activated	   Notch1	   (NICD)	   (Abcam,	   CatNo:	  
ab8925;	  IF	  of	  tissue:	  1:200),	  and	  Pan	  Laminin	  (Sigma;	  CatNo:	  L9393;	  IF	  of	  tissue:	  1:500).	  The	  
following	  secondary	  antibodies	  were	  used:	  goat	  anti–rabbit	  Alexa488	  (CatNo:	  A11008),	  	  goat	  
anti–human	   	   Alexa488	   (CatNo:	   A11013),	   	   goat	   anti–mouse	   	   Alexa488	   (CatNo:	   A11029),	  	  
donkey	   anti–goat	   	   Alexa488	   (CatNo:	   A11055),	   goat	   anti-­‐guinea	   pig	   Alexa	   594	   (CatNo:	  
A11076),	   goat	   anti-­‐mouse	   Alexa546	   (CatNo:	   A11003),	   goat	   anti–rabbit	   Alexa546	   (CatNo:	  
A11010)	   (all	   from	   Invitrogen,	   FACS:	   1:500,	   IF:	   1:500),	   streptavidin-­‐Cy5	   (Dianova;	   CatNo:	  
016170084;	  FACS:	  1:400),	  goat	  anti–rat	  HRP	  (Dianova;	  CatNo:	  712035150;	  W:	  1:10000),	  goat	  
anti–mouse	  HRP	   (CatNo:	  172-­‐1011)	  and	  goat	  anti–rabbit	  HRP	   (CatNo:	  172-­‐1019)	   	   (all	   from	  
Biorad;	  W:	  1:10000).	  For	  mouse	  monoclonal	  primary	  antibodies	  M.O.M	  kit	  (Vector	  Labs)	  was	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used	  according	  to	  the	  manufacturer's	  protocol.	  Mast	  cells	  were	  stained	  for	  mast	  cell	  heparin	  
with	  avidin-­‐FITC	   (Invitrogen;	  CatNo:	  43-­‐4411;	   IF	  of	   tissue:	  1:100)	  as	  previously	  described64.	  
Nuclei	  were	  stained	  with	  4',6-­‐diamidino-­‐2-­‐phenylindole	  (DAPI;	  Sigma).	  
Notch	  signaling	  inhibitor	  DAPT	  (Selleckchem;	  CatNo:	  S2215)	  was	  dissolved	  in	  ethanol	  at	  25	  
µg	  µl–1.	  Wnt	  inhibitor	  IWP-­‐2	  (Calbiochem;	  CatNo:	  681671)	  and	  IWR-­‐1	  (Sigma;	  CatNo:	  I0161)	  
were	  dissolved	  in	  DMSO	  at	  2.5	  µg	  µl–1	  (IWP-­‐2)	  or	  10	  µg	  µl–1	  (IWR-­‐1). 
BrdU	  labeling	  
LRC	  assay	  was	  performed	  as	  previously	  described27.	  Briefly,	  10	  d	  old	  mice	  were	   injected	  4	  
times	  with	  50	  mg	  kg–1	  bodyweight	  BrdU	  every	  12	  h	  to	  label	  mitotic	  cells	  and	  then	  mice	  were	  
maintained	   for	   indicated	   chase	   periods.	   	   To	   determine	   LRCs	   per	   HF	   bulge,	   tail	   epidermal	  
whole	   mounts	   were	   prepared,	   z	   projections	   were	   acquired	   using	   a	   Leica	   SP5	   confocal	  
microscope	   (objective	  20×)	  and	  BrdU-­‐positive	  cells	  were	  counted	   from	  ≥30	  HFs	  per	  animal	  
from	  different	  whole	  mounts.	  
Cell	  culture	  	  	  
TGFβ	  reporter	  cell	   line	  tMLEC	  and	  LTBP1-­‐TGFβ	  matrix	  producing	  CHO-­‐LTBP	  cells	  were	  used	  
as	   described	  previously34.	   Primary	   keratinocytes	  were	   isolated	   at	   P21	  or	   at	   indicated	   time	  
points	   as	   described	   previously65.	   To	   generate	   clonal	   keratinocyte	   cell	   lines,	   primary	   cells	  
from	   Kindlin-­‐1fl/fl	   mice	   were	   spontaneously	   immortalized,	   single	   clones	   were	   picked	   and	  
Kindlin-­‐1	  ablation	  was	   induced	  by	  transient	  transfection	  with	  an	  adenovirus	  expressing	  Cre	  
recombinase.	  Keratinocytes	  were	  cultured	   in	  KGM	  containing	  8%	  chelated	  FCS	   (Invitrogen)	  
and	  45	  µM	  Ca2+	  in	  a	  5%	  CO2	  humidified	  atmosphere	  on	  plastic	  dishes	  coated	  with	  a	  mixture	  
of	  30	  µg	  ml–1	  collagen	  I	  (Advanced	  BioMatrix)	  and	  10	  µg	  ml–1	  FN	  (Invitrogen).	  
Inhibition	  of	  premature	  anagen	  induction	  and	  increased	  Notch	  signaling	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At	  telogen	  onset	  (P49)	  back	  skin	  of	  control	  and	  Kind1-­‐K5	  mice	  was	  shaved	  and	  100	  µl	  of	  200	  
µM	  IWR-­‐1	  or	  IWP-­‐2	  (diluted	  in	  PBS)	  was	  subcutaneously	  injected	  every	  24	  h	  into	  a	  marked	  
skin	   region.	   100	   µl	   DMSO	   diluted	   in	   PBS	   was	   used	   for	   control	   experiments.	   At	   P56	   the	  
treated	  back	   skin	  was	   isolated,	   sectioned	  and	   stained	  with	  H/E.	  Ten	   serially	   sectioned	  HFs	  
per	  animal	  were	  counted.	  To	  analyze	  Notch	  signaling	  back	  skin	  section	  were	  stained	  for	  NICD	  
and	  NICD-­‐positive	  nuclei	  were	  quantified.	  	  
Constructs	  and	  transfections	  
Wnt4	   expression	   constructs	   (gift	   from	  Andreas	   Kispert,	   University	   of	   Hannover,	   Germany)	  
and	   the	   human	   β-­‐catenin	   expression	   construct	   (gift	   from	   Jürgen	   Behrens,	   University	   of	  
Erlangen,	   Germany).	   Human	   WNT5A	   (ID18032),	   LEF1	   (ID16709),	   pHes1-­‐luc	   (ID43806),	  
SuperTOPFlash	   (ID17165)	   and	   FOPFlash	   (ID12457)	   reporter	  plasmids	  were	  purchased	   from	  
Addgene.	  	  pEGFP-­‐C1	  expression	  vector	  was	  acquired	  from	  Clontech.	  	  
GFP-­‐tagged	  Kindlin-­‐1,	  -­‐2	  and	  Kindlin-­‐1-­‐QWAA	  expression	  constructs	  were	  described3	  and	  the	  
Kindlin1-­‐NLS	   construct	   was	   generated	   by	   fusing	   SV40	   NLS	   motifs	   to	   the	   N-­‐terminus	   of	  
Kindlin-­‐1.	  The	  expression	  cassettes	  were	  driven	  by	  a	  CAG	  promotor	  and	  flanked	  by	  two	  ITR	  
sites	   recognized	   by	   sleeping	   beauty	   transposase	   100×	   (SB100×)66	   and	   transiently	   co-­‐
transfected	  with	  SB100×	  vector	  in	  a	  1:1	  ratio	  using	  Lipofectamine	  2000	  (Invitrogen)	  following	  
the	  manufacturer's	   instructions.	   After	   two	   passages	   cells	   stably	   expressing	   the	  GFP-­‐fusion	  
protein	   were	   FACS	   sorted	   for	   equal	   expression	   levels,	   which	   was	   further	   confirmed	   by	  
western	  blotting.	  
Histology	  and	  immunostainings	  
Small	  pieces	   from	  back	   skin	  were	  either	  PFA	   fixed	  and	  embedded	   in	  paraffin	  or	   frozen	  on	  
dry-­‐ice	   in	   cryo-­‐matrix	   (Thermo)	  and	   sectioned.	   Tail	   skin	  whole-­‐mounts	  were	  prepared	  and	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immunostained	  as	  described27.	  	  Immunohistochemistry	  (H/E,	  DAPI,	  OilRedO,	  AP	  and	  Xgal)	  of	  
skin	   sections	   and	   tail	   whole	   mounts	   and	   immunofluorescence	   staining	   of	   tissue	   sections	  
were	  carried	  out	  as	  described25.	  	  To	  better	  visualize	  the	  blue	  β-­‐Gal	  stain	  the	  epidermal	  whole	  
mount	  was	  overlaid	  with	  a	  grayscale	   image.	   Immunostaining	  of	  human	  skin	  sections	  for	  β6	  
integrin	  followed	  published	  protocols67.	  
HF	   bulge	   sizes	   were	   quantified	   in	   epidermal	   tail	   whole	   mounts	   stained	   for	   Krt-­‐15	   and	   z-­‐
projections	  that	  were	  collected	  with	  a	  confocal	  microscope	  using	  a	  20×	  objective.	  Length	  and	  
diameter	   of	   Krt-­‐15	   positive	   bulge	   area	   was	   measured	   with	   the	   ImageJ	   software	   (Version	  
1.41n)	  and	  bulge	  volumes	  were	  calculated	  using	  the	  circular	  cylinder	   formula	   (v=π×r2×h;	  v,	  
volume;	   r,	   radius;	   h,	   height).	   The	   HF	   numbers	   were	   quantified	   in	   serial	   sections	   of	  
comparable	   back	   skin	   regions	   from	  at	   least	   three	  mice	   per	   genotypes	   and	   indicated	   ages.	  
HFs	  per	  10×	  objective	  field	  of	  H/E	  stained	  sections	  were	  counted.	  HFs	  in	  anagen	  and	  early	  HF	  
development	  were	  staged	  as	  described	  previously68,69.	  	  	  	  	  
Images	  were	  collected	  by	  confocal	  microscopy	  (DMIRE2	  or	  SP5;	  Leica)	  with	  a	  10×	  ,	  20×	  	  NA	  
1.4	   or	   40×	   oil	   objective	   using	   the	   Leica	   Confocal	   Software	   (version	   2.5	   Build	   1227)	   or	   by	  
bright	  field	  microscopy	  (Axioskop;	  Carl	  Zeiss	  with	  a	  10×	  NA	  0.3,	  20×	  NA	  0.5	  or	  40×	  NA	  0.75	  
objective	  and	  	  camera	  DC500	  with	  IM50	  software	  (Leica).	  
In	  situ	  hybridization	  
Antisense	  riboprobes	   for	  mouse	  Fzd4	   (SpeI-­‐EcoRI	   fragment	  of	  mouse	  FZD4	  3’-­‐UTR),	  Wnt5a	  
(gift	   from	   Irma	   Thesleff,	   University	   of	   Helsinki,	   Finland)	   and	   Hes1	   (gift	   from	   Ryoichiro.	  
Kageyama,	  Kyoto	  University,	  Japan)	  were	  synthesized	  with	  T7	  RNA	  polymerase	  (New	  England	  
Biolabs)	   and	   DIG	   RNA	   Labeling	  Mix	   according	   to	   the	  manufacturer’s	   instructions	   (Roche).	  
Isolated	  tail	  skin	  epidermis	  was	  fixed	   in	  4%	  PFA	  in	  PBS,	  washed	  in	  PBS	  for	  5	  min	  twice	  and	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then	   twice	   for	   15	   min	   in	   PBS	   with	   0.1%	   active	   diethylpyrocarbonate	   followed	   by	   15	   min	  
equilibration	  in	  5×	  saline-­‐sodium	  citrate	  (SSC).	  Samples	  were	  first	  pre-­‐hybridized	  for	  1	  h	  at	  58	  
°C,	  in	  50%	  formamide,	  5×	  SSC,	  40	  μg/ml	  salmon	  sperm	  DNA,	  then	  hybridized	  for	  16	  h	  at	  58	  °C	  
with	  400	  ng	  ml–1	  of	  DIG-­‐labeled	  probe	  in	  pre-­‐hybridization	  mix,	  washed	  twice	  for	  30	  min	  in	  
2×	  SSC	  at	  RT,	  followed	  by	  60	  min	  wash	  at	  65	  °C	  in	  2×	  SSC	  and	  then	  60	  min	  wash	  at	  65	  °C	  in	  
0.2×	  SSC.	  The	   tissues	  were	  washed	   in	  TBS	   for	  5	  min	   three	   times,	  blocked	   in	  0.5%	  blocking	  
reagent	   (Roche)	   in	   0.1%	   Tween20/TBS	   (TBST)	   for	   90	  min	   at	   RT,	   then	   incubated	   in	   1:5000	  
diluted	   anti-­‐DIG	  AP	   (Roche)	   in	   0.5%	  blocking	   reagent	   in	   TBST	   at	   4	   °C	   overnight.	   Following	  
three	  60	  min	  washes	  in	  TBST,	  tissues	  were	  incubated	  in	  NTMT	  (100	  mM	  NaCl,	  100	  mM	  Tris	  
pH	   9.5	   50	  mM	  MgCl2,	   0.1%	   Tween	   20)	   for	   10	  min	   at	   RT.	   Color	   was	   developed	   using	   BM	  
Purple	  AP	  substrate	  precipitating	  reagent	  (Roche)	  at	  37	  °C.	  The	  reaction	  was	  stopped	  for	  15	  
min	  with	  TE	  buffer	  (Tris	  10	  mM,	  EDTA	  1	  mM,	  pH	  8.0)	  and	  samples	  were	  mounted	  with	  70%	  
glycerol.	  
Peptide	  pull-­‐downs	  
Pull-­‐downs	   were	   performed	   with	   β1	   wt	   tail	   peptide	  
(HDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGK-­‐OH),	   β1	   scrambled	   peptide	  
(EYEFEPDKVDTGAKGTKMAKNEKKFRNYTVHNIWESRKVAP-­‐OH),	   β6	   wt	   tail	   peptide	  
(HDRKEVAKFEAERSKAKWQTGTNPLYRGSTSTFKNVTYKHREKHKAGLSSDG-­‐OH)	  and	  β6	  scrambled	  
peptide	   (KTDHAVQGDKKLSHKKNRGTSKATFPKVRHYETEEWAALESGYGSRTFKNSR-­‐OH).	   All	  
peptides	   were	   desthiobiotinylated.	   Prior	   to	   use,	   peptides	   were	   immobilized	   on	   35	   μl	  
Dynabeads	  MyOne	  Streptavidine	  C1	  (10	  mg	  ml–1,	  Invitrogen)	  for	  3	  h	  at	  4	  °C.	  
Keratinocytes	   were	   lysed	   on	   ice	   in	   Mammalian	   Protein	   Extraction	   Reagent	   (Thermo	  
Scientific)	  and	  1	  mg	  of	  cell	  lysate	  was	  incubated	  with	  the	  indicated	  peptides	  for	  4	  h	  at	  4	  °C.	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After	  three	  washes	  with	   lysis	  buffer	  the	  beads	  were	  boiled	   in	  SDS-­‐PAGE	  sample	  buffer	  and	  
the	  supernatant	  loaded	  on	  8%	  SDS-­‐PAGE	  gels.	  
Preparation	  of	  αvβ6	  antibody-­‐coated	  cover	  slips	  
Antibody	  coating	  was	  carried	  out	  as	  described70.	  Briefly,	  glass	   slides	   (24×24;	  Menzel)	  were	  
sterilized,	   coated	  with	   collagen	   I	   (Advanced	  BioMatrix)	   for	  1	  h	  at	  37	   °C,	   air	  dried,	   covered	  
with	   nitrocellulose	   dissolved	   in	  methanol	   and	   air	   dried	   again.	   Slides	   were	   incubated	  with	  
αvβ6	  antibody	  (10D5;	  10	  µg	  ml
–1;	  Chemicon)	  diluted	  in	  PBS	  over	  night	  at	  4	  °C	   in	  a	  humidity	  
chamber,	  washed	  once	  with	  PBS	  and	  blocked	  with	  1%	  BSA	  for	  1	  h	  at	  RT.	  
Generation	  of	  dense	  gold	  nanoarrays	  functionalized	  with	  cyclic-­‐RGD	  
In	  a	  typical	  synthesis,	  7	  mg	  ml–1	  of	  polystyrene(154)-­‐block-­‐poly(2-­‐vinylpyridine)(33)	  (PS154-­‐b-­‐
P2VP33,	   Polymer	   Source)	   was	   dissolved	   at	   RT	   in	   p-­‐xylene	   (Sigma)	   and	   stirred	   for	   2	   d.	  
Hydrogen	  tetrachloroaurate	  (III)	  trihydrate	  (HAuCl4·∙3H2O;	  Sigma)	  was	  added	  to	  the	  block	  co-­‐
polymer	  solution	  (1	  HAuCl4	  per	  2	  P2VP	  units)	  and	  stirred	  for	  2	  d	  in	  a	  sealed	  glass	  vessel.	  Glass	  
cover	   slips	   (Carl	   Roth)	  were	   cleaned	   in	   a	   piranha	   solution	   for	   at	   least	   2	   h	   and	   extensively	  
rinsed	  with	  MilliQ	  water	   and	  dried	  under	   a	   stream	  of	   nitrogen.	  Micellar	  monolayers	  were	  
prepared	  by	  dip-­‐coating	  a	  glass	  cover	  slip	  into	  previously	  prepared	  solutions	  with	  a	  constant	  
velocity	  equal	  to	  24	  mm	  min–1.	  The	  dip-­‐coated	  glass	  slides	  were	  exposed	  to	  oxygen	  plasma	  
(150	  W,	  0.15	  mbar,	  45	  min,	  PVA	  TEPLA	  100	  Plasma	  System).	  To	  prevent	  nonspecific	  protein	  
adsorption	   or	   cell	   binding,	   the	   glass	   background	   was	   covalently	   modified	   with	   silane-­‐
terminated	  polyethylene	  glycol	  (PEG;	  molecular	  weight	  2000)71.	  	  Thiol-­‐terminated	  cyclic-­‐RGD	  
was	  synthesized	  as	  described	  before72.	  The	  gold	  nanoparticles	  were	  then	  functionalized	  with	  
this	   ligand	   by	   incubating	   the	   PEG-­‐functionalized	   substrates	   in	   100	   μl	   of	   a	   50	   μM	  aqueous	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solution.	   The	   substrates	  were	   then	   thoroughly	   rinsed	   and	   incubated	  overnight	  with	  water	  
and	  finally	  dried	  with	  nitrogen.	  
Spreading	  assay	  
A	  single	  cell	  suspension	  with	  1.0	  ×105	  cells	  per	  well	  in	  a	  6-­‐well	  plate	  was	  plated	  in	  serum	  free	  
KGM	  (1%	  BSA;	  1%	  Penicillin-­‐Streptomycin)	  on	  FN-­‐coated	  glass	  cover	  slips	   (10	  µg	  ml–1	  FN	   in	  
PBS	  for	  1	  h	  at	  RT)	  or	  indicated	  substrates	  for	  3	  h	  at	  37	  °C.	  Cells	  were	  imaged	  by	  bright	  field	  
Axiovert	  40	  CFL	  microscope	  (20×	  objective;	  Carl	  Zeiss)	  and	  CV640	  camera	  (Prosilica)	  before	  
fixation	   in	  4%	  PFA-­‐PBS	  and	   immunostaining	  with	   indicated	  antibodies.	   Spreading	  area	  was	  
quantified	   after	   staining	   with	   phalloidin	   Alexa488	   (Invitrogen)	   with	   an	   AxioImager	   Z1	  
microscope	  (20×	  objective,	  Carl	  Zeiss)	  using	  the	  ImageJ	  software	  (Version	  1.41n).	  
TGFβ	  stimulation	  assays	  
Keratinocytes	   were	   starved	   for	   several	   hours	   and	   stimulated	   with	   5	   ng/ml	   recombinant	  
human	  TGFβ-­‐1	  (PEROTech)	  in	  serum	  free	  KGM	  for	  indicated	  time	  points,	  lysed	  and	  analyzed	  
by	   western	   blotting.	   TGFβ	   modulated	   proliferation	   was	   determined	   in	   70%	   confluent	  
keratinocytes	   cultured	   in	   6-­‐well	   plates,	   incubated	   for	   8	   h	   with	   10	   µM	   5-­‐ethynyl-­‐2´-­‐
deoxyuridine	   (EdU;	   Invitrogen)	   and	   indicated	   concentrations	   of	   TGFβ-­‐1	   and	   analyzed	  with	  
Click-­‐iT	  EdU	  Alexa	  Fluor488	  Flow	  Cytometry	  Assay	  Kit	  (Invitrogen).	  
TGFβ	  release	  assay	  
TGFβ	  release	  was	  determined	  as	  described34.	  Briefly,	  CHO	  LTBP1	  cell	  were	  seeded	  (5.0	  ×	  104	  
cells	  per	  well)	  for	  48	  h	  in	  a	  96	  well	  plate	  in	  triplicates	  to	  deposit	  an	  LTBP1-­‐TGFβ	  rich	  matrix.	  
Cells	   were	   then	   detached	   with	   PBS/15	   mM	   EDTA,	   the	   remaining	   LTBP1-­‐TGFβ	   rich	   matrix	  
washed	  twice	  with	  PBS	  and	  incubated	  with	  keratinocytes	  (2.0	  ×	  104	  cells	  per	  well)	  and	  tMLEC	  
cells	  (1.5	  ×	  104	  cells	  per	  well)	   in	  a	  100	  µl	  final	  volume	  either	   in	  the	  absence	  or	  presence	  of	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αvβ6	  integrin	  blocking	  antibody	  (10D5;	  20	  µg	  ml
–1;	  Chemicon)	  or	  TGFβ	  neutralizing	  antibody	  
(1D11;	  15	  µg	  ml–1;	  BD	  Biosciences).	  The	  amount	  of	  released	  TGFβ	  was	  measured	  after	  16–24	  
h	  using	  Bright	  Glo	  luciferase	  Kit	  (Promega).	  
Wnt	  and	  Notch	  reporter	  assay	  	  
Cells	  were	  plated	  on	  FN	  and	  collagen	  I	  coated	  12-­‐well	  plates	  (6.0	  ×	  105	  cells	  per	  well)	  before	  
transient	  transfection	  with	  0.5	  µg	  of	  pHes1-­‐luc,	  SuperTOPFLASH	  or	  SuperFOPFLASH	  reporter,	  
indicated	   expression	   plasmid	   and	   50	   ng	   thymidine	   kinase-­‐driven	   renilla	   (Promega)	   for	  
controlling	   transfection	  efficiency.	   The	   total	   amount	  of	   transfected	  plasmid	  DNA	  was	   kept	  
constant	   at	   1.5	   µg	   per	   well	   by	   using	   pEGFP-­‐C1	   expression	   vector	   as	   transfection	   control	  
(Clontech).	   After	   24	   h	   (Wnt	   reporter)	   or	   48	   h	   (Notch	   reporter)	   luciferase	   activity	   was	  
analyzed	  with	   a	   Dual	   Luciferase	   reporter	   assay	   system	   (Promega).	   To	   determine	   effect	   of	  
Wnt	  or	  Notch	  signaling	  cells	  were	  treated	  with	  indicated	  inhibitor	  18	  h	  after	  transfection	  and	  
luciferase	  activity	  was	  measured	  24	  h	  later.	  
Statistical	  Analysis	  
Analyses	  were	  performed	  with	  GraphPad	  Prism	  software	  (version	  5.00,	  GraphPad	  Software).	  
Experiments	   were	   routinely	   repeated	   at	   least	   3	   times	   and	   repeat	   number	   was	   increased	  
according	  to	  effect	  size	  or	  sample	  variation.	  If	  not	  mentioned	  otherwise	  in	  the	  figure	  legend,	  
statistical	   significance	   (*P	   <	   0.05;	   **P	   <	   0.01;	   ***P	   <	   0.001;	   ns,	   not	   significant)	   was	  
determined	  by	  the	  unpaired	  t-­‐test	  (for	  biological	  effects	  with	  assumed	  normal	  distribution)	  
or	  Mann-­‐Whitney	  U-­‐test.	   In	  boxplot	  panels	  the	  middle	  line	  represents	  the	  median,	  the	  box	  
ends	  the	  25th	  and	  75th	  percentile	  and	  the	  whisker	  ends	  show	  Min/Max	  distribution	  or	  are	  at	  
1.5	   interquartile	   range	  while	  outliers	  are	   shown	  as	  dots,	   as	   indicated	   in	   the	   figure	   legend.	  
Unbiased	  and	  reproducible	  identification	  of	  cells	  with	  positive	  nuclear	  staining	  for	  β-­‐catenin,	  
______________________________________________________________________________________________________________
304
Appendix
31 
 
Lef1	  and	  NICD	  was	  ensured	  by	  quantification	  of	  nuclear	  staining	  intensities	  with	  ImageJ	  tool	  
(version1.41n).	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Figure	  legends	  
Figure	   1	  Kindlin-­‐1	   controls	   HF	   growth.	   (a)	  Model	   of	   Kindlin-­‐1	   and	   β1	   integrin	   functions	   in	  
mice;	   Kind1-­‐K5	   mice	   lack	   Kindlin-­‐1	   in	   keratinocytes	   and	   TTAA-­‐K5	   mice	   express	   a	   Kindlin-­‐
binding	  deficient	  β1	   integrin	  in	  which	  threonines-­‐788/789	  are	  substituted	  with	  alanines.	  (b)	  
Appearance	  of	  7	  months	  old	  control,	  Kind1-­‐K5	  and	  TTAA-­‐K5	  mice.	   (c)	  View	  of	  shaved	  back	  
skin	  of	  7	  months	  old	  control,	  Kind1-­‐K5	  and	  TTAA-­‐K5	  mice.	  (d)	  Immunofluorescence	  staining	  
of	  back	  skin	  from	  P21	  and	  7	  months	  old	  mice	  for	  LN-­‐332	  (red)	  and	  α6	  integrin	  (green).	  Nuclei	  
are	  stained	  with	  DAPI	  (blue).	  (e)	  H/E	  staining	  of	  back	  skin	  from	  6	  months	  old	  mice.	  Kind1-­‐K5	  
and	  TTAA-­‐K5	  skin	  shows	  hyperthickened	  skin,	  hyperkeratosis	  and	  blisters	  (arrowhead)	  at	  the	  
epidermal-­‐dermal	   junction.	   (f)	   Integrin	   activation	   index	   on	   primary	   Kind1-­‐K5	   and	   TTAA-­‐K5	  
keratinocytes	  reported	  as	  mean	  9EG7	  binding	  normalized	  to	  total	  β1	  integrin	  level	  ±	  SD	  (n=3	  
technical	   replicates).	   (g,h)	   H/E	   stained	   back	   skin	   sections	   of	   7	  months	   old	   Kind1-­‐K5	  mice.	  
Scale	  bar	  indicates	  5	  mm	  in	  (c),	  50	  µm	  in	  (d,e,g)	  and	  100	  µm	  in	  (h).	  
Figure	  2	  Premature	  anagen	  induction	  and	  ectopic	  HF	  development	  in	  Kind1-­‐K5	  skin.	  (a)	  H/E	  
stained	  back	  skin	  sections	  of	  P56	  mice.	  (b)	   Immunostaining	  of	  HFs	  from	  P56	  mice	  for	  CD34	  
(red)	  and	  CDP	  (green).	  Nuclei	  are	  stained	  with	  DAPI	  (blue).	  (c)	  The	  percentage	  of	  anagen	  HFs	  
at	   indicated	   time	  points	   (mean	  ±	  SD,	  n=4	  mice	  per	  genotype,	  ≥8	  10×	  objective	   fields	  were	  
counted).	  (d)	   Immunostaining	  of	  tail	  epidermal	  whole	  mounts	  for	  CDP	  (green),	  Krt-­‐15	  (red)	  
and	  DAPI	  (blue)	  of	  P80	  mice.	  Note	  ectopic	  HF	  growth	  in	  IFE	  of	  Kind1-­‐K5	  mice.	  (e)	  Ectopic	  HF	  
outgrowth	  from	  a	  preexisting	  HF	  of	  the	  back	  skin	  in	  a	  6	  months	  old	  Kind1-­‐K5	  mouse	  stained	  
for	  CDP	  (green)	  and	  DAPI	  (blue).	  Scale	  bar	  indicates	  50	  µm	  in	  (a,b)	  and	  100	  µm	  in	  (d,e).	  Bu,	  
bulge;	   SG,	   sebaceous	   gland;	   HG,	   hair	   germ;	   HF,	   hair	   follicle;	   DP,	   dermal	   papilla;	   IFE,	  
interfollicular	  epidermis;	  Ec,	  ectopic	  HF.	  
______________________________________________________________________________________________________________
316
Appendix
43 
 
Figure	   3	   Kindlin-­‐1	   regulates	   cutaneous	   epithelial	   SC	   homeostasis.	   (a)	   Distribution	   and	  
expression	   of	   marker	   genes	   in	   SC	   subpopulations	   of	   murine	   HFs.	   (b–d)	   Back	   skin	  
immunostaining	  from	  6	  months	  old	  mice	  for	  Krt-­‐15	  (red)	  and	  Npnt	  (green)	  (b),	  (Npnt	  (green)	  
and	  α6	  integrin	  (red)	  (c),	  and	  for	  Lrig1	  (green)	  and	  α6	  integrin	  (red)	  (d).	  Arrowheads	  indicate	  
Krt-­‐15	  positive	   cells	   (b),	  Npnt	  deposition	   (c)	   and	   Lrig1	  expression	   (d)	   in	  Kind1-­‐K5	  mice.	   (e)	  
Keratinocytes	  from	  P40	  old	  mice	  were	  separated	  by	  FACS	  into	  α6	  integrin-­‐high	  and	  -­‐low	  and	  
further	  analyzed	  for	  CD34	  and	  Sca1	  expression.	  (f)	  Gated	  populations	  (1–6)	  were	  quantified	  
and	   represented	   as	   mean	   ±	   SD	   (n=5	   Control	   and	   3	   Kind1-­‐K5	   mice).	   Color	   code	   in	   (e–f)	  
corresponds	   to	   the	   cell	   population	   denoted	   in	   (a).	   (g)	   The	   relative	   amounts	   of	   SC	  
subpopulations	  over	  time	  analyzed	  by	  FACS.	  Data	  show	  average	  fold	  increase	  (±	  SD)	  relative	  
to	   control	   mice	   (n	   and	   P-­‐values	   are	   listed	   in	   Supplementary	   Table	   1).	   (h)	   BrdU	   (green)	  
retaining	   cells	   in	   Krt-­‐15	   (red)	   stained	   tail	   whole	   mounts	   after	   indicated	   chase	   times.	   (i)	  
Numbers	  of	  LRC	  per	  HF	  after	  indicated	  chasing	  periods	  were	  quantified	  as	  boxplots	  (10	  d	  n=5	  
Control	  and	  3	  Kind1-­‐K5;	  32	  d	  n=3	  Control	  and	  4	  Kind1-­‐K5;	  80	  d	  n=4	  Control	  and	  3	  Kind1-­‐K5).	  
Boxplot	  whisker	  ends	  show	  Min/Max	  distribution	  and	  middle	  line	  reports	  the	  median.	  Nuclei	  
are	  stained	  with	  DAPI	  (blue)	  (b–d,h).	  Scale	  bar	  indicates	  50	  µm	  (b–d)	  and	  100	  µm	  in	  (h).	  Bu,	  
bulge;	  SG,	  sebaceous	  gland;	  HF,	  hair	  follicle;	  IFE,	  interfollicular	  epidermis;	  UI,	  upper	  isthmus;	  
IJ,	  interfundibulum	  junctional	  zone.	  
Figure	   4	   Kindlin-­‐1	   promotes	   αvβ6	   integrin	   induced	   TGFβ	   release	   in	   vitro	   and	   in	   vivo.	   (a)	  
Representative	   histogram	   of	   integrin	   levels	   on	   freshly	   isolated	   keratinocytes	   analyzed	   by	  
FACS	  (n=3	  biological	  replicates).	  (b)	  Immunofluorescence	  analysis	  of	  back	  skin	  from	  P44	  mice	  
for	  β6	   integrin	   (cyan),	  CD34	   (green)	   and	  Npnt	   (red).	   (c)	  Brightfield	   images	  of	   keratinocytes	  
plated	  on	  FN-­‐,	  αvβ6-­‐	  and	  cRGD-­‐coated	  surfaces.	  (d)	  Immunostaining	  of	  keratinocytes	  plated	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on	   αvβ6	   and	   cRGD	   surfaces	   for	   paxillin	   (red)	   and	   F-­‐actin	   or	   β6	   integrin	   (green).	   (e)	   TGFβ	  
release	   from	   extracellular	   matrix	   by	   keratinocytes	   from	   control	   or	   Kind1-­‐K5	   mice	   in	   the	  
absence	   or	   presence	   of	   indicated	   blocking	   antibodies	  monitored	  with	   the	   tMLEC	   reporter	  
cell	   line.	   Luciferase	   activity	   is	   reported	   as	   mean	   ±	   SEM	   (n=3	   biological	   replicates).	   (f)	  
Immunostaining	  of	  a	  HF	  from	  4	  months	  back	  skin	  for	  pSmad2/3	  (green)	  and	  CD34	  (red).	  (g)	  
Streptavidin-­‐bead	   pull-­‐down	   assay	   with	   biotinylated	   wild	   type	   (WT)	   integrin	   tails	   or	  
scrambled	   (Scr)	   peptides	   from	   keratinocyte	   lysates.	   (h,i)	   Immunofluorescence	   staining	   of	  
skin	  sections	  from	  control	  and	  individuals	  with	  KS	  for	  β6	  integrin	  (h)	  and	  pSmad2/3	  (i).	  Nuclei	  
are	  stained	  with	  DAPI	   (blue)	   (b,d,f,h,i).	  Scale	  bar	   indicates	  50	  µm	  (b,c,h,i)	  and	  25	  µm	  (d,f).	  
NHS,	   normal	   human	   skin;	   KS,	   Kindler	   syndrome;	   Bu,	   bulge;	   DP,	   dermal	   papilla;	   HF,	   hair	  
follicle;	  IFE,	  interfollicular	  epidermis.	  
Figure	  5	  Kindlin-­‐1	  controls	  Wnt-­‐β-­‐catenin	  signaling.	   (a)	   Immunofluorescence	  staining	  for	  β-­‐
catenin	  (green)	  of	  	  HF	  (P44)	  	  (left	  panel)	  and	  IFE	  (P55)	  (middle	  panel)	  and	  for	  Lef1	  and	  CD34	  
(red)	   of	  HF	   and	   IFE	   (4	  months)	   (right	   panel)	   from	   control	   and	  Kind1-­‐K5	  mice.	  Arrowheads	  
indicate	   aberrant	   β-­‐catenin	   (left	   panel)	   and	   Lef1	   (right	   panel)	   localization.	   (b)	   IFE	  
immunofluorescence	   staining	   for	   NICD	   (green)	   from	   P44	   control	   and	   Kind1-­‐K5	   mice.	   (c)	  
TOPgal	   reporter	   activity	   in	   tail	   HFs	   (left	   panel)	   and	   IFE	   (right	   panel)	   from	   3	   months	   old	  
control	   and	   Kind1-­‐K5	   mice.	   Arrowheads	   indicate	   HF	   with	   abnormal	   TOPgal	   activity.	   (d)	  
Immunofluorescence	   staining	   of	   human	   skin	   from	   normal	   and	   individuals	   with	   KS	   for	   β-­‐
catenin	   (left	   panel)	   and	   LEF1	   (right	   panel).	   (e)	   Skin	   gene	   expression	   profile	   of	   NHS	   (n=3)	  
versus	   KS	   (n=3)	   assessed	  with	  microarray	   and	   shown	   as	   volcano	   plot.	   Genes	  with	   ≥2	   fold	  
change	   in	  KS	  were	  plotted	  according	   to	   the	   Log2	   fold	   change	   (x-­‐axis)	   and	   Log10	  P-­‐value	   (y-­‐
axis).	   (f)	   Immunofluorescence	  staining	  for	  WNT5A	  (green)	   in	  skin	  of	  normal	  and	   individuals	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with	   KS.	   (g)	   Volcano	   plot	   of	   qPCR	   gene	   expression	   profile	   of	   keratinocytes	   from	   control	  
versus	   Kind1-­‐K5	  mice.	  Mean	   expression	   relative	   to	  Gapdh	   of	  Wnt	   ligands	   (circle,	   red)	   and	  
receptors	  (triangle,	  green)	  were	  plotted	  according	  to	  the	  Log2	  fold	  change	  (x-­‐axis)	  and	  log10	  
P-­‐value	  (y-­‐axis).	  (n=3	  biological	  replicates,	  for	  mean	  ±	  SEM	  values	  see	  Supplementary	  Table	  
3).	   (h)	   Transient	   overexpression	   of	   GFP,	  Wnt4	   and	  Wnt5a	   in	   floxed	   (WT)	   and	   Adeno-­‐Cre	  
treated	  Kindlin-­‐1	  deficient	   (KO)	  keratinocytes	  expressing	  the	  TOPFlash	  reporter.	  Values	  are	  
corrected	  for	  the	  renilla	  control	  and	  represented	  as	  mean	  ±	  SEM	  fold	  increase	  relative	  to	  WT	  
cells	   (n=5	   biological	   replicates).	   (i)	   TOPFlash	   reporter	   activity	   in	   cells	   stably	   re-­‐expressing	  
Kindlin-­‐1-­‐GFP,	   integrin-­‐binding	   deficient	   Kindlin-­‐1-­‐GFP,	   NLS-­‐tagged	   Kindlin-­‐1-­‐GFP	   and	  
Kindlin-­‐2-­‐GFP,	  respectively.	  Values	  are	  corrected	  for	  the	  renilla	  control,	  represented	  as	  fold	  
increase	  relative	  to	  WT	  cells	  and	  reported	  as	  mean	  ±	  SEM	  (n=21	  	  WT,	  KO;	  13	  Kind1-­‐GFP;	  9	  	  
Kind1-­‐QW-­‐GFP,	   5	   Kind1-­‐NLS-­‐GFP,	   Kind2-­‐GFP;	   all	   biological	   replicates).	   (j)	   H/E	   staining	   of	  
control	  and	  Kind1-­‐K5	  mice	  one	  day	  after	  treatment	  with	  indicated	  Wnt	  inhibitor.	  Nuclei	  are	  
stained	  with	  DAPI	  (blue)	  (a,b,d,f).	  All	  scale	  bars	  indicate	  50	  µm.	  	  NHS,	  normal	  human	  skin;	  KS,	  
Kindler	   syndrome,	   Bu,	   bulge;	   SG,	   sebaceous	   gland;	   HG,	   hair	   germ;	   HF,	   hair	   follicle;	   DP,	  
dermal	  papilla.	  
Figure	   6	   Loss	   of	   Kindlin-­‐1	   increases	   skin	   tumor	   incidence.	   (a–e)	   Two	   stage	   carcinogenesis	  
(n=26	   Control	   and	   23	   Kind1-­‐K5	   mice).	   (a)	   Tumor	   incidence	   (P-­‐value	   by	   log-­‐rank	   test),	   (b)	  
burden	  and	  (c)	  skin	  lesions	  per	  animal	  (reported	  as	  mean	  ±	  SD)	  after	  25	  weeks	  of	  treatment.	  
(d)	  Tumor	  growth	  reported	  as	  diameter	  is	  shown	  in	  a	  boxplot	  where	  whisker	  ends	  are	  at	  1.5	  
interquartile	  ranges	  and	  middle	  lines	  represent	  the	  median.	  (e)	  The	  percentage	  of	  skin	  lesion	  
subtypes	   from	   control	   (n=25	   lesions)	   and	   Kind1-­‐K5	   mice	   (n=47	   lesions)	   were	   staged	   by	  
histology	   and	   immunofluorescence	   analysis	   (see	   Supplementary	   Fig.	   8a).	   (f–i)	   One	   stage	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carcinogenesis	  with	  DMBA.	  (f)	  Tumor	  incidence,	  (g)	  skin	  lesion	  number,	  (h)	  frequency	  and	  (i)	  
size	   of	   control	   (n=10)	   and	   Kind1-­‐K5	   (n=10)	   mice	   monitored	   as	   in	   (a–d).	   (j)	   Molecular	  
functions	   of	   Kindlin-­‐1;	   in	   normal	   cells	   (left	   panel)	   Kindlin-­‐1	   activates	   β1-­‐class	   integrins	   and	  
αvβ6	   integrin	   to	   facilitate	   adhesion	   and	   TGFβ	   liberation	   from	   LAP,	   respectively.	   Free	   TGFβ	  
activates	   TGFβR	   leading	   to	   nuclear	   translocation	   of	   phosphorylated	   Smad2/3,	   which	  
promotes	   SC	   quiescence.	   In	   Kindlin-­‐1	   deficient	   cells	   (right	   panel)	   activation	   of	   β1-­‐class	  
integrins	   and	   αvβ6	   is	   impaired	   leading	   to	   adhesion	   defects	   and	   loss	   of	   TGFβ-­‐mediated	   SC	  
quiescence.	   In	  addition,	  dysregulated	  Wnt	   ligand	  expression	   leading	  to	  elevation	  of	  Wnt5a	  
leads	  to	  canonical	  Wnt-­‐β-­‐catenin	  signaling	  via	  the	  Lrp5/6-­‐Fzd4	  complex.	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CD98hc facilitates B cell proliferation and adaptive
humoral immunity
Joseph Cantor1, Cecille D Browne2, Raphael Ruppert3, Chloe´ C Fe´ral4, Reinhard Fa¨ssler3, Robert C Rickert2
& Mark H Ginsberg1
The proliferation of antigen-specific lymphocytes and resulting clonal expansion are essential for adaptive immunity. We report
here that B cell–specific deletion of the heavy chain of CD98 (CD98hc) resulted in lower antibody responses due to total
suppression of B cell proliferation and subsequent plasma cell formation. Deletion of CD98hc did not impair early B cell
activation but did inhibit later activation of the mitogen-activated protein kinase Erk1/2 and downregulation of the cell cycle
inhibitor p27. Reconstitution of CD98hc-deficient B cells with CD98hc mutants showed that the integrin-binding domain of
CD98hc was required for B cell proliferation but that the amino acid–transport function of CD98hc was dispensable for this.
Thus, CD98hc supports integrin-dependent rapid proliferation of B cells. We propose that the advantage of adaptive immunity
favored the appearance of CD98hc in vertebrates.
Adaptive immunity is a vertebrate specialization that requires the
selective proliferation of antigen-specific lymphocytes1,2. The CD98
heavy chain (CD98hc; also called 4F2hc; A000262), encoded by Slc3a2,
is a vertebrate membrane protein whose expression is much higher in
proliferating lymphocytes3. Originally described 25 years ago as a
lymphocyte-activation antigen3, the function of CD98hc in the
immune system has remained obscure. CD98 has two distinct func-
tions: facilitating amino acid transport4,5 and mediating integrin
signaling6,7. The 80-kilodalton CD98hc is covalently linked to one
of several 40-kilodalton light chains, which function as amino acid
transporters4,5. Transport of leucine and isoleucine is mediated by the
CD98 heterodimer4,5; these amino acids are important regulators of
the mTOR pathway, which governs nutrient-regulated lymphocyte
function8,9. CD98hc also interacts with certain integrin b-subunits to
mediate signaling events that control cell migration, survival and
proliferation7. CD98hc is first found in primitive vertebrates, coin-
cident with the appearance of adaptive immunity2,10. Consequently,
we hypothesized that CD98hc could be involved in the rapid lym-
phocyte proliferation required for effective adaptive immunity.
Here we report that CD98hc facilitates humoral immunity by
supporting the rapid proliferation of B cells that is necessary for
clonal expansion and subsequent differentiation into plasma cells. We
deleted CD98hc in B cells by crossing mice bearing a loxP-flanked
(floxed) Slc3a2 allele (Slc3a2f/f) with those expressing Cre recombinase
in B cells (CD19-Cre+). The resultant Slc3a2f/f CD19-Cre+ had normal
maturation and distribution of peripheral B cells and normal mor-
phology of secondary lymphoid organs. Slc3a2f/fCD19-Cre+ mice
immunized with T cell–dependent or T cell–independent antigens had
much lower antibody responses than did control Slc3a2f/f mice with-
out CD19-Cre, because of complete suppression of B cell proliferation
and plasma cell formation by CD98hc-null B cells. A mutant form of
CD98hc that mediates integrin signaling but not amino acid transport
supported the proliferation of CD98hc-deficient B cells; hence, the
region of CD98hc that mediates integrin interaction is required for B
cell proliferation and the domain that facilitates the amino acid–
transport function is dispensable for this. Furthermore, mitogenic
stimulation of a mixture of CD98hc-deficient and CD98hc-sufficient
B cells resulted in considerable enrichment for CD98hc-sufficient cells;
this finding establishes the ability of CD98hc to confer a strong
selective advantage during rapid B cell proliferation. Thus, the ability
of CD98hc to enable clonal expansion, which is necessary for adaptive
immunity, may have favored the appearance and retention of CD98hc
in vertebrates10.
RESULTS
B cell CD98hc is needed for antibody responses
Because germline loss of CD98hc is embryonically lethal11, we targeted
CD98hc by flanking exons 1 and 2 of Slc3a2 with loxP sites that
specified Cre recombinase–mediated deletion of the cytoplasmic and
transmembrane region of CD98hc (Supplementary Fig. 1a online),
thus leading to complete loss of CD98hc expression12. We crossed
Slc3a2f/f mice with mice bearing Cre recombinase under control of the
endogenous B cell–specific Cd19 locus13. The resulting Slc3a2f/fCD19-
Cre+ mice had specific deletion of CD98hc in B lymphocytes
Received 14 August 2008; accepted 27 January 2009; published online 8 March 2009; doi:10.1038/ni.1712
1Department of Medicine, University of California San Diego, La Jolla, California, USA. 2Program of Inflammatory Disease Research, Infectious and Inflammatory Disease
Center, Burnham Institute for Medical Research, La Jolla, California, USA. 3Department of Molecular Medicine, Max Planck Institute of Biochemistry, Martinsried,
Germany. 4Institut National de la Sante´ et de la Recherche Me´dicale, Nice-Sophia Antipolis University, Nice, France. Correspondence should be addressed to M.H.G.
(mhginsberg@ucsd.edu) or R.C.R. (robert@burnham.org).
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beginning at the transition from pro–B cell to pre–B cell, when CD19
expression is first induced14. In the splenic B cell compartment,
70–90% of cells lacked CD98hc (Fig. 1a), and we did not detect any
deletion in T cells or monocytes-macrophages (Fig. 1b), consistent
with the efficiency and specificity of CD19-Cre–mediated recombina-
tion13. B cells from Slc3a2flf littermates lacking CD19-Cre (Slc3a2f/f
CD19-Cre– mice) were uniformly positive for CD98hc (Fig. 1a).
To assess whether CD98hc is important for the secretion of anti-
bodies by B cells, we measured circulating immunoglobulin in Slc3a2f/f
CD19-Cre+ and Slc3a2f/fCD19-Cre– mice. Whereas basal circulating
concentrations of immunoglobulin M (IgM) were not significantly
lower (P 4 0.05) in naive Slc3a2f/fCD19-Cre+ mice, we noted sig-
nificantly less (P o 0.025) class-switched IgG in these mice (Supple-
mentary Fig. 1b). Furthermore, after challenge with T cell–independent
antigen in PBS (Fig. 2a) or T cell–dependent antigen in complete
Freund’s adjuvant (CFA; Fig. 2b), we noted much lower antigen-
specific IgM and IgG concentrations in Slc3a2f/fCD19-Cre+ mice than
in Slc3a2f/fCD19-Cre– mice. This defect was not specific to Toll-like
receptor signals, because we obtained similar results after immunization
with T cell–dependent antigens in adjuvant lacking microbial compo-
nents (incomplete Freund’s adjuvant; Fig. 2c). In addition, this corre-
lated with the ‘gene dosage’ of Slc3a2; Slc3a2f/–
CD19-Cre+ mice had a more severe defect
than did Slc3a2f/+CD19-Cre+ mice (Supple-
mentary Fig. 2 online). Thus, B cell CD98hc
is important for mounting specific antibody
responses to antigenic challenge.
CD98hc is involved in integrin signaling,
and integrins are involved in the localization
and distribution of B cells subsets15,16. In
addition, CD98hc is important for integrin-
mediated migration of mesenchymal cells7.
To test whether loss or misdistribution of B
cell subsets could explain the impaired anti-
body production of Slc3a2f/fCD19-Cre+ mice,
we examined lymphoid tissue for the pre-
sence and localization of B cell subsets.
Despite the involvement of CD98hc in adhe-
sive signaling and amino acid transport6,7,17,
CD98hc-deficient follicular B cells, marginal
zone B cells, transitional B cells and
peritoneal B1 cells were present in normal
percentages in the periphery; in addition, pro–B cells, pre–B cells,
immature B cells, and mature B cells were present in normal propor-
tions in the bone marrow (Fig. 3a). Similarly, we detected no
significant difference in the absolute numbers of these subsets in
Slc3a2f/fCD19-Cre+ versus Slc3a2f/fCD19-Cre– mice (P 4 0.05; Sup-
plementary Fig. 3 online). Slc3a2f/fCD19-Cre+ mice also had normal
splenic architecture, as follicular B cells segregated with intact mar-
ginal zones, and Slc3a2f/fCD19-Cre– and Slc3a2f/fCD19-Cre+ mice had
similar numbers of germinal centers (Fig. 3b). Finally, we detected no
differences between naive Slc3a2f/fCD19-Cre– and Slc3a2f/fCD19-Cre+
mice in terms of formed elements of the blood (Supplementary Fig. 4
online) or the concentration of circulating natural IgM (Fig. 3c).
Thus, CD98hc is not required for the formation of mature B cells or
their ability to populate secondary lymphoid organs.
B cell CD98hc is necessary for plasma cell formation
B cells differentiate into antibody-secreting plasma cells after antigenic
challenge, which suggests that a requirement for CD98hc in plasma
cell formation might explain the lower humoral immune responses of
Slc3a2f/fCD19-Cre+ mice. To test that idea, we purified resting splenic
B cells from Slc3a2f/fCD19-Cre+ mice, depleted the population of
Slc3a2 f/fCD19-Cre–
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Figure 1 Deletion of CD98hc in Slc3a2f/fCD19-
Cre+ mice. (a) CD98hc expression (filled
histograms) and staining with isotype-matched
control antibody (open histograms) in bone
marrow cells isolated from adult Slc3a2f/fCD19-
Cre+ and control Slc3a2f/fCD19-Cre– mice and
measured at various stages of B cell maturation.
BM, bone marrow. Data are from an experiment
repeated once. (b) Flow cytometry of CD98hc
expression (filled histograms) and staining with
isotype-matched control antibody (open
histograms) on T cells (CD3+), monocytes or
macrophages (CD11b+B220–) and B cells
(B220+) among peripheral blood and spleen
cells from Slc3a2 f/fCD19-Cre+ and control
Slc3a2f/fCD19-Cre– mice, prepared by lysis of
erythrocytes. Data are from one mouse of each
genotype in an experiment repeated once
(n ¼ 4 mice per group for each).
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Figure 2 Impaired antibody responses in Slc3a2f/fCD19-Cre+ mice. (a) Direct ELISA of anti-TNP IgM
or anti-TNP IgG3 in the serum of adult Slc3a2 f/fCD19-Cre+ and control Slc3a2 f/fCD19-Cre– mice 8–12
weeks of age, immunized with 50 mg TNP-LPS (T cell–independent antigen) in PBS; serum is from
blood obtained before immunization (Pre-immune) and 1 week after immunization. (b,c) Direct ELISA
of anti-TNP IgM and anti-TNP IgG in the serum of Slc3a2 f/fCD19-Cre+ and control Slc3a2 f/fCD19-Cre–
mice immunized with 100 mg TNP-KLH (T cell–dependent antigen) in CFA (b) or incomplete Freund’s
adjuvant (c). A405, absorbance at 405 nm. *, P ¼ 0.057 and **, P o 0.025 (two-tailed
t-test). Data are from an experiment repeated once (error bars, s.e.m. of five mice per group).
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any B cells expressing CD98hc and stimulated the remaining
population with lipopolysaccharide (LPS) to induce the formation of
plasma cells. B cells from Slc3a2f/fCD19-Cre+ mice were defective
both in class switching (Fig. 4a) and in development into CD138+
plasma cells (Fig. 4b). This phenotype bears similarities to that
of b1 integrin–deficient B cells16. The few plasma cells formed by
Slc3a2f/fCD19-Cre+ B cells expressed CD98hc (Supplementary Fig. 5
online), which indicated that they were the progeny of a few remain-
ing CD98hc-expressing cells that had escaped Cre-mediated recombi-
nation and in vitro depletion. Indeed, when we omitted the step of
in vitro depletion of CD98hc-expressing cells, the 10–20% of B cells
that expressed CD98hc in Slc3a2f/fCD19-Cre+ mice generated near
normal percentages of plasma cells in vitro (Supplementary Figs. 6
and 7 online).
Consistent with the defective formation of antibody-secreting
plasma cells, B cells from Slc3a2f/fCD19-Cre+ mice also had impaired
antibody secretion after LPS stimulation in vitro (Fig. 4c). As
shown by enzyme-linked immunospot assay, Slc3a2f/fCD19-Cre+
mice immunized with a T cell–dependent antigen also had fewer
cells that secreted antigen-specific antibody immediately after isolation
than did immunized Slc3a2f/fCD19-Cre– mice (Fig. 4d). These data
collectively show that without CD98hc, B cells are considerably
impaired in their ability to form plasma cells.
CD98hc is required for rapid B cell proliferation
Differentiation into plasma cells is preceded by many rounds of
proliferation, which leads to larger numbers of antigen-specific B
cells18; class switching is also independently regulated by cell divi-
sion19. Published reports using blocking or crosslinking antibody
suggest that CD98hc is involved in the proliferation of T cells20,21
and keratinocytes22. To assess the function of CD98hc in B cell
proliferation, we purified CD98hc-deficient or CD98hc-sufficient
resting splenic B cells from Slc3a2f/fCD19-Cre+ or Slc3a2f/fCD19-
Cre– mice, respectively, labeled them with the intracellular dye
CFSE, stimulated them with B cell mitogens and measured their
proliferation by flow cytometry asessing dye dilution. By 5 d after
stimulation, B cells from Slc3a2f/fCD19-Cre– mice had divided five to
eight times, as shown by discrete populations of daughter cells with
exponential dilution of fluorescence (Fig. 5a). In contrast, B cells from
Slc3a2f/fCD19-Cre+ littermates showed minimal division in response
to the B cell antigen receptor–crosslinking agent antibody to IgM
(anti-IgM), provided alone or together with interleukin 4 (IL-4) or
anti-CD40; we obtained similar data by directly counting viable cells
(Supplementary Fig. 8 online). A few cells from Slc3a2f/fCD19-Cre+
Figure 4 Defective formation of plasma cells in
Slc3a2f/fCD19-Cre+ mice. (a,b) Flow cytometry of
surface IgG3 (a) and CD138 (syndecan-1, a
plasma cell marker; b) on splenic B cells (CD43–
and CD98hc deficient) purified from Slc3a2f/f
CD19-Cre+ and littermate control Slc3a2f/fCD19-
Cre– mice and cultured for 5 d with LPS. Graphs
present IgG3+ or CD138+ B220lo cells among
total B cells. Numbers adjacent to outlined areas
(b, top) indicate percent B220loCD138+ cells. *,
P o 0.025 (two-tailed t-test). Data are from an
experiment with one mouse or an experiment
repeated once with similar results (error bars,
s.e.m. of three mice per group). (c) Sandwich
ELISA of total IgM and IgG in supernatants of
B cells stimulated for 4 d with LPS. *, P o 0.05
(two-tailed t-test). Data are from an experiment
repeated once with similar results (error bars, s.e.m. of four mice per group). (d) TNP-specific IgG–secreting plasma cells among splenocytes obtained from
Slc3a2f/fCD19-Cre+ and control mice 1 week after immunization with TNP-KLH in CFA, then cultured for 2–3 h on TNP-coated polyvinylidene difluoride–
membrane 96-well plates, followed by washing to remove cells and incubation with horseradish peroxidase–conjugated anti-IgG (secondary antibody);
3-amino-9-ethyl carbazole substrate was used to develop red spots. *, P ¼ 0.05 and **, P ¼ 0.08 (two tailed t-test). Data are from an experiment repeated
once (error bars, s.e.m. of four mice per group).
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Figure 3 Normal B cell distribution and natural antibody concentrations in
Slc3a2f/fCD19-Cre+ mice. (a) Flow cytometry of B cell subsets from the
spleen, bone marrow and peritoneum of adult Slc3a2f/fCD19-Cre+ and
control Slc3a2f/fCD19-Cre– mice 8–12 weeks of age. Foll, follicular; MZ,
marginal zone. Data are from an experiment repeated once with similar
results (error bars, s.e.m. of four mice per group). (b) Secondary lymphoid
architecture of frozen spleen sections from Slc3a2f/fCD19-Cre+ and
littermate control Slc3a2f/fCD19-Cre– mice, stained to detect B220+ B
cells, metallophilic macrophages that outline the marginal zone (MOMA-1+),
T cells (CD5+) and germinal center B cells (positive for binding of peanut
agglutinin (PNA)). Original magnification, "10. Results are representative of
three experiments. (c) Sandwich ELISA of total natural IgM in the serum of
naive adult Slc3a2f/fCD19-Cre+ and control Slc3a2f/fCD19-Cre– mice 8–12
weeks of age. P ¼ 0.11 (two-tailed t-test). Data are from one experiment
(error bars, s.e.m. of 30 mice per group).
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mice did undergo one to two divisions in response to stimulation
with a high dose of LPS (Fig. 5a). However, those divided cells
expressed CD98hc (Fig. 5b), which suggests that they had escaped
Cre-mediated deletion of Slc3a2. Thus, CD98hc is necessary for the
rapid proliferation of mature B cells in response to antigen or other
mitogenic signals. In the absence of stimulation, the lack of CD98hc
did not appreciably alter the viability of cultured B cells (Supplemen-
tary Fig. 8), which suggests that the low CD98 expression in the
resting state is not required for B cell survival. Thus, CD98hc is crucial
for the rapid B cell population expansion and plasma cell formation in
response to external stimuli that drive adaptive humoral immunity.
CD98hc has two well documented biochemical functions. First, it
interacts with certain integrin b-subunits to mediate integrin signal-
ing6,23 and therefore influences adhesion-induced signaling events
such as activation of the kinases pp125FAK, PI(3)K and Akt and the
adhesion molecule p130CAS, which control cell proliferation7. In
addition, by associating with CD98 light chains such as Lat-1,
CD98hc facilitates the transport of amino acids such as leucine and
isoleucine4,5. These amino acids are important regulators of mTOR24,
a critical ‘node’ in a signaling pathway that controls immune
responses8,9. Chimeric constructs in which portions of CD98hc are
replaced with portions of CD69, another type II transmembrane
protein, allow distinct separation of these two CD98hc functions17
(Fig. 6a). We used such chimeras to identify the mechanism whereby
CD98hc enables B cell proliferation.
To study the function of these chimeras in primary B cells, we
infected bone marrow from Slc3a2f/fCD19-Cre+ mice with retrovirus
containing bicistronic mRNA encoding either human CD98hc or a
human CD98-CD69 chimera followed by an internal ribosomal entry
site and a cassette encoding green fluorescent protein (GFP). We used
these transduced bone marrow cells to reconstitute lethally irradiated
recipient mice to create mice in which B cells that developed and
continued to express a human CD98-CD69 chimera were marked by
GFP fluorescence (Fig. 6a and Supplementary Figs. 9 and 10a
online). Staining with an antibody specific for mouse CD98hc enabled
us to identify B cells that lacked mouse CD98hc but expressed
retrovirus-encoded human CD98hc chimeras; these cells were present
in the blood beginning as early as 3 weeks after bone marrow transfer.
Furthermore, all B cells that expressed GFP also stained for either
human CD98hc or CD69 (Supplementary Fig. 10b). At 6 weeks after
bone marrow transfer, we purified resting CD98hc-null mouse splenic
B cells, labeled them with the membrane dye DiD to monitor
proliferation and stimulated them with LPS. Then, 4 d later, we
analyzed proliferation by means of flow cytometry assessing dye
dilution (Fig. 6b). We found proliferation of B cells reconstituted
with full-length human CD98hc or with the integrin-interacting
chimera C98T98E69 (consisting of the cytoplasmic (C) domain of
CD98hc, the transmembrane (T) domain of CD98hc and the extra-
cellular (E) domain of CD69). In contrast, the C98T69E98 chimera,
which interacts with Lat-1 and mediates isoleucine transport but does
not interact with integrins, failed to reconstitute proliferation. Thus,
the integrin-signaling portion of CD98hc is necessary and sufficient
for the proliferation of mature B cells.
Loss of CD98hc inhibits integrin-dependent events
Integrin ligation leads to signals that result in cell spreading and
migration25. In addition, integrins act in synergy with certain tyrosine
kinase receptors to prolong and sustain activation of the mitogen-
activated protein kinase Erk1/2, which promotes cell proliferation26 by
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Figure 5 Proliferation of splenic B cells from Slc3a2f/fCD19-Cre+ mice.
(a) Flow cytometry of the proliferation of B cells (CD43 and CD98 deficient)
purified from splenocytes of Slc3a2f/fCD19-Cre+ and littermate control
Slc3a2f/fCD19-Cre– mice 8–12 weeks of age, then labeled with CFSE and
left unstimulated (resting cells; open histograms) or cultured with various
stimuli (left margin) for 5 d at a density of 4 " 105 cells per well in 48-well
plates (filled histograms), assessed by CFSE dilution. a-, anti-. Data are
from one mouse in one experiment (representative of three mice of each
genotype), repeated twice with additional mice. (b) Two-parameter flow
cytometry of CD98hc expression on CFSElo (dividing) and CFSEhi
(nondividing) cells after stimulation with LPS. Data are from an experiment
repeated once.
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Figure 6 Mechanism by which CD98hc enables B cell proliferation.
(a) CD98-CD69 chimeric constructs encoded by retroviruses. Cyt,
cytoplasmic domain; TM, transmembrane domain; 98, CD98; 69, CD69.
(b) Two-parameter flow cytometry to assess the proliferation of B cells (CD43–
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or cultured with LPS (at a density of 3.5 " 105 cells per well in a 48-well
plate; filled histograms), measured as DiD dilution; fewer dots (right)
indicate lack of proliferation. Data are from an experiment repeated twice.
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downregulating cyclin-dependent kinase inhibitors27 and facilitating
progression through the G1 phase of the cell cycle28,29. B cells from
Slc3a2f/fCD19-Cre+ mice had less phosphorylation of Erk1/2 at 17 h
after BCR ligation (Fig. 7a). In contrast, early activation (o1 h) of the
kinases Erk1/2, Akt and Syk was intact in B cells lacking CD98hc
(Supplementary Fig. 11a–c online), as was the expression of activa-
tion markers (Supplementary Fig. 11d). However, coincident with a
failure to sustain Erk1/2 activation, Slc3a2f/fCD19-Cre+ B cells showed
impaired downregulation of the cyclin-dependent kinase inhibitor p27
(Fig. 7b), consistent with the observed lack of proliferation. Thus,
the absence of CD98hc selectively impairs sustained activation of
Erk1/2 after BCR ligation, an event known to depend on integrins in
other cell types.
To directly assess the effect of CD98hc deficiency in B cells on
another integrin-dependent function, we used a B cell adhesion and
spreading assay30,31. Activated B cells from Slc3a2f/fCD19-Cre+ mice
failed to spread after direct antibody-mediated ligation of the integrin
aLb2 (LFA-1; Fig. 7c). In contrast, CD98hc-bearing B cells from their
Slc3a2f/fCD19-Cre– littermates spread extensively, as shown by their
twofold larger cell area and perimeter relative to that of the CD98hc-
deficient B cells. In sum, these data point to the potential importance
of integrin signaling in B cell proliferation.
As an initial test of that idea, we analyzed responses to crosslinking
of the B cell antigen receptor on B cells from mice engineered to lack
all leukocyte integrins32. Even though some of these B cells expressed a
small quantity of integrin b1, they showed less proliferation in
response to BCR ligation (Supplementary Fig. 12 online), which
provides direct evidence of the involvement of integrins in B cell
proliferation. The occurrence of some proliferation of these B cells
raises the possibility that the loss of amino acid transport resulting
from CD98hc deficiency may also contribute to the more profound
defect in proliferation of CD98hc-deficient B cells.
CD98hc confers a selective advantage on B cells
During T cell–dependent responses, antigen-specific B cell populations
expand in germinal centers in competition for limited antigen33. The
experiments reported above indicated that CD98hc conferred a strong
selective advantage during B cell population expansion in vitro. To
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Figure 7 Integrin signaling defects in B cells lacking CD98hc.
(a) Immunoblot analysis (top) of Erk1/2 phosphorylation (p-Erk) in B cells
(CD43–CD98–) purified from splenocytes of Slc3a2f/fCD19-Cre+ mice
(n ¼ 4) and littermate control Slc3a2f/fCD19-Cre– mice (n ¼ 3) 8–12 weeks
of age and stimulated for 17 h with anti-IgM (30 mg/ml) and IL-4 (15 ng/ml),
then immediately washed with ice-cold PBS and lysed. Faint bands are
present in the Slc3a2f/fCD19-Cre+ lanes. Each lane represents one mouse.
(b) Immunoblot analysis (top) of p27 in B cells purified from Slc3a2f/fCD19-
Cre+ or littermate control Slc3a2f/fCD19-Cre– mice and stimulated for 0, 12
or 24 h with anti-IgM and IL-4, then washed and lysed (intervening bands
are omitted for clarity). Below (a,b), staining of phosphorylated Erk1/2 (a) or
p27 (b) normalized to that of total Erk. Data in a,b are from an experiment
repeated once (error bars, s.e.m. of three mice per group). (c) Integrin-
dependent spreading of B cells purified from Slc3a2f/fCD19-Cre+ mice
(right) or littermate control Slc3a2f/fCD19-Cre– mice (left), then stimulated
for 24 h with anti-CD40 and IL-4 and plated for 16 h on anti-LFA-1.
Original magnification, "40. Data are from an experiment repeated once
(error bars, s.e.m. of 30 cells per group). *, P o 0.015 (two-tailed t-test).
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Figure 8 Selection for CD98hc+ B cells during activation. (a) Flow cytometry
of in vivo CD98hc expression (filled histograms) on B cells isolated from
spleens of Slc3a2f/fCD19-Cre+ and control Slc3a2f/fCD19-Cre– mice
immunized with the T cell–dependent antigen TNP-KLH in CFA (one half
of each spleen is used here). Open histograms, isotype-matched control
antibody. max, maximum. (b) Microscopy of frozen sections of the remaining
halves of the spleens in a, stained for B220 and CD98hc to assess selection
of CD98hc+ B cells in vivo; germinal centers were verified by staining with
peanut agglutinin. Original magnification, "10. Data in a,b are from one
representative mouse of each genotype in an experiment repeated once
(n ¼ 3 mice per group). (c) Flow cytometry of CD98hc expression on splenic
B cells purified from Slc3a2f/fCD19-Cre+ mice without depletion of
CD98hc+ cells or from control Slc3a2f/fCD19-Cre– mice, assessed before
(resting; left) and after (right) culture for 4 d with LPS, and stained for
B220, CD98hc and CD138 (plasma cell marker) to assess selection of
CD98hc+ B cells in vitro. Numbers above bracketed lines indicate percent
CD98hc+ cells. Data are from one mouse in an experiment repeated twice
(n ¼ 3 mice per group).
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measure that advantage in vivo, we immunized Slc3a2f/fCD19-Cre+
mice with trinitrophenyl–keyhole limpet hemocyanin (TNP-KLH), a
T cell–dependent antigen, and analyzed CD98hc expression on splenic
B cell subsets. In this experiment, CD98hc was present on less than
10% of resting splenic B cell subsets (Fig. 8a). However, during the
germinal center response, B cells undergo a proliferative burst and are
selected for the ability to bind antigen with high affinity. At this stage,
the percentage of CD98hc-expressing cells in the Slc3a2f/fCD19-Cre+
mice increased from less than 10% to 40% (Fig. 8a). Furthermore,
after class switching, over 99% of plasma cells in Slc3a2f/fCD19-Cre+
mice had detectable surface expression of CD98hc (Fig. 8a). Thus,
there were no detectable CD98-null plasma cells in Slc3a2f/fCD19-
Cre+ mice; these observations are consistent with our in vitro finding
that CD98hc was required for the rapid proliferation of mature B cells
and subsequent formation of plasma cells.
Slc3a2f/fCD19-Cre+ mice had considerably fewer germinal center
B cells and plasma cells than Slc3a2f/fCD19-Cre– mice had at 1 week
after immunization (data not shown), probably because they had far
fewer CD98hc-expressing precursor cells able to proliferate in germ-
inal centers and form plasma cells. However, at 2–3 weeks after
immunization, titers of antibodies specific for TNP-KLH in Slc3a2f/f
CD19-Cre+ mice were similar to those in Slc3a2f/fCD19-Cre– mice,
probably because of germinal center selection for the few pre-existing
CD98hc-expressing antigen-specific B cells (Supplementary Fig. 13
online). This strong selection for CD98hc-expressing B cells can thus
account for the relatively modestly lower basal serum IgG concentra-
tions in Slc3a2f/fCD19-Cre+ mice. Immunohistochemical staining for
CD98hc in spleens of immunized mice confirmed that, in contrast to
the surrounding follicular B cells, germinal center B cells in Slc3a2f/f
CD19-Cre+ mice expressed CD98hc (Fig. 8b). In vitro analysis of B
cells purified from Slc3a2f/fCD19-Cre+ mice without depletion of
CD98-expressing cells provided further confirmation of the strong
selective advantage conferred by CD98hc; after 4 d in culture, 99% of
plasma cells expressed CD98hc (Fig. 8c).
CD98hc is upregulated 20- to 30-fold after B cell activation, and we
have shown here that CD98hc was required for B cells to proliferate
and to differentiate into plasma cells. Hence, we propose that upregu-
lation of CD98hc can serve as a checkpoint in the progression to
humoral immunity. Consequently, the expression and function of
CD98hc are potential targets for the modulation of antibody responses.
DISCUSSION
CD98hc was one of the earliest lymphocyte activation antigens
described3, yet its function in the immune response has remained
obscure. Although studies in which T cells were treated with anti-
CD98hc in vitro20,21,34 have suggested that CD98hc is involved in
T cell activation, the function of CD98hc in lymphocytes in vivo has
remained unknown. Here we have shown that CD98hc is absolutely
required for the rapid B cell clonal proliferation necessary for their
subsequent differentiation into antibody-secreting plasma cells. Con-
sequently, higher CD98hc expression provides antigen-stimulated
B cells with a profound selective advantage.
The linkage of the integrin-binding function of CD98hc to B cell
proliferation suggests a new paradigm for the function of integrin
signaling in lymphocytes. In addition to functioning in hematopoiesis,
trafficking and the formation of immune synapses16,35–39, our work
has indicated that integrin signaling is involved in clonal proliferation
during immune responses. CD98hc serves two cellular functions; the
first is amino acid transport, through interaction with one of several
CD98 light chains4,5. The extracellular domain of CD98hc is respon-
sible for this function, and reconstitution with a chimeric protein
containing this domain of CD98hc was not sufficient to restore the
proliferation of CD98-null B cells. The second main function of
CD98hc is mediating integrin signaling6,7. The transmembrane and
cytoplasmic domains of CD98hc are necessary for interaction with
integrin b-subunits, which leads to pp125FAK-dependent activation of
Akt by PI(3)K and p130CAS-mediated activation of the small GTPase
Rac7. Reconstitution with a chimeric protein that contained only the
transmembrane and cytoplasmic portions of CD98hc was sufficient to
restore the proliferation of CD98hc-null B cells.
Integrins can act together with immunoreceptors, using similar
‘downstream’ signaling proteins, to promote lymphocyte proliferation
and activation40. Thus, our findings establish a nexus of CD98hc-
dependent integrin and immunoreceptor signaling pathways that
regulate the proliferation of lymphocytes. CD98hc could function
by allowing integrins to lower the threshold for cellular activation41
by efficiently organizing components of the immunological
synapse; however, we found that CD98hc was not required for early
activation events. Instead, our data support a mechanism whereby
CD98h-mediated integrin signals can extend the kinetics of
immunoreceptor signals42 to the point of driving cell division and
clonal expansion.
Integrins drive fibroblast proliferation by sustaining Erk activation.
Without integrin-mediated adhesion, growth factor signals are tran-
sient and are unable to downregulate cyclin-dependent kinase inhibi-
tors such as p27, and cells fail to exit the G1 phase of the cell
cycle26,28,29. Our data have indicated that a similar mechanism is
operative in B cells. CD98hc-deficient B cells were able to generate
early B cell antigen receptor signals but could not sustain late Erk1/2
signaling or downregulate p27 and failed to divide. The inability of
CD98hc-deficient B cells to spread on integrin-specific antibodies
confirmed the integrin signaling defect of CD98hc-deficient B cells.
Published work using supported lipid bilayers or plate-bound anti-
bodies30 to study the formation of immunological synapses has shown
that B cells spread rapidly after activation of the B cell antigen receptor
in an integrin-dependent way30,43; we have now shown that this
spreading is CD98hc dependent. Thus, CD98hc could promote
integrin-dependent changes in cell shape that might stabilize interac-
tions with antigen-bearing cells.
One implication of our work relates to the origin of the adaptive
immune system. CD98hc orthologs first appeared in primitive verte-
brates10, as did sequences in integrin b-cytoplasmic domains that
permit CD98hc to interact with integrins44. The coincidence of those
events with the appearance of adaptive immunity2,10 suggests that the
survival advantage conferred by adaptive immunity was among the
factors that favored the maintenance of CD98hc and its ability to
mediate integrin signaling. CD98hc is overexpressed in many cancers
and mediates tumorigenesis7,45–47. In particular, published work has
emphasized the importance of integrin signaling25 in the development
and maintenance of epithelial cancers48,49 and of CD98hc in poten-
tiating the growth of cancer cells7,47. Thus, the appearance of CD98hc
in vertebrates, which enabled an adaptive immune response, may have
led to greater susceptibility to cancer.
METHODS
Mice. Mice with floxed Slc3a2 were generated by flanking of exons 1 and 2,
which encode the transmembrane portion of CD98hc, with loxP sites12. The
neomycin-selection cassette used to select embryonic stem cell clones positive
for a floxed Slc3a2 allele was flanked by Flp sites and thus was excised when
mice with floxed Slc3a2 were bred with human b-actin FLPe deleter mice
(Jackson Laboratories). Slc3a2f/fCD19-Cre+ mice were the result of crossing
Slc3a2f/f with the CD19-Cre+ strain13. Slc3a2f/+CD19-Cre+ offspring were
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identified by PCR and were backcrossed with Slc3a2f/f mice to create mice
heterozygous for CD19-Cre and homozygous for the Slc3a2 floxed allele
(Slc3a2f/fCD19-Cre–). This littermate comparison was used wherever possible.
For Supplementary Figures 2 and 4, the offspring of Slc3a2+/– " Slc3a2f/f
CD19-Cre+ matings were used. All mice were housed at the University of
California San Diego animal facility, and all experiments were approved by the
Institutional Animal Care and Use Committee. ‘Pan-integrin’-deficient mice
were generated as described32. Integrins were ablated by crossing of Itgb1flf,
Itgavflf, Itgb2–/– or Itgb7–/– mice (deficient in integrin b1, aV, b2 or b7,
respectively) with mice carrying an Mx1-Cre transgene. Cre expression in
hematopoietic cells was induced by intraperitoneal injection of 250 mg poly-
inosinic-polycytidylic acid (Amersham Biosciences); 8 d later, mice were used
for B cell–proliferation assays.
Flow cytometry of B cell subsets. Bone marrow cells were prepared by
dissection of femur and tibia bones from adult Slc3a2f/fCD19-Cre+ mice
(10–20 weeks of age) and flushing with media with a 23-gauge needle. After
two passages through the 23-gauge needle, erythrocytes were lysed for 8 min at
25 1C with ammonium chloride–potassium bicarbonate lysis buffer (Biowhit-
taker). Splenic single-cell suspensions were prepared by dissociation of whole
spleens with a 7-ml tissue grinder (Kontes) and lysis of erythrocytes as
described for bone marrow. Cells from peritoneal lavage were isolated from
adult mice by flushing of the peritoneum with 10 ml complete medium (RPMI
medium and 10% (vol/vol) FBS, supplemented with L-glutamine, penicillin
and streptomycin) in batches of 1–2 ml. After being counted, bone marrow,
spleen, or peritoneal cells were stained in 100 ml staining buffer (0.5% (wt/vol)
BSA in PBS) containing fluorochrome-conjugated antibody to mouse B220
(RA3-6B2), IgM (II/41), CD21 (7G6), CD23 (B3B4), CD98hc (RL388), GL7
(GL7), CD138 (281-2) or Fas (Jo2) at optimal concentrations (all from BD
Biosciences). After incubation of cells on ice for 30–45 min, followed by three
washes in staining buffer, subsets were analyzed by flow cytometry with a
FACSAria or FACSCalibur (BD Biosciences).
Immunohistochemistry. For analysis of CD98 selection after immunization,
adult Slc3a2f/fCD19-Cre+ mice and littermate control (Slc3a2f/fCD19-Cre–)
mice were immunized intraperitoneally with 100 mg TNP-KLH (Biosearch)
emulsified in CFA (250 ml). Then, 7 d later, spleens were embedded in Tissue-
Tek optimum cutting temperature compound (Sakura Finetek USA) and were
frozen at #80 1C. Sections 8 mm in thickness were mounted on microscope
slides, were fixed for 10 min in cold acetone, were blocked for 1 h with blocking
buffer (0.5% (wt/vol) BSA in PBS), and were stained for 1 h at 25 1C with
fluorescein isothiocyanate–conjugated peanut agglutinin (FL-1071; Vector
Labs) and anti-B220 (BRA3-6B2), anti-CD5 (53-7.3), anti-CD3 (145-2C11)
or anti-CD98 (RL388; all from BD Biosciences) or anti-MOMA-1 (MOMA-1;
BaChem). After being washed with PBS containing 0.5% (vol/vol) Tween,
sections were covered with Gel/Mount (Biomeda) and were sealed with glass
coverslips. Images were acquired with Zeiss Axiocam M1 microscope (Zeiss)
and Slidebook software (Intelligent Imaging Innovations).
Antibody analysis. For antigen-specific antibody responses, adult Slc3a2f/f
CD19-Cre+ and control littermate Slc3a2f/fCD19-Cre– mice were injected
intraperitoneally with 50 mg TNP-LPS (Sigma) in 250 ml PBS (T cell–
independent antigen) or 100 mg TNP-KLH (Biosearch) emulsified in 250 ml
CFA (T cell–dependent antigen). Blood serum was collected by centrifugation
of tail vein blood (100–200 ml with a solution of 1–2 mM EDTA as an
anticoagulant) before and 1, 2 and 3 weeks after immunization. Concentrations
of TNP-specific antibody in blood sera were assessed by direct enzyme-linked
immunosorbent assay (ELISA) with TNP-ovalbumin as the coating antigen and
alkaline phosphatase–conjugated polyclonal anti–mouse IgG (A4312; Sigma),
polyclonal anti–mouse IgM (A7784; Sigma) or monoclonal anti–mouse IgG3
(R40-82; BD Biosciences) as the detection antibody. Because of inconsistencies
in commercially available anti-TNP standards, the ELISA data in Figure 2 and
Supplementary Figure 13 were quantified by multiplication of the absorbance
‘reading out’ of three to four dilutions of sample that was in the linear portion
of the assay with the dilution factor to obtain the values presented. Concentra-
tions of circulating IgG and IgM from naive mice and from in vitro
splenic B cell stimulations were measured by sandwich ELISA with polyclonal
anti–mouse IgG (715-005-150) or anti–mouse IgM (115-006-020; both from
Jackson Immunoresearch), the detection antibodies described for the direct
ELISA and standard curves obtained with purified polyclonal IgG or IgM.
In vitro proliferation and differentiation of resting B cells. Resting B cells
(defined as CD43–) were purified from spleen cell suspensions of
Slc3a2f/fCD19-Cre+, ‘pan-integrin’-deficient or wild-type control mice by
depletion of CD43+ cells (and depletion of CD98hc+ B cells for Slc3a2f/f
CD19-Cre+ mice or depletion of b1 integrin–positive cells for ‘pan-integrin’-
deficient mice) with B cell magnetic beads (Dynal). Purity was routinely 95–
98%, as assessed by staining with anti-B220 (RA3-6B2) or anti-CD43 (eBioR2-
60) and flow cytometry. Resting B cells were plated in 48-well plates at a density
of 4 " 105 cells per well and were stimulated for 3–5 d with Ultrapure LPS
(20 mg/ml; InVivoGen), F(ab¢)2 goat anti–mouse IgM (30 mg/ml; Jackson
Immunoresearch), anti-CD40 (2 mg/ml; 3/23; BD Biosciences) or recombinant
mouse IL-4 (50 ng/ml; Peprotech). Unstimulated resting cells were cultured
with medium alone. Staining with anti-CD138 (DL-101; eBioscience), anti-
IgG3 (R40-82; BD Biosciences) and anti-B220 (RA3-6B2; eBioscience) and
flow cytometry were used to assess class switching and differentiation
into plasma cells. For measurement of proliferation, purified resting B cells
were labeled with 2 mM CFSE (carboxyfluorescein diacetate succinimidyl
ester; Molecular Probes) and were analyzed by flow cytometry at 3–5 d
for dilution of fluorescence (cell division). Because the extent of CFSE
labeling varied among samples, unstimulated cells were also assessed (Supple-
mentary Fig. 12). For some differentiation or proliferation experiments,
cells were also stained with anti-CD98 (RL388; eBioscience). Propidium
iodide exclusion and automated counting by flow cytometry were used for
analysis of the expansion of cell populations. In this in vitro culture system,
many cells die or are lost during collecting or staining and a smaller subset
divides rapidly.
Retroviral infection of mouse bone marrow and transplantation into
recipient mice. The bone marrow transplant protocol was from S. Rowland
in the lab of R. Pelanda. Donor mice were treated intraperitoneally with 5-
fluorouracil (Adrucil; Sicor Pharmaceuticals) in 200 ml PBS at a dose of 4 mg
per mouse. Then, 3 d later, EcoPack 293 packaging cells (Imgenex) were
transfected with pCl-Eco (Imgenex) and one of four retroviral constructs
(C98T98E98, C98T69E98, C98T98E69 or C69T69E69, on a backbone of
MSCV-IRES-GFP)50, followed by culture for 48 h. On day 4, donor mice were
killed and bone marrow was cultured overnight in complete medium contain-
ing IL-3 (25 ng/ml), IL-6 (50 ng/ml) and stem cell factor (50 ng/ml; all from
Peprotech). Viral supernatants were collected from packaging cells on day 5 and
were used to ‘spin-infect’ bone marrow on days 5 and 6 for 90 min at 1,000g
and at 25 1C. Bone marrow cells were collected on day 7 and were injected
intravenously at a dose of 2.5 " 105 cells in 100 ml PBS per mouse. Small
samples were retained and were stained with antibody to Sca-1 (D7;
eBioscience), a marker of stem cells. In all samples, 24–29% of Sca-1+
populations were GFP+ before injection. At 6–8 weeks after transplantation,
resting B cells deficient in mouse CD98hc were purified from spleens of
recipient mice, then were labeled and were stimulated with LPS. Proliferation
and plasma cell differentiation was assessed as described above but with DiD
(1,1¢-dioctadecyl-3,3,3¢,3¢-tetramethylindodicarbocyanine; Molecular Probes),
which emits in a range distinct from that of GFP.
Additional methods. Information on hematology, enzyme-linked immunospot
assays, spreading assays, signaling and statistical analysis is available in the
Supplementary Methods online.
Accession code. UCSD-Nature Signaling Gateway (http://www.signaling-
gateway.org): A000262.
Note: Supplementary information is available on the Nature Immunology website.
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Summary
Increased ligand binding to cellular integrins (‘‘activation’’)
plays important roles in processes such as development,
cell migration, extracellular matrix assembly, tumor metas-
tasis, hemostasis, and thrombosis [1–5]. Integrin activation
encompasses both increased integrin monomer affinity
and increased receptor clustering [6] and depends on
integrin-talin interactions [5]. Loss of kindlins results in
reduced activation of integrins [7–13]. Kindlins might pro-
mote talin binding to integrins through a cooperative mech-
anism [5, 14–16]; however, kindlins do not increase talin
association with integrins [17]. Here, we report that, unlike
talin head domain (THD), kindlin-3 has little effect on the
affinity of purified monomeric aIIbb3, and it does not
enhance activation by THD. Furthermore, studies with li-
gands of varying valency show that kindlins primarily
increase cellular aIIbb3 avidity rather thanmonomer affinity.
In platelets or nucleated cells, loss of kindlins markedly
reduces aIIbb3 binding to multivalent but not monovalent
ligands. Finally, silencing of kindlins reduces the clustering
of ligand-occupied aIIbb3 as revealed by total internal
reflection fluorescence and electron microscopy. Thus, in
contrast to talins, kindlins have little primary effect on in-
tegrin aIIbb3 affinity for monovalent ligands and increase
multivalent ligand binding by promoting the clustering of
talin-activated integrins.
Results
Kindlin-3 Has a Minimal Effect on the Affinity of Monomeric
aIIbb3
To assess the effect of kindlins on individual integrins, we
added purified kindlin-3, the isoform in platelets, to mono-
meric platelet integrin aIIbb3 inserted in 10–12 nm diameter
phospholipid bilayers (nanodiscs) [18]. Since aIIbb3 clustering
cannot occur under these conditions, ligand bindingmeasures
the affinity of integrin monomers [18]. Recombinant purified
kindlin-3 was monomeric (see Figure S1A available online)
and was well folded as judged by a sharp melting point
(48!C) in differential scanning calorimetry (data not shown).
Kindlin-3, at a concentration that saturated b3 integrin binding
[14, 17], was >25-fold less active than talin head domain (THD)
in increasing binding of PAC1, an activation-specific antibody,
to aIIbb3 nanodiscs, and it failed to enhance PAC1 binding
induced by THD (Figures 1A and S1B). Indeed, kindlin-3
reduced THD-induced PAC1 binding, possibly due to compe-
tition between THD and kindlin-3 for binding to the limited lipid
surface present in the nanodiscs, rather than to the b3 integrin
[14, 17]. Recombinant kindlin-3 bound to the b3 cytoplasmic
domain (Kd = 676 9 nM), but not to a kindlin binding-defective
b3mutant [b3(Y759A); Figure S1C]. Kindlin-3 also bound aIIbb3
nanodiscs (Figure S1D). Thus, in contrast to THD, recombinant
kindlin-3 did not increase the ligand-binding affinity of mono-
meric aIIbb3 in nanodiscs.
Kindlins Selectively Increase the Binding of Multivalent
Ligands to Recombinant Integrin aIIbb3
The foregoing results suggest that kindlin-3may regulate ligand
binding to integrins by a mechanism other than modulation of
monomer affinity. Platelet activation clusters integrin aIIbb3,
and aIIbb3 dimerization can cooperate with increased mono-
mer affinity to increase thebinding ofmultivalent but notmono-
valent ligands [6, 20, 21]. These observations led us to compare
the effects of kindlins on the binding of multivalent versus
monovalent ligands. Kindlin-1 and kindlin-2 are thought to pro-
mote aIIbb3 activation in nonhematopoietic cells via a mecha-
nism similar to that of kindlin-3 in platelets and are thus used
to study aIIbb3 regulation in such cells [11–13, 22]. Kindlin-1
did not synergize with THD to increase monovalent PAC1 Fab
binding to integrin aIIbb3 in HEK293 cells but dramatically
increasedTHD-inducedbindingofdecavalentPAC1(Figure1B).
To extend this finding, we used the monovalent fibronectin
tenth type III repeat (3FN10), an activation-dependent ligand
for integrin aIIbb3 [23], because it can be expressed in prokary-
otic systems at the high concentrations required for this exper-
iment, can be directly labeled (e.g., with biotin), and binds to
murineaIIbb3. Again, kindlin-1 did not synergizewith THD to in-
crease the specific binding of 3FN10 to integrin aIIbb3,
measured as binding inhibitable by an aIIbb3-specific antago-
nist, eptifibatide (Figures 1C and S1E). 3FN10 binding was not
maximal in the THD-transfected cells, because addition of
Mn2+ markedly increased binding (Figure 1C). Mn2+ enhanced
THD-induced 3FN10 binding, indicating that Mn2+ binding to
the extracellular domain can synergize with talin to increase in-
tegrinmonomer affinity. In sharpcontrast to resultswith 3FN10,
kindlin-1markedlysynergized [13,22]withTHD in thebindingof
decavalent PAC1 immunoglobulin M (IgM) (Figures 1C and
S1E). The increase of PAC1 binding upon THD expression
was greater than that observed with monomeric 3FN10, prob-
ably reflecting both the clustering [24] and conformational
changes [18] of aIIbb3 induced by THD.
To directly test the role of ligand valency in 3FN10 binding,
we chemically crosslinked 3FN10 and isolated a mixed
population of oligomers. In contrast to monovalent 3FN10 or
GST-3FN10, kindlin-1 and kindlin-2 markedly increased the
capacity of THD to enhance the specific binding of multivalent
GST-3FN10 to aIIbb3 (Figure 1D). Mutation of the RGD
sequence in 3FN10 to AAA abolished the binding of both
monomeric and oligomeric 3FN10 (Figure S1F), confirming its
4Present address: Division of Surgical Research, Alpert Medical School,
Brown University, Providence, RI 02903, USA
*Correspondence: mhginsberg@ucsd.edu
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specificity. The kindlin-induced increase in multivalent ligand
binding was independent of an intact actin cytoskeleton or
myosin II-mediated contractility, as latrunculin A, an inhibitor
of actin polymerization, or blebbistatin, a myosin II ATPase
inhibitor, was without effect (Figure S1G). Thus, kindlins syner-
gized with THD in stimulating the binding of multivalent but not
monovalent ligands to aIIbb3, and this effect required neither
an intact actin cytoskeleton nor myosin II-driven contractility.
Silencing of Kindlin-2 Selectively Inhibits the Binding of
Multivalent Ligands to Recombinant Integrin aIIbb3
We then asked whether depletion of kindlins selectively
impairs binding of multivalent integrin ligands. HEK293 cells
express both kindlin-1 and kindlin-2 [25], making it difficult to
perform small interfering RNA (siRNA)-mediated silencing.
Thus, we turned to Chinese hamster ovary (CHO) cells, which
express only kindlin-2 [13, 17]. In CHO cells expressing an
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Figure 1. Kindlins Selectively Increase the Binding of Multivalent Ligands to Recombinant Integrin aIIbb3 Cells, but Not to Monomeric Integrins, in
Nanodiscs
(A) Activation of aIIbb3 in nanodiscs was assayed by PAC1 binding as described in the Supplemental Information. Increase in integrin activation is
calculated as (Li–L0), where Li is the eptifibatide-inhibitable PAC1 binding (luminescence) in the presence of THD (2.5 mM), kindlin-3 (2.5 mM), or
THD+kindlin-3 and L0 is PAC1 binding to integrin nanodiscs alone, which was 535,000 arbitrary units. Error bars indicate 6SEM of three independent
determinations.
(B) HEK293 cells stably expressing aIIbb3 were transfected with cDNA encoding kindlin-1, THD, or kindlin-1+THD. Twenty-four hours after transfection,
cells were harvested, split into three groups, and stained separately with PAC1, PAC1Fab, or D57 (anti-aIIbb3). Cells were then fixed in 3.7% formalde-
hyde. The quantity of PAC1 (decavalent), PAC1Fab (monovalent), or D57 bound was assayed by APC-conjugated anti-IgM (m chain specific) and anti-IgG
and analyzed by flow cytometry. The aIIbb3-specific ligand binding was calculated as described in the Supplemental Information. The right panel
shows the western blots confirming the abundance of expressed proteins in the transfected cells. Error bars indicate 6SEM of three independent
experiments. PAC1 Fab was purified by gel filtration to remove protein aggregates and used at a concentration at least 25-fold higher than that used
by Bunch [19].
(C) HEK293 cells stably expressing aIIbb3were transfected with cDNA encoding kindlin-1, THD, or kindlin-1+THD. The cells were processed as described in
(B), and the binding of PAC1 (decavalent), D57, or 3FN10 (GST removed, monovalent) was assayed. The aIIbb3-specific ligand binding was calculated as
described in the Supplemental Information. Error bars indicate 6SEM of four independent experiments.
(D) HEK293 cells stably expressing aIIbb3were transfected with cDNA encoding kindlin-1, THD, or kindlin-1+THD. The cells were harvested, and the binding
of D57, biotinylated 3FN10 monomer (with GST removed), GST-3FN10, or oligomeric GST-3FN10 was then assayed. Depicted is the aIIbb3-specific ligand
binding as described in the Supplemental Information. Error bars indicate 6SEM of four independent experiments.
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active aIIbb3(D723R) mutant [26], silencing kindlin-2 inhibited
the binding of oligomeric 3FN10, but it had no effect on
the binding of monovalent 3FN10. This was a specific effect,
as reintroducing small hairpin RNA (shRNA)-resistant
kindlin-2 restored the binding of oligomeric 3FN10 (Fig-
ure 2A). Moreover, kindlin-2 depletion resulted in similar
selective inhibition of oligomeric but not monomeric 3FN10
binding to an active integrin chimera expressed in CHO
cells [27, 28](Figure S2A). Furthermore, adhesion of aIIbb3-
expressing CHO cells to surface-bound 3FN10, which is
functionally multivalent, was reduced in kindlin-2-silenced
cells (Figure S2B). Thus, kindlin-2 silencing inhibits binding
of multivalent but not monovalent ligands to aIIbb3 ex-
pressed in nucleated cells.
Kindlin-3-Deficient Platelets Are Primarily Defective in
Binding to Multivalent but Not Monovalent aIIbb3 Ligands
Next, we sought to determine how kindlins function in
regulation of aIIbb3 in platelets. Mice lacking kindlin-3 suffer
embryonic and perinatal lethality, recurrent infections, and
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Figure 2. Depletion of Kindlins Primarily Inhibits the Binding of Multivalent Ligands to Integrin aIIbb3 in Nucleated Cells and in Mouse Platelets
(A) Cells expressing an active aIIbb3(D723R) mutant were transduced with lentivirus expressing a GFP marker and either a scrambled shRNA (control) or
kindlin-2 shRNA1. To confirm the specificity of previously characterized kindlin-2 knockdown constructs [17], we transiently cotransfected shRNA1-
transduced cells with a shRNA-resistant human kindlin-2 and tdTomato as a transfection marker (at a 50:1 ratio of kindlin-2:tomato ). The cells were
then harvested, and binding of anti-aIIbb3 (D57), monomeric 3FN10 (with GST removed), or GST-3FN10 oligomers was used to measure the aIIbb3-specific
ligand binding as described in the Supplemental Information. Error bars indicate 6SEM of three independent experiments. Kindlin-2 expression level was
assessed by immunoblotting as shown in the right panel. The western blot was performed with total cells, whereas the only transduced (GFP-positive) and
transfected (tomato-positive) cells were analyzed for ligand binding by flow cytometry.
(B) Generation of chimeric mice as described in the Supplemental Information. For intracellular flow cytometry, platelets were fixed with 2% formaldehyde,
permeabilized, and stained with rabbit anti-kindlin-3 polyclonal antibody or biotinylated anti-talin monoclonal antibody (clone 8d4). After washing, bound
antibodies were detected with either FITC-anti-rabbit secondary antibody or APC-strepavidin, respectively. The dot plots show the reduced expression of
kindlin-3 and talin1 in DsRed-negative Fermt32/2 and Tln12/2 platelets, respectively.
(C) PAR4-stimulated binding of 3FN10 to platelets. Platelets from irradiatedmice reconstitutedwithmixtures of DsRed-expressing wild-type (WT) and either
Fermt32/2 or Tln12/2 hematopoietic stem cells were incubated in the presence of the indicated concentration of PAR4 agonist peptide or buffer. Eptifiba-
tide-inhibitable specific binding of 3FN10 (with GST removed) to aIIbb3 on DsRed-negative Fermt3–/– or Tln12/2 or DsRed-positive wild-type platelets was
assessed by fluorescence-activated cell sorting (FACS). Cells were separately stained with anti-CD41 (aIIb) to calculate ligand binding as described in the
Supplemental Information. 3FN10 at 100 mg/ml (9.4 mM) was used. In both (C) and (D), error bars indicate SEM (seven chimeric mice for each genotype).
(D) PAR4-stimulated binding of fibrinogen to platelets. In an experiment conducted on the same day as that described in (C), 3FN10 was replaced by
FITC-conjugated fibrinogen.
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erythrocyte defects in addition to reduced aIIbb3 functions
[8, 11, 29]. To examine the consequences of loss of kindlin-3,
encoded by the Fermt3 locus, in healthy adult mice, we
reconstituted irradiated mice with kindlin-3 or talin null
hematopoietic cells mixed with wild-type hematopoietic cells
expressing DsRed (Figure 2B). Intracellular staining of iso-
lated platelets indicated that kindlin-3 or talin was depleted
from the respective (DsRed negative) platelet population
(Figure 2B).
PAR4 thrombin receptor agonist peptide stimulated similar
binding of monovalent 3FN10 to aIIbb3 in both kindlin-3 null
and wild-type platelets, whereas loss of platelet talin-1 signif-
icantly inhibited 3FN10 binding (Figure 2C). In contrast, and
as expected [11, 30, 31], loss of either kindlin-3 or talin-1
impaired the binding of multivalent fibrinogen, which has at
least four potential aIIbb3 binding sites (Figure 2D). Further-
more, loss of kindlin-3 had little effect on either fibrinogen
or 3FN10 binding when platelets were activated exogenously
by Mn2+, consistent with previous reports that Mn2+ can pro-
mote both affinity increase [32, 33] and integrin clustering
[24, 34] (Figure S2C). Deletion of talin reduced binding of
3FN10 but not fibrinogen to Mn2+-stimulated platelets (Fig-
ure S2C), suggesting that talin binding synergizes with
Mn2+ in increasing integrin monomer affinity. At higher
agonist concentration (1 mM PAR4 peptide), the defect in
fibrinogen binding to kindlin-3 null platelets was even less
pronounced. To better quantify this result, we examined
binding of various concentrations of 3FN10 to wild-type or
kindlin-3 null platelets. The binding isotherms of 3FN10 to
wild-type and kindlin-3 null platelets virtually overlapped
(Figures S2D and S2F), indicating that a lack of kindlin-3
does not change the affinity of 3FN10 for aIIbb3 on activated
platelets or the capacity of a thrombin receptor agonist
peptide to stimulate increased binding of a monovalent
ligand to aIIbb3 (Figures S2E and S2F). Therefore, in
agonist-stimulated platelets, as in nucleated cells, lack of
kindlin-3 has a major effect on the binding of multivalent
but not monovalent aIIbb3 ligands, whereas lack of talin
has major effects on both ligand types.
Kindlins Promote Clustering of Occupied Integrins
Integrin clustering increases binding of multivalent ligands
without affecting the affinity of integrin aIIbb3 monomers
[6], suggesting that integrin clustering might account for
most of kindlins’ effects. We used total internal reflection
fluorescence (TIRF) microscopy, an established method for
studying clustering [24, 35], to measure aIIbb3 clustering at
the submicron scale. Initial cell adhesion to immobilized
fibrinogen is aIIbb3 activation independent [36, 37], possibly
due to increased ligand density and altered fibrinogen con-
formation [38], enabling us to examine effects of kindlins
independent of their effects on integrin activation per se.
Silencing of kindlin-2 with two different shRNAs significantly
reduced both the brightness and size of integrin puncta (Fig-
ures 3A, 3B, and 3D), even though it had little or no effect on
integrin expression (Figures 3A and 3C). Furthermore,
silencing of kindlin-2 by these shRNAs did not affect the dis-
tance of the plasma membrane from the substrate, since
fluorescence intensity of a membrane-intercalated dye was
equal in control and kindlin-2-silenced cells (Figures S3A
and S3B) in TIRF images.
To assess integrin clustering at the nanoscale, we used
electron microscopy to examine ventral membranes of
fibrinogen-adherent aIIbb3-expressing CHO cells [39]. In
control shRNA-transduced cells, we observed numerous clus-
ters, each containing more than five gold particles and usually
less than 200 nm in size, i.e., they account for the point sources
seen in the TIRF images (Figure 4A, left panel). In sharp
contrast, in kindlin-2-silenced cells, gold particles were pre-
sent; however, there were many fewer clusters (Figures 4A,
middle panel, and 4B). The total number of gold particles
was also reduced, likely reflecting an overall decreased abun-
dance of integrins in the ventral membrane. Only occasional
random gold particles were seen in irrelevant IgG-stained
membranes (Figure 4A, right panel). Thus, kindlin-2 promotes
the clustering of ligand-occupied aIIbb3 at the nanoscale.
Kindlins could increase aIIbb3 clustering either before or
after ligand binding. We reasoned that in the latter case,
kindlin-dependent increases in ligand binding would be pre-
vented by fixing the cells before addition of ligand. When cells
were fixed before adding ligands to aIIbb3-expressing HEK293
cells, THD induced a near 3-fold increase in PAC1 binding, but
kindlin-1 failed to synergizewith THD in inducing PAC1binding
(Figure S4A). In contrast, kindlin-1 dramatically increased
THD-induced PAC1 binding in cells fixed after ligand addition
(Figure S4A). Furthermore, consistent with earlier reports that
clustering requires occupancy of the integrin [40], when the
ability of aIIbb3 to bind ligand was blocked by a b3 Asp119
mutation, the integrin remained diffusely distributed as judged
by TIRF microscopy (Figure S4B). Thus, the effect of kindlins
on multivalent ligand binding to integrin aIIbb3 is mediated
by their capacity to promote the clustering of ligand-occupied
aIIbb3.
Discussion
These results pinpoint the locus of kindlin action in mediating
integrin aIIbb3 activation. Earlier studies in invertebrates
[41, 42] and cultured cells [43, 44] showed that kindlins
mediate formation of integrin-mediated adhesions and fore-
shadowed studies showing that kindlins regulate the capacity
of integrins to bind soluble ligands [7, 8, 10, 11, 13] and to pro-
mote integrin signals that regulate the cytoskeleton [12]. Here,
we found that the kindlins increase soluble ligand binding to
aIIbb3 primarily by increasing avidity for multivalent ligands
due to kindlins’ ability to promote clustering of ligand-occu-
pied integrins. Our results now explain why kindlins alone
have little apparent effect on soluble ligand binding to cellular
integrins in the absence of talin-mediated activation and
comport with the finding that kindlin-3 does not induce
changes in b3 transmembrane domain topology, which
induces integrin aIIbb3 activation [45].
We utilized 3FN10 as a monovalent ligand because it binds
to both murine and human aIIbb3, and for technical ease of
crosslinking. Previous studies showed that kindlin-3 overex-
pression increased 3FN(7–10) (seventh to tenth type III fibro-
nectin repeats) [11] binding to integrin a5b1 in RAW264.7 cells.
In contrast to 3FN10, 3FN(7–10) contains a free cysteine [46]
and two integrin binding sites, one in 3FN9 and the other in
3FN10 [47], and is thus not monovalent. In addition, there
may be cell-specific, kindlin-specific, and integrin-specific
mechanisms of regulation, as (1) kindlin-1 and kindlin-2 syner-
gize with THD to activate aIIbb3 but inhibit THD-induced a5b1
activation in CHO cells [22]; (2) overexpressed kindlin-3 is
functional in RAW 264.7 cells, but not in CHO cells [11]; and
(3) kindlin-3 is required for aLb2- but not a4b1-increased cell
adhesiveness under fluid shear stresses [9]. Secondary
antibodies can oligomerize monovalent PAC1 Fab under
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appropriate conditions, converting it into a multivalent ligand
[19]. We formaldehyde fixed the cells before adding secondary
antibody or streptavidin, as recommended by Bunch [19], to
avoid potential oligomerization of the 3FN10. Indeed, when
highly concentrated PAC1 Fab was used to overcome its low
affinity as a monovalent ligand [19], we obtained results com-
parable to those using 3FN10 (Figure 1B). Thus, when sec-
ondary antibody-induced oligomerization is avoided, kindlins
have little effect on the binding of an authentic monovalent
ligand to integrin aIIbb3.
Reduced soluble ligand binding alone might not account for
the defective platelet aggregation and increased bleeding
observed in kindlin-3 null mice and patients. The combined
effects of reduced surface integrin expression [11], defective
integrin clustering, and impaired integrin outside-in signaling
[10–12, 43] may all make important contributions to the hemo-
static defect. Similarly, the effect of kindlin-mediated clus-
tering on avidity can be a major contributor to kindlin-3’s
capacity to support the function of b1 or b2 integrins that
mediate increased resistance of leukocytes to detachment
under flow [8, 48, 49]. Kindlin-mediated leukocyte arrest is
associated with an additional conformational change in aLb2
that can be driven by shear stress on the integrin [9, 49].
Thus, in addition to effects on soluble ligand binding, it is clear
that kindlin-3 makes multiple contributions to the adhesive
functions of blood cells.
Integrin-bound kindlins might promote integrin clustering by
redistributing integrins between different pools, such as those
on the cell surface, in storage pools, and in recycling pathways
[50, 51]. Indeed, loss of kindlin-3 is associated with reduced
aIIbb3 surface expression in murine platelets by about 25%
([11] and our unpublished data), and overexpression of kind-
lins can increase integrin expression in a CHO cell clone [22].
Alternatively, kindlins can recruit migfilin [43] and integrin-
linked kinase (ILK) [12] to occupied integrins, thereby enabling
the further recruitment of actin-binding proteins such as
filamins, PINCHs, and parvins [52] that could promote
cooperative integrin clustering. Kindlins can also bind to
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Figure 3. Kindlins Promote Clustering of Occupied Integrins
(A) Cells expressing aIIb-GFPb3 transducedwith lentivirus encoding both kindlin-2 shRNA and DsRedweremixed with uninfected cells and plated on fibrin-
ogen-coated coverslips. The left panels are TIRF images of the distribution of aIIb-GFPb3 at the cell-substrate interface in uninfected cells (DsRed negative)
and shRNA-transduced cells (DsRed positive, white arrows). DsRed epi-illuminated fluorescence images in themiddle panel indicate shRNA lentiviral trans-
duction. GFP epi-illuminated fluorescence images in the right panels indicate comparable aIIbb3 fluorescence in uninfected control cells and kindlin-2
shRNA-expressing cells. Scale bar represents 10 mm.
(B) Fluorescence intensities of integrin puncta were measured and averaged as described in the Supplemental Information. Error bars indicate SEM of n =
1,223, 1,204, and 1,008 puncta in uninfected cells or those transduced with kindlin-2 shRNA1 or shRNA2, respectively.
(C) Cells from the experiment depicted in (A) were stained with anti-aIIbb3 (D57) and analyzed by FACS to assess aIIbb3 surface expression. Data are
expressed as percent of aIIbb3 expressed in control shRNA-infected cells. Error bars indicate 6SEM of three independent experiments.
(D) DsRed-positive shRNA-transduced cells were isolated by FACS, and kindlin-2 expression was assessed by western blotting.
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polyphosphoinositides [53–56], thereby localizing integrins in
membrane domains that might favor clustering. The present
work will enable further studies to evaluate the precise roles
of kindlin-binding proteins and phospholipids in the capacity
of kindlins to increase clustering of integrins, thereby enhanc-
ing multivalent ligand binding.
Supplemental Information
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cub.2013.09.050.
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Knock-down and knockout of β1-integrin in hepatocytes impairs 
liver regeneration through inhibition of growth factor signaling. 
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Abstract	  
The	  liver	  has	  a	  unique	  regenerative	  capability,	  which	  involves	  extensive	  remodelling	  of	  cell-­‐
cell	   and	  cell-­‐matrix	   contacts.	   Surprisingly,	  however,	   the	   roles	  of	  different	   integrins	   in	   liver	  
regeneration	  have	  not	  been	  determined.	  Here	  we	  used	  Cre/loxP-­‐mediated	  gene	  deletion	  or	  
intravenous	  delivery	  of	  siRNA	  formulated	  into	  nanoparticles	  to	  efficiently	  ablate	  β1-­‐integrin	  
expression	  in	  hepatocytes	  of	  mice.	  While	  short-­‐term	  loss	  of	  β1-­‐integrin	  was	  not	  detrimental	  
for	   the	   non-­‐challenged	   liver,	   severe	   liver	   necrosis	   and	   reduced	   hepatocyte	   proliferation	  
were	  observed	  after	  partial	  hepatectomy.	  Mechanistically,	  loss	  of	  β1-­‐integrin	  in	  hepatocytes	  
impaired	   the	   ligand-­‐induced	   phosphorylation	   of	   the	   epidermal	   growth	   factor	   and	  
hepatocyte	  growth	  factor	  receptors	  and	  down-­‐stream	  signalling	   in	  vitro	  and	   in	  vivo.	  These	  
results	   identify	   a	   crucial	   role	   and	   novel	   mechanism	   of	   action	   of	   β1-­‐integrins	   in	   liver	  
regeneration	   and	   demonstrate	   that	   protein	   depletion	   by	   nanoparticle-­‐based	   delivery	   of	  
specific	  siRNA	  is	  a	  powerful	  strategy	  to	  study	  gene	  function	  in	  the	  regenerating	  liver.	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Introduction	  	  
Due	  to	  the	  essential	  functions	  of	  the	  liver	  in	  metabolism	  and	  compound	  detoxification,	  it	  is	  
pivotal	  to	  guarantee	  a	  rapid	  and	  efficient	  repair	  of	  the	  organ	  after	  injury	  caused	  by	  viruses,	  
toxins	  or	   autoimmune	  attacks	   as	  well	   as	   after	   liver	   transplantation	  or	   tumor	   surgery.	   The	  
model	  of	  two-­‐third	  partial	  hepatectomy	  (PH)	  in	  rodents	  is	  widely	  used	  to	  study	  the	  different	  
stages	   of	   liver	   regeneration,	   including	   hepatocyte	   cell	   cycle	   entry,	   cell	   proliferation,	   and	  
termination,	   which	   finally	   result	   in	   the	   restoration	   of	   the	   initial	   liver	   mass	   1,2.	   Growth	  
factors,	   cytokines	   and	   their	   corresponding	   receptors	   control	   these	   different	   stages,	   and	  
regulate	  activation,	  proliferation	  and	  survival	  of	  liver	  cells	  during	  the	  regeneration	  process	  3.	  
Although	  hepatocytes	  express	  multiple	  adhesion	  molecules	  including	  integrins,	  surprisingly	  
little	  is	  known	  about	  their	  roles	  in	  liver	  regeneration.	  
Integrins	  form	  a	  large	  family	  of	  transmembrane	  cell	  surface	  receptors,	  comprising	  18	  α	  and	  
8	  β	  subunits	  that	  assemble	  into	  24	  non-­‐covalently	  associated	  heterodimers	  with	  distinct,	  but	  
overlapping	   specificities	   for	   ligands	   4.	   Besides	   their	   role	   in	   cell	   anchorage	   via	   cell-­‐cell	   and	  
cell-­‐matrix	   interactions,	   integrins	   assemble	   large	   signalling	   hubs	   that	   control	   cell	   survival,	  
proliferation,	  differentiation,	  and	  migration	  in	  normal,	  injured	  and	  cancerous	  tissues	  4-­‐6.	  The	  
β1-­‐integrin	  subunit	   (Itgb1)	  associates	  with	  at	   least	  10	  α	  subunits,	  giving	  rise	  to	  the	   largest	  
integrin	   subfamily	   4.	   Interestingly,	   gene	   expression	   profiling	   revealed	   that	   various	   genes	  
involved	   in	   the	   integrin	   signalling	  pathway	  were	   regulated	  during	   rat	   liver	   regeneration	   7.	  
This	  is	  obviously	  of	  functional	  relevance,	  since	  liver-­‐specific	  ablation	  of	  integrin	  linked	  kinase	  
(ILK)	  interfered	  with	  the	  proper	  termination	  of	  liver	  regeneration,	  resulting	  in	  enlarged	  livers	  
after	   PH	   8.	   However,	   the	   role	   of	   individual	   integrin	   subunits	   in	   liver	   regeneration	   has	   not	  
been	   determined	   and	   their	   mechanisms	   of	   action	   in	   the	   normal	   and	   regenerating	   liver	  
remain	  to	  be	  investigated.	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In	   this	   study	   we	   used	   a	   dual	   approach	   to	   study	   the	   role	   of	   Itgb1	   in	   liver	   regeneration	   –	  
inducible	  Cre/loxP-­‐mediated	  gene	  deletion	  and	  siRNA-­‐mediated	  knock-­‐down	  in	  hepatocytes	  
in	   vivo.	   The	   use	   of	   genetically	   modified	   mice	   with	   gain-­‐	   or	   loss-­‐of-­‐function	   of	   individual	  
genes	   is	   the	  gold	   standard	   to	   study	   the	   involvement	  of	  proteins	   in	   a	  biological	  process	   in	  
vivo.	   Their	   use	   for	   liver	   regeneration	   studies	   identified	   the	   contribution	  of	   growth	   factors	  
and	   their	   corresponding	   receptors	   to	   this	   process.	   Of	   particular	   importance	   are	   the	  
hepatocyte	  growth	  factor	   (HGF)	  receptor	  c-­‐Met	  and	  the	  epidermal	  growth	  factor	  receptor	  
(EGFR).	  Inducible	  deletion	  of	  c-­‐Met	  in	  the	  liver	  resulted	  in	  reduced	  hepatocyte	  proliferation	  
and	   concomitant	   impairment	   of	   liver	   regeneration	   9.	   Constitutive	   hepatocyte-­‐specific	  
knockout	   of	   c-­‐Met	   caused	   severe	   liver	   necrosis	   after	   PH	   and	   reduced	   the	   survival	   of	   the	  
animals	  10.	  Mice	  lacking	  the	  EGFR	  in	  the	  liver	  showed	  increased	  mortality,	  liver	  cell	  damage	  
and	  reduced	  hepatocye	  proliferation	  resulting	  from	  a	  defective	  entry	  into	  the	  G1-­‐S	  phase	  of	  
the	  cell	  cycle	  11.	  	  
Considerable	   effort	   has	   been	   directed	   towards	   developing	   effective	   delivery	   systems	   for	  
siRNAs	   in	   vivo	   12-­‐14.	   Plasmid-­‐based	   expression	  of	   short	   hairpin	   (sh)	   RNA	  has	   been	  used	   to	  
study	   the	   role(s)	  of	  HGF/c-­‐Met	  and	  EGFR	  during	   liver	   regeneration	   in	   rats	   15,16,	  and	  stable	  
delivery	  of	  pools	  of	  shRNAs	  into	  mouse	  livers	  lead	  to	  the	  identification	  of	  the	  kinase	  MKK4	  
as	   a	   major	   regulator	   of	   liver	   regeneration	   17.	   Additional	   siRNA	   delivery	   systems	   were	  
invented	  to	  improve	  tissue	  specificity	  and	  low-­‐dose	  efficacy.	  In	  particular,	  lipid	  nanoparticle	  
formulations	  were	  developed,	  which	  efficiently	  and	  predominantly	  delivered	   siRNA	   to	   the	  
liver	   and	   allowed	   knock-­‐down	   of	   several	   genes	   simultaneously	   after	   a	   single	   injection	   of	  
multiple	   siRNAs	   18-­‐20.	   Therefore,	   we	   used	   this	   powerful	   strategy	   in	   combination	   with	   a	  
knockout	  approach	  to	  determine	  the	  outcome	  of	  the	  loss	  of	  β1-­‐integrin	  in	  hepatocytes	  for	  
liver	  regeneration	  after	  PH.	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Generation	  of	  mice	  lacking	  Itgb1	  in	  the	  liver	  
Mice	  with	  floxed	   Itgb1	  alleles	  (Itgb1f/f	  mice)	  21	  were	  mated	  with	  MxCre	  mice,	   in	  which	  Cre	  
expression	   can	   be	   induced	   by	   2	   injections	   of	   poly-­‐IC	  with	   a	   2-­‐day	   interval.	   This	   has	   been	  
shown	  to	   result	   in	  complete	  deletion	  of	   floxed	  alleles	   in	   the	   liver	  and	   to	  almost	  complete	  
deletion	   in	   the	  spleen.	  By	  contrast,	  deletion	   in	  other	  tissues	   is	  much	   less	  efficient	  or	  even	  
absent	   22.	   The	   double	   transgenic	   progeny	   was	   designated	   Itgb1f/f/MxCre	   mice	   23,24.	   Mice	  
were	  injected	  twice	  with	  a	  2-­‐day	  interval	  with	  Poly-­‐IC.	  Already	  14	  days	  after	  the	  last	  poly-­‐IC	  
injection,	   the	   Itgb1	   alleles	   were	   efficiently	   deleted	   in	   the	   liver	   of	   Itgb1f/f/MxCre	   mice	   as	  
shown	  by	  staining	  for	  β-­‐galactosidase	  (β-­‐gal),	  whose	  expression	  is	  induced	  upon	  deletion	  of	  
the	  floxed	  allele	  21	  (Fig.	  1A).	  No	  staining	  was	  seen	  in	  the	  intestine	  where	  recombination	  had	  
not	  occurred	  (Fig.	  1B).	  As	  expected,	  a	  strong	  reduction	  in	  the	  levels	  of	  Itgb1	  mRNA	  was	  also	  
seen	   in	   the	   spleen,	   although	   to	   a	  much	   lesser	   extent	   than	   in	   the	   liver.	  No	   reduction	  was	  
seen	  in	  the	  lung	  (Fig.	  1C).	  Immunofluorescence	  staining	  verified	  the	  efficient	  gene	  knockout	  
in	   hepatocytes,	   whereas	   PECAM-­‐1	   positive	   endothelial	   cells	   were	   still	   Itgb1	   positive	   (Fig.	  
1D,E).	   In	   addition,	   co-­‐staining	   for	   Itgb1	   and	   F4/80	   or	   α	   smooth	   muscle	   actin	   (α-­‐SMA)	  
showed	  that	  Kupffer	  cells	  and	  stellate	  cells	  also	  remained	  Itgb1	  positive	  (Fig.	  1F,	  Suppl.	  Fig.	  	  
S1A).	   Therefore,	   Mx-­‐Cre-­‐mediated	   loss	   of	   Itgb1	   was	   obviously	   restricted	   to	   hepatocytes.	  
Poly-­‐IC-­‐injected	   Itgb1f/f/MxCre	   mice	   did	   not	   show	   obvious	   health	   impairments,	   and	   a	  
histological	  analysis	  of	  liver	  tissue	  showed	  no	  gross	  morphological	  abnormalities	  during	  the	  
first	   4	   weeks	   after	   Itgb1	   deletion	   (Supplementary	   Fig.	   S2A).	   Furthermore,	   there	   were	   no	  
obvious	   vascular	   abnormalities	   as	   shown	   by	   PECAM-­‐1	   staining	   (Supplementary	   Fig.	   S2B).	  
However,	   despite	   the	   normal	   liver	   morphology,	   serum	   activities	   of	   aspartate	  
aminotransferase	  (AST),	  alanine	  aminotransferase	  (ALT),	  and	  lactate	  dehydrogenase	  (LDH),	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and	   serum	   concentrations	   of	   bilirubin	   were	   increased	   14	   days	   after	   poly-­‐IC	   injection,	  
indicating	   initiation	   of	   liver	   damage	   by	   knockout	   of	   Itgb1	   (Supplementary	   Fig.	   S2C).	   By	  
contrast,	   albumin	   levels	   were	   not	   affected,	   suggesting	   that	   liver	   function	   is	   not	   severely	  
compromised	  (Supplementary	  Fig.	  S2C).	  In	  line	  with	  these	  findings,	  all	  animals	  survived	  the	  
observation	  period.	  	  
	  
Itgb1	  is	  required	  for	  liver	  regeneration	  and	  survival	  after	  PH	  
Fourteen	  days	  after	  the	  second	  poly-­‐IC	  injection	  mice	  were	  subjected	  to	  PH.	  Our	  complete	  
treatment	   scheme,	   shown	   schematically	   in	   Fig.	   2A,	   caused	  47%	   lethality	   of	   Itgb1f/f/MxCre	  
mice,	  but	  only	  7%	   lethality	   in	   control	  mice	  within	  24-­‐48	  hours	  after	  PH	   (Fig.	  2B).	   Since	  all	  
Itgb1f/f/MxCre	  mice	   survived	   the	   first	   24h	  after	   surgery,	  we	   conclude	   that	   a	  defect	   in	   the	  
onset	   of	   regeneration	   and/or	   metabolic	   abnormalities	   rather	   than	   acute	   surgical	  
complications	  caused	  the	  death	  of	  the	  animals.	  	  
The	   liver-­‐to-­‐body-­‐weight	   ratio	   was	   not	   significantly	   different	   between	   Itgb1f/f/MxCre	   and	  
control	  mice	  at	  48h	  after	  surgery	  (Fig.	  2C).	  However,	  we	  detected	  a	  further	  increase	  in	  the	  
activities	  of	  ALT,	  AST,	  and	  LDH,	  enhanced	  levels	  of	  bilirubin,	  and	  reduced	  levels	  of	  albumin	  
in	  the	  serum	  of	  Itgb1f/f/MxCre	  mice	  48h	  after	  PH,	  indicating	  liver	  damage	  and	  impaired	  liver	  
function	  (Fig.	  2D).	   Indeed,	  Itgb1f/f/MxCre	  mice	  displayed	  severe	  liver	  necrosis	  48h	  after	  PH	  
(Fig.	   2E),	   which	   was	   accompanied	   by	   enhanced	   infiltration	   of	   neutrophils	   (Fig.	   1F).	   The	  
number	  of	  apoptotic	  cells	  as	  determined	  by	  TUNEL	  staining	  (Fig.1G)	  or	  staining	  for	  cleaved	  
caspase-­‐3	   (Supplementary	   Fig.	   S2D)	   was	   also	   increased,	   while	   the	   hyperproliferation	   of	  
hepatocytes	   that	   occurred	   in	   control	   mice	   48h	   after	   PH	   was	   strongly	   reduced	   in	  
Itgb1f/f/MxCre	   mice	   (Fig.	   1H).	   Since	   Poly-­‐IC-­‐induced	   expression	   of	   Cre	   recombinase	   also	  
occurs	  in	  haematopoietic	  cells,	  we	  generated	  bone	  marrow	  chimeric	  mice	  by	  transplanting	  
______________________________________________________________________________________________________________
345
Appendix
	   7	  
Itgb1f/f/MxCre	  bone	  marrow	  into	  γ-­‐irradiated	  wild-­‐type	  mice,	  and	  we	  subsequently	  induced	  
Itgb1	   deletion	   in	   blood	   cells.	   Successful	   transfer	   of	   bone	   marrow	   and	   poly-­‐IC-­‐induced	  
knockout	  after	  complete	  engraftment	  of	  the	  recipient	  mice	  was	  verified	  by	  the	  detection	  of	  
β-­‐galactosidase	  activity	  in	  platelets	  of	  bone	  marrow	  chimeric	  mice	  (Supplementary	  Fig.	  S3A).	  
None	   of	   the	   animals	   showed	   tissue	   damage	   48h	   after	   PH	   (Supplementary	   Fig.	   S3B),	  
indicating	   that	   loss	   of	   Itgb1	   in	   haematopoietic	   cells	   is	   not	   the	   primary	   reason	   for	   the	  
regeneration	  defect	  of	  poly-­‐IC-­‐treated	  Itgb1f/f/MxCre	  mice.	  Rather,	  the	  regeneration	  defect	  
in	  Itgb1f/f/MxCre	  mice	  results	  from	  loss	  of	  Itgb1	  in	  hepatocytes.	  
	  
Knock-­‐down	  of	  Itgb1	  in	  hepatocytes	  in	  vivo	  
To	  further	  verify	  the	  importance	  of	  Itgb1	  in	  hepatocytes	  for	  liver	  regeneration	  after	  PH	  and	  
to	   compare	   the	   outcome	   after	   genetic	   knockout	   with	   siRNA-­‐mediated	   knock-­‐down	   in	  
hepatocytes	   in	   vivo,	   we	   used	   lipid-­‐based	   nanoparticles	   to	   deliver	   Itgb1	   siRNA,	  which	   had	  
been	  optimized	  for	  liver	  specific	  targeting	  19.	  A	  single	  injection	  of	  Itgb1	  siRNA	  reduced	  Itgb1	  
mRNA	   levels	   by	   more	   than	   85%	   in	   comparison	   to	   a	   mock	   injection	   with	   luciferase	   (Luc)	  
siRNA.	   Importantly,	   the	  knock-­‐down	  was	  maintained	   for	  more	   than	  10	  days	  after	  a	   single	  
injection	   of	   siRNA	   (see	   Bogorad	  et	   al.,	   submitted).	   As	   a	   consequence	   of	   the	   Itgb1	   knock-­‐
down,	  adhesion	  of	  isolated	  hepatoctytes	  on	  collagen	  was	  strongly	  reduced	  (Bogorad	  et	  al.,	  
submitted).	  	  
To	  ensure	  a	  prolonged	  and	  efficient	   strong	  knock-­‐down,	  we	   injected	  siRNA	  twice	  within	  a	  
five	   day	   interval.	   Five	   days	   after	   the	   last	   injection	   the	   animals	   were	   subjected	   to	   PH	   as	  
shown	  schematically	  in	  Fig.	  3A.	  At	  the	  time	  of	  surgery,	  the	  liver	  tissue	  showed	  a	  more	  than	  
90%	  reduction	  in	  Itgb1	  mRNA	  levels	  (Fig.	  3B).	  Western	  blotting	  revealed	  an	  siRNA-­‐mediated	  
reduction	   of	   Itgb1	   protein	   in	   total	   liver	   lysates,	   and	   a	   complete	   loss	   of	   Itgb1	   protein	   in	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purified	  primary	  hepatocytes,	  indicating	  that	  the	  residual	  Itgb1	  detected	  in	  total	  liver	  results	  
from	   expression	   in	   non-­‐parenchymal	   liver	   cells,	   which	   were	   apparently	   not	   efficiently	  
targeted	  by	  the	  nanoparticles	  (Fig.	  3C).	  Itgb1	  immunostaining	  of	  the	  tissue	  removed	  during	  
surgery	   and	   48h	   after	   PH	   confirmed	   the	   knock-­‐down	   in	   hepatocytes	   (Fig.	   3D),	   while	   co-­‐
staining	   of	   Itgb1	  with	   PECAM-­‐1,	  α-­‐SMA,	   or	   F4/80	   revealed	   that	   endothelial	   cells,	   stellate	  
cells	  and	  Kupffer	  cells	  were	  still	  Itgb1	  positive	  (Supplementary	  Fig.	  S4A-­‐C).	  	  
Consistent	   with	   previous	   findings	   demonstrating	   that	   more	   than	   90%	   of	   injected	   siRNA-­‐
loaded	   lipid	  nanoparticles	  accumulated	   in	   the	   liver	   25,	  no	   reduction	   in	   the	  mRNA	   levels	  of	  
Itgb1	  was	  observed	  in	  the	  lung,	  kidney,	  and	  heart	  (Supplementary	  Fig.	  S5A)	  or	  in	  the	  adipose	  
tissue	   (Bogorad	   et	   al.,	   submitted).	   Spleen	   was	   the	   only	   tissue	   in	   which	   siRNA-­‐loaded	  
nanoparticles	   reduced	   Itgb1	   mRNA	   levels	   by	   around	   50%	   (Supplementary	   Fig.S5A).	   We	  
assume	  that	  the	  Itgb1	  reduction	  in	  spleen	  is	  unlikely	  causing	  phenotypic	  abnormalities,	  since	  
a	  constitutive	  heterozygous	  deletion	  of	  the	  Itgb1	  gene	  in	  mice	  lead	  to	  no	  apparent	  defects	  
26,	   and	   since	   loss	   of	   Itgb1	   in	   haematopoietic	   cells	   did	   not	   affect	   the	   normal	   liver	   or	   the	  
regeneration	  process	  after	  PH	  (see	  above).	  
The	   siRNA	   treatment	   neither	   induced	   the	   expression	   of	   interferon	   γ	   mRNA	   under	   our	  
experimental	  conditions,	  nor	  histological	  or	  vascular	  abnormalities	  in	  the	  liver	  at	  day	  5	  after	  
the	   second	   siRNA	   injection	   (Supplementary	   Fig.	   S5B,C).	   In	   contrast	   to	   the	   knockout	  mice,	  
serum	  parameters	  remained	  normal	  upon	  Itgb1	  knock-­‐down	  (Supplementary	  Fig.	  S5D),	  and	  
all	  animals	  survived	  the	  observation	  period.	  
siRNA-­‐mediated	  Itgb1	  knock-­‐down	  leads	  to	  a	  mild	  regeneration	  defect	  
In	   contrast	   to	   Itgb1f/f/MxCre	   mice,	   the	   survival	   of	   Itgb1	   knock-­‐down	   animals	   was	   not	  
reduced	  48h	  after	  PH	  (Fig.	  3E).	  Surprisingly,	  the	  animals	  even	  showed	  an	  increase	  in	  liver-­‐to-­‐
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body-­‐weight	  ratio	  compared	  to	  control	  animals	  (Fig.	  3F).	  At	  the	  histological	  level,	  however,	  
we	  found	  similar	  abnormalities	  in	  Itgb1	  knock-­‐down	  and	  knockout	  animals,	  including	  severe	  
necrotic	   tissue	   damage,	   concomitant	   neutrophil	   infiltration	   (Fig.	   3G,H),	   and	   reduced	  
proliferation	  (Fig.	  2I).	  The	  latter	  defect	  in	  combination	  with	  the	  increased	  liver/body	  weight	  
ratio	  suggested	  hypertrophy	  of	  hepatocytes,	  and	  this	  was	   indeed	  confirmed	  by	  analysis	  of	  
cell	  size	  upon	  staining	  of	  the	  actin	  cytoskeleton	  (Supplementary	  Fig.	  S6A).	  	  
To	  test	  if	  the	  liver	  necrosis	  that	  we	  observed	  after	  PH	  in	  mice	  with	  Itgb1	  knockout	  or	  knock-­‐
down	  was	  due	  to	  enhanced	  sensitivity	  to	  the	  anaesthetic	  and/or	  analgesic	  compounds	  that	  
we	   used	   during	   PH,	   we	   treated	   Itgb1f/f/MxCre	   mice,	   Itgb1	   knock-­‐down	   mice,	   and	   the	  
corresponding	   control	   mice	   with	   isoflurane	   and	   buprenorphine,	   similar	   to	   the	   treatment	  
used	   for	   PH.	   48h	   later	   mice	   were	   sacrificed,	   livers	   were	   analyzed	   by	   H/E	   staining,	   and	  
transaminase	   activities	   were	   measured	   in	   the	   serum.	   Importantly,	   neither	   knockout	   nor	  
knock-­‐down	  animals	   showed	   treatment-­‐induced	   liver	  damage	   (Supplementary	   Fig.	   S6B,C).	  
Transaminase	  activities	  of	  Itgb1f/f/MxCre	  mice	  treated	  with	  isoflurane	  and	  morphine	  were	  in	  
the	  same	  range	  as	  in	  untreated	  Itgb1f/f/MxCre	  mice	  (Supplementary	  Fig.	  S2C).	  
Due	  to	  the	  better	  health	  status	  of	  the	  knock-­‐down	  compared	  to	  the	  knockout	  mice	  and	  their	  
survival	   post	   48h	   PH,	   we	   were	   able	   to	   analyze	   later	   stages	   of	   the	   regeneration	   process.	  
Therefore,	  we	  next	  analyzed	  the	  effect	  of	  Itgb1	  knock-­‐down	  5d	  after	  PH.	  The	  lasting	  knock-­‐
down	  at	  the	  5-­‐day	  time	  point	  was	  confirmed	  by	  qRT-­‐PCR	  (Fig.	  4A)	  and	  immunofluorescence	  
staining	   (Fig.	  4B).	  We	  also	  analyzed	  an	  early	   time	  point	   (6h	  after	  PH)	  and	   found	  no	   tissue	  
damage	  in	  animals	  treated	  with	  siRNA	  either	  against	  luciferase	  or	  Itgb1	  (Fig.	  4C).	  Five	  days	  
post	  PH	  we	  still	  observed	  some	  necrotic	   tissue	   in	   the	   Itgb1	   knock-­‐down	  animals	   (Fig.	  4C),	  
but	   to	   a	   much	   lesser	   extent	   than	   48	   post	   PH	   (Fig.	   3G).	   Proliferation	   of	   hepatocytes	   had	  
declined	   to	   almost	   basal	   levels	   in	   knock-­‐down	   and	   control	   mice,	   and	   the	   liver-­‐to-­‐body-­‐
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weight	  was	  also	  similar	  at	   this	   late	  time	  point,	  demonstrating	  that	  regeneration	  can	  occur	  
under	  these	  conditions	  (Fig.	  4D,E).	  Since	  we	  observed	  a	  uniform	  knock-­‐down	  of	  Itgb1	  even	  5	  
days	   after	   PH,	   it	   seems	   unlikely	   that	   cells	   with	   inefficient	   knock-­‐down	   preferentially	  
contributed	   to	   regeneration.	   Taken	   together,	   these	   data	   reveal	   that	   Itgb1	   knock-­‐down	  
impairs	  liver	  regeneration,	  but	  does	  not	  prevent	  it.	  	  
	  
Itgb1	  controls	  c-­‐Met	  and	  EGFR	  activation	  
Since	  EGFR	  ligands	  and	  HGF	  are	  major	  mitogens	  for	  hepatocytes	  in	  the	  regenerating	  liver	  1,3	  
and	   since	  mice	   lacking	  EGFR	  or	   the	  HGFR	  c-­‐Met	   in	   the	   liver	   revealed	   similar	   regeneration	  
abnormalities	   as	   the	   Itgb1f/f/MxCre	   and	   Itgb1	   knock-­‐down	  mice	   9-­‐11,	  we	   tested	   a	   possible	  
involvement	   of	   impaired	   EGFR	   and/or	   c-­‐Met	   signalling	   in	   the	   proliferation	   and	   survival	  
defect	  of	   Itgb1-­‐deficient	  hepatocytes.	  Levels	  of	  phosphorylated	  c-­‐Met	   (Tyr1003)	  and	  EGFR	  
(Tyr1068)	  were	  indeed	  reduced	  in	  Itgb1	  knockout	  animals	  0h	  and	  48h	  post	  PH	  (Fig.	  5A),	  and	  
reduced	   phosphorylation	   of	   EGFR	  was	   also	   observed	   in	  mice	  with	   Itgb1	   knock-­‐down	   48h	  
after	  PH	   (Fig	  5B).	   Levels	  of	   total	  and	  phosphorylated	   focal	  adhesion	  kinase	   (FAK),	  a	  major	  
relay	  of	  integrin	  signalling,	  were	  not	  affected	  by	  loss	  of	  Itgb1	  (Fig.	  5A).	  	  
To	   test	   if	   Itgb1	  directly	  controls	  hepatic	  EGFR	  signalling,	  we	   injected	  EGF	   intraperitoneally	  
into	  mice	  with	   Itgb1	   knockout	  or	   knock-­‐down	  and	  analyzed	  EGFR	  activation.	  15	  min	  after	  
EGF	  injection	  we	  observed	  strong	  phosphorylation	  of	  the	  EGFR	  in	  control	  animals,	  but	  not	  in	  
knockout	   animals	   (Fig.	   6A).	   Itgb1	   knock-­‐down	   mice	   showed	   increased	   levels	   of	  
phosphorylated	   EGFR	   in	   unstimulated	   conditions,	   which,	   however,	   only	   mildly	   increased	  
upon	   EGF	   injection	   (Fig.	   6B).	   To	   determine	   if	   the	   inhibition	   of	   EGFR	   and	   c-­‐Met	   signalling	  
upon	   loss	   of	   Itgb1	   is	   a	   cell	   autonomous	   effect,	   primary	   hepatocytes	   were	   cultured	   after	  
siRNA-­‐mediated	  knock-­‐down	   in	  vivo.	  Efficient	  knock-­‐down	  of	  Itgb1	  in	  cultured	  hepatocytes	  
______________________________________________________________________________________________________________
349
Appendix
	   11	  
was	   confirmed	   by	   immunostaining	   and	   western	   blotting	   (Fig.	   6C,D).	   Interestingly,	   EGF-­‐
induced	  EGFR	  phosphorylation	  was	  also	  abolished	  in	  cultured	  hepatocytes	  with	  Itgb1	  knock-­‐
down	  (Fig.	  6D).	  In	  contrast	  to	  the	  in	  vivo	  situation,	  basal	  levels	  of	  pEGFR	  were	  not	  increased	  
upon	  Itgb1	  knock-­‐down	   in	  vitro,	   indicating	  that	  the	  enhanced	  levels	   in	  vivo	  result	  from	  cell	  
types	   other	   than	   hepatocytes.	   Concomitant	   with	   the	   impaired	   receptor	   phosphorylation,	  
EGF-­‐induced	  phosphorylation	  of	  Erk	  was	  strongly	  reduced	  and	  phosphorylation	  of	  Akt	  was	  
abolished	  in	  cultured	  Itgb1	  knock-­‐down	  hepatocytes	  (Fig	  6D).	  HGF-­‐induced	  phosphorylation	  
of	   c-­‐Met	   and	  Erk1/2	   activation	  were	   also	   impaired	   in	   Itgb1	   knock-­‐down	  hepatocytes	   (Fig.	  
6E).	  In	  addition,	  internalization	  of	  fluorophor-­‐labelled	  EGF	  was	  significantly	  diminished	  (Fig.	  
6F).	  Taken	  together,	  these	  findings	  demonstrate	  that	  loss	  of	  Itgb1	  impaired	  EGFR	  and	  c-­‐Met	  
phosphorylation,	   EGFR	   internalization,	   and	   activation	   of	   mitogenic	   signalling	   pathways	  
downstream	  of	  EGFR	  and	  c-­‐Met.	  These	  abnormalities	   in	  growth	  factor	  signalling	  provide	  a	  
plausible	  explanation	  for	  the	  impaired	  hepatocyte	  proliferation	  in	  the	  Itgb1	  knock-­‐down	  and	  
knockout	  mice.	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Discussion	  
In	   this	   study	   we	   demonstrate	   (i)	   that	   β1-­‐integrins	   in	   hepatocytes	   are	   essential	   for	   liver	  
regeneration,	   (ii)	   that	   they	   execute	   the	   regeneration	   promoting	   function	   by	   cooperating	  
with	  growth	  factor	  signalling,	  and	  (iii)	  that	  siRNA-­‐mediated	  knock-­‐down	  in	  hepatocytes	  is	  a	  
potent	  strategy	  to	  study	  gene	  function	  in	  the	  regenerating	  liver	  in	  vivo.	  	  	  
	  
The	  generation	  of	  knockout	  mice	  guarantees	  a	  complete	  loss	  of	  a	  protein,	  but	  it	  is	  time-­‐	  and	  
cost-­‐intensive,	   and	   permits	   to	   delete	   only	   a	   few	   genes	   in	   a	   mouse.	   	   Furthermore,	   many	  
abnormalities	   in	   humans	   do	   not	   result	   from	   a	   complete	   loss	   of	   a	   gene,	   but	   rather	   from	  
reduced	   levels	  of	   (a)	  protein(s).	  Therefore,	  a	  knock-­‐down	  approach	  can	  sometimes	   reflect	  
more	  closely	  the	  situation	  that	  occurs	  in	  human	  diseases.	  In	  this	  study	  we	  describe	  the	  first	  
phenotypic	  comparison	  of	  a	  genetic	  knockout	  with	  siRNA-­‐mediated	  knock-­‐down	  in	  vivo	  in	  a	  
tissue	  regeneration	  model	  within	  one	  species.	  The	  similar	  phenotypes	  that	  we	  observed	  in	  
knock-­‐down	  and	  knockout	  mice	  highlight	  the	  usefulness	  of	  the	  siRNA	  approach.	  The	  slightly	  
milder	   phenotype	  of	   the	   knock-­‐down	  animals	   prevented	   the	   lethality	   associated	  with	   the	  
knockout	  and	  thus	  allowed	  us	  to	  extend	  mechanistic	  studies.	  	  
	  
We	  chose	  to	  deplete	  Itgb1,	  since	  there	   is	  as	  yet	   little	   information	  on	  the	  role	  of	   individual	  
integrins	   in	   liver	   regeneration.	   This	   is	   surprising,	   given	   their	   high	   expression	   level	   on	  
hepatocytes	   and	   the	   extensive	  matrix	   remodelling	   that	   occurs	   early	   after	   PH,	   which	   was	  
suggested	   to	   promote	   the	   onset	   of	   hepatocyte	   proliferation	   27,28.	   However,	   the	  
consequences	  of	  the	  loss	  of	  individual	  integrin	  subunits	  for	  liver	  regeneration	  had	  previously	  
not	  been	  determined.	  Our	   results	   revealed	   that	   complete	   loss	  of	   Itgb1	  using	   the	   loxP/Cre	  
approach	  still	  enabled	   liver	  homeostasis	   for	  a	   limited	  period	  of	   time,	  but	  was	  detrimental	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for	  liver	  regeneration	  as	  reflected	  by	  the	  strongly	  enhanced	  lethality	  observed	  between	  24	  
and	  48h	  after	  PH	  in	  knockout	  mice.	  As	  the	  underlying	  mechanism	  we	  identified	  severe	  liver	  
necrosis	  and	  strongly	  impaired	  hepatocyte	  proliferation.	  This	  defect	  was	  recapitulated	  after	  
Itgb1	   knock-­‐down,	   although	  without	   lethality.	   This	   difference	   is	   not	   surprising,	   since	   –	   in	  
contrast	   to	   a	   knockout	   –	   a	   knock-­‐down	   approach	   never	   leads	   to	   a	   complete	   loss	   of	   the	  
expression	  of	  a	  gene.	  Thus,	  very	  low	  levels	  of	  Itgb1	  in	  hepatocytes	  already	  prevent	  lethality.	  
It	   is	   also	   possible	   that	   remnants	   of	   type	   I	   interferons	   induced	   by	   the	   poly-­‐IC	   treatment	  
represent	  a	   further	   challenge	   for	   the	   liver,	   resulting	   in	  more	   severe	   liver	  damage	   in	   Itgb1	  
knockout	  mice.	  	  
	  
Although	   neither	   the	   knockout	   nor	   the	   knock-­‐down	   approach	   that	   we	   used	   resulted	   in	  
specific	   deletion	   of	   Itgb1	   in	   hepatocytes,	   several	   results	   obtained	   in	   this	   study	   strongly	  
suggest	  that	  the	   loss	  of	   Itgb1	   in	  these	  cells	   is	  responsible	  for	  the	  phenotype:	  (1)	  Liver	  was	  
the	  only	  tissue	  where	  an	  efficient	  knockout	  and	  knock-­‐down	  was	  achieved,	  (2)	  co-­‐stainings	  
of	   liver	   sections	   for	   Itgb1	   and	   cell-­‐type	   specific	  markers	   revealed	   that	   hepatic	   endothelial	  
cells,	   stellate	   cells	   and	  Kupffer	   cells	   retained	   Itgb1	  expression	   in	   the	  knockout	  and	  knock-­‐
down	  mice,	  (3)	  loss	  of	  Itgb1	  in	  haematopoietic	  cells	  did	  not	  affect	  liver	  regeneration,	  and	  (4)	  
the	  impairment	  in	  growth	  factor	  signalling	  in	  the	  absence	  of	  Itgb1	  was	  observed	  in	  cultured	  
primary	  hepatocytes,	  demonstrating	  that	  this	   is	  a	  cell	  autonomous	  effect.	  Finally,	  the	  data	  
presented	  in	  the	  accompanying	  manuscript	  demonstrate	  that	  loss	  of	  Itgb1	  in	  hepatoma	  cells	  
alone	  is	  sufficient	  to	  inhibit	  liver	  tumorigenesis	  (Bogorad	  et	  al.,	  submitted).	  
	  
Integrins	  assemble	  a	   large	  number	  of	  signalling	  and	  adaptor	  proteins	  at	  the	  adhesion	  site,	  
which	  transduce	  integrin	  signals	  to	  various	  subcellular	  compartments.	  Integrin-­‐linked	  kinase	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(ILK)	   is	  a	  major	  adaptor	   that	  directly	  binds	   the	  β1-­‐integrin	   tail	   and	  plays	  essential	   roles	   in	  
integrin-­‐mediated	   actin	   reorganization	   and	   growth	   factor	   signalling.	   Therefore,	   it	   was	  
unexpected	  that	  our	  phenotype	  markedly	  differed	  from	  the	  abnormalities	  observed	  in	  mice	  
lacking	  ILK	  in	  hepatocytes	  8.	  The	  only	  similarities	  were	  the	  enhanced	  liver/body	  weight	  ratio,	  
which	   was,	   however,	   much	   more	   pronounced	   in	   the	   ILK-­‐deficient	   mice.	   By	   contrast,	  
hepatocyte-­‐specific	   Ilk	   gene	   disruption	   in	   mice	   resulted	   in	   excessive	   rather	   than	  
delayed/impaired	   regeneration	   through	   sustained	   hepatocyte	   proliferation	   and	  
inappropriate	  termination	  of	   the	  PH-­‐induced	  regeneration	  process.	  This	   resulted	   in	  severe	  
liver	  enlargement	  8.	  Our	  data	  suggest	  that	  Itgb1	  controls	  negative	  regulators,	  such	  as	  ILK,	  as	  
well	  as	  positive	  regulators,	  and	  the	  latter	  seem	  to	  dominate	  during	  liver	  regeneration	  in	  our	  
mouse	  models.	  
	  
The	  liver	  regeneration	  phenotype	  that	  we	  observed	  in	  Itgb1	  knock-­‐down	  and	  knockout	  mice	  
is	   remarkably	   reminiscent	   of	   the	   abnormalities	   seen	   in	   mice	   lacking	   c-­‐Met	   or	   EGFR	   in	  
hepatocytes,	   suggesting	   that	   Itgb1	   signalling	   is	   required	   for	   signalling	   by	   these	   receptors.	  
This	  hypothesis	   is	  strongly	  supported	  by	  several	  results	  obtained	  in	  this	  study:	  (i)	  Levels	  of	  
phosphorylated	   EGFR	   and	   c-­‐Met	  were	   reduced	   after	   knockout	   or	   knock-­‐down	   of	   Itgb1	   in	  
hepatocytes	   in	   the	   regenerating	   liver,	   (ii)	   EGF-­‐induced	   receptor	   phosphorylation	   was	  
diminished	  after	  knockout	  or	  knock-­‐down	  of	  Itgb1	  in	  hepatocytes	  in	  vivo,	  (iii)	  EGF-­‐	  and	  HGF-­‐
induced	   receptor	   phosphorylation	   and	   subsequent	   Erk1/2	   activation	   were	   decreased	   in	  
primary	  hepatocytes	  after	  Itgb1	  knock-­‐down,	  and	  (iv)	  EGF	  internalization	  was	  reduced	  after	  
Itgb1	  knock-­‐down	  in	  primary	  hepatocytes.	  Taken	  together,	  these	  data	  strongly	  suggest	  that	  
loss	  of	   Itgb1	   in	  hepatocytes	   impairs	  EGFR	  and	  c-­‐Met	  activation	  on	   the	  cell	   surface	  and/or	  
after	   internalization	   on	   endosomes,	   resulting	   in	   attenuated	   intracellular	   signalling.	   These	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results	  are	  consistent	  with	  previous	  findings	  that	  demonstrated	  the	  importance	  of	  integrins	  
for	  EGFR	  activation	  and	  signalling,	  whereby	  the	  interaction	  can	  occur	  at	  various	  levels	  28-­‐30.	  
For	  example,	  it	  has	  been	  reported	  that	  integrin-­‐mediated	  EGFR	  phosphorylation	  may	  occur	  
in	  the	  absence	  of	  EGF	  31,	  and	  that	  Itgb1	  knock-­‐down	  affects	  EGFR	  signalling	  and	  subsequent	  
cell	  proliferation	  in	  human	  lung	  cancer	  cells	  through	  impairment	  of	  EGFR	  turnover	  at	  the	  cell	  
membrane	   32.	  However,	   an	  effect	  of	   integrins	  on	   ligand-­‐induced	  phosphorylation	  of	   EGFR	  
and	   the	   subsequent	   receptor	   internalization	   as	   shown	   in	   our	   study	   has	   not	   been	  
demonstrated	  yet.	  Most	   importantly,	   loss	  of	   Itgb1	  not	  only	  affected	   the	  EGFR,	  but	  also	  c-­‐
Met,	   a	   second	   key	   player	   in	   liver	   regeneration.	   Therefore,	   our	   findings	   unravel	   a	   more	  
general	  role	  of	  Itgb1	  in	  the	  growth	  factor	  receptor	  signalling	  cross-­‐talk	  in	  hepatocytes.	  	  
	  
The	   impaired	   EGFR	   and	   c-­‐Met	   signalling	   provides	   an	   obvious	   explanation	   for	   the	  
proliferation	   defect	   that	   we	   observed	   in	   Itgb1	   knockout	   and	   knock-­‐down	   mice.	   This	  
hypothesis	   is	   further	   supported	   by	   the	   similar	   regeneration	   abnormalities	   of	  mice	   lacking	  
EGFR	   or	   c-­‐Met	   in	   the	   liver,	  which	   also	   suffered	   from	   delayed	   proliferation	   and	   enhanced	  
necrosis,	  resulting	  in	  increased	  mortality	  after	  PH	  9-­‐11.	  The	  extensive	  necrosis	  and	  apoptosis	  
is	  most	   likely	   a	   consequence	  of	   the	   failure	   to	   restore	   the	   liver	  mass	   required	   for	  efficient	  
detoxification	  of	  exogenous	  and	  endogenous	  compounds.	   In	  addition,	   the	   loss	  of	   the	  pro-­‐
survival	  activity	  of	   the	   Itgb1/EGFR/c-­‐Met	  axis	  may	   further	  contribute	   to	   the	  phenotype	  as	  
suggested	   by	   the	   reduced	   EGF-­‐mediated	   activation	   Akt	   in	   the	   absence	   of	   Itgb1.	   These	  
results	   highlight	   the	   importance	   of	   the	   cross-­‐talk	   between	   growth	   factor	   and	   integrin	  
signalling	  and	  suggest	   that	  proper	  activation	  of	  growth	   factor	   receptors	   is	  a	  major	   role	  of	  
integrins	  in	  regenerating	  tissues.	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Methods	  	  
	  
Animals	  
Mouse	  maintenance	  and	  experiments	  had	  been	  approved	  by	  the	  local	  veterinary	  authorities	  
(Kantonales	  Veterinäramt	  Zürich	  or	  Regierung	   von	  Oberbayern,	   respectively).	   The	  animals	  
were	   free	   of	   pathogens,	   including	  mouse	   hepatitis	   virus.	  Mice	  with	   floxed	   Itgb1	   alleles	   21	  
were	  mated	  with	  MxCre	  mice	  22,	  which	  allow	  activation	  of	  Cre	  recombinase	  upon	  treatment	  
with	  poly-­‐IC.	  Single	  and	  double	  mutant	  mice	  were	  injected	  intraperitoneally	  (i.p.)	  twice	  with	  
poly-­‐IC	  (250mg/animal	  poly-­‐IC,	  Amersham	  Biosciences,	  Piscataway,	  NJ)	  with	  a	  time	  interval	  
of	  2	  days.	  After	  additional	  14	  days	  mice	  were	  used	  for	  experiments.	  
siRNA-­‐mediated	  knockdown	  
The	  following	  siRNAs	  were	  used:	  	  
Itgb1	   Sense	  	  5’-­‐AGAuGAGGuucAAuuuGAAdTsdT-­‐3’	  
	   Antisense	  5’-­‐UUcAAAUUGAACCUcAUCUdTsdT-­‐3’	  
control	   Sense	  5’-­‐cuuAcGcuGAGuAcuucGAdTsdT-­‐3’	  
	   Antisense	  5’-­‐UCGAAGuACUcAGCGuAAGdTsdT-­‐3’	  
	  
2′-­‐OMe	  modified	  nucleotides	  are	  in	  lower	  case,	  and	  phosphorothioate	  linkages	  are	  indicated	  
by	   ‘s’.	   siRNAs	  were	   formulated	   in	   lipid	   nanoparticles	   (C12-­‐200	   lipoids)	   19.	   Seven	  week-­‐old	  
C57BL/6	   male	   mice	   received	   formulated	   siRNA	   directed	   against	   luciferase	   or	   Itgb1	  
(0.5mg/kg)	  via	  tail	  vein	  injection	  in	  a	  volume	  of	  5ml/kg	  body	  weight	  at	  day	  1	  and	  day	  5.	  At	  
day	   10,	   the	   knock-­‐down	   efficiency	   was	   determined	   in	   the	   liver	   tissue	   that	   was	   removed	  
during	  PH	  (0h	  time	  point).	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Generation	  of	  bone	  marrow	  chimeric	  mice	  	  
Bone	   marrow	   chimeras	   were	   generated	   by	   injecting	   6x106	   bone	   marrow	   cells	   from	  
Itgb1f/f/MxCre	  mice	   into	  the	  tail	  vein	  of	   lethally	   irradiated	  8	  week-­‐old	  C57BL/6	  mice	  33.	  Six	  
weeks	   after	   bone	   marrow	   transfer,	   Cre	   expression	   in	   the	   haematopoietic	   system	   was	  
induced	  by	  poly-­‐IC	  as	  described	  above.	  
Partial	  hepatectomy	  	  	  	  
Eight-­‐	  to	  ten-­‐week-­‐old	  male	  mice,	  which	  received	  food	  and	  water	  ad	  libitum	  before	  surgery,	  
were	   anaesthetized	   by	   inhalation	   of	   isoflurane	   (2%).	   PH	   was	   performed	   in	   the	   morning	  
between	  8	  and	  12	  a.m.	  as	  previously	  described	   34.	  After	   surgery,	  mice	  were	   injected	  with	  
buprenorphine	  for	  analgesia	  (Temgesic;	  Essex	  Chemie	  AG,	  Luzern,	  Switzerland;	  0.1mg/kg	  of	  
body	   weight).	   They	   were	   euthanized	   by	   CO2	   inhalation,	   and	   the	   remaining	   liver	   was	  
harvested	  at	  different	  time	  points	  after	  PH	  for	  further	  analysis.	  	  
Histology	  and	  histomorphometry	  	  	  	  
Liver	  samples	  were	  fixed	  in	  4%	  paraformaldehyde	  (PFA)	  in	  PBS	  or	  in	  95%	  ethanol/1%	  acetic	  
acid	   and	   embedded	   in	   paraffin.	   Sections	   (3.5µm)	   were	   stained	   with	   haematoxylin/eosin	  
(H&E)	   and	   photographed	   (3–5	   pictures	   per	   animal);	   the	   necrotic	   area	   was	   determined	  
morphometrically.	  For	  the	  identification	  of	  cell	  size,	  unfixed	  cryosections	  (10µm)	  were	  fixed	  
in	  4%	  PFA/PBS	  and	  permeabilized	   for	  5min	   in	  0.1%	  Triton-­‐X100	   in	  PBS.	  Unspecific	  binding	  
sites	  were	  then	  blocked	  with	  3%	  BSA/PBS	  for	  30	  min	  at	  RT.	  Rhodamine-­‐coupled	  phalloidin	  
(Life	  Technologies,	  Carlsbad,	  CA)	  was	  applied	  to	  stain	  the	  actin	  cytoskeleton	  and	  incubated	  
overnight	   at	   4°C.	   Nuclei	   were	   counterstained	   with	   4',6-­‐diamidino-­‐2-­‐phenylindole	   (DAPI).	  
Sections	  were	  mounted	  with	  Mowiol.	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Identification	  of	  proliferating	  cells	  
Proliferating	   cells	   were	   identified	   by	   5-­‐bromo-­‐2`-­‐deoxyuridine	   (BrdU)	   labelling	   2h	   before	  
livers	  were	   harvested	   and	   subsequent	   staining	   of	   sections	  with	   a	   BrdU	   antibody	   35.	   BrdU	  
positive	   cells	   were	   counted	   in	   4	   independent	  microscopic	   fields	   (200x	  magnification)	   per	  
animal.	  
Terminal	  dUTP	  nick-­‐end	  Labeling	  (TUNEL)	  	  	  
The	  In	  Situ	  Cell	  Death	  Detection	  Kit	  (Roche,	  Basel,	  Switzerland)	  was	  used	  for	  the	  detection	  of	  
apoptotic	  cells.	  
LacZ	  staining	  and	  activity	  assay	  
Non-­‐fixed	   cryo-­‐sections	   (10µm)	   were	   stained	   with	   lacZ	   for	   detection	   of	   β-­‐galactosidase	  
activity	   29.	   For	  detection	  of	  β-­‐galactosidase	  activity	   in	  platelets,	   lysates	  were	   incubated	  at	  
37°C	  in	  assay	  buffer	  overnight	  and	  absorbance	  was	  monitored	  photometrically	  at	  420	  nm.	  	  
Serum	  collection	  and	  analysis	  
Mice	  were	  euthanized	  by	  CO2	  inhalation,	  and	  blood	  was	  taken	  by	  heart	  punctuation.	  After	  
coagulation,	   serum	  was	  harvested	  and	  snap-­‐frozen.	   It	  was	  analyzed	  using	  a	  Cobas	   Integra	  
400	  Chemistry	  Analyzer	  (GMI,	  Ramsey,	  MN)	  and	  the	  corresponding	  reagents	  (Roche).	  
Injection	  of	  EGF	  into	  mice	  
Murine	   EGF	   (Peprotech,	   Rocky	   Hill,	   NJ;	   0.05mg/kg	   body	   weight	   in	   0.1%	   BSA	   in	   isotonic	  
saline)	  was	  injected	  i.p.	  into	  mice.	  	  
Establishment	  and	  growth	  factor	  treatment	  of	  primary	  mouse	  hepatocytes	  
Murine	   hepatocytes	   were	   isolated	   as	   described	   36,	   plated	   on	   6-­‐well	   dishes	   coated	   with	  
collagen	   R	   (Serva,	   Heidelberg,	   Germany;	   0.2mg/mL)	   in	   RPMI	  medium	   at	   a	   density	   of	   4	   x	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10
5
cells/well,	  and	  left	  to	  adhere	  for	  3h.	  The	  medium	  was	  changed	  to	  remove	  non-­‐attached	  
cells,	  and	  after	  30min	  10ng/ml	  murine	  EGF	  or	  HGF	  were	  added.	  Cells	  were	  lysed	  at	  different	  
time	  points	  after	  growth	  factor	  addition	  and	  analyzed	  by	  western	  blotting.	  	  
EGF	  internalization	  
Internalization	  of	  EGF	  was	  determined	  as	  previously	  described	  37.	  Briefly,	  after	  adherence	  of	  
hepatocytes	   for	   3h,	   the	   medium	   was	   replaced	   by	   ice-­‐cold	   medium	   containing	   10ng/ml	  
fluorescein-­‐conjugated	  EGF	   (Life	   Technologies)	   and	   incubated	   for	   30min	   to	   allow	  efficient	  
ligand	   binding.	   Cells	   were	   washed	   with	   ice-­‐cold	   PBS,	   prewarmed	   RPMI	   was	   added,	   and	  
plates	   were	   incubated	   at	   37°C	   for	   5min	   to	   adjust	   the	   temperature.	   Internalization	   was	  
stopped	  at	  different	  time	  points	  by	  placing	  samples	  on	  ice	  and	  washing	  for	  5min	  with	  0.2M	  
acetic	  acid,	  500mM	  NaCl,	  pH2.8.	  Cells	  were	  then	  washed	  with	  ice-­‐cold	  PBS,	  scraped	  off	  the	  
dish,	   transferred	   into	   tubes	   in	   1%	  PFA,	   110mM	  glucose,	   50mM	   sodium	  acide	   in	   PBS,	   and	  
fixed	   for	   20min.	   After	   centrifugation,	   they	  were	   resuspended	   in	   2.5mM	   EDTA,	   0.1%	   BSA,	  
15mM	   sodium	   acide	   in	   PBS	   and	   analyzed	   by	   FACS	   using	   FloJo	   software	   (TreeStar	   Inc.,	  
Ashland,	  OR).	  	  
Identification	  of	  neutrophils	  by	  immunohistochemistry	  
Paraffin	  sections	  of	  tissue	  fixed	  with	  95%	  ethanol/1%	  acetic	  acid	  were	  incubated	  for	  30min	  
in	   12%	   BSA	   in	   PBS/0.025%	  NP-­‐40	   to	   block	   unspecific	   binding	   sites.	   The	   primary	   antibody	  
(anti-­‐Ly6G;	   BD	   Pharmingen,	   Allschwil,	   Switzerland)	   was	   diluted	   in	   blocking	   buffer	   and	  
incubated	  overnight	  at	  4°C.	  Sections	  were	  stained	  using	  the	  ABC	  Vectastain	  Peroxidase	  Kit	  
(Vector	   Laboratories,	   Burlingame,	   CA)	   according	   to	   the	   manufacturer`s	   protocol,	  
counterstained	  with	  haematoxylin,	  rehydrated,	  and	  mounted.	  	  
	  
______________________________________________________________________________________________________________
358
Appendix
	   20	  
Detection	  of	  Itgb1	  by	  immunofluorescence	  
Unfixed	  cryosections	  (10µm)	  were	  dried	  30min	  at	  RT,	  fixed	  for	  20min	  at	  RT	  in	  4%	  PFA/PBS,	  
permeabilized	   for	   5	   min	   in	   0.1%	   Triton-­‐X100	   in	   PBS,	   and	   unspecific	   binding	   sites	   were	  
blocked	  in	  3%	  BSA/PBS	  for	  30min	  at	  RT.	  A	  rat	  monoclonal	  antibody	  against	  Itgb1	  (Millipore,	  
Zug,	   Switzerland),	   was	   applied	   and	   incubated	   overnight	   at	   4°C.	   Sections	   were	   incubated	  
with	   Cy3-­‐conjugated	   secondary	   antibody	   (Jackson	   ImmunoResearch	   Laboratories,	   West	  
Grove,	   PA)	   diluted	   in	   3%BSA/PBS	   and	   Hoechst	   (Molecular	   Probes,	   Basel,	   Switzerland)	   to	  
counterstain	  the	  nuclei,	  and	  mounted	  with	  Mowiol.	  
Co-­‐immunofluorescence	  staining	  of	  Itgb1	  and	  F4/80	  	  
Unfixed	  cryosections	  (10µm)	  were	  equilibrated	  at	  RT,	  fixed	  for	  10min	  in	  -­‐20°C	  cold	  acetone,	  
dried	   on	   air	   and	   rehydrated	  with	   PBS.	   After	   blocking	   for	   1h	  with	   Dako	   blocking	   solution,	  
primary	   antibodies	   were	   applied	   for	   1h	   (rat	   monoclonal	   Itgb1	   antibody	   labeled	   with	  
DyLight647	  and	  F4/80	   (BM8,	  Biolegend,	  San	  Diego,	  CA)	  conjugated	  with	  Alexa488).	  Nuclei	  
were	  counterstained	  with	  Hoechst.	  Images	  were	  taken	  using	  a	  Zeiss	  LSM	  700	  laser	  scanning	  
confocal	  microscope.	  
Co-­‐immunofluorescence	  staining	  of	  Itgb1	  and	  α-­‐SMA	  or	  PECAM-­‐1	  
Unfixed	   cryosections	   (10µm)	  were	   dried	   30min	   at	   RT,	   fixed	   for	   5min	   at	   4°C	   in	  methanol,	  
permeabilized	  for	  5min	  on	  ice	  in	  0.1%	  Triton-­‐X100/PBS,	  washed	  once	  in	  PBS	  and	  unspecific	  
binding	  sites	  were	  blocked	  in	  0.7%	  fish	  gelatin,	  3%	  BSA,	  donkey	  serum	  1:20	  in	  PBS	  for	  2h	  at	  
RT.	  After	  washing	  in	  PBS	  the	  primary	  antibodies	  anti-­‐Itgb1	  (Cell	  Signaling,	  Danvers,	  MA)	  and	  
anti-­‐α-­‐SMA-­‐Cy3	   (Sigma,	   Buchs,	   Switzerland)	   or	   anti-­‐PECAM-­‐1	   (Milipore,	   Zug,	   Switzerland)	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were	  applied	  overnight	  at	  4°C.	  After	  washing,	  anti-­‐rat-­‐Alexa	  488	  (Jackson),	  anti-­‐hamster-­‐Cy3	  
and	  Hoechst	  were	  applied	  for	  1h	  at	  RT.	  After	  washing	  in	  PBS	  the	  samples	  were	  mounted.	  
Staining	  for	  cleaved	  caspase-­‐3	  	  
Unfixed	  cryosections	   (10µm)	  were	  dried	  30min	  at	  RT,	   fixed	   for	  15min	  at	  4°C	   in	  methanol,	  
washed	  once	  in	  PBS	  and	  unspecific	  binding	  sites	  were	  blocked	  in	  3%	  BSA/PBS.	  After	  washing	  
in	  PBS,	  anti-­‐cleaved	  caspase-­‐3	  antibody	  (Cell	  Signaling)	  was	  applied	  overnight	  at	  4°C.	  After	  
washing	   in	   PBS,	   anti-­‐rabbit-­‐Cy3	   antibody	   (Jackson)	   and	   Hoechst	   (Molecular	   Probes)	   were	  
applied	  for	  1h	  at	  RT,	  followed	  by	  washing	  in	  PBS	  and	  mounting.	  
RNA	  isolation	  and	  qRT–PCR	  analysis	  	  
Total	   cellular	  RNA	  was	   isolated	   from	   liver	   tissue	  as	  described	   38,	   including	   a	  DNase	  digest	  
(Promega,	   Dübendorf,	   Switzerland).	   cDNA	   synthesis	   and	   qRT-­‐PCR	   were	   carried	   out	   as	  
described	  previously	  34.	  The	  following	  primers	  were	  used:	  Gapdh:	  	  5’-­‐TCG	  TGG	  ATC	  TGA	  CGT	  
GCC	  GCC	  TG-­‐3`	  and	  5`-­‐	  CAC	  CAC	  CCT	  GTT	  GCT	  GTA	  GCC	  GTA	  T-­‐3`;	  Itgb1	  5’-­‐	  ATG	  CCA	  AAT	  CTT	  
GCG	  GAG	  AAT-­‐3	  and	  5’-­‐	  TTT	  GCT	  GCG	  ATT	  GGT	  GAC	  ATT-­‐3`.	  
	  
Preparation	  of	  protein	  lysates	  and	  Western	  blot	  analysis	  
Frozen	  tissue	  was	  homogenized	  in	  T-­‐PER	  tissue	  protein	  extraction	  reagent	  (Pierce,	  Rockford,	  
IL)	   containing	   Complete	   Protease	   Inhibitor	   Cocktail	   and	   PhosSTOP	   Phosphatase	   Inhibitor	  
Cocktail	  (Roche).	  Lysates	  were	  cleared	  by	  sonication	  and	  centrifugation	  (13	  000rpm,	  30min,	  
4°C),	  snap	  frozen,	  and	  stored	  at	  -­‐80°C.	  The	  protein	  concentration	  was	  determined	  using	  the	  
BCA	   Protein	   assay	   (Pierce).	   Proteins	   were	   separated	   by	   SDS-­‐PAGE	   and	   transferred	   onto	  
nitrocellulose	   membranes.	   The	   following	   antibodies	   were	   used:	   anti-­‐P-­‐ERK1/2,	   anti-­‐total	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ERK1/2,	  anti-­‐P-­‐FAK	  Y379	   (Life	  Technologies),	  anti-­‐total	  FAK	   (BD	  Biosciences,	  San	   Jose,	  CA),	  
anti-­‐P-­‐EGFR	   (Tyr1068),	   anti-­‐Itgb1	   (all	   from	   Cell	   Signaling),	   anti-­‐P-­‐FAK	   (Tyr379),	   anti-­‐total	  
EGFR,	   anti-­‐total	   c-­‐Met	   (all	   from	   Santa	   Cruz,	   Santa	   Cruz,	   CA),	   anti-­‐GAPDH	   (HyTest,	   Turku,	  
Finland),	  anti-­‐P-­‐c-­‐Met,	  (Tyr	  1003)	  (Sigma),	  and	  anti-­‐ASGPR2	  (Abcam,	  Cambridge	  UK).	  	  
	  
Statistical	  analysis	  
Statistical	  analysis	  was	  performed	  using	   the	  Prism4	  software	   (GraphPad	  Software	   Inc,	   San	  
Diego,	   CA).	  Quantitative	   data	   are	   expressed	   as	  mean	   	   ±	   SEM.	   Significance	  was	   calculated	  
with	   the	   Mann–Whitney	   U	   test;	   *P	   ≤0.05,	   **P	   ≤0.01,	   and	   ***P	   ≤0.001.
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Figure	  legends	  
Fig.	   1.	   Mx-­‐Cre-­‐mediated	   knockout	   of	   Itgb1	   occurs	   predominantly	   in	   hepatocytes.	   Cre-­‐
mediated	   deletion	   of	   the	   Itgb1	   alleles,	   resulting	   in	   knockout	   of	   Itgb1	   and	   concomitant	  
expression	   of	  β-­‐galactosidase,	  was	   analyzed	  by	   lacZ	   staining	   on	   liver	   (A)	   and	   intestine	   (B)	  
from	  poly-­‐IC-­‐treated	   Itgb1f/f/MxCre	  mice	  (Itgb1	  ko)	  and	  control	   littermates	  (ctrl).	   	  (C)	   Itgb1	  
mRNA	  levels	  relative	  to	  Gapdh	  were	  analyzed	  by	  qRT-­‐PCR	  using	  RNAs	  from	  liver,	  spleen	  and	  
lung.	  N	  ≥	  3	  per	  genotype.	  (D)	  Immunofluorescence	  staining	  for	  Itgb1	  (red)	  was	  performed	  on	  
liver	   sections	   from	   Itgb1f/f/MxCre	   mice	   (Itgb1	   ko)	   and	   control	   littermates	   (ctrl).	   (E,F)	   Co-­‐
staining	  for	   Itgb1	  (red)	  and	  PECAM-­‐1	  (green)	  (E)	  or	  F4/80	  (green)	  (F)	  of	   liver	  sections	  from	  
poly-­‐IC-­‐treated	   Itgb1f/f/MxCre	   and	  MxCre	   control	  mice.	  Nuclei	  were	   stained	  with	  Hoechst	  
(blue).	   (N≥3)	  Representative	  pictures	  were	  chosen.	  Scale	  bars	  represent	  100	  µm	  (A-­‐E)	  and	  
20	  µm	  (F)	  .	  Bars	  in	  (D)	  represent	  SEM.	  	  
	  
Fig.	   2.	   Loss	   of	   Itgb1	   in	   the	   liver	   reduces	   survival,	   enhances	   tissue	   damage,	   and	   impairs	  
hepatocyte	   proliferation	   after	   PH.	   (A)	   Scheme	   of	   Poly-­‐IC-­‐induced	   knockout	   of	   Itgb1.	   (B)	  
Survival	  index	  48h	  after	  PH	  (N≥16	  mice	  per),	  (C)	  liver-­‐to-­‐body-­‐weight	  ratio,	  (D)	  AST,	  and	  ALT	  
activities,	  bilirubin,	  and	  albumin	  levels	  in	  the	  serum	  48h	  after	  PH	  of	  control	  (white	  bars)	  and	  
Itgb1f/f/MxCre	   mice	   (black	   bars)	   (N≥8	   per	   genotype).	   (E)	   Representative	   pictures	   of	   liver	  
tissue	   and	   quantification	   of	   necrotic	   area	   (N≥10	   per	   genotype),	   (F)	   immunostaining	   for	  
neutrophils	   and	   quantification	   (N≥3),	   positive	   cells	   are	   indicated	   by	   arrows,	   (G)	   TUNEL	  
staining	  of	  apoptotic	  cells	  and	  quantification	  (N≥7),	  positive	  nuclei	  are	  indicated	  by	  arrows,	  
and	   (H)	   BrdU	   immunostaining	   and	   quantification	   (N≥5),	   positive	   nuclei	   are	   indicated	   by	  
arrows,	  48h	  after	  PH	  of	  poly-­‐IC-­‐treated	  control	  (white	  bars)	  and	  Itgb1f/f/MxCre	  mice	  (black	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bars).	  Scale	  bars	  in	  (E-­‐H)	  represent	  100	  µm.	  Bars	  in	  (B-­‐H)	  represent	  mean	  	  ±	  SEM.	  *P	  ≤0.05,	  
**P	  ≤0.01,	  and	  ***P	  ≤0.001	  (Mann-­‐Whitney	  U-­‐test).	  	  
	  
Fig.	  3.	  siRNA-­‐mediated	  knock-­‐down	  of	  Itgb1	  phenocopies	  Itgb1	  knockout	  
(A)	   Scheme	  of	   siRNA-­‐mediated	   Itgb1	  knock-­‐down	   and	   the	   following	   PH	   experiment.	  Mice	  
were	  treated	  twice	  with	  siRNA	  against	  luciferase	  (Luc)	  or	  Itgb1	  (Itgb1)	  with	  a	  time	  interval	  of	  
5	  days.	  After	  additional	  5	  days	  animals	  were	  used	  for	  experiments.	  (B)	  Verification	  of	  siRNA-­‐
mediated	  knock-­‐down	  of	  Itgb1	  mRNA	  in	  the	  liver	  by	  qRT-­‐PCR	  (normalized	  to	  Gapdh)	  5	  days	  
after	   the	   second	   siRNA	   injection	   (N≥8	   per	   treatment	   group).	   (C)	   Immunoblotting	   of	   Itgb1	  
and	  asialoglycoprotein	  receptor	  (ASGPR2)	  as	   loading	  control	  using	  total	   liver	  homogenates	  
or	  lysates	  from	  isolated	  primary	  hepatocytes	  after	  siRNA-­‐mediated	  knock-­‐down	  in	  vivo.	  (D)	  
Immunostaining	   for	   Itgb1	   (red)	   and	   DAPI	   nuclear	   counterstain	   (blue)	   on	   cryosections	   of	  
tissue	   removed	  during	  PH	  and	  48h	  after	  PH.	   (E)	   Survival	   index	   (N≥12)	  48	  after	  PH	  and	   (F)	  
liver-­‐to-­‐body-­‐weight	  ratio	   (N≥12)	  48h	  after	  PH.	   (G)	  Necrosis	   (N≥12),	   (H)	  neutrophils	   (N≥5),	  
positive	   cells	   are	   indicated	   by	   arrows	   and	   (I)	   BrdU-­‐positive	   cells,	   (N≥11)	   48h	   after	   PH,	  
positive	  nuclei	  are	  indicated	  by	  arrows.	  Scale	  bars	  in	  (D-­‐I)	  represent	  100	  	  µm.	  Bars	  in	  (B)	  and	  
(E-­‐I)	  represent	  mean	  	  ±	  SEM.	  **P	  ≤0.01,	  and	  ***P	  ≤0.001	  (Mann-­‐Whitney	  U-­‐test).	  	  
	  
Fig.	  4.	  Effect	  of	  siRNA-­‐mediated	  Itgb1	  knock-­‐down	  6h	  and	  5d	  after	  PH	  
(A)	  Verification	  of	   siRNA-­‐mediated	  knock-­‐down	  of	   Itgb1	  mRNA	  by	  qRT-­‐PCR	   (normalized	   to	  
Gapdh)	   (N≥5	  per	   treatment	  group	  and	   time	  point)	  and	   (B)	   immunostaining	   for	   Itgb1	   (red)	  
and	   DAPI	   nuclear	   counterstain	   (blue)	   on	   cryosections	   of	   tissue	   removed	   5d	   after	   PH.	   (C)	  
Necrotic	  area	  6h	  and	  5d	  after	  PH	  (N≥5	  per	  genotype	  and	  time	  point),	  (D)	  BrdU-­‐positive	  cells	  
5d	  after	  PH	  (N≥5),	  and	  (E)	  liver-­‐to-­‐body-­‐weight	  ratio	  of	  Luc	  and	  Itgb1	  siRNA	  treated	  animals	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6h	  and	  5d	  after	  PH	  (N≥5).	  Scale	  bars	  in	  (B)	  represent	  100	  µm.	  Bars	  in	  (A)	  and	  (C-­‐E)	  represent	  
mean	  	  ±	  SEM.	  *P	  ≤0.05,	  and	  **P	  ≤0.01	  (Mann-­‐Whitney	  U-­‐test).	  	  
	  
Fig.	  5.	  Loss	  of	  Itgb1	  affects	  phosphorylation	  of	  c-­‐Met	  and	  EGFR	  during	  liver	  regeneration	  
(A)	  Immunoblotting	  of	  Itgb1,	  phosphorylated	  and	  total	  c-­‐Met,	  EGFR,	  and	  FAK	  and	  of	  GAPDH	  
(loading	   control)	   using	   homogenates	   from	   livers	   of	   three	   poly-­‐IC-­‐treated	   control	   and	  
Itgb1f/f/MxCre	  mice	  removed	  during	  surgery	  (0h)	  and	  48h	  after	  PH.	  Densitometric	  analysis	  
was	   performed	   for	   phosphorylated	   EGFR	   and	   c-­‐Met.	   (B)	   Immunoblotting	   of	   Itgb1,	  
phosphorylated	  and	  total	  EGFR	  and	  GAPDH	  using	  homogenates	  from	  livers	  of	  three	  Luc	  or	  
Itgb1	   siRNA	   pre-­‐treated	   animals	   removed	   during	   PH	   (0h)	   and	   after	   48h.	   Densitometric	  
analysis	  was	  performed	  for	  phosphorylated	  EGFR.	  Bars	  represent	  mean	  	  ±	  SEM.	  	  
	  
Fig.	  6.	  Itgb1	  controls	  growth	  factor	  receptor	  activation	  in	  hepatocytes	  in	  vitro	  and	  in	  vivo	  	  
Liver	  lysates	  from	  poly-­‐IC-­‐injected	  control	  and	  Itgb1f/f/MxCre	  mice	  (A)	  and	  from	  knock-­‐down	  
mice	   (B)	  15min	  after	   i.p.	   injection	  of	  EGF	  or	  vehicle	  were	  analyzed	  by	   immunoblotting	   for	  
Itgb1,	  phosphorylated	  and	  total	  EGFR	  and	  GAPDH	  (loading	  control).	  Densitometric	  analysis	  
was	   performed	   for	   phosphorylated	   EGFR.	   C)	   Itgb1	   knock-­‐down	   in	   primary	   hepatocytes	  
prepared	   from	  Luc	  or	   Itgb1	   siRNA	  pre-­‐treated	  mice	  was	  confirmed	  by	   immunostaining	   for	  
Itgb1	   (red).	   Nuclei	   were	   countersained	  with	   DAPI	   (blue).	   (D,E)	   Primary	   hepatocytes	   were	  
incubated	   for	  15min	  with	  EGF	   (D)	  or	   for	   the	   indicated	  periods	  with	  HGF	   (E).	   Lysates	  were	  
used	   for	   immunoblotting	  of	   Itgb1,	  phosphorylated	  and	   total	   EGFR,	   c-­‐Met,	   Erk,	  Akt	   and	  as	  
loading	  control	  for	  GAPDH.	  Densitometric	  analysis	  was	  performed	  for	  phosphorylated	  EGFR	  
and	   c-­‐Met.	   (F)	   EGFR	   internalization	   upon	   stimulation	   with	   EGF	   was	   monitored	   by	   FACS	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analysis	   in	   primary	   hepatocytes	   from	   Luc	   or	   Itgb1	   siRNA	   pre-­‐treated	   mice	   (N≥3	   per	  
treatment	  group	  and	  time	  point).	  Bars	  in	  (A)	  and	  (B)	  represent	  mean	  ±	  SEM.	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